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Abstract 
Scoring systems in medicine are not a new concept. There are examples from the early 
1950s, from around the same time as the polio epidemic in Copenhagen resulted in the 
birth of modern Intensive Care. Many scores have subsequently been developed 
specifically for Intensive Care patients. The majority summarise the overall physiological 
state of the patient in a variety of different ways.  
 
A clinical interest in ascertaining whether haemodialysis causes cardiovascular instability 
in Intensive Care patients led to an initial simple experiment examining stability using a 
small number of cardiovascular parameters. It became apparent that to answer the question 
properly a physiologically based score which could be calculated automatically in real 
time, and which took into account the level of physiological or pharmacological support 
the patient was receiving would have to be developed, to counter or to mitigate the 
drawbacks of the main scoring systems in common use at the time. 
 
This thesis describes the development and first stage in the validation of a novel 
physiologically based scoring system for Intensive Care patients which overcomes some of 
the major disadvantages of existing scores. The score was then used to investigate other 
clinical questions. Myocardial damage in Intensive Care is common and associated with a 
poor outcome. Aspects of the developed score were used to ascertain if it is possible to 
detect and predict myocardial damage occurring in Intensive Care patients based on 
physiological disturbance rather than a rise in biomarkers. The score was subsequently 
used to examine Intensive Care patient outcomes. 
 
The introductory chapter describes the history of Intensive Care, the mechanism of data 
collection for patients in Scottish Intensive Care Units and its analysis to enable 
comparison of different units. Reviewing currently available scoring systems places this 
work in context and highlights the need for a new score. An overview of renal replacement 
therapy modalities follows, as an interest in cardiovascular stability during haemodialysis 
led to the idea for a new scoring system. Myocardial damage in Intensive Care patients is 
common and indicative of poorer outcomes. This is reviewed, as the developed score was 
used to detect and then predict where myocardial damage was occurring in critically ill 
patients, based on physiological disturbance rather than on raised biomarkers. 
 
In Chapter 2, data from dialysis sessions in critically ill patients was collected, prc-
processed, and analysed for cardiovascular instability. Using an arbitrary definition of 
  
3 
instability as a 20% change in mean arterial pressure or heart rate in either direction, 65% 
of dialysis sessions were stable and 35% unstable. This simple experiment suggested that 
haemodialysis is less cardiovascularly destabilising than previously believed. However a 
major deficiency was the lack of consideration of the level of physiological support 
required during dialysis. To investigate this and other clinical problems better, it became 
apparent that a new score would have to be developed. 
 
Chapter 3 describes the development of a novel quantitative score which takes into account 
the amount of physiological and pharmacological support a patient is receiving.  
Physiological parameters were separated into those recorded regularly and those recorded 
intermittently. They were subsequently divided into ranges, scoring increasing points 
depending upon the degree of derangement. Ranges were based on an extensive literature 
search, currently available scores, and clinical opinion. Two key parameters viz. mean 
arterial pressure and oxygen saturation, were then weighted against a range of factors 
which can either increase or decrease their value. A score of instability could then be 
calculated by adding points for the weighted and unweighted parameters. After reflection 
using common clinical scenarios, some of the points scored in different ranges and 
weightings were revised to give the final quantitative score. 
 
In Chapter 4, the quantitative score was tested against data sets from actual Intensive Care 
patients to produce graphs of overall cardiovascular stability against time. Although this 
approach did capture improvements and deteriorations it had several disadvantages. It 
captured the expertise of a single clinician only, gave an arbitrary number which could be 
difficult to interpret, and the emphasis given by the clinician to the relative importance of 
different physiological or pharmacological parameters would not be obvious to others. 
Clinical reflection led to a new approach to the problem, viz. the development of the 5 
point qualitative scale described in Chapter 5. 
 
Chapter 5 describes the development of a 5 point qualitative score for cardiovascular 
instability, underpinned by complex physiological rules, and capturing the expertise of 
several senior Intensive Care Clinicians. This is the Intensive Care Unit - Patient Scoring 
System (ICU-PSS). I scored data sets comprising thousands of predominantly hourly 
commonly recorded physiological and pharmacological parameters on a 5 point scale of 
cardiovascular stability (A to E). I also described rules in the form of different parameter 
ranges to indicate why I had scored time points as stable (A) through to unstable (E). These 
rules were incorporated into a computer programme which scored unseen data sets which I 
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also then scored. The computer’s predicted A to E score based on these rules and my own 
score were compared in a confusion matrix. Mismatches with the computer prediction 
(based on my initial rules) were analysed and I either rescored the data if I considered that 
I had not assigned the correct level of instability, or modified the rule base. Through this 
process clinical expertise was better captured. This process was repeated with two other 
clinicians using my rules as a starting point. This led to further refinements of the rule 
base. The result was a sophisticated set of rules underpinning a 5 point, easily 
understandable scale of cardiovascular stability crystallising the expertise of 3 senior 
Intensive Care clinicians. 
 
The ICU-PSS was tested in a discrimination experiment to ascertain if clinicians could 
agree with the score moving in a one step and two step change. This is the first stage in full 
validation of the score 
 
In Chapter 6, the first stage in the validation of the ICU-PSS is described, using 10 
clinicians from a city teaching and a district general hospital. It was hypothesised that if 
they were shown two consecutive hourly time points of physiological data from real 
patients and asked whether they were improving or deteriorating, they should agree with 
the ICU-PSS score in more than 50% of cases (random chance). In two discrimination 
experiments the consultants were, in random order, shown 4 examples of each type of two 
step improvement or deterioration in the score, e.g. A to C, and 4 examples of each type of 
one step change, e.g. E to D. In the two step experiment there was 92.9% agreement with 
the score, and in the one step change experiment, 90.9% agreement. Both were highly 
statistically significant. 
 
Chapter 7 describes the first of the applications of the validated score. Myocardial damage 
is common in Intensive Care patients and is an independent risk factor for both short and 
long term mortality. The mechanism in Intensive Care patients is likely to be the so-called 
type II damage caused by extremes of physiological derangement leading to a myocardial 
oxygen supply and demand imbalance. I hypothesised that it should be possible to use 
aspects of the score to confirm and subsequently predict where this damage is occurs based 
on physiological disturbance alone rather than on a rise in cardiac biomarkers. Two 
clinicians agreed that a subset of the level E, D and C rules from the ICU-PSS occurring in 
3 out of 5 consecutive time points would represent conditions likely to lead to myocardial 
damage in the critically ill. Data sets with known sequences of troponin rises were scanned 
to ascertain if the above conditions were met around the time of a troponin rise within a 
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sequence of troponin rises, given the natural decay of troponin. This was indeed the case in 
75.8% of cases (95% CI: 57.7% to 88.9%). Similarly this set of conditions was applied to 
the same data sets, looking at time periods before a first troponin rise. These conditions 
were met in 87.5% of cases (95% CI: 61.6% to 98.1%). However, as the confidence 
intervals are wide (and also for the positive and negative predictive values of these tests), 
this early work is at best hypothesis generating. It will have to be repeated using much 
larger data sets. 
 
In Chapter 8, the correlation between the mean ICU-PSS score and outcome was 
examined. A data set of patients was prepared from Ward Watcher with an approximate 
50:50 split of medical and surgical diagnoses. The physiological data from these patients 
was extracted from CareVue and anonymised. A mean ICU-PSS score was calculated for 
different points during the patient stay. The data were analysed to ascertain if there were 
differences in mean ICU-PSS scores at different time periods among the survivors and 
non-survivors within the medical and surgical groups. There is a suggestion that the mean 
scores are different in certain patient groups between survivors and non-survivors. 
However, at the time this work was undertaken the computing system used was not yet 
able to apply appropriate statistical tests. Future work will focus address this problem and 
also examine the different proportions of the patient’s stay spent in different categories of 
the score. This would avoid the difficulties above of converting ordinal to numerical data. 
 
In a final analysis I ascertained the relationship between degree of any troponin rise and 
outcome, in the population of patients at Glasgow Royal Infirmary. In a study of 100 
consecutive patients, troponin rises were grouped into three categories. These were low 
(0.04-0.19), medium, (0.2-1.99) and high (≥2.0 micromoles/litre). Intensive Care mortailty 
was 13.3%, 22.7% and 40% respectively. This association is consistent with findings from 
similar studies elsewhere in the literature. 
 
In summary, I have developed a quantitative score of cardiovascular stability, and have 
developed, and partially validated, a more effective qualitative score for use in Intensive 
Care patients. I believe it overcomes the salient disadvantages of other currently available 
scores. I have demonstrated that it may be possible to confirm the presence of, and detect, 
where myocardial damage is occuring. Work thus far suggests that there may be an 
association between this score alone and outcome. Future work will focus on translating 
the score into a bedside monitor to give a continuous reading of the overall physiological 
state of the patient, to detect deterioration before it becomes clinically obvious. 
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Characteristic patterns of deterioration associated with impending myocardial damage will 
be displayed at the bedside with the prospect of earlier intervention aimed at preventing 
myocardial damage and its associated poor outcome. 
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Chapter 1: Introduction 
1.1. Abstract 
Intensive Care is a relatively new specialty within the history of medicine. It is an 
expensive and precious resource. It relies more heavily than other disciplines on scoring 
systems to predict outcomes, guide therapy and compare the performance of different 
Intensive Care Units. Currently available scores have certain limitations. This thesis 
describes the development of a new quantitative and qualitative scoring system for 
critically ill patients, the first stage of validation of the qualitative score and in its clinical 
applications. 
 
To set the work in its context, the history of critical care is described. There is a review of 
currently available and historical scores for use in the critically ill. The reasons why a new 
score might be useful are put forward. The mechanism of data collection for patients in 
Scottish Intensive Care Units and its reporting are included. As the work involved a 
collaboration with computing scientists a section is included on machine learning in 
healthcare with respect to the handling of very data sets. The process of validation of a new 
score in the absence of a gold standard is challenging. Methodology for validation is 
described.  
 
The idea for a new score arose from my interest in, but an inability to characterise properly 
cardiovascular stability during haemodialysis. A review of renal replacement therapy in the 
critically ill is therefore provided, with a specific comparison of haemodialysis and 
haemofiltration.  
 
The newly developed score was tested in a clinical practice. Initially this was to ascertain if 
it were possible to detect and predict where myocardial damage was occurring in Intensive 
Care patients from physiological disturbance alone (and confirmed by cardiac biomarkers. 
This is relevant as it is associated with a poor outcome. Therefore the introduction 
concludes with a review of myocardial damage in Intensive Care. 
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1.2. Definition of an Intensive Care Unit 
An Intensive Care Unit (ICU) is a “geographically defined area in the hospital providing 
care for critically ill patients with specialised personnel and complex equipment” 1. This is 
the definition by Vincent et al. in The European Society of Intensive Care Medicine 
“Guidelines for the utilisation of intensive care units.” They further define the need for 
admission to such an area if patients have an “unstable condition with impaired organ 
function” or a “high risk of developing serious and preventable complications”. They 
should not be admitted if they have “no chance of recovering to a reasonable quality of 
life”. 
 
1.2.1. Levels of patient care 
In 2000 the Department of Health published a review of adult critical care services in 
which it went further, defining the levels of care patients need during critical illness, while 
recovering from critical or at risk of critical illness 
2
. A summary of these levels is as 
follows: 
“Level 0   Ward level care in an acute hospital. 
Level 1  Patients at risk of deteriorating or those stepped down from higher levels of 
care who can be cared for on an acute ward with support from the critical 
care team. 
Level 2 Patients requiring support for a single failing organ system, those requiring 
more detailed observation or those stepping down from level 3 care. 
Level 3 Patients requiring advanced respiratory support or basic respiratory 
support plus support of two or more failing organ systems”. 
 
The definitions were further refined by the Standards Committee of the Intensive Care 
Society of the United Kingdom 
3
. This enabled the definitions to reflect the Critical Care 
minimal data set collected in England, which comprises 34 fields of administrative and 
clinical data, allowing it to analyse activity and guide capacity planning 
4
. The refined 
definitions of the Intensive Care Society include detailed examples of what is meant by 
each level of care. They also highlight that the level of care which patients receive is not 
related to their location. 
 
1.3. The history of Intensive Care  
Critical care practised in such an organised and structured manner is a relatively new 
phenomenon. However, the recognition of the importance of organ support has much 
earlier roots.  
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In both World Wars various techniques were used to resuscitate injured soldiers on the 
battlefield. It was as a result of the 1952/3 polio epidemic in Copenhagen, Denmark that 
modern intensive care was born. H. Lassen described the treatment of the associated 
respiratory failure with “iron lung” negative pressure ventilators in a landmark paper in the 
Lancet 
5
. Mortality was high at over 80%, and the Blegdan Hospital was overwhelmed. On 
the recommendation of a colleague, Mogens Björneboe, Dr. Lassen contacted the 
physician-turned-anaesthetist, Dr. Björn Ibsen. He described positive pressure ventilation 
via a tracheostomy in a 12 year old girl who was deteriorating with negative pressure 
ventilation 
6, 7
. It is worth noting that Asclepiades of Persia is credited as the first person to 
perform a tracheostomy as long ago as 124 AD although the term tracheostomy itself was 
first used by Thomas Feyens (1567-1631)
8
. The girl lived and the management of these 
patients was changed to a high tracheostomy just below the larynx, regular suctioning or 
postural drainage of secretions, and positive pressure ventilation via a cuffed rubber tube. 
Mortality fell in this polio epidemic to 40%. 
 
Following the successes in Denmark, there was widespread adoption of these techniques 
for the treatment of respiratory failure from a number of causes. Further advances in the 
management of other aspects of the critically ill followed, including relatively better 
monitoring. However, in the UK at this time, arrangements were not structured for the care 
of the critically ill, often occurring in side rooms on wards where primitive ventilators 
were moved to the patient, but with no dedicated medical staff to look after them. This is 
described in a transcript of a Witness Seminar held at University College London by the 
Wellcome Trust Centre for the History of Medicine in 2010
9
.  
 
There was an increasing recognition of the inadequacy of care, and recommendations were 
made in a 1962 Department of Health publication “Progressive Patient Care” 10. One of the 
recommendations was that “between 2% and 5% of a hospital’s acute beds should be 
earmarked for care of patients who were severely ill or required specialist acute care”. It 
also recommended that patients should be grouped together, and treated according to their 
level of dependency. 
 
Financial support to hospitals followed, and the first Intensive Care Units were established. 
Greater understanding of the physiological disturbance resulting from disease processes, its 
manipulation and correction, followed in the 1970s to 80s. This was paralleled by large 
advances in monitoring techniques and equipment. 
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1.3.1. Modern Intensive Care 
As of 2012 Critical Care patients in Scotland are managed in 25 Intensive Care Units with 
274 actual beds. This figure includes cardiothoracic and neurosurgical capacity. There is 
funding in place for the equivalent of 183.8 of these beds 
11
. It is worth noting that in the 
UK in 2010 health funding accounted for 9.6% of gross domestic product which was 
higher than the Organisation for Economic Co-operation and Development (OECD) 
average 
12
. Despite this in 2010 the number of acute care beds per 1000 population was 2.4 
compared to the OECD average of 3.4. Specifically for Intensive Care in 2010 there were 
3.5 ICU beds per 100 000 of the population. This is fewer than our European neighbours 
e.g. Germany had 24.6 ICU beds per 100 000 of the population in the same year 
13
. 
 
In Scotland, during the last period for which data are available (2012), a total of 13103 
patients were admitted to ICUs or combined ICU / High Dependency Units (HDU) and 
26977 patients to HDU. Mean bed occupancy in ICUs or combined units was 71.4%. Of 
the patients admitted to ICUs and combined units 20% died before hospital discharge 
11
. 
 
1.3.2. Description of Glasgow Royal Infirmary Intensive Care Unit 
The majority of the work leading to this thesis was carried out at Glasgow Royal Infirmary. 
This is a teaching hospital of over 1000 beds serving the population of the North East of 
the city. It has a 20 bed Intensive Care Unit which deals with all common medical and 
surgical conditions needing Intensive Care admission. The regional burns service is located 
in the Royal Infirmary, as is that for hepatobiliary disease, and in particular the 
management of complicated pancreatic conditions. As a result the ICU is also a tertiary 
referral centre for these specialties. 
 
1.4. The need for Scoring Systems in Intensive Care 
The cost of Intensive Care is high. The average expenditure on a patient who is admitted to 
Glasgow Royal Infirmary ICU is £4828 
14
. In the period from April 2011 to March 2012 
the Royal Infirmary ICU admitted 1048 patients, accounting for 5137 bed days with a total 
cost of £5,059,447 
14
. This equates to a total cost per bed day of £984.90 with an average 
length of stay of 4.9 days 
14
. These sorts of costs are repeated throughout the country. 
Intensive care is therefore an expensive and precious resource.  
 
It would clearly be unethical to randomise a critically ill patient to receive or not receive 
critical care support. Given the enormous cost of this resource a number of scoring systems 
have been developed to aid decision making on suitability for admission, quantifying 
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disease severity, predicting outcome, comparing performance between different units, 
improving quality of patient care and as research tools.  
 
1.4.1. Mechanism of data handling and collection for scores in Scotland 
A national audit infrastructure exists to collect and analyse the data which are fed into a 
number of commonly used scores. This is managed through the Scottish Intensive Care 
Society Audit Group (SICSAG) founded in 1992 
15
. A national database has existed since 
1995. 
 
Data are collected prospectively using the purposely designed Ward Watcher system. 
Included are all general adult Intensive Care Units, approximately 90% of High 
Dependency Units and all Combined Units
 11
. These data are validated by the Information 
Services Division (ISD) of the NHS National Services Scotland 
16
. Missing data or queries 
about e.g. patient outcomes, discharges and treatment are identified and highlighted to 
individual ICUs by local and regional audit coordinators. All of the SICSAG data between 
1998 and 2012 have been linked to the SMR01 data set held by ISD.  This data set relates 
to general and acute inpatient day cases. Every patient appearing in the SICSAG database 
should have an SMR01 entry relating to the same admission. The advantage of this linkage 
is data that is enhanced by providing fields such as hospital or overall outcome. As of the 
2013 SICSAG audit of critical care, reporting on the year 2012, overall 96% of SIGSAG 
entries have been linked to the equivalent SMR01 entry 
11
. 
 
The most commonly used score into which data are fed is APACHE II (Acute Physiology 
and Chronic Health Evaluation). This will be fully described in a review of scoring 
systems to follow. One of the end products of this score is an ability, when combined with 
a patient diagnosis, to give a predicted mortality. Unit predicted mortality can be calculated 
and compared with actual mortality to give a standardised mortality ratio (SMR)
 11
. These 
and other data are published in the SICSAG annual Audit of Critical Care in Scotland. The 
first audit was published in 1998.  
 
1.5. A review of scoring systems applicable to Intensive Care 
1.5.1. Early scoring systems used in Intensive Care 
Scoring systems are not a new concept. Virginia Apgar published a score in 1951 to 
examine the state of the newborn 
17
. It comprises 5 variables and is performed at 1 and 5 
minutes after birth. Its ease and simplicity mean it is still routinely done 60 years after it 
was conceived. In 1976 Ranson described a score for predicting the severity of acute 
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pancreatitis 
18
. The most famous of the early scores from the early 1970s still in use 
worldwide is the Glasgow Coma Score of 1974 
19
. It documents the conscious level of a 
patient based upon the best motor, verbal and eye response. Originally out of 14 it was 
subsequently revised to give a score between 3 and 15 points.  
 
Early scores therefore tended to focus and prognosticate in patients with a single diagnosis. 
The 1980s saw a rapid increase in developments in Intensive Care. New technologies and 
therapies were expensive, even more so as described earlier. This led to the development of 
scores of a more global nature which could help prognosticate as to who might benefit 
from admission to ICU.  
 
1.5.2. Types of scoring systems in Intensive Care 
For the initial search of the scoring systems a sample of the leading textbooks in critical 
care was reviewed. All the original descriptions were obtained and papers in which the 
scoring systems were described. An Ovid Medline search was also performed to identify 
any other descriptions of scoring systems that had been potentially missed, but none were 
identified.  
 
There is no agreed classification of types of score
20
 but it is useful to group them as  
physiological, intervention based / therapeutic weighted, assessment of organ failures, or 
disease specific / miscellaneous scores. Mortality rates in intensive care are far higher than 
on general hospital wards. This is why, quite reasonably, many scoring systems use 
mortality at various stages in the patient stay as the primary outcome measure. 
 
1.5.3. Physiological Scores 
1.5.3.1. Acute Physiology and Chronic Health Evaluation (APACHE) score 
Of the physiological scoring systems, one of the best known is APACHE II (Acute 
Physiology and Chronic Health Evaluation II) which was developed in 1985 by Knaus et 
al. 
21
. As the APACHE II score is the score most commonly used in Scotland, I will 
include more detail about its development and use than on other scores. The APACHE II 
score superseded the original prototype APACHE 
22
. The original system was developed 
on the premise that the severity of acute disease could be measured by quantifying the 
degree of abnormality of different physiological variables. The original score contained 34 
such variables, the degree of derangement of which scoring 1 to 4 points, summed to 
produce an acute physiology score (APS). The greatest derangement of each variable 
within the first 24 hours after admission to ICU was used to score points. This time frame 
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was chosen to ensure the greatest chance of all relevant parameters being recorded and 
available for scoring. The 34 variables were selected after a literature review and weighted 
by a panel of clinicians based on their clinical experience.  It was recognised that chronic 
disease of differing severity decreased the likelihood of surviving Intensive Care. The 
initial APACHE score therefore incorporated a 4 letter code (A-D) representing the 
severity of chronic disease. This was done by means of a health questionnaire. 
 
The original APACHE score was found to have a direct correlation with hospital  
mortality 
22
. It was also useful for comparing the success of different treatment 
programmes and for evaluating the outcome of Intensive Care 
22
. However, it soon became 
apparent that it contained too many variables, was unnecessarily complex and lacked 
robust validation. 
 
1.5.3.2. Acute Physiology and Chronic Health Evaluation II (APACHE II)  
A desire to simplify and validate the original APACHE score was therefore the driving 
force behind the development of APACHE II 
23
. The number of physiological variables 
comprising the acute physiology score was reduced from 34 to 12. Firstly, ones which 
were not often recorded, e.g. serum osmolarity, were deleted. A set of essential clinical 
variables was then established. By a process of multivariate analysis of the original 
APACHE system, variables which added little to survival prediction were also deleted. 
These included urine output, albumin and glucose. The authors postulated that they added 
little to the core parameters as they were more heavily influenced by intervention than 
actual disease severity. The authors appreciated that a patient’s physiological reserve 
decreases with increasing age and points were now awarded for 5 different age ranges. The 
chronic health questionnaire was replaced by chronic health points for severe organ 
insufficiency (liver, cardiovascular, respiratory and renal) or immuno-compromise with a 
weighting for nonoperative or emergency postoperative procedures versus elective 
postoperative procedures. The significance of emergency surgery as a predictor of worse 
outcome was also now appreciated. 
 
 The process of simplifying the number of variables and changing their relative weightings 
used the methodology designed by Gustafon et al. 
24
 who described a strategy of 
developing a replicable index. Up until this point there had been no clear descriptions in 
the literature of methodology for developing severity indices, nor of different panels of 
clinicians producing severity indices with similar performance characteristics. By 
illustrating the development of a heart disease severity index the authors outlined their 
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method and a test of the method’s transportability. To that end, some of the weightings 
assigned to the original APACHE variables were changed, as it was appreciated that a low 
Glasgow Coma Scale and acute renal failure were very poor prognostic signs.  
 
To calculate the APACHE II score, the acute physiology points are added to those for 
increasing age and chronic ill-health to give a maximum score of 71. The variables are 
illustrated in table 1-1 (adapted from Knaus W.A. et al. APACHE - acute physiology and 
chronic health evaluation: A physiologically based classification system
22
.) 
 
Table 1-1: Variables used in the calculation of the APACHE score 
Score Component Variables with maximum score 
 
Acute Physiology Score 
(APS) 
 
Maximum  =  60 
 
Temperature (
0
C)  - (4) 
Mean Arterial Pressure (mmHg) - (4) 
Heart Rate (Ventricular Response) - (4) 
Respiratory Rate (non-ventilated or ventilated) - (4) 
Oxygenation, A-aDO if FiO2 >0.5, PaO2 (mmHg) if FiO2 <0.5 - (4) 
Arterial pH - (4) 
Serum Sodium (mMol/L) - (4)  
Serum Potassium (mMol/L) - (4) 
Serum Creatinine (mg/100ml), points doubled if acute renal failure - 
(4 / 8) 
Haematocrit (%) - (4) 
White blood count (total/mm
3
 in 1000s) - (4) 
Glasgow Coma Score (GCS). Score = 15 minus actual GCS - (12) 
 
 
Age Points 
 
Maximum  = 6  
 
Age (yrs) 
< 44 -  (0) 
45-54 - (2) 
55-64 - (3) 
65-74 - (5) 
≥ 75 - (6) 
 
 
Chronic Health Points 
 
Maximum = 5 
 
History of severe organ system insufficiency or is immuno-
compromised plus 
a. Non operative or emergency postoperative  patient - (5) 
b. Elective post operative patient - (2) 
 
 
The score was validated by examining its association with hospital mortality in unselected 
ICU admissions from 13 hospitals in the United States between 1979 and 1982. 5815 ICU 
admissions were included. It was shown that there was a relationship between an 
increasing APACHE II score calculated within the first 24 hours and hospital mortality. 
However, the score alone could not predict a specific risk of death unless a diagnostic 
category was included. Patients on admission to ICU in the above analysis were assigned 
to a specific diagnostic category according to their principal reason for admission. The 
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overall risk of death varied with the diagnostic category assigned and whether the patient 
had received emergency surgery. By a process of multiple logistic regression, diagnostic 
category weightings were derived. In other words, the APACHE II score could be 
combined with specific diagnostic categories to give predicted hospital mortality. The 
individual risk (R) of hospital death is given by the equation (R/1-R) = -3.517 + (APACHE 
II score x 0.146) + (0.603 if post emergency surgery) + (Diagnostic category weight). A 
list of principal diagnostic categories leading to ICU admission is given in the appendix of 
the original paper 
21
.  
 
1.5.3.3. Acute Physiology and Chronic Health Evaluation III (APACHE III) 
Score 
The APACHE III prognostic system was published in 1991 by the same authors 
25
. The 
aim was of improving the risk prediction available with APACHE II, to make a distinction 
between predictive estimates of mortality for groups of patients versus individual mortality 
estimates, predict unit length of stay and to examine the relationship between timing of 
ICU admission and outcome. 
 
The APACHE III score comprises (as in APACHE II) physiological variables (up to 252 
points), age (up to 24 points) and chronic ill-health (up to 23 points) which are summed to 
give a maximum score of 299. This score can be combined with a single disease category 
to perform a relative risk stratification.  Interestingly, after multivariable logistic regression 
analysis, there are up to 17 physiological variables in this score as opposed to the 12 in 
APACHE II. The added variables were blood urea nitrogen, urine output, serum albumin, 
bilirubin and glucose i.e. some variables previously considered not to add to the predictive 
power of the score. It was also appreciated, on analysis of their large data set of 17440 ICU 
admissions, that the predictive power of extremes of physiology had been underestimated, 
in particular hypotension, and that a narrower range of physiological variables should be 
assigned a zero weighting. Seven chronic health comorbidities were found to be 
statistically useful, but not in elective postoperative patients, and are thus excluded from 
the calculation of the score for these patients.  
 
The result was a system with two major components, an APACHE III score and an 
APACHE III predictive equation. The APACHE III score can be used to provide initial 
risk stratification for severely ill patients within defined patient groups. The APACHE III 
predictive equation uses the APACHE III score and reference data on major disease 
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categories, plus the patient’s location before Intensive Care admission, to provide an 
individual risk estimate of hospital mortality for different Intensive Care patients. 
 
It is worth noting that, in an analysis by Woods et al
 26
 of 22 Scottish ICUs over a two year 
period, unit length of stay, predicted by APACHE III, did not correlate well with the actual 
length of stay. The length of stay in Scottish ICUs was consistently less than that predicted 
by a system based on American practice. Further, in a comparison of 5 intensive care 
scoring models using data from 22 general ICUs in Scotland, Livingston et al. concluded 
that the APACHE II score’s calibration made it the most suitable for comparison of 
mortality rates 
27
. It is worth noting, however, that new coefficients for the APACHE II 
score have been created for analysis of Scottish data, rather than those used in Knaus’s 
original paper. This is because standardised mortality ratios (SMRs) in Scottish Units have 
been falling, coupled with varying mortality prediction accuracy 
28
. The new coefficients 
have been used since November 2012, although the latest report from SICSAG shows 
SMRs based upon both the original and the recalibrated coefficients.
 
 
1.5.3.4. Simplified Acute Physiology Score (SAPS) 
Following APACHE other physiological based scores have emerged. Le Gall et al in 1984 
described the Simplified Acute Physiology Score (SAPS) 
29
. This utilises 14 clinical and 
biological variables in a simple score to classify patients into groups of increasing risk of 
death. It was evaluated in 679 consecutive patients admitted to 8 Intensive Care Units in 
France. The classification into groups of increasing risk of death was shown to hold, 
irrespective of diagnosis. The authors argued that it was less time consuming to calculate, 
given its simplicity, yet compared well to the more complex Acute Physiology Score.   
 
1.5.3.5. Simplified Acute Physiology Score II (SAPS II) 
In the early 1990s the number of scoring systems available to clinicians was growing. 
Increasing complexity meant a longer time and greater expenditure were required to collect 
data to input into the scores. There is merit in simplicity, and in 1993 Le Gall et al 
published their new Simplified Acute Physiology Score (SAPS II) 
30
. This European and 
North American study analysed data from 13152 patients. It comprises 17 variables, 12 of 
which are physiological. These are all readily available. The aim had been to have a purely 
physiologically based score leading to a prediction of hospital mortality which was 
independent of diagnosis. However, the authors found that the model performed more 
favourably if combined with 3 underlying disease variables (metastatic cancer, 
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haematological malignancy, AIDS), age, and type of admission. It is still true to say, 
however, that the SAPS II score is independent of the primary diagnosis.  
 
1.5.3.6. Mortality Probability Model (MPM) 
The Mortality Probability Model (MPM) was described by Lemeshow et al in 1985 
31
. 
Unlike SAPS or APACHE this was the first attempt at a score which was purely 
statistically derived. That is to say, the relative weights of variables were not subjectively 
determined. An analysis was undertaken of 755 general medical and surgical patients. 137 
variables were collected at admission, and 75 at 24 hours after admission. Using statistical 
techniques the relative importance of each variable was determined and only those with a 
strong association with outcome retained. This resulted in 7 variables collected at 
admission and 7 at 24 hours. Again, unlike APACHE and SAPS, this model could be 
applied at the time of admission. 
 
Although I have classed this as a physiologically based score there is a greater emphasis on 
condition-based variables than in APACHE e.g. the presence or absence of a cardiac 
arrhythmia. Further the physiological variables are recorded as affirmative or negative 
rather than as an actual number.  
 
Lemeshow published an updated form of the model, the MPM II in 1993 
32
. Using two 
much larger data sets, 19124 patients in total from multiple ICUs were analysed. This 
resulted in two models, MPM0 at admission MPM24 at 24 hours. Again, as in the MPM, the 
variables are recorded as simple yes or no answers. For example, in relation to blood 
pressure the model states “record whether the systolic blood pressure was noted to be less 
than or equal to 90mmHg within 1 hour before or after ICU admission”. MPM0 requires 
the collection of 15 and MPM24 a further 8 variables. Both models were shown to be good 
systems for reliably estimating hospital mortality. At that time MPM0 was, by definition, 
the only model for estimating hospital mortality which was independent of treatment. 
 
1.5.3.7. Physiological and Operative Severity Score for the enumeration of 
Mortality and Morbidity (POSSUM) 
Copeland et al published the Physiological and Operative Score for the enumeration of 
Mortality and Morbidity (POSSUM) in 1991
33
. It is different from the previous scores 
described, as it was designed to enable comparisons between general surgical patients 
having a wide variety of operations, by risk adjusting them based upon their physiological 
condition. In this score, 12 physiological parameters, shown by multivariate analysis (out 
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of an original 62) to independently predict outcome, are analysed, and graded into 
categories scoring 1, 2, 4 or 8 points depending upon their degree of derangement. These 
are combined to give a POSSUM physiology score. Six operative parameters are similarly 
graded. These include blood loss, the presence of peritoneal contamination and malignancy 
status. The physiology and operative severity scores are combined in the following formula 
to predict mortality risk (given by the letter R): 
 
Ln R/1-R = -7.04 + (0.13 x physiological score) + (0.16 x operative severity score). 
 
Prytherch et al in 1998 claimed that the POSSUM score over-predicts mortality, especially 
for patients with a low risk (5% or less) 
34
. They modified the original POSSUM logistic 
regression equation by analysing 10,000 general surgical cases between 1993 and 1995. 
2500 cases from the 10,000 were used to modify the equation and the new equation was 
tested on the remaining 7500. This formed the Portsmouth- POSSUM or P-POSSUM 
score. They showed that the new equation fits the observed in-hospital mortality better. 
The revised equation is: 
 
Ln R/1-R = -9.065 + (0.1692 x physiological score) + (0.1550 x operative severity score). 
 
 
1.5.4. Intervention based / Therapeutic weighted scores 
Intervention based (or therapeutic weighted) scores assume that critically ill patients 
require more medical and nursing intervention than those who are less unstable. That is to 
say, the amount of intervention is a surrogate for the severity of illness. The most widely 
known of this type of score is the Therapeutic Intervention Scoring System (TISS), devised 
by Cullen et al in 1974
 35
. Up to 76 different therapeutic activities score a certain number 
of points, e.g. central line insertion, the need for renal replacement therapy, number of 
vasoactive drugs etc. It therefore allows an assessment of cost as well as severity, but there 
were drawbacks to this type of score. It was time consuming and the 76 therapeutic items 
did not always reflect the amount of care the nursing staff would need to give an individual 
patient. Although it correlated reasonably well with severity of illness, its use for that 
purpose decreased with the advent of more specific systems such as APACHE
22
. It 
remained a useful tool for quantifying nurse workload and resource utilisation. Miranda et 
al revised the original TISS-76 in 1996. Using 10,000 random records of TISS-76 items 
from 903 consecutive ICU admissions, and through a process of multivariable regression 
analysis, they reduced the number of variables to 28. This is the simplified TISS or TISS-
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28 
36
. This system is widely used, and a study by Lefering et al in 2000 showed that, in an 
analysis of 1986 patients equating to 10,448 observation days, the TISS-28 adequately 
reflects the amount of critical care provided, and in the context of a surgical ICU, may also 
provide useful information about prognosis
37
. 
 
1.5.5. Assessment of organ failure scores 
1.5.5.1. Sequential Organ Failure Assessment (SOFA)  
By its nature, organ failure is common in the critically ill. It is not surprising that a group 
of scores have been developed specifically looking at organ failure and outcome. Vincent 
et al. published the Sequential Organ Failure Assessment (SOFA) score in 1996
38
. It was 
created during a consensus meeting of the European Society of Intensive Care Medicine in 
1994, and revised in 1996, with the aim of producing a simple and continuous (sequential) 
score that could be widely used. It looks at 6 organ systems (respiratory, cardiovascular, 
renal, hepatic, central nervous system, and coagulation). As would be expected, as the 
number of organs which have failed increases, so does the mortality. Both the highest and 
mean SOFA scores are good predictors of outcome. Unlike APACHE II it is calculated on 
the day of admission and subsequent days in ICU. Other advantages over APACHE II are 
that it takes into account the level of cardiovascular support (dobutamine, noradrenaline or 
adrenaline) that the patient is receiving.  
 
1.5.5.2. Multiple Organ Dysfunction Score (MODS)  
The Multiple Organ Dysfunction Score (MODS)
 39
 was published in 1995 during the 
refinement period of the SOFA score. It looks at the same 6 parameters as SOFA, the 
major difference being the method of cardiovascular assessment. MODS utilises the 
pressure-adjusted heart rate, defined as the heart rate multiplied by the ratio of right atrial 
pressure to mean arterial pressure. Given the similarity of the data collected, it is 
unsurprising that both give similar mortality predictions. However, in a study of 949 
patients by Bota et al. comparing the outcome prediction of the two scores, cardiovascular 
dysfunction was better related to outcome using the SOFA, rather than the MODS  
model 
40
. 
 
1.5.6. Miscellaneous scores 
For completeness, it is worth mentioning briefly several scores which do not fit neatly to 
the above classification, but nonetheless are of relevance to critical care. 
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Examples include the TRISS (Trauma Injury Severity Score) for severe trauma 
41
. This 
score combines a weighted Revised Trauma Score, Injury Severity Score, and a score for 
the patient’s age, and it also takes into account the mechanism of injury (blunt or 
penetrating trauma). The CURB-65 score is validated for predicting mortality in 
community acquired pneumonia 
42
. It makes an assessment of confusion, urea, respiratory 
rate, and blood pressure. The rate of death at 30 days increases with an increasing score. 
The rule of nines for the assessment of burn area is now several decades old but still in 
widespread use 
43
. The original Baux score 
44
 from 1961, (age plus percentage of burn), for 
predicting mortality after a burn, was not modified until 2010 by Osler et al.  The new 
revised Baux score now includes smoke inhalation as a contributing factor for mortality 
prediction 
45
. 
 
1.6. The need for a novel score 
As can be seen, numerous elaborate and sophisticated scoring systems exist. However, 
they all have drawbacks and limitations of varying degree. In general, the statistical 
analysis underpinning the variables selected, and the relative weights given, often come 
from studying large American databases of patients treated in the early 1980s. These may 
not be entirely applicable to a European population. Several scores e.g. APACHE II, give 
only a snapshot of what is occurring during the first 24 hours after admission, and take no 
account of how much the patient is being supported when interpreting the physiological 
data collected, e.g. scoring a “normal” blood pressure when the patient is receiving high 
doses of vasopressor or inotrope. All the scores described fall short of what would be 
regarded as the “ideal score”.  
 
1.6.1. The properties of the ideal scoring system 
In 1998 Saxon Ridley described an ideal scoring system 
46
 as one that is: 
- Validated (where its ability to predict mortality is tested on a different population 
from that used to create the score). 
- Calibrated (how closely the score’s mortality estimation correlates with actual 
mortality over the range of probabilities). 
- Accurate (its ability to discriminate between patients who will live and die). 
Interestingly, physicians are in general better at discriminating who will survive or 
not survive at the very ill / very well end of the spectrum. Scoring systems tend to 
perform better in the mid-range of mortality risk 
46
. 
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- Reliable (which relates to intra- and inter-observer agreement for e.g. in data 
collection. If there is wide variation in the choice of primary diagnosis, the system 
may be unreliable). 
- Has content validity (a measure of the comprehensiveness of the score). 
- Has methodological rigour (bias is avoided by basing the score on a large data base 
of consecutive patients).  
 
Other important properties of an ideal score would be that it: 
- Is based upon routinely collected data. 
- Takes into account treatment effect. 
- Can be calculated and displayed in real time. 
- Is repeatable an infinite number of times. 
- Is automated. 
- Is widely applicable. 
- Does not exclude patients groups e.g. patients less than 18 years, burns, pregnancy, 
readmissions to ICU. 
- Is possibly diagnosis independent. 
- Can be used as a research tool. 
- Predicts outcome. 
 
1.7. Applicability of previous scores to the work in this thesis 
In this thesis I describe the development of a novel quantitative and then qualitative score 
of cardiovascular instability in Intensive Care Patients. As well as setting the work of this 
thesis in context, the initial reason for reviewing the scoring systems was to establish 
which criteria were used and the weights attributed to the derivation of each variable in 
measuring the severity of critical illness. Some of the ranges used could then be 
incorporated into the novel quantitative score. The first scoring systems in general were 
used to predict or explain mortality, rather than cardiovascular stability. Although they are 
discussed in the introduction of the thesis, to start with, outcomes were a secondary 
consideration as the initial aim of the research was to devise a new score to capture 
instability.  Of particular interest was the physiological component of each score and 
whether it was validated for calculation once e.g. APACHE II, more frequently e.g. SOFA 
or if any scores summarising the physiological state of a patient came close to what this 
research was attempting to create i.e. a score that could be repeatedly calculated. In table  
1-2 the main scores reviewed are summarised along with their strengths, weaknesses and 
applicability to the novel quantitative score described in chapter 3 of this thesis. 
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Table 1-2: Applicability of previous scores to the work in the thesis 
 
Score Outcome  Strengths / 
weaknesses 
Helpful for my new 
score? 
APACHE II Mortality Calculated once in 24 
hours 
Burns excluded 
Readmissions 
excluded 
Age < 16 excluded 
Some ranges from the 
acute physiology score 
incorporated 
SAPS II Mortality Easier to calculate than 
APACHE II (less 
variables) 
Independent of 
primary diagnosis 
Ranges for heart rate 
and temperature useful 
as a guide. 
MPM Mortality Could be calculated at 
0 and 24 hours 
Interesting as 
statistically derived, 
but mainly condition-
based variables so of 
less use for a new 
score. 
POSSUM Mortality Allowed comparison 
between general 
surgical patients 
having a wide variety 
of operations. 
Useful guide to ranges 
for heart rate 
SOFA Morbidity 
(subsequently 
association with 
mortality) 
Characterises organ 
failure as a continuum 
rather than present or 
absent 
Useful guide to ranges 
for adrenaline / 
noradrenaline 
TISS / TRISS / 
CURB-65/ Rule of 
9s 
Various - Included for 
completeness 
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1.8. Introduction to machine learning in a healthcare setting 
The work in this thesis involved collaboration with computing science colleagues from 
Aberdeen University. During this time, large quantities of data were extracted from the 
Electronic Patient Records of Intensive Care patients at Glasgow Royal Infirmary, 
processed and analysed. This posed many challenges. However, with greater experience, 
the handling and processing of the data became more sophisticated. An introduction to this 
field of computing science is described below. 
 
Making computers more intelligent is the branch of computing science known as Artificial 
Intelligence 
47
. To become intelligent you have to learn and machine learning is the science 
of computational methods for inducing knowledge through a process of “accumulating, 
altering and updating knowledge within intelligent systems” 48. There has been an interest 
in modelling algorithms to analyse large datasets since the first primitive computers were 
introduced in the 1950s. Machine learning can be regarded as a development of Artificial 
Intelligence with the aim of pattern recognition within data and with the learned patterns 
performs meaningful inferences. Machine learning applications are therefore useful for 
pattern recognition, classification problems and in prediction 
49
. There are two main types 
of inference. “Classification” is where unseen data is analysed and a determination made as 
to which of a number of classes it belongs to. “Regression” is where unseen data are used 
in the prediction of behaviour in one or a series of random variables 
50
. The determination 
of physiological stability or instability is a form of “classification”. 
There are several major obstacles to be overcome for classification or regression inferences 
to be meaningful. Large amounts of data are often involved in these processes. The quality 
of the data is important e.g. inconsistency in the units used for recording a parameter, 
inconsistently recorded parameters and missing data. This can lead to some models being 
developed or conclusions being drawn which are not credible (or that are blindingly 
obvious to a clinician). A lot of sophisticated software for processing is required but it only 
works if it actually reflects the sophisticated manner in which data is actually interpreted 
by clinicians in real time. However, there is also a real need to actually avoid opinion (or 
biases) in the traditional sense of the word i.e. what is really needed is the ability to capture 
expertise as it is reliably applied in the clinical situation. 
 
1.9. Methodology for assessing validity 
The thesis describes the development of a quantitative and then qualitative score. There are 
many challenges in the validation of a novel score, particularly in the absence of a previous 
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gold standard. An overview of the major types of validity and how they may apply to 
developing a scoring system is therefore provided here.  
 
Validity derives from the Latin word validatis meaning strong. Of all types of validity, face 
validation (sometimes known as surface validity) is perhaps the easiest (but weakest) form 
to undertake. It examines whether a test covers subjectively what it is supposed to be 
measuring. For example if you set an examination for students in a subject and show the 
examination paper to a group of colleagues then they may agree that “on the face of it” the 
examination is a fair reflection of the subject matter to be covered. Face validation is often 
considered a minimum validation requirement 
51
. A novel rule based physiological scoring 
system designed to capture improvement or deterioration in a patient could be shown to 
expert colleagues and they may agree that on the surface that it adequately captures 
improvements or deteriorations. However, this approach has disadvantages. As a 
subjective method it is inherently weak. Just because other experts agree that on the 
surface a scoring system captures changes in the state of a patient, it does not mean that 
any of them are correct. Further, they could be influenced by the manner in which 
questions about a new score are put to them. Finally colleagues may not wish to contradict 
other colleagues’ work. 
 
Another non-statistical validity related to face validity is content validity. Here the issue is 
adequacy of sampling and it is therefore a measure of how much an “empirical 
measurement reflects a specific domain of content” 52 i.e. does the test represent all aspects 
of the construct being studied? Bachmann in 1990 summarised the difference between face 
and content delivery with “face validity is the appearance of real life (and) content 
relevance the representation of real life” 53. Content validity is used predominantly in 
devising educational tests and in psychology. It has to rely on experts who are familiar 
with the area in which the test is measuring. Typically to confirm content validity, experts 
would be shown the measurement tool and asked to provide feedback as to how well it 
measures the construct being considered 
52
. For a physiological score of instability experts 
would have to provide feedback that the parameters used in the score to capture instability 
was a fair representation of parameters that could cause instability. The major problem 
with content validity is that it still relies upon consensual professional judgement as to 
whether the test content adequately covers the domain in question 
54
. Further there are no 
agreed upon criterion for determining content validity. 
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Criterion Validity assesses the degree of correlation of a test with a gold standard 
51
(the 
best available test 
55
) and can be divided into concurrent and predictive validity. For a test 
to have concurrent validity it has to be simultaneously applied to a previously validated 
gold standard test for the phenomenon under investigation and the results compared. For 
the test to have predictive validity it has to predict an outcome from the phenomenon under 
consideration compared with a previously validated gold standard test applied in the same 
manner. Traditionally the degree of concurrent validity has been assessed by linear 
regression and correlation statistics. However Bland and Altman whilst conceding that the 
correct statistical test is not obvious, state that correlation measures “strength of a relation 
between two variables, not the agreement between them”. 56 They are of the opinion that 
the use of precision and bias statistics is more appropriate. However it does appear that 
linear regression and correlation coefficients are still commonly used tools. For example, 
in a recent study quantifying the concurrent validity of hamstring length measures the 
authors used a combination of linear regression, correlation and kappa statistics 
57
. In a test 
of a new scoring system of instability there is unfortunately no gold standard so criterion 
validity cannot be used. 
 
Construct validity of a test is established by demonstrating that the test or measurement 
tool “measures the variables or constructs that it proposes to identify or measure”. 58 In 
other words does the test measure what it claims to be measuring? This form of validity is 
useful when no universally criterion exists. Researchers have to identify other measures 
that would theoretically support the concept (or construct) being measured 
59
.Two subtypes 
of construct validity are convergent and discriminant validity. Convergent validity refers to 
the degree to which two measures that should be related are, whereas discriminant validity 
is a test of whether measures that theoretically should be unrelated are indeed unrelated. 
With a new scoring system of instability if two lines of physiological data are unrelated 
(because the scoring system judges them to be in different categories of stability) and a 
clinician agrees that there has been either improvement or deterioration then this could be 
argued to be a form of convergent validity. Similarly if two lines of physiological data are 
judged to be the same (because they place the patient at the same level of stability) and a 
clinician agrees that there has been no change then this is a form of convergent validity. 
 
The narrative above highlights that for a novel score of stability there is no one form of 
validation test that can be applied. To successfully validate a score in the absence of a 
previously validated gold standard would require a number of tests. Table 1-3 summarises 
the main types of validity and their applicability to a novel instability score. 
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Table 1-3: Types of validity and their applicability to a novel instability score 
Type of 
validity 
Pragmatic definition in 
relation to a novel 
instability score 
Can it be used 
to validate a 
new score of 
instability? 
Comments 
Face validity Score appears on the face of 
it to be a reasonable score of 
instability 
Yes Simple to do and useful. A 
weak form of validity as 
relies on expert opinion. They 
may all be incorrect.  
Content 
validity 
The score takes into account 
what most would regards 
are the key parameters of 
instability  
Yes Important to do but still relies 
upon professional consensual 
judgement. 
Criterion 
validity 
Score is correlated to a 
previously validated gold 
standard of instability 
No Cannot be done as there is no 
gold standard. 
Convergent 
validity 
When there is no change in 
level of instability in the 
score a clinician agrees 
Yes Useful in the absence of a 
gold standard. 
Discriminant 
validity 
When there is a change in 
the level of instability as 
judged by the score the 
clinician agrees 
Yes Useful in the absence of a 
gold standard. 
 
 
For completeness it is worth discussing reliability. Where validity is the extent to which a 
test or measurement actually measures what it is supposed to measure, reliability is the 
extent to which a test or measurement gives consistent results 
60
. An analogy is darts 
thrown at a dartboard. If all the darts hit the bull’s eye then there is high reliability and 
validity. If all the darts hit the bottom of the board there is high reliability but low validity. 
If there is a scatter of darts then there is low validity and low reliability. Theoretically if the 
relevant variables for the score have been collected, they have been collected correctly, the 
equipment recording the variables is in good working order and the data is processed 
properly then the score should be reliable (even if not fully validated). 
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1.10. Cardiovascular stability during renal replacement therapy 
1.10.1. Incidence of Acute Kidney Injury 
The incidence of acute kidney injury in Intensive Care in some studies approaches 70% 
61
. 
This figure is based on studies using the Risk, Injury, Failure, Loss and end-stage renal 
disease (RIFLE) criteria for acute kidney injury, defined by the Acute Dialysis Quality 
Initiative in 2004 
62
, and refined by the Acute Kidney Injury Network in 2007 
63
. Overall, 
12% of patients in Scottish Intensive Care, or combined Intensive Care and High 
Dependency Units, require some form of renal replacement therapy. The figure for 
Intensive Care units which do not have a high dependency component is slightly higher 
64
. 
 
1.10.2. Modalities of renal replacement therapy 
There are two principal modes of renal replacement therapy which are used in Intensive 
Care Units, viz. continuous haemofiltration, and intermittent haemodialysis. There are also 
various hybrid techniques. 
 
The process of haemofiltration was first introduced by Henderson in 1967 
65
. Continuous 
haemofiltration was described by Kramer in 1977 as a technique for the management of 
fluid overload, in patients who were unresponsive to diuretics in the Intensive Care Unit 
66
. 
During this process a positive hydrostatic pressure forces water and solutes across a semi-
permeable membrane. The solute is cleared by convection. A recent study revealed that 
continuous veno-venous haemofiltration remains the first line modality in 65% of Intensive 
Care Units in the UK 
67
. By contrast, the less frequently used haemodialysis has earlier 
roots. In 1948 Bywaters described the first haemodialysis in the UK for patients with acute 
kidney injury 
68
. Using counter current flow, solute diffuses down a concentration gradient 
through a semi-permeable membrane. 
 
1.10.3. Comparison of haemodialysis and haemofiltration 
Although there is no conclusive evidence that diffusive therapy (intermittent 
haemodialysis) is superior to convective therapy (continuous haemofiltration) in terms of 
outcome, haemodialysis does have some practical advantages. A study by  
Srisawat et al. showed that intermittent techniques were on average cheaper than 
continuous techniques 
69
. They took into consideration nursing costs, dialysate and fluid 
replacement costs, anticoagulant and extra-corporeal circuit costs. Other advantages 
include less time in which a patient’s blood is passing through a hazardous extra-corporeal 
circuit, less nursing input required and better and more rapid solute clearance. 
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1.10.4. Haemodynamic instability during intermittent haemodialysis 
Despite the apparent advantages of intermittent haemodialysis, continuous convective 
techniques remain the norm, perhaps because of the widely held notion that they offer 
greater haemodynamic stability, and that any technique which causes cardiovascular 
instability will lead to a worsening of other organ failures.  
 
The evidence to support this view-point is weak. In a widely quoted study from 1993, 
Davenport et al randomised 32 consecutive patients to receive intermittent machine 
haemofiltration, or a continuous technique, either arteriovenous haemofiltration or 
arteriovenous haemofiltration with dialysis
 70
. Measurements included cardiac index, mean 
arterial pressure, pulmonary artery occlusion pressure, and tissue oxygen delivery. His 
group reported a fall in all of these parameters, leading to their conclusion that continuous 
forms of renal replacement therapy are preferred due to increased cardiovascular 
tolerability. It is worth noting that they used arteriovenous haemofiltration or 
haemodiafiltration, as opposed to the venovenous modes used in current practice. The 
patient population was not typical, as the centre was a quaternary centre for liver 
transplant, all the patients in the study also having hepatic failure.   
 
A study by Vinsonneau, comparing continuous venovenous haemodiafiltration with 
intermittent haemodialysis in patients with multi-organ failure and acute renal failure 
published in 2006 
71
, showed no significant difference in arterial hypotension between the 
two groups. This was a well constructed, prospective, multicentre trial with 360 patients 
from 21 Intensive Care Units in France. Moreover, the definition of hypotension was wide, 
with either a drop of systolic arterial pressure of >50mmHg from the baseline value, or a 
systolic arterial pressure of <80mmHg.  
 
Most other studies in the literature in this area are of small scale, and are crossover in 
design. Further, they are of short duration, and have recruited small numbers of patients 
72
.  
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1.11. Myocardial infarction in Intensive Care 
1.11.1. Diagnostic difficulty 
The diagnosis of myocardial infarction in the Intensive Care Unit can be challenging. We 
are dealing, on the whole, with a population of patients who are sedated, intubated, and 
ventilated. Traditional symptoms such as chest pain, which may alert the clinician to the 
possibility of ischaemia, may not be apparent. Instead the clinician may have to rely on 
physiological disturbance, e.g. hypotension, hypoxia or cardiac arrhythmia, as an initial 
indicator of ischaemia 
73
. However, both of these strategies have their limitations. With the 
advent of more specific and sensitive markers of myocardial injury, e.g. troponin (a 
regulatory protein of the thin actin filament), it is possible to detect myocardial injury more 
easily in the absence of overt ischaemia.
74
 
 
In recent years there have been several consensus conferences to refine the diagnostic 
criteria for acute myocardial infarction. In 1999, the European Society of Cardiology and 
the American College of Cardiology recommended that cardiac troponins (I or T) are the 
preferred markers for the diagnosis of myocardial injury. They further added that 
detectable increases in biomarkers of cardiac injury were indicative of injury to the 
myocardium, but were not synonymous with an ischaemic mechanism, and, as such, could 
not mandate the diagnosis of myocardial infarction.
75
 In 2007 the recommendations of a 
further global taskforce were published 
76
. Myocardial infarction was classified into five 
clinical types. Type 2 is most relevant to intensive care, i.e. myocardial infarction 
secondary to ischaemia due to either increased oxygen demand or decreased supply, e.g. 
hypotension or arrhythmias. This would be more common than spontaneous myocardial 
infarction related to ischaemia due to a primary coronary event (type one). Specifically for 
Type 1 and 2 the term myocardial infarction should be used when there is evidence of 
myocardial necrosis in the context of a clinical setting consistent with myocardial 
ischaemia. In practice, this requires a rise in a cardiac biomarker (preferably troponin) with 
at least one value above the 99
th
 percentile of the upper reference limit, plus one out of - 
symptoms of ischaemia, ECG changes indicative of new ischaemia, the development of 
pathological Q waves, or imaging evidence which can take the form of new loss of viable 
myocardium, or new regional wall motion abnormality. 
 
In 2012, the Third Universal Definition of Myocardial Infarction was published 
77
. The 5 
types of myocardial infarction were refined with new imaging and ECG criteria added. The 
Taskforce behind the guidelines was careful to define these criteria in line with modern 
management of those suspected of having a myocardial infarction, with particular 
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emphasis on the clinical context, e.g. a myocardial supply / demand imbalance in the 
critically ill 
78
. In contrast, the observation of ECG changes, or abnormality on 
echocardiography, characterising a territorial myocardial infarction, is a rare occurrence in 
our clinical practice 
79
. 
 
1.11.2. Significance of myocardial injury in the critically ill 
There is a growing body of evidence that raised cardiac biomarkers are independent risk 
factors for in-hospital, short, and long term mortality, even after adjustment for severity of 
disease. Babuin et al demonstrated a 30 day mortality of 35% in patients with a rise in the 
cardiac biomarker troponin T of ≥ 0.01 micrograms/litre, and a mortality of 14% without 
elevation
 80
. In a study in 2008, Lim and colleagues systematically screened 103 
consecutive patients on admission to intensive care with troponin measurements and  
ECGs 
81
. These were repeated at serial intervals until death or discharge from Intensive 
Care, for a maximum of two months. The ECGs were screened for evidence of ischaemia 
as per the European Society of Cardiology and the American College of Cardiology 
guidelines for the purposes of diagnosing myocardial infarction. 35.9% had a myocardial 
infarction, 14.6% had an elevated troponin only, and 49.5% had no troponin rise. They 
showed that patients with an elevated troponin had a higher hospital mortality than those 
who had no rise. Of note was that screening detected a large proportion of myocardial 
infarctions not diagnosed clinically (62.2% ultimately diagnosed). Outcomes were similar 
in patients diagnosed with myocardial infarction clinically and in those patients where the 
infarction had been detected by screening alone. 
 
It has been shown that myocardial infarctions, and troponin rises per se, are far more 
common than previously imagined in intensive care patients. This evidence comes from 
systematic screening studies. In one recent prospective study, the authors demonstrated a 
troponin rise in 47% of a critically ill cohort 
82
. The incidence may be as high as 71 % 
depending upon the particular troponin used and the level selected to define myocardial 
damage 
83
. There is little evidence based guidance on the management of intensive care 
patients who have an isolated troponin rise, or even a myocardial infarction. Early 
diagnosis, e.g. from subtle physiological disturbance, and early intervention are likely, but 
have not yet been proven, to be important. 
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1.12. Aims of this research 
The initial premise of the quantitative (and later qualitative) scores was to capture 
cardiovascular instability in Intensive Care Patients in a more sophisticated manner than 
was possible before. The need for such scores arose from an initial interest in trying to 
establish whether haemodialysis was a cardiovascularly destabilising therapy.  As the work 
developed, there was an interest to ascertain, if having devised scores of instability, 
whether they could have wider applicability. This is where the research was expanded into 
prediction of myocardial events and some very preliminary work examining mortality 
outcomes. 
 
In this thesis I therefore describe: 
 
- A simple experiment to quantify cardiovascular instability during haemodialysis, and 
the need for a sophisticated scoring system. 
 
- The development of a quantitative score to capture cardiovascular instability in the 
critically ill. 
 
- The development and initial validation of a qualitative score to capture 
cardiovascular instability in the critically ill. 
 
- The wider applications of the qualitative score: Association and prediction of 
myocardial events and preliminary work on outcomes in the critically ill.  
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Chapter 2: Quantifying cardiovascular instability during intermittent 
haemodialysis and the need to design a sophisticated scoring system 
 
2.1. Abstract 
2.1.1. Background 
Acute renal failure requiring renal replacement therapy is common in critically ill patients. 
Haemofiltration is often favoured over haemodialysis as the method of renal replacement 
therapy, due to a belief that haemofiltration is less cardiovascularly unstable. There is little 
evidence in the literature to support this view. In a small proof-of-concept study, 
cardiovascular stability was characterised in a cohort of patients requiring haemodialysis in 
Glasgow Royal Infirmary Intensive Care Unit.  
 
2.1.2. Methods 
Physiological data were collected from the Electronic Patient Records of 10 critically ill 
patients undergoing a total of 23 dialysis sessions. The data were anonymised, pre-
processed and analysed. For the purposes of this experiment, cardiovascular instability was 
defined as a 20% change, in either direction, of heart rate or mean arterial pressure. In a 
second analysis, the dialysis sessions were examined to ascertain what percentage of mean 
arterial pressures stayed within an arbitrary “normal” range of 70-109, or moved around 
the range in different directions. 
 
2.1.3. Results 
Using the definition of a 20% change in heart rate or mean arterial pressure as representing 
cardiovascular instability, 65% of the sessions were stable and 35% unstable. Taking a 
normal mean arterial pressure as 70-109, 40% of mean arterial pressures changed from low 
to normal, 50% stayed within that range, and 10% changed from normal to high. 
 
2.1.4. Conclusions 
In this simple experiment there was a signal that haemodialysis was not a cardiovascularly 
unstable therapy. In fact, stability improved in a percentage of patients. The experiment did 
not take into account the amount of physiological or pharmacological support the patient 
was receiving to achieve the measured heart rate, or mean arterial pressure. This flaw is 
common to a lot of currently available scores. To overcome this problem, a new score 
would have to be developed. 
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2.2. Introduction 
Acute renal failure requiring renal replacement therapy occurs in approximately 12% of 
patients admitted to Scottish Intensive Care Units 
84
. Whereas renal units tend to use 
intermittent haemodialysis, critical care units more often use haemofiltration as the 
modality of renal replacement. This is due to a widely held belief that haemofiltration 
offers greater cardiovascular stability than haemodialysis, but with little evidence to 
support this view in the literature 
71
.  
 
The definition of what constitutes hypotension is controversial. For example some 
clinicians define it as an arbitrary 20% drop in blood pressure 
85
. In one of the most 
comprehensive multicentre prospective comparisons of haemofiltration and haemodialysis, 
Vinsonneau used a much broader definition of hypotension, namely a drop of systolic 
arterial pressure of >50mmHg from the baseline value, or a systolic arterial pressure of 
<80mmHg 
71
. As can be seen, the definition of cardiovascular stability is extremely 
challenging. Even in national clinical guidelines (Scottish Intercollegiate Guidelines 
Network - Postoperative management in adults) this expert group could not define ranges 
for cardiovascular stability either for heart rate or for other cardiovascular variables 
86
. 
 
The evidence to support haemodialysis being a cardiovascularly destabilising therapy is 
weak. In a widely quoted study from 1993, Davenport et al. randomised 32 consecutive 
patients to receive intermittent machine haemofiltration or a continuous technique, either 
arteriovenous haemofiltration or arteriovenous haemofiltration with dialysis 
70
. 
Measurements included cardiac index, mean arterial pressure, pulmonary artery occlusion 
pressure and tissue oxygen delivery. His group reported a fall in all these parameters 
leading to their conclusion that continuous forms of renal replacement therapy are 
preferred due to increased cardiovascular tolerability. It is worth noting that they used 
arteriovenous haemofiltration or haemodiafiltration, as opposed to the venovenous modes 
used in current practice. The patient population was not typical as the centre was a 
quaternary centre for liver transplant, all the patients in the study also having hepatic 
failure.  In the 2006 study by Vinsonneau mentioned above, comparing continuous 
venovenous haemodiafiltration with intermittent haemodialysis in patients with multi-
organ failure and acute renal failure, there was no significant difference in arterial 
hypotension between two groups 
71
. This was a well constructed prospective, multicentre 
trial with 360 patients from 21 Intensive Care Units in France. As above their definition of 
hypotension was wide. Most other studies in the literature in this area are of small scale 
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and are crossover in their design. Further they are of short duration and have recruited 
small numbers of patients 
72
. 
 
With the advent of the means to analyse and process large quantities of physiological data, 
I hypothesise that, on closer scrutiny of key cardiovascular parameters, it is possible to 
refute haemodialysis causing cardiovascular instability. 
 
2.3. Methods 
As a small proof-of-concept study, anonymised physiological data were collected from 10 
patients in Glasgow Royal Infirmary Intensive Care Unit undergoing 23 dialysis sessions 
among them, in total. The data contained predominantly hourly time points.  The Royal 
Infirmary ICU has dispensed with traditional paper based records and replaced them with 
an Electronic Patient Record, the Philips CareVue System 
87
. This system allows the 
collection and storage of vast quantities of readily accessible patient data. These are 
entered into the electronic system by the nurse at a terminal beside the patient’s bed and 
then verified, again by nursing staff. An example is shown in figure 2-1. Different 
physiological parameters or aspects of care can be accessed by clicking on the tabs in the 
far left column. In this example, the Renal Support tab has been clicked to reveal 
information about this patient’s renal replacement therapy. The red circle indicates blood 
pump speed on dialysis, which is the method used by the CareVue administrators to extract 
data about patients receiving haemodialysis from the CareVue system (described below). 
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Figure 2-1: A screenshot showing the renal replacement therapy tab as displayed 
in the CareVue system 
 
 
 
Data from the CareVue system is automatically manipulated by a programme within the 
system, and different aspects of the data are stored in relevant tables within the CareVue 
SQL database. SQL (Structured Query Language) is a programming language designed to 
manage data held within database management systems. These tables store data from all 
patients e.g. in Glasgow. Examples include an allergy table, an intervention table, and a 
treatment table. In other words, the allergy table within the SQL database holds 
information about many different patients’ allergies. It is these tables which are 
interrogated by the CareVue administrators to extract data of interest. Figure 2-2 shows a 
screenshot from the treatment table within the SQL database. The circle shows some of the 
different treatments, e.g. cardiac ECHO and endotracheal intubation. Note that several 
different patients are contained within this particular table. 
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Figure 2-2:  A screenshot from the treatment SQL database 
 
 
 
 
For this experiment, the CareVue administrators interrogated the CareVue SQL treatment 
table to look for instances where blood pump speed was recorded. This identifies when 
dialysis was occurring. Other tables were interrogated simultaneously to extract 
corresponding physiological parameters of interest, e.g. heart rate and mean arterial 
pressure. The queries were run using Microsoft Access software. Figure 2-3 shows an 
example of a query looking for blood pump speed (and by definition periods where 
haemodialysis is occurring). Note the number circled (47) in figure 2-2 is a unique 
identifying code for Glasgow Royal Infirmary, so that data for other patients held within 
the treatment database are not extracted. 
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Figure 2-3: A screenshot showing a query interrogating the treatment CareVue 
SQL database for blood pump speed 
 
 
 
Once the query was run, the data were exported into a Microsoft Excel spreadsheet. Figure 
2-4 gives an example of such a spreadsheet. As the query was for blood pump speed, time 
periods between dialysis sessions were not detected. These had to be detected manually by 
looking for breaks in the predominantly hourly time points in the far left hand column 
titled Date and Time. Examples of sessions are circled. The process is anonymised at this 
stage as data relating to a particular patient’s admission now receive a unique encounter 
identification, shown in the far right column of figure 2-4. These can if necessary be de-
anonymised by the CareVue administrators. 
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Figure 2-4: An example of the query data exported into a Microsoft Excel 
Spreadsheet 
 
 
 
Finally, the relevant physiological data corresponding to the blood pump speed data were 
extracted by a number of queries, and combined to make a final Excel spreadsheet for 
analysis by our collaborating computing scientist colleagues. An example of the final 
spreadsheet is shown in figure 2-5. Different physiological parameters can be accessed by 
clicking on the tabs at the bottom of the screenshot (circled). A proportion of data (ranging 
between 10 and 20%) is always cross checked with the live patient records to ensure the 
reliability and validity of the data extracted. 
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Figure 2-5: Final Excel spreadsheet prepared by the CareVue administrators for 
analysis by computing science colleagues 
 
 
 
The process of downloading the physiological and pharmacological information from 
CareVue by the administrators to get the “raw data” into basic Excel spreadsheets is 
described above A further example with a range of different parameters is shown in figure 
2-6. 
Figure 2-6: Final Excel spreadsheet with a range of parameters for analysis by 
computing science colleagues 
 
08/12/2006 18:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 18:00 Noradrenaline 24mg/240ml(mg/hr), 4.8 mg/hr 
08/12/2006 20:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 20:00 Noradrenaline 24mg/240ml(mg/hr), 4.8 mg/hr 
08/12/2006 21:00 Noradrenaline 24mg/240ml(mg/hr), 3 mg/hr 
08/12/2006 21:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 21:43 Alfentanil 25000mcg(mg/hr), 2500 1 mg/hr 
 
As can be seen the data in its raw state comprises lines of information in an Excel 
spreadsheet which were not ordered in a manner by which they could be interpreted. It was 
appreciated that when larger data sets were starting to be analysed that there would need to 
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be a mechanism to view and annotate the data in an intelligible way and be able to apply 
rules to extrapolate where data were parameters were missing at different time points. Our 
computing science colleagues devised a web based tool ACHE (an Architecture for 
Clinical Hypothesis Examination) 
88
 to deal with these specific problems. It has two main 
components. ACHE “annotate” which allows the raw data to be viewed in an ordered 
fashion within the excel spread sheets and ACHE “pre-process” allows for any 
extrapolation rules to be applied to the data at this point. This was essential, as with the 
number of data points in some of the spreadsheets manual pre-processing of this time 
series data would have been impossible. 
 
In this chapter where a small proof of concept study examining stability during dialysis is 
described, the only pre-processing which took place was a transformation of the raw data 
within the excel spread sheets. In this study the stability was assessed by examining two 
parameters, heart rate and mean arterial pressure. The average of these parameters was 
calculated before, during and after dialysis. A change of greater than 20% of baseline was 
the definition taken as representing “instability.” Therefore as averages were being 
calculated, missing time points were less important as the average would be calculated for 
the available number of time points. It is unusual for nursing staff not to record these key 
parameters 
 
Focusing on two key cardiovascular parameters, heart rate and blood pressure, I selected a 
change in these parameters of greater than 20% in either direction as representing 
cardiovascular instability. This was based on an accepted definition in the literature 
85
. I 
rejected the wider definition of Vinsonneau 
71
, as I felt that a narrower 20% is still of 
clinical significance. The dialysis sessions were then analysed in this manner using the 
ACHE architecture. I thought it important to examine the cardiovascular state of the patient 
before and after the session, as this could have a bearing on the stability during the dialysis. 
Therefore, the blood pressure and heart rate were examined for 3 hours before the dialysis 
was commenced, and 4 hours afterwards.  
 
Potential cardiovascular instability was also examined in a different manner. Selecting a 
“normal” mean arterial pressure in ICU of 70-109, the sessions were examined to ascertain 
what percentage of patients changed their mean arterial pressure within this range, from a 
low mean arterial pressure into the normal range, from a normal range to a low mean 
arterial pressure, from a normal range to a high mean arterial pressure, and from a high 
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mean arterial pressure into the normal range. This range was selected as it is one of the 
ranges from Knaus’s original APACHE II paper 21. 
 
Throughout the thesis, when a data set was analysed, all available time points were 
analysed with the exception in the later chapters of first 6 hours. This is because 
immediately after admission the patient is often unstable and nursing attention is focused 
more on admitting and stabilising the patient. Omissions in data entry were highest during 
this period. Otherwise when the scores were tested on data sets, every available time point 
was analysed. 
 
The frequency of data entry at Glasgow Royal Infirmary ICU is hourly. Occasionally there 
are additional time points in between. These are sometimes associated with a clinical event 
e.g. starting haemodialysis.  
 
To illustrate this, here is an example of a longer data set from patient 708 (one of the data 
sets on which the quantitative score described in chapter 3 was tested on). This patient was 
in Intensive Care for 3 days (19.45 on day one to 09.00 on day 3). 40 time points worth of 
data were recorded. These were all hourly except for the first one (19.45) and in day 2 
where an extra time point is recorded at 13.37.  
 
In other words, aberrant time points tended to be in addition to the hourly ones. It was 
unusual for there to be more than 2 extra time points in a 24 hour period i.e. no more than 
26. 
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2.4. Results 
Using a 20% change in mean arterial pressure or heart rate as a definition of instability, 
65% of dialysis sessions were stable and 35% unstable.  
 
Table 2-1 shows the percentage of changes in mean arterial pressure within an arbitrary 
normal range, from a low mean arterial pressure into the normal range, from a normal 
range to a low mean arterial pressure, from a normal range to a high mean arterial pressure 
and from a high mean arterial pressure into the normal range. 
 
Table 2-1: Change in mean arterial pressure around an arbitrary normal range 
  
 Change 
from low to 
normal 
mean 
arterial 
pressure 
Change 
within an 
arbitrary 
normal mean 
arterial 
pressure 
range 
Change from 
normal to 
low mean 
arterial 
pressure 
Change from 
normal to 
high mean 
arterial 
pressure 
Change from 
high to normal 
mean arterial 
pressure 
Percentage of 
significant 
changes in mean 
arterial pressure 
40 50 10 0 0 
 
 
2.5. Discussion 
The results of this small study suggest that haemodialysis is not a cardiovascularly unstable 
therapy. Specifically examining mean arterial pressure, most patients do not move out of 
what is regarded by many clinicians as a normal blood pressure. Further, it appears that 
mean arterial pressure may improve form low to normal in a significant proportion of 
cases. The mechanism may be due to removal of pro-inflammatory cytokines such as 
tumour necrosis factor- alpha, interleukin-1 beta and interleukin-6 
89
. The first dialysis 
session at the Royal Infirmary ICU is limited to 2 hours, and this is the session most often 
associated with instability. Risk factors which may contribute to this are patients who are 
already hypovolaemic, have valvular heart disease, poor left ventricular systolic function, 
patients greater than 65 years of age and patients with diabetic autonomic neuropathy.  
 
As described previously, many of the studies embracing the stability of continuous 
techniques have small numbers of patients, and are crossover in nature. It is difficult under 
these circumstances to standardise other factors which may have an effect on 
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cardiovascular stability. These include the dialysate buffer, calcium, temperature, patient 
position, and the degree of purity of the water used 
90, 91
.  
 
This small study had a number of weaknesses. Although it did appear that haemodialysis 
was not on the whole, a cardiovascularly unstable therapy, an arbitrary 20% change in 
heart rate or blood pressure is a very crude measure. It does not take into account the 
amount of physiological support the patient is receiving at the time. This might include 
inotropes, vasoconstrictors, or fluid boluses. On the other hand, when apparently unstable, 
the patient could be receiving a bolus of anaesthetic, or analgesic agent, or be undergoing 
ultrafiltration. None of these was standardised in this experiment. 
 
To investigate this clinical problem further and to improve on this simple experiment, I 
concluded that I would have to design a more comprehensive score which took into 
account the amount of physiological or pharmacological support the patient was receiving. 
This was the aim of the work described in the rest of this thesis.  
 
This work is being taken forward by another MD student who is planning a much larger 
study looking at both haemodialysis and haemofiltration and outcome. This modality is 
now possible at Glasgow Royal Infirmary ICU following a recent merger with a unit 
predominantly using this therapy. 
 
2.6. Conclusion 
From a simple experiment focusing on the measurement of two key cardiovascular 
parameters, there is a signal that it may not be an unstable therapy. This will need to be 
confirmed or refuted by repeating the experiment with a much larger number of data sets. 
Further, a scoring system which takes into account the amount of physiological support the 
patient is receiving at the time would have to be derived. 
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Chapter 3: Development of the Quantitative Score 
3.1. Abstract 
3.1.1. Background 
In a simple experiment to quantify cardiovascular stability, preliminary results suggested 
that haemodialysis is not as cardiovascularly unstable a therapy as previously imagined. 
However, the experiment did not take into account the amount of physiological or 
pharmacological support the patient was receiving. To answer this question properly, a 
quantitative score which took these factors into account would have to be developed. 
 
3.1.2. Methods 
Physiological parameters were separated into those recorded at regular intervals and those 
recorded intermittently. After an extensive literature search, ranges were defined for each 
parameter, the more points being scored, the greater the derangement. Two parameters 
(mean arterial pressure and oxygen saturation) were then weighted against a range of 
pharmacological and physiological variables. 
 
3.1.3. Results 
Adding the weighted score for mean arterial pressure and oxygen saturation to the other 
physiological parameters recorded at regular intervals gives an overall score of 
cardiovascular instability. This is therefore weighted and influenced by the amount of 
pharmacological and physiological support the patients is receiving. The score was run in 
some hypothetical clinical scenarios, resulting in some of the weightings being altered to 
reflect clinical experience more closely. The outcome was the final quantitative score. 
 
3.1.4. Conclusion 
I had developed a novel quantitative score summarising the cardiovascular state of a 
patient. Unlike many currently available scoring systems, it takes into account the amount 
of pharmacological and physiological support the patient is receiving. 
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3.2. Introduction 
3.2.1. Need for a quantitative score 
As illustrated by the attempt to answer the question of whether haemodialysis is a 
cardiovascularly unstable therapy, I had concluded that I would have to design a new 
quantitative scoring system for cardiovascular instability. This was because, on reviewing 
the literature, one of the major problems of currently available scores is that they do not 
take into account, or only partially take into account, the level of physiological support the 
patient is receiving. For example, in a particular score a patient could have a “normal” 
blood pressure, but simultaneously be receiving large quantities of inotropes, 
vasoconstrictors and fluid boluses to maintain this apparent normality. The score would not 
therefore adequately quantify the severity of the underlying physiological disturbance. By 
taking into account the amount of pharmacological or other support the patient was 
receiving to maintain a range of physiological parameters at a particular level, the 
quantitative score was the first attempt to overcome the shortcomings of currently available 
scores. 
 
3.3. Methods  
3.3.1. Division of the parameters into ranges and their basic unweighted 
score 
In the construct of a new model, Ridley states that it should “be based on a small number 
of explanatory variables that are routinely collected.” 92. On review of the electronic patient 
record, CareVue, the parameters regularly displayed at the bedside and (reliably) recorded 
were oxygen saturation, inspired oxygen concentration, heart rate, mean arterial pressure, 
propofol and alfentanil sedation, fluid administration, temperature, urine output and 
inotrope doses. Further, many of these parameters are those which form the physiological 
components of currently available scores e.g. the acute physiology score in APACHE II, 
multiple organ dysfunction score and SAPS II.  
I therefore separated the parameters in my quantitative score into key ones which are 
recorded at regular intervals (above), and those recorded only intermittently in the 
Intensive Care Unit. The parameters only intermittently recorded are central venous 
pressure, cardiac output, cardiac index, stroke volume, stroke volume variance, systemic 
vascular resistance, systemic vascular resistance index and oxygen delivery. 
Along the X-axis I divided each parameter into 3 broad ranges i.e. low abnormal range, 
normal, and high abnormal range. If appropriate, the low abnormal range and the high 
abnormal range were divided into 3 further subdivisions scoring +1, +2 and +3 points 
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respectively, if increasingly abnormal in the high range or increasingly abnormal in the low 
range. The normal range scored 0. Obviously, the ranges are subjective, but I undertook an 
extensive literature search to review other scores and the physiological limitations in an 
adult to inform my decisions about the upper and lower limits for each range in the score.  
This is represented in Table 3-1. 
 
Table 3-1: Divisions of ranges 
Low Abnormal Range Normal High Abnormal Range 
Subdivision Subdivision Subdivision  Subdivision Subdivision Subdivision 
+3 Points +2 Points +1 Point 0 Points + 1 Point + 2 Points + 3 Points 
 
 
3.3.2. Derivation of the ranges for the parameters recorded at regular 
intervals 
I shall now describe the justification for the ranges for each parameter, dealing first with 
the parameters recorded at regular intervals (Tables 3-2 to 3-6). Where there is an 
explanation for the range, then it was based on ranges used in a previous score or is a 
standard physiological fact. Otherwise the ranges represent opinion based on my clinical 
experience. To avoid confusing numerical reference numbers with ranges in the score, the 
references in the table are designated a letter, explained in the narrative below each table 
and at that point given a corresponding numerical designator. All references can be viewed 
at the end of the thesis. 
 
Table 3-2:  Mean arterial pressure (mmHg) 
Low Abnormal Range Normal High Abnormal Range 
<40 
 
40-49 
 
50-69 
(A) 
70-109 
(A) 
110-129 
(A) 
130-159 
(A) 
160 
(A) 
+3 +2 +1 0 +1 +2 +3 
 
Low Abnormal Range  
+1 Range is as per APACHE II score (A) 
21 
Normal Range 
Range is as per APACHE II score (A) 
21
 
High Abnormal Range 
+1  Range is as per APACHE II score (A) 
21 
+2 Range is as per APACHE II score (A) 
21 
+3 Range is as per APACHE II score (A) 
21
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Table 3-3: Heart Rate (Beats per minute) 
Low Abnormal Range Normal High Abnormal Range 
≤ 35 
 
36-39 
(C) 
40-49 
(B) 
50-59 
91-140 
(D) 
141-179 
(E) 
 180 
(F) 
+3 +2 +1 0 +1 +2 +3 
 
Low Abnormal Range 
+1 Heart rate of less than 50 is generally regarded as the lower limit of a sinus 
bradycardia (B) 
93
 
+2 Heart rate of 39 is generally regarded as the “normal” upper limit of escape rhythm 
in complete heart block (C) 
94
 
High Abnormal Range 
+1 Heart rate >90 is one of the 4 SIRS criteria (D)
 95
  
+2 Heart rate>140 is the point where ventricular filling in early diastole becomes 
compromised (E) 
96
 
+3 Heart rate of 180 is approximately the maximum ventricular rate in man (F) 
97
 
 
 
Table 3-4: Oxygen Saturation, SpO2 (%) 
Low Abnormal Range Normal High Abnormal Range 
<75 
(I) 
75-89 
(H) 
90-94 
(G) 
95-100 
 
N/A N/A N/A 
+3 +2 +1 0 - - - 
 
Low Abnormal Range 
+1 SpO2 of 95% is regarded as the lower limit of normal in health (also, the definition 
of hypoxaemia is a PaO2 of <80mmHg – approximately an SpO2 of 95% while 
breathing air) (G) 
98
 
+2 SpO2 below 90% (PaO2 of 60mmHg) is the definition of respiratory failure (H) 
99
. 
+3 SpO2 of 75% is the mixed venous oxygen saturation (I) 
100
 
High Abnormal Range 
There is no score, as saturations above 100% are physiologically impossible 
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Table 3-5: Urine Output (mls/h) 
Low Abnormal Range Normal High Abnormal Range 
<2 
(J) 
2-19 
(J) 
20-35 
 
>35 
 
N/A N/A N/A 
+3 +2 +1 0 - - - 
 
Low Abnormal Range 
+2 Oliguria is usually described as a urine output <20mls/h (J) 
101
 
+3 Anuria is usually described as a urine output of <50mls/day (approximately 2mls/h) 
(J) 
101
 
 
 
Table 3-6: Temperature (ºC) 
 
Low Abnormal Range Normal High Abnormal Range 
<32 
(L) 
32-35 
(K) 
35-36 
(D) 
36-38 
 
>38-40 
(D)(L) 
>40-42.1 
(K) 
>42.1 
(L) 
+3 +2 +1 0 +1 +2 +3 
 
Low Abnormal Range 
+1 Temperature <36(ºC) is one of the 4 SIRS criteria (D) 
95
 
+2 Temperature <35(ºC) is the definition of hypothermia (K) 
102
 
+3 Temperature <32(ºC) is the definition of moderate hypothermia (K) 
102
 
High Abnormal Range 
+1 Temperature >38(ºC) is one of the 4 SIRS criteria (D) 
95
 (with standard definition 
of a fever being a temperature >38.3(ºC) (L) 
103
. 
+2 Temperature >40(ºC) is the definition of hyperpyrexia (K) 
102
. 
+3 Temperature >42.1(ºC) is the temperature at which cell damage may occur  
(L) 
103
. 
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3.3.3. Final unweighted score for the parameters recorded at regular 
intervals  
The final unweighted score for the parameters recorded at regular intervals is shown in 
table 3-7. 
 
Table 3-7: Final unweighted score for the parameters recorded at regular   
intervals 
 
Mean arterial pressure (mmHg) 
Low Abnormal Range Normal High Abnormal Range 
<40 40-49 50-69 70-109 110-129 130-159 160 
+3 +2 +1 0 +1 +2 +3 
 
Heart rate (beats per minute) 
Low Abnormal Range Normal High Abnormal Range 
≤ 35 36-39 40-49 50-90 91-140 141-179 180 
+3 +3 +1 0 +1 +1 +3 
 
Oxygen Saturation, SpO2 (%) 
Low Abnormal Range Normal High Abnormal Range 
<75 75-89 90-94 95-100 N/A N/A N/A 
+3 +2 +1 0 - - - 
 
Urine Output (mls/h) 
Low Abnormal Range Normal High Abnormal Range 
<2 2-19 20-35 >35 N/A N/A N/A 
+3 +2 +1 0 - - - 
 
Temperature (ºC) 
Low Abnormal Range Normal High Abnormal Range 
<32 32-35 35-36 36-38 >38-40 >40-42.1 >42.1 
+3 +2 +1 0 +1 +2 +3 
 
To calculate the score, the value assigned to each of the 5 key parameters is summed 
to give the final score. By way of illustration, a patient with a mean arterial blood 
pressure of 55, a heart rate of 145, a normal oxygen saturation, a urine output of 
18mls/h and a normal temperature would score 4 points in the score developed thus 
far. 
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3.3.4. Derivation of the ranges of parameters recorded intermittently 
Similar methodology for deriving ranges for the parameters recorded at regular intervals, 
was applied to those recorded only intermittently (tables 3-8 to 3-15) 
 
Table 3-8: Central Venous Pressure, CVP (cmH2O) 
Low Abnormal Range Normal High Abnormal Range 
- - 0-2 3-10 11-18 19-24 >24 
N/A N/A +1 0 +1 +2 +3 
 
For this parameter, all the points were judgements based on my clinical experience. 
 
 
Table 3-9: Cardiac Output, CO (l/min) 
Low Abnormal Range Normal High Abnormal Range 
<2.5 2.5-3.4 3.5-4.9 
5-6 
(I) 
6.1-15 15.1-29.9 
30 
(M) 
+3 +3 +1 0 +1 +2 +3 
 
Low Abnormal Range 
+2 3.5l/min chosen as it would be the cardiac output generated with a heart rate of 50 
(lowest generally accepted for a sinus bradycardia) and a stroke volume of 70mls. 
Normal Range 
 5-6l/min is the normal cardiac output in a 70kg man (I) 
100
 
High Abnormal Range 
+3 30l/min is the maximum cardiac output which can be achieved in a healthy adult 
under conditions of extreme exercise (M) 
104
 
 
 
Table 3-10: Cardiac Index, CI (l/min/m2) 
Low Abnormal Range Normal High Abnormal Range 
<1.5 
 
1.5-2.0 
 
2.1-2.9 
 
3-3.5 
(I) 
3.6-8.8 8.9-16.9 17 
+3 +2 +1 0 +1 +2 +3 
 
Ranges were derived from those given for cardiac output, taking 1.7 m
2
 as body 
surface area, e.g. 3-3.5 l/min/m
2
 would be a normal cardiac output using this figure. 
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Table 3-11: Stroke Volume, SV (mls) 
Low Abnormal Range Normal High Abnormal Range 
<40 
40-54 
 
55-69 
 
70-80 
(I) 
81-90 91-100 
>100 
(I) 
+3 +2 +1 0 +1 +2 +3 
 
Normal Range 
 70-80 mls is regarded as a normal stroke volume in a 70kg man (I) 
100
 
High Abnormal Range 
+3 Value of 100mls chosen as, under normal circumstances, this is at the start of the 
plateau of the Frank-Starling curve (I) 
100
 
 
 
Table 3-12: Stroke Volume Variance, SVV (%) 
Low Abnormal Range Normal High Abnormal Range 
- - - 
<10 
(N) 
10-13 13-18 18 
N/A N/A N/A 0 +1 +2 +3 
 
The values chosen were clinical except for normal value of <10% where patients are 
unlikely to be preload responsive (N) 
105
 
 
 
Table 3-13: Systemic Vascular Resistance, SVR (dynes x s/cm5) 
Low Abnormal Range Normal High Abnormal Range 
<450 
(O) 
451-700 
 
701-899 
 
900-1400 
 
1401-1600 
 
1601-1800 
 
>1800 
 
+3 +2 +1 0 +1 +2 +3 
 
Low Abnormal Range 
+3 Value of 450dynes.s/cm5 chosen, as it has been shown that below this level 
mortality is much greater, irrespective of aetiology (O) 
106
.  
 
 
Table 3-14: Systemic Vascular Resistance Index, SVRI (dynes × s/cm5/m2) 
 
Low Abnormal Range Normal High Abnormal Range 
<765 765-1189 1190-1529 1530-2380 2381-2720 2721-3060 >3060 
+3 +2 +1 0 +1 +2 +3 
 
These values were derived from Systemic Vascular Resistance (SVR) using 
1.7 m
2
 as the value for body surface area when calculating cardiac index 
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Table 3-15: Oxygen Delivery, DO2 (mls/min) 
Low Abnormal Range Normal High Abnormal Range 
<300 300-699 700-999 1000-1200 1201-3000 3001-5980 >5980 
+3 +2 +1 0 +1 +2 +3 
 
These figures were derived from those given for Cardiac Output assuming the 
oxygen content of arterial blood to be 20mls/100mls 
 
 
3.3.5. Final unweighted score for the parameters recorded intermittently 
The final unweighted score for those parameters recorded intermittently is recorded in 
table 3-16. 
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Table 3-16: Final unweighted score for the parameters recorded intermittently 
Central Venous Pressure, CVP (cmH2O) 
Low Abnormal Range Normal High Abnormal Range 
- - 0-2  11-18 19-24 >24 
N/A N/A +1 0 +1 +2 +3 
 
Cardiac Output, CO (l/min) 
Low Abnormal Range Normal High Abnormal Range 
<2.5 2.5-3.4 3.5-4.9 5-6 6.1-15 15.1-29.9 30 
+3 +3 +1 0 +1 +2 +3 
 
Cardiac Index, CI (l/min/m2)  
Low Abnormal Range Normal High Abnormal Range 
<1.5 1.5-2.0 2.1-2.9 3-3.5 3.6-8.8 8.9-16.9 17 
+3  +2 +1 0 +1 +2 +3 
 
Stroke Volume, SV (mls)  
Low Abnormal Range Normal High Abnormal Range 
<40 40-54 55-69 70-80 81-90 91-100 >100 
+3 +2 +1 0 +1 +2 +3 
 
Stroke Volume Variance, SVV (%) 
Low Abnormal Range Normal High Abnormal Range 
- - - <10 10-13 13-18 18 
N/A N/A N/A 0 +1 +2 +3 
 
Systemic Vascular Resistance, SVR (dynes x s/cm5) 
Low Abnormal Range Normal High Abnormal Range 
<450 451-700 701-899 900-1400 1401-1600 1601-1800 >1800 
+3 +2 +1 0 +1 +2 +3 
 
Systemic Vascular Resistance Index, SVRI (dynes × s/cm5/m2) 
Low Abnormal Range Normal High Abnormal Range 
<765 765-1189 1190-1529 1530-2380 2381-2720 2721-3060 >3060 
+3 +2 +1 0 +1 +2 +3 
 
Oxygen Delivery, DO2 (mls/min) 
Low Abnormal Range Normal High Abnormal Range 
<300 300-699 700-999 1000-1200 1201-3000 3001-5980 >5980 
+3 +2 +1 0 +1 +2 +3 
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3.3.6. Adjustment of the ranges of parameters to take into account the level 
of physiological or pharmacological support 
In the next stage of development, I selected the two physiological parameters which I felt 
were not adequately captured by existing scores as they can be substantially affected by 
other physiological processes, or the degree of pharmacological support. These are mean 
arterial pressure and oxygen saturation. Table 3-17 shows the main factors which can be 
affected by other parameters. 
 
Table 3-17: Factors that can either positively or negatively change mean 
arterial pressure or oxygen saturation 
 
Parameter Mean Arterial Pressure Oxygen Saturation 
Factors negatively (-ve) or 
positively (+ve) affecting the 
parameter 
Adrenaline (+ve) 
Noradrenaline (+ve) 
Fluid Input (+ve) 
Propofol (-ve) 
Alfentanil (-ve) 
Inspired Oxygen Fraction (+ve) 
Positive End Expiratory Pressure 
(+ve) 
Continuous Positive Airway Pressure 
(+ve) 
 
For each factor I gave points based on my clinical judgement on how much that 
factor, at a particular level, would affect either the mean arterial pressure or the oxygen 
saturation (tables 3-18 and 3-19). The ranges for the drug doses in two instances were 
based on maximum recommended amounts of the drug, or doses used in previous research. 
Specifically 0.5mcg/kg/min of adrenaline or noradrenaline (2.1mg/h in a 70kg man) is the 
upper limit quoted for cardiovascular support in the critically ill (P) 
107
. 4mls/kg/hour of 
propofol (or 280mg/h in a 70kg man) is the maximum rate recommended for sedation in 
ICU in the British National Formulary (Q) 
108
. 
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Table 3-18: Weighting of the various factors on Mean Arterial Pressure 
 
 Low Abnormal Range Normal High Abnormal Range 
Mean Arterial Pressure (MAP) 
(mmHg) 
<40 40-49 50-69 70-109 110-129 130-159 ≥160 
Unweighted 
Score 
 3 2 1 0 1 2 3 
Adrenaline 
(mg/h) 
<0.2 0 0 0 0 0 0 0 
0.2-1.0 4 3 2 1 1 1 1 
1.1-2.0 5 4 3 2 2 2 2 
>2.0  
(P) 
6 5 4 3 3 3 3 
Noradrenaline 
(mg/h) 
<0.1 0 0 0 0 0 0 0 
0.1-1.0 4 3 2 1 1 1 1 
1.1-2.1 5 4 3 2 2 2 2 
>2.1  
(P) 
6 5 4 3 3 3 3 
Fluid Input 
(mls/h) 
0-125 0 0 0 0 0 0 0 
126-250 4 3 2 1 1 1 1 
251-500 5 4 3 2 2 2 2 
>500 6 5 4 3 3 3 3 
Propofol 
(mg/h) 
<10 0 0 0 0 0 0 0 
10-100 -1 -1 -1 -1 -2 -3 -4 
110-280 -2 -2 -2 -2 -3 -4 -5 
>280  
(Q) 
-3 -3 -3 -3 -4 -5 -6 
Alfentanil 
(mg/h) 
<0.5 0 0 0 0 0 0 0 
0.5-2.5 -1 -1 -1 -1 -2 -3 -4 
3-4 -2 -2 -2 -2 -3 -4 -4 
>4 -3 -3 -3 -3 -4 -5 -6 
 
Table 3-19: Weighting of the various factors on Oxygen Saturation 
 
 
Oxygen Saturation (Sp02) 
(%) 
<75 75-89 90-94 95-100 - - - 
Unweighted 
Score 
Air 3 2 1 0 - - - 
Inspired 
Oxygen 
Fraction 
(FiO2) 
 
0.22-0.49 4 3 2 1 - - - 
0.5-0.79 5 4 3 2 - - - 
≥0.80 6 5 4 3 - - - 
PEEP / CPAP 
(cmH20) 
0-5 0 0 0 0 - - - 
6-8 4 3 2 1 - - - 
9-11 5 4 3 2 - - - 
≥12 6 5 4 3 - - - 
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3.4. Results 
3.4.1. First version of completed quantitative score 
The parameters continuously recorded (with some now weighted to take into account the 
level of physiological or pharmacological support) were combined to produce the first 
version of the completed quantitative score of cardiovascular instability as shown in figure 
3-1. 
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Figure 3-1: First version of completed quantitative score 
Parameters recorded at regular intervals 
Low Abnormal Range Normal High Abnormal Range 
 
 Mean Arterial Pressure (MAP) 
(mmHg) 
<40 40-49 50-69 70-109 110-129 130-159 ≥160 
Unweighted 
Score 
 3 2 1 0 1 2 3 
Adrenaline 
(mg/h) 
<0.2 0 0 0 0 0 0 0 
0.2-1.0 4 3 2 1 1 1 1 
1.1-2.0 5 4 3 2 2 2 2 
>2.0  6 5 4 3 3 3 3 
Noradrenaline 
(mg/h) 
<0.1 0 0 0 0 0 0 0 
0.1-1.0 4 3 2 1 1 1 1 
1.1-2.1 5 4 3 2 2 2 2 
>2.1  6 5 4 3 3 3 3 
Fluid Input 
(mls/h) 
0-125 0 0 0 0 0 0 0 
126-250 4 3 2 1 1 1 1 
251-500 5 4 3 2 2 2 2 
>500 6 5 4 3 3 3 3 
Propofol 
(mg/h) 
<10 0 0 0 0 0 0 0 
10-100 -1 -1 -1 -1 -2 -3 -4 
110-280 -2 -2 -2 -2 -3 -4 -5 
>280  -3 -3 -3 -3 -4 -5 -6 
Alfentanil 
(mg/h) 
<0.5 0 0 0 0 0 0 0 
0.5-2.5 -1 -1 -1 -1 -2 -3 -4 
3-4 -2 -2 -2 -2 -3 -4 -4 
>4 -3 -3 -3 -3 -4 -5 -6 
 
Heart Rate (HR) 
(Beats/min) 
<35 35-39 40-49 60-90 91-140 141-179 ≥160 
 
 
Oxygen Saturation (Sp02) 
(%) 
<75 75-89 90-94 95-100 - - - 
Unweighted 
Score 
Air 3 2 1 0 - - - 
Inspired 
Oxygen 
Fraction 
(FiO2) 
 
0.22-0.49 4 3 2 1 - - - 
0.5-0.79 5 4 3 2 - - - 
≥0.80 6 5 4 3 - - - 
PEEP / CPAP 
(cmH20) 
0-5 0 0 0 0 - - - 
6-8 4 3 2 1 - - - 
9-11 5 4 3 2 - - - 
≥12 6 5 4 3 - - - 
 
Urine Output 
(mls/h) 
<2 2-19 20-35 >35 - - - 
 
Temperature 
(ºC) 
<32 32-35 35.1-35.9 36-38 38.1-40 40.1-42.1 >42.1 
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Parameters Intermittently Recorded 
Low Abnormal Range Normal High Abnormal Range 
 
Score 3 2 1 0 1 2 3 
Central Venous Pressure 
(CVP) (cmH20) 
<-6 -5 to -3 0-2 2-10 11-18 19-24 >24 
Cardiac Output (CO) 
(l/min) 
<2.5 2.5-3.4 3.5-4.9 
5-6 
 
6.1-15 15.1-29.9 ≥30 
Cardiac Index (CI) 
(l/min/m2) 
<1.5 1.5-2.0 2.1-2.9 
3-3.5 
 
3.1-8.8 8.9-16.9 ≥17 
Stroke volume (SV) 
(mls)  
<40 40-54 55-69 
70-80 
 
81-90 91-100 >100 
Stroke Volume Variance 
(%) 
- - - 
<10 
 
10-13 13-18 18 
Systemic Vascular 
Resistance (SVR) 
(dynes × s/cm5) 
<450 
 
451-700 701-899 900-1400 
1401-
1600 
1601-
1800 
>1800 
Systemic Vascular 
Resistance Index (SVRI) 
(dynes × s/cm5/m2) 
<765 765-1189 
1190-
1529 
1530-
2380 
2381-
2720 
2721-
3060 
>3060 
Oxygen Delivery (D02) 
(mls/min) 
<300 300-699 700-999 
1000-
1200 
1201-
3000 
3001-
5980 
>5980 
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3.4.2. An example of calculating a score 
To give an example of how the final score works, the first points comprise the parameters 
recorded at regular intervals.  
- Take the unweighted score of mean arterial pressure and add or subtract points 
depending on the amount of adrenaline, noradrenaline, fluid, propofol or alfentanil 
the patient is receiving.  
- Add the score for heart rate.  
- Add the score for oxygen saturation, ALREADY weighted by points for level of 
inspired oxygen concentration, to the weighting for the amount of PEEP or CPAP. 
- Add the score for temperature. 
- Add the score for urine output. 
 
This gives a total score of -3 to 48 for parameters recorded at regular intervals. It may be 
the case that this is all that is being recorded in the patient, in which case the score 
terminates here. If any of the parameters recorded intermittently are present, they can then 
be added to this score but, for the score to be reliable over time, they have to be present 
each time the score is recalculated. An example is shown in table 3-20. 
 
Table 3-20: An example of calculating a patient’s score 
Parameter Value Score 
Unweighted Mean Arterial Pressure 53 +1 
Adrenaline dose (When MAP 53) 1.8mg/h +3 
Noradrenaline dose (When MAP 53) 1.0mg/h +2 
Fluid rate (When MAP 53) 250mls/h +2 
Propofol dose (When MAP 53) 130mg/h -2 
Alfentanil dose 3mg/h -2 
Heart Rate 130 beats/min +1 
Oxygen Saturation already weighted by 
inspired oxygen concentration 
83% Saturated with FiO2 of 0.9 +5 
Oxygen Saturation weighted by amount of 
PEEP/ CPAP 
83% Saturated with PEEP of 12 +5 
Urine Output 8mls/hour +2 
Temperature 39.3 (ºC) +1 
 
The total score for this patient at that moment is this sum of all of the above scores and, is 
18. 
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3.4.3. Clinical reflection and alteration of parameters 
Some adjustments were made to the first version of the completed score to produce a final 
version, for the following reasons. I ran various virtual clinical scenarios to ascertain if the 
new score gave clinically credible results. By using this approach, now with the means to 
utilise the score as a whole, it emerged that some parameters needed to make a greater or 
lesser contribution to the score. 
 
For example, patients with a mean arterial pressure of 41, with no inotropic or 
vasoconstrictor support, would score 2 points. Further, if their urine output was  
19 mls/hour they would also score two points. In a score capturing cardiovascular 
instability, borderline urine output, while noteworthy and requiring action, is not as acutely 
important or potentially as dangerous. Therefore I changed the unweighted score of mean 
arterial pressure to give more importance to extreme hypotension.  
 
Similarly, if patients were hypertensive, yet receiving adrenaline, noradrenaline or large 
volumes of fluid, they would gain points. This is an unlikely clinical scenario and could 
possibly represent excessive dosing, or patient recovery. To represent this in the score, I 
now deducted points if hypertensive whilst simultaneously receiving adrenaline or 
noradrenaline, and made the score point neutral if hypertensive and being administered 
large amounts of fluid. 
 
Until this point, if patients were hypertensive despite large doses of propofol or alfentanil, 
then they had points deducted. Again, after reflection, it was more clinically credible to 
gain points, since to be hypertensive despite, e.g., the vasodilating effect of propofol in 
large amounts, then this represents marked cardiovascular instability. I also took the 
opportunity to decrease the number of dosing bands of alfentanil from four to three, as I 
felt that, clinically, alfentanil induces less cardiovascular instability than propofol. 
 
Finally, and for similar reasons to the unweighted mean arterial pressure scores being 
changed, I also changed the heart rate scores to reflect the importance of extreme 
bradycardia and tachycardia. 
 
These changes are highlighted in table 21. Changes from the previous version are marked 
in bold. Note that no changes were made to parameters collected only intermittently.  
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Table 3-21: Changes to the scores for mean arterial pressure and heart rate 
 
Parameters recorded at regular intervals 
Low Abnormal Range Normal High Abnormal Range 
 
 Mean Arterial Pressure (MAP) 
(mmHg) 
<40 40-49 50-69 70-109 110-129 130-159 ≥160 
Unweighted 
Score 
 7 5 3 0 1 2 3 
Adrenaline 
(mg/h) 
<0.2 0 0 0 0 -1 -2 -3 
0.2-1.0 4 3 2 1 -1 -2 -3 
1.1-2.0 5 4 3 2 -1 -2 -3 
>2.0  6 5 4 3 -1 -2 -3 
Noradrenaline 
(mg/h) 
<0.1 0 0 0 0 -1 -2 -3 
0.1-1.0 4 3 2 1 -1 -2 -3 
1.1-2.1 5 4 3 2 -1 -2 -3 
>2.1  6 5 4 3 -1 -2 -3 
Fluid Input 
(mls/h) 
0-125 0 0 0 0 0 0 0 
126-250 4 3 2 1 0 0 0 
251-500 5 4 3 2 0 0 0 
>500 6 5 4 3 0 0 0 
Propofol 
(mg/h) 
<10 0 0 0 0 0 0 0 
10-100 -1 -1 0 0 1 1 -1 
110-280 -2 -2 -1 0 1 1 2 
>280  -3 -3 -2 0 1 2 2 
Alfentanil 
(mg/h) 
<0.5 0 0 0 0 0 0 0 
0.5-2.1 
(R) 
0 0 0 0 0 0 0 
>2.1 -1 -1 -1 0 1 1 1 
 
Heart Rate (HR) 
(Beats/min) 
<35 35-39 40-49 60-90 91-140 141-179 ≥160 
5 3 1 0 1 3 5 
 
3.4.4. The final quantitative score 
The alterations to the parameters recorded regularly, based upon clinical reflection, could 
now be couple to the parameters which were only recorded intermittently to give the final 
quantitative score. This is shown in figure 3-2. The score was now ready to be tested 
against data from actual Intensive Care Patients. This is the subject for discussion in the 
next chapter. 
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Figure 3-2: The final quantitative score 
 
Parameters recorded at regular intervals 
Low Abnormal Range Normal High Abnormal Range 
 
 Mean Arterial Pressure (MAP) 
(mmHg) 
<40 40-49 50-69 70-109 110-129 130-159 ≥160 
Unweighted 
Score 
 7 5 3 0 1 2 3 
Adrenaline 
(mg/h) 
<0.2 0 0 0 0 -1 -2 -3 
0.2-1.0 4 3 2 1 -1 -2 -3 
1.1-2.0 5 4 3 2 -1 -2 -3 
>2.0  6 5 4 3 -1 -2 -3 
Noradrenaline 
(mg/h) 
<0.1 0 0 0 0 -1 -2 -3 
0.1-1.0 4 3 2 1 -1 -2 -3 
1.1-2.1 5 4 3 2 -1 -2 -3 
>2.1  6 5 4 3 -1 -2 -3 
Fluid Input 
(mls/h) 
0-125 0 0 0 0 0 0 0 
126-250 4 3 2 1 0 0 0 
251-500 5 4 3 2 0 0 0 
>500 6 5 4 3 0 0 0 
Propofol 
(mg/h) 
<10 0 0 0 0 0 0 0 
10-100 -1 -1 0 0 1 1 -1 
110-280 -2 -2 -1 0 1 1 2 
>280  -3 -3 -2 0 1 2 2 
Alfentanil 
(mg/h) 
<0.5 0 0 0 0 0 0 0 
0.5-2.1 0 0 0 0 0 0 0 
>2.1 -1 -1 -1 0 1 1 1 
 
Heart Rate (HR) 
(Beats/min) 
<35 35-39 40-49 60-90 91-140 141-179 ≥160 
5 3 1 0 1 3 5 
 
 
Oxygen Saturation (Sp02) 
(%) 
<75 75-89 90-94 95-100 - - - 
Unweighted 
Score 
Air 3 2 1 0 - - - 
Inspired 
Oxygen 
Fraction 
(FiO2) 
 
0.22-0.49 4 3 2 1 - - - 
0.5-0.79 5 4 3 2 - - - 
≥0.80 6 5 4 3 - - - 
PEEP / CPAP 
(cmH20) 
0-5 0 0 0 0 - - - 
6-8 4 3 2 1 - - - 
9-11 5 4 3 2 - - - 
≥12 6 5 4 3 - - - 
 
Urine Output 
(mls/h) 
<2 2-19 20-35 >35 - - - 
 
Temperature 
(ºC) 
<32 32-35 35.1-35.9 36-38 38.1-40 40.1-42.1 >42.1 
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Parameters Intermittently Recorded 
Low Abnormal Range Normal High Abnormal Range 
 
Score 3 2 1 0 1 2 3 
Central Venous Pressure 
(CVP) (cmH20) 
<-6 -5 to -3 0-2 2-10 11-18 19-24 >24 
Cardiac Output (CO) 
(l/min) 
<2.5 2.5-3.4 3.5-4.9 
5-6 
 
6.1-15 15.1-29.9 ≥30 
Cardiac Index (CI) 
(l/min/m2) 
<1.5 1.5-2.0 2.1-2.9 
3-3.5 
 
3.1-8.8 8.9-16.9 ≥17 
Stroke volume (SV) 
(mls)  
<40 40-54 55-69 
70-80 
 
81-90 91-100 >100 
Stroke Volume Variance 
(%) 
- - - 
<10 
 
10-13 13-18 18 
Systemic Vascular 
Resistance (SVR) 
(dynes × s/cm5) 
<450 
 
451-700 701-899 900-1400 
1401-
1600 
1601-
1800 
>1800 
Systemic Vascular 
Resistance Index (SVRI) 
(dynes × s/cm5/m2) 
<765 765-1189 
1190-
1529 
1530-
2380 
2381-
2720 
2721-
3060 
>3060 
Oxygen Delivery (D02) 
(mls/min) 
<300 300-699 700-999 
1000-
1200 
1201-
3000 
3001-
5980 
>5980 
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3.5. Discussion 
In this chapter the design of a new quantitative scoring system of instability in Intensive 
Care patients is described, which takes into account the amount of physiological and 
pharmacological support the patient is receiving. There were several advantages to this 
approach. The score was diagnosis independent (unlike the APACHE II system), could be 
repeated at regular intervals to give a trend of improvement or deterioration and was 
simple to calculate at the bedside. This score comprised ranges of physiological and 
pharmacological parameters, some of which were weighted against each other. There are 
various ways that this could have been undertaken. There were no similar scores available 
for comparison to design this new construct. As a pragmatic starting point the literature of 
currently available scores which use similar (unweighted) parameters was reviewed. 
Ranges were used from some of these scores and others devised from either common 
physiological facts (e.g. maximum ventricular rate before filling is impaired) and my own 
clinical opinion. In other words the process started with a combination of single “expert” 
opinion, common physiological facts and ranges from previous physiologically based 
scores (albeit devised for a different purpose).  
 
There are other techniques that could have been employed to make this process more 
sophisticated. Brain storming was described by the advertising writer Alex Osborn as a 
means of using the brains to “storm a problem.” 110. The premise of brainstorming is that 
members of a group generate as many ideas on a topic that they can. Osborne defined 4 
rules for a session. Members of a session should generate as many ideas as they can (and 
not worry about quality), further ideas should be generated from thoughts from other 
participants, judgement on ideas should be deferred and there should be no criticism of 
other’s thoughts. Related to brainstorming sessions are group interviews in so-called focus 
groups. These are more structured in nature.  The Delphi method was designed mainly by 
Dalkey and Helmer in the 1960s 
111. In this, experts’ opinion to a problem is sought in two 
or sometimes more rounds. After each round a researcher provides a summary of the 
answers given in the previous round with reasons. In the next round the experts are asked 
to revise their answers in the light of the other opinions. Over time the range of opinion is 
decreased and consensus reached. This has the advantage over single surveys, whereby a 
researcher has to summarise opinion and there is more chance of bias. The anonymity 
achieved in the Delphi exercise is useful. In brainstorming sessions there is a danger of 
participants not speaking freely if there is a dominant member of the group. Individual 
interviews (which can be structured “qualitative” or unstructured) are another option. The 
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risk with this technique is that the researcher leading the sessions can unintentionally 
introduce bias by the direction in which the questioning follows. Structured interviews are 
preferred over unstructured as they are more reproducible, systematic, transparent and 
reliable. 
 
The quantitative score developed has two components, one based on regularly recorded 
parameters and a possible score for parameters recorded intermittently. The score is tested 
in the next chapter using the first part of the score only. The second part is not used. Before 
this testing occurred, various problems were considered. If a parameter is only recorded 
intermittently then the score could change because this parameter is or is not being 
recorded, rather than the patient improving or deteriorating. A possible solution is to 
ascertain which of the intermittent parameters are being recorded, if the is occurring 
regularly, and at what frequency. These scores could be calculated, the maximum score for 
these intermittent parameters calculated, and added to the basic score out of -3 to + 48. The 
final score would be out of a value dependent on the parameters being recorded in a 
particular patient. This enhanced score could be tested against the basic score in clinical 
scenarios to ascertain if it better fits with clinical opinion. The reality however is that 
different intermittent parameters are likely to be recorded at different times e.g. a nurse 
calibrates the cardiac output monitor and takes a reading at one time point but measures 
CVP at another. 
 
A related problem that applies to the first part of the score is unmeasured variables. It is 
unlikely, but not impossible that an Intensive Care patient would have one or more of the 
key parameters measured e.g. heart rate, blood pressure, oxygen saturation and so on (and 
this was one of the reasons they were chosen for the first part of the score). The solution is 
an algorithm that detects which parameters are present prior to analysis. If there is a 
missing parameter the only solution is that the final score is out of a value of less than 48. 
This would have to be made clear as it could affect how well the model fits real patient 
data in future testing. Another difficulty is the mathematically related intermittent 
variables. These are cardiac output / cardiac index and systemic vascular resistance / 
systemic vascular resistance index. There are three possibilities, namely the basic variable 
is being recorded, the mathematically derived index of the variable is being recorded, or 
both. If the latter then an algorithm could be designed to ignore the basic variable and only 
use the index. Further, in the score as it stands just now, for these two parameters (and their 
related index) the points scored are the same at different levels of derangement, so it is 
perhaps less important if there is inconsistency as to which is recorded. 
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To develop the score further to include parameters recorded intermittently would have 
required more algorithm development. Although there are possible solutions, to ultimately 
have a score that produces different value dependent on what parameters are recorded is 
unsatisfactory. These are the reasons this part of the score was not developed further at this 
time. 
 
Various issues would have to be overcome prior to testing the first part of the quantitative 
score (parameters recorded at regular intervals) on real patient data sets. Data points are 
predominantly recorded at hourly intervals at the Royal Infirmary. There are occasional 
data points in between the hour if something of clinical importance has occurred. A greater 
frequency of recordings would have been useful but was not practical. A particular 
disadvantage of this approach is evident in a later chapter where I describe the association 
and prediction of troponin positive events in Intensive Care. A weakness of this model is 
that with only hourly data an extreme physiological event could occur within that period 
and be missed by the model. Greater frequency of data recording may be possible in the 
future as the CareVue system has an auto chart function and it may be possible to record 
this data for research purposes.  
 
The potential for missing data affecting the score was a concern. That is to say the score 
increasing or decreasing not because the patient’s clinical condition had changed but 
because a parameter was omitted. In the next chapter I describe the algorithm employed to 
overcome the missing data, the effect the algorithm had and possible further solutions to 
improve on this problem. Another difficulty was a parameter that had not just been 
recorded on an hourly time point, but one which had been omitted altogether. This was one 
of the reasons that such key parameters were chosen for the first part of the score. It is 
highly unlikely that a nurse at the bed space would consistently not record heart rate or 
mean arterial pressure. In this event the score would still be able to show trends but be out 
of a total of less than 48 (as long as the parameter was consistently missing). 
The weighting of the quantitative score is difficult as there is no reference standard to 
model against. Parameters were selected and weighted after a literature review i.e. a single 
“expert” based approach. As described earlier in the chapter there are a number of 
techniques that could have been used at an earlier stage e.g. brainstorming sessions or 
Delphi exercises rather than rely on one clinician. This is one of the weaknesses of the 
score. Had a greater number of clinicians been involved, using one of the above 
techniques, the methodology would have been similar (though not on the same scale or 
degree of sophistication) used by Knaus to develop the APACHE score 
22
. In this, he led a 
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panel of clinicians who, after a literature review, weighted 34 variables. They were able to 
simplify the number and change some of the weightings in APACHE II 
21
 using a process 
of multivariate analysis. This was possible because they were using survival prediction as 
an endpoint. A further example is the sequential organ failure assessment (SOFA) score 
38
. 
This was developed in 1994 by Vincent et al. in October 1994 during a consensus meeting 
of the European Society of Intensive Care Medicine meeting in Paris, and revised in 1996. 
Internationally renowned critical care doctors from over Europe were invited. The aim of 
this score was to describe in a quantitative manner the degree of organ dysfunction over 
time in patients. Interestingly it was not designed to compete with other severity indices 
and predict outcome, rather it was to describe morbidity secondary to critical illness. The 
clinicians, after a literature review, limited the number of organ systems used in the score 
to six. Each organ system could score between 0 and 4 points (most abnormal) and ranges 
for the single parameter used as a marker for each failing organ system were decided by 
the clinicians. Although not designed to predict mortality, a prospective analysis of 1449 
patients in 40 Intensive Care Units in 20 countries did show a correlation between raised 
SOFA scores and poor outcome across the 6 organ systems. 
 
The starting point for the two scores above was consensus opinion. An alternative 
statistical approach was used in the development of the Logistic Organ Dysfunction Score 
(LODS). This was designed by Le Gall et al. in 1996 
112
. Rather than start from consensus 
opinion they compiled a database comprising 13152 admissions from 12 countries and 137 
Intensive Care Units. Using multiple logistical regression, 12 variables were identified and 
weightings determined based on prognostic significance to capture the function of 6 
different organ systems. The authors argued that organ dysfunction was being determined 
objectively by this methodology rather than by expert opinion. The score was subsequently 
validated on 2605 patients from the database. There was a strong correlation with 
mortality. 
 
In selecting a methodology, there did not exist a large database of Intensive Care 
Admissions. Using statistical logistic regression was not practical. Further, the weightings 
in the LODS score were still based against prognostic significance. Further, the developed 
score was one of cardiovascular stability, rather than a predictor of outcome. An expert 
based approach is valid. The weakness of this score was not using more clinicians in the 
initial design of the construct. Also, in the absence of a reference standard, the score would 
either have had to be justified as a predictor of, for example, outcomes or tested against 
expert opinion. That is to say in clinical scenarios where a patient deteriorates or improves, 
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is the score and the weightings of the parameters credible to a group of clinicians. On 
reflection greater involvement of more clinicians would have undoubtedly improved the 
score. Nevertheless, the focus moved to develop a qualitative score. Rather than design an 
arbitrary quantitative score, and then justify it clinically, an alternative approach worth 
exploring was to base the actual score on clinical expertise. 
 
In the quantitative score developed thus far a single researcher opinion was used to select 
the parameters, define ranges and add weightings. Although as can be seen in the next 
chapter the score does, on the face of it, show patient improvements and deteriorations, the 
single researcher approach is its major weakness and could be improved. As I have 
discussed, the design of a new score in the absence of a standard for comparison is 
extremely challenging.  
 
Future work to refine the score will be as follows: 
 
Senior clinicians not previously involved in this work will be invited to a brainstorming 
session. Using the regularly recorded parameters selected as a starting point, consensus 
will be sought from the clinicians whether they thought these were reasonable. Additions 
or deletions could be made at this point. In the next stage going through each parameter in 
turn, possibly in the context of clinical scenarios consensus would be sought on parameter 
ranges. These parameters and ranges would be collated in a document and sent out to a 
further group of clinicians for comment and potential further refinement.   
 
In the absence of a reference standard the consensus score would initially have to be tested 
against expert opinion. That is to say, in a variety of scenarios, is the score credible to more 
clinicians not involved in its development, in particular the emphasis given to particular 
parameters. (As an aside, as the score was not designed to predict mortality, statistical 
regression techniques applied to a large prospectively collected database would be less 
useful.) 
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3.6. Conclusion 
I had developed a quantitative score which took into account the amount of physiological 
and pharmacological support the patient was receiving.  This was through the interaction of 
common physiological and pharmacological factors on two key physiological parameters, 
viz. mean arterial pressure and oxygen saturation. This now required to be tested on real 
patient data. 
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Chapter 4: Handling missing data for large volume analysis, testing of the 
Quantitative Score and need for a Qualitative Score 
 
4.1. Abstract 
4.1.1. Background 
The quantitative score described in the last chapter was now ready to be tested against real 
patient data sets. Before this could occur, the raw data would have to be cleaned, to take 
account of missing values and inconsistencies in the way the data were recorded. 
 
4.1.2. Methods 
The relevant physiological and pharmacological data which were required for quantitative 
scoring were extracted from the CareVue system for 3 patients. The raw data were 
examined and rules created to deal with missing values, or inconsistencies in the manner in 
which a parameter was recorded.  The data were pre-processed in this way to be ready for 
analysis in the score. 
 
4.1.3. Results 
The data sets were analysed by the scoring system pre- and post-extrapolation, and a score 
of cardiovascular stability was displayed, either as a raw number or in graphical form over 
time. 
 
4.1.4. Conclusion 
With appropriate pre-processing of data, the quantitative score could give a read-out of 
cardiovascular stability over time from real patients in Intensive Care. 
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4.2. Introduction 
The quantitative score described in the previous chapter now needed to be tested against 
data obtained from patients in Intensive Care, to ascertain if it gave clinically credible 
results. That is to say, the score increased as the patient deteriorated and decreased as the 
patient improved, i.e. it had a high degree of predictive validity. This task would have been 
extremely difficult to achieve if the scores had had to be calculated manually, and would 
have been prone to error. The interrogation and extraction of data from CareVue is already 
described. I now describe how any inconsistencies in the data or missing data were 
overcome. This was an important task prior to testing the quantitative score on real patient 
data. The testing was semi-automated thanks to our group’s collaboration with Prof. Derek 
Sleeman of the Computing Science Department at Aberdeen University. 
 
4.3. Methods  
4.3.1. Data Collection  
An approach was made to the Scotland A Research Ethics Committee rather than a local 
ethics committee as the aim was to analyse data from patients who are in Intensive Care, 
many of whom will have had an adults with incapacity form completed. Their view was 
that if the analysis was only of routinely collected physiological, pharmacological and 
biochemical data, this work did not require a formal ethics application as what was 
proposed was within the scope of service development and audit. It was also stated that the 
data would be downloaded, anonymised by the CareVue administrators and stored on NHS 
servers. There would be no patient identifiers but each patient data set would be given a 
unique identifying number. Any data would be sent from an NHS server to colleagues at 
Aberdeen University. Only the CareVue administrators could (theoretically) de-anonymise 
the data sets. Although not asked to by the ethics committee, we placed notices in the 
foyers of the Intensive Care unit that data was collected for routine analysis.  
 
The quantitative score has two components, a score for parameters collected at regular 
intervals and a score for parameters collected intermittently. To make interpretation 
meaningful and compare the score over time, the same parameters need to be recorded. 
Therefore the CareVue administrators were asked to extract at least the core parameters 
recorded at regular intervals. These are mean arterial pressure, heart rate, oxygen 
saturation, urine output and temperature. The regularly recorded parameters involved in the 
weightings were similarly extracted, namely quantities of adrenaline, noradrenaline, fluid, 
propofol, alfentanil and the amount of PEEP. Other parameters extracted were some of 
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those intermittently recorded, and included cardiac output and cardiac index. In the rest of 
this chapter, when referring to the testing of the quantitative score, it is only on the 
component using regularly recorded parameters. 
 
The criteria for selecting the patients whose data was to be downloaded by the CareVue 
administrators was that they had received haemodialysis, as this was the initial question 
which led to the need for developing a new score which took into account the amount of 
physiological and pharmacological support was receiving. (Although no medical 
information about the patients was available the fact they were receiving haemodialysis 
could be deduced by looking for “blood pump speed” in the query. In the testing of the 
quantitative score, it was run against datasets of patients who had received haemodialysis 
 
As the patients had dialysis-dependent renal failure they were likely to be more ill, 
possibly more cardiovascularly unstable, and have greater amounts of cardiovascular 
monitoring e.g. Lithium Dilution Cardiac Output (LiDCO) Monitoring. The LiDCO is the 
Royal Infirmary Intensive Care Unit’s cardiac output monitoring device of choice which 
uses lithium chloride dilution and the Stewart-Hamilton principle
113
. 
 
In the testing of the quantitative score, 3 data sets numbered 708, 728, and 733 were used. 
At the beginning of this work the number of data sets available for analysis was small and 
these particular data sets were amongst the first to be downloaded by the CareVue 
administrators.  
 
Description of the three patient data sets. 
In the following description of the 3 data sets used, the first and last “days” do not mean 
that the patient is in Intensive Care for the whole 24 hours. 
 
Patient 708:  
This patient was in Intensive Care for 3 days (19.45 on day one to 09.00 on day 3). 
40 time points worth of data were recorded. These were all hourly except for the first one 
(19.45) and in day 2 where an extra time point is recorded at 13.37. 
The patient had one session of haemodialysis on day 2 between 18.00 and 20.00 
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Patient 728: 
This patient was in Intensive Care for 12 days (17.00 on day 1 to 14.00 on day 12).  
278 time points were recorded. These were all hourly except for extra time points as 
follows: Day 1 at 17.51/20.07, Day 2 at 09.30/19.22, Day 3 at 10.12, Day 4 at 05.05/12.08, 
Day 5 at 08.48/09.16, Day 6 at 11.24, Day 7 at 09.27/11.32, Day 8 at 10.15/11.41, Day 9 at 
10.56/12.26, Day 10 at 09.39, Day 11 at 14.59. 
The patient had the following dialysis sessions: Day 2 (19.21-21.00), Day 3 (13.00-18.00), 
Day 4 (10.00-16.00), Day 5 (09.00-14.00), Day 6 (11.24-16.00), Day 7 (12.00-20.00), Day 
8 (16.00-02.00) and Day 10 (12.00-14.00). 
 
Patient 733: 
This patient was in Intensive Care for 16 days (07.00 on day 1 to 17.00 on day 12).  
395 time points were recorded. These were all hourly except for extra time points as 
follows: Day 1 at 07.42/10.23, Day 2 at 10.35/13.31/16.01, Day 3 at 11.09, day 4 at 
05.20/12.54, Day 5 at 0844/1156/1256, Day 6 at 1003/2333, Day 7 at 
11.09/12.32/16.29/18.04, Day 8 at 1509, Day 9 at 10.30, Day 10 at 15.33, Day 12 at 11.17, 
Day 13 at 10.12, Day 14 at 06.30/06.50/06.55/11.24, Day 15 at 1152 and Day 16 at 12.57. 
The patient had the following dialysis sessions: Day 2 (16.01-18.00), Day 3 (11.00-16.00), 
Day 4 (05.20-10.00), Day 5 (18.00-00.00), Day 6 (17.00-19.00) and (22.00-02.00), Day 7 
(12.32-19.00), Day 8 (06.00-15.00), Day 9 (13.00-17.00), Day 10 (11.00-17.00), Day 11 
(12.00-18.00), Day 12 (12.00-18.00), Day 13 (06.00-12.00), Day 14 (06.30-13.00), Day 15 
(06.00-12.00) and Day 16 (11.00-16.00). 
 
The complete data set for patient 708 is recorded in Appendix I (the complete data sets for 
patients 728 and 733 are not included due to their size). Only parameters which are 
recorded at regular intervals, for the purpose of analysis with the quantitative scoring 
system, are shown. 
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4.3.2. Presentation of data  
An example of the ”raw data” as it is produced by the CareVue administrators is shown 
below. The process of extracting the data up until this point is described in detail in 
Chapter 2. The data extracted at this point is already in a basic form within an excel 
spreadsheet of which an example is shown in table 4-1. 
 
Table 4-1: Example of the presentation of the raw data 
Date & Time Infusion Dose units 
08/12/2006 18:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 18:00 Noradrenaline 24mg/240ml(mg/hr), 4.8 mg/hr 
08/12/2006 20:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 20:00 Noradrenaline 24mg/240ml(mg/hr), 4.8 mg/hr 
08/12/2006 21:00 Noradrenaline 24mg/240ml(mg/hr), 3 mg/hr 
08/12/2006 21:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 21:43 Alfentanil 25000mcg(mg/hr), 2500 1 mg/hr 
08/12/2006 22:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
08/12/2006 22:00 Noradrenaline 24mg/240ml(mg/hr), 3.5 mg/hr 
08/12/2006 22:00 Alfentanil 25000mcg(mg/hr), 2500 1 mg/hr 
08/12/2006 23:00 Noradrenaline 24mg/240ml(mg/hr), 3.5 mg/hr 
08/12/2006 23:00 Propofol 2%(mg/hr), 1000 mg/50 m 100 mg/hr 
 
The data in its raw state comprises lines of information in an Excel spreadsheet which are 
not ordered in a manner by which they could be interpreted. There was an appreciation that 
when  larger data sets required  to be analysed that it would be important  to be able to  
view and annotate the data in an intelligible way and also to be able to apply rules to 
extrapolate where data were parameters were missing at different time points. The Royal 
Infirmary ICU has 20 beds, and if we take an average of 10 parameters collected per hour 
for a patient at each bed space, which is open 365 days per year, then the number of pieces 
of data collected each year is 20 beds x 10 parameters x 24 hours x 365 days which equals 
1.75 million pieces of data. This is theoretical, hypothetical and probably an 
underestimation. The CareVue system is capable of collecting many times more data than 
this. It illustrates that manual pre-processing and analysis would be an impossible task on 
that scale.  
 
Our computing science colleagues devised a web based tool ACHE (an Architecture for 
Clinical Hypothesis Examination) 
88
 to deal with these specific problems. It has two main 
components. ACHE “annotate” which allows the raw data to be viewed in an ordered 
fashion within the excel spread sheets and ACHE “pre-process” allows for any 
extrapolation rules to be applied to the data at this point. This was essential, as with the 
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number of data points in some of the spreadsheets manual pre-processing of this time 
series data would have been impossible.  
An example of formatted data as it would appear in ACHE is given in table 4-2. 
 
Table 4-2:  Example of formatted data (as it would be presented in ACHE) 
Time  Noradrenaline Fluids Propofol Alfentanil HR SpO2 FiO2 Urine Temp MAP 
            
Day 1                       
            
05/01/2007 17:00:00  1500.0 100.0 1.0 96.0   100.0   
05/01/2007 17:51:01     96.0 99.0   37.1 50.0 
05/01/2007 18:00:00 0.5 2000.0 100.0 1.0 95.0 99.0 100.0 0.0 37.1 50.0 
05/01/2007 19:00:00 1.0 500.0 100.0 1.0 106.0 100.0 80.0 0.0  57.0 
05/01/2007 20:00:00 1.2  40.0 1.0 102.0 100.0 70.0  37.0 54.0 
05/01/2007 20:07:38     106.0 100.0 80.0   57.0 
05/01/2007 21:00:00 1.2  40.0 1.0 100.0 97.0    55.0 
05/01/2007 22:00:00 1.4  40.0 1.0 98.0 96.0 70.0 5.0  58.0 
05/01/2007 23:00:00 1.4 500.0 40.0 1.0 98.0 95.0 70.0  36.6 62.0 
 
 
4.3.3. Types of entered data errors  
As can be seen from the extract from ACHE above, although the data are more organised 
for semi-automated analysis, there are missing figures which could lead to meaningless 
values being generated by the quantitative score. Although the data can be auto-charted 
into the CareVue system and then verified, current practice at the Royal Infirmary ICU is 
that data are entered manually, at hourly time points, by the nursing staff.  On further 
analysis three sources of error were identified. These are missing data points, a data point 
entered incorrectly and inconsistency in the manner in which the data point is recorded 
(e.g. mls/h or mg of a drug). 
 
4.3.4. Mechanism for handling different types of missing data 
The outcome of a discussion with the computing scientists was that missing values were to 
be dealt with in a pragmatic clinical manner rather than using a complex calculation. The 
quantitative score has two components, a score calculated using parameters recorded 
regularly and a score calculated using parameters recorded intermittently. In the data sets 
analysed, the quantitative score was calculated using the parameters recorded regularly. An 
analysis of the data sets used in this chapter showed that for the parameters recorded 
regularly it was unusual for nursing staff (as you might expect) to have omitted recording 
one of these key parameters for more than one hour (with the exception of urine output if 
only being averaged every few hours). The discussion therefore focussed on dealing with a 
single missing value.  
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There was more than one option. The most pragmatic (and simplest do achieve) was to use 
the previously recorded value. There were two exceptions. For urine output, nursing staff 
sometimes record a much larger volume every few hours, rather than measure every hour. 
In the absence of concurrent medical information (to perhaps show what the nursing staff 
were doing) the decision was taken that if there was a missing value and the previous value 
was less than 100mls then we would use the previous value. If there was a missing value 
and a previous value of 100mls or over the algorithm looked forward to the next available 
time point and calculated an average. For fluids it was assumed that one (or more) missing 
value was a conscious decision as fluids can be started and stopped at points throughout 
the day, and so took no action. A consideration was made to taking an average of the value 
(or values) before and after a single missing time point, but on reflection it was thought the 
other approach simpler (with less complicated algorithms). A summary of the actions taken 
is shown in the table 4-3. 
 
Table 4-3: Mechanism for handling missing values 
Parameter Action for a Single Missing Value 
Adrenaline Use previously recorded value 
Noradrenaline Use previously recorded value 
Propofol Use previously recorded value 
Alfentanil Use previously recorded value 
Heart Rate Use previously recorded value 
SpO2 Use previously recorded value 
FiO2 Use previously recorded value 
Urine If previous value less than 100 replace missing 
value with previous value. 
 
Otherwise look forward in the data to the next 
value, take the average of it over the missing 
values and then replace missing values with that 
average. 
Temperature Use previously recorded value 
MAP Use previously recorded value 
Fluids Do nothing 
 
 
No consideration was made for multiple missing values for parameters recorded at regular 
intervals (other than urine and a conscious decision to take “missing fluids” at face value). 
The following analysis shows the results of this strategy in the 3 patients analysed (using 
the part of the quantitative score with parameters recorded at regular intervals).  
In the tables below each column represents parameters recorded at regular intervals with 
the number of times the algorithm for dealing with single missing values does not work 
when there is more than one time point missing for a parameter. This figure is shown in the 
  
95 
bottom row and the day (D) within the ICU stay and the relevant missing time points 
shown above.  (Note fluids and urine output are not included). A gap in the column 
showing the time points separates different periods of multiple missing data. An analysis is 
given for each patient (tables 4-4 to 4-6). This forms the basis of a more informed 
approach as to how we might deal with these in the future (discussed below). 
 
Table 4-4: Analysis of rules for handling missing values on patient 708 
 
PATIENT 708 (40 time points) 
Mean arterial 
Pressure 
Heart 
Rate 
Adren. Noradr Propofol Alfentanil FIO2 SpO2 Temp. 
nil nil N/A nil nil nil nil nil 
D1 2300 
D2 0000 
 
D2 1300 
D2 1337 
 
D2 1900 
D2 2000 
 
D2 2200 
D2 2300 
 
D3 0100 
D3 0200 
D3 0300 
0 0 N/A 0 0 0 0 0 5 
 
 
 
In this patient the algorithms would have dealt with all missing parameters except for 
temperature. However, all of the missing temperature data falls within scoring no points or 
one point, this only making a very slight inaccuracy with the final score out of 48 for the 
parameters recorded at regular intervals.  
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Table 4-5: Analysis of rules for handling missing values on patient 728 
PATIENT 728 (278 time points) 
 
MAP HR Adren. Norad. Propofol Alfent. FIO2 SpO2 Temp. Temp. 
(Cont) 
Temp. 
(Cont) 
nil nil N/A nil nil D8 1200 
D8 1226 
D8 1300 
D8 1400 
D8 1500 
D8 1600 
D8 1700 
D8 1800 
D8 1900 
D11 
1800 
D11 
1900 
 
D12 
0300 
D12 
0400 
 
D12 
0300 
D12 
0400 
 
D1 2007 
D12100 
D1 2200 
 
D2 0400 
D2 0500 
 
D2 1300 
D2 1400 
 
D2 1800 
D2 1900 
 
D2 2100 
D2 2200 
 
D3 0000 
D3 0100 
 
D3 0300 
D3 0400 
D3 0500 
 
D3 1012 
D3 1100 
 
D4 0300 
D4 0400 
 
D4 0505 
D4 0600 
 
D4 1200 
D4 1208 
 
D4 2100 
D4 2200 
 
D5 0600 
D5 0700 
 
D5 0916 
D5 1000 
 
D5 1800 
D5 1900 
 
D5 2100 
D5 2200 
D5 2300 
D6 0000 
D6 0000 
D6 0100 
 
D6 1100 
D6 1156 
 
D6 1500 
D6 1600 
D6 1700 
 
D6 2100 
D6 2200 
 
D7 0927 
D7 1000 
D7 1100 
D7 1132 
 
D7 1300 
D7 1400 
 
D7 1800 
D7 1900 
 
D8 0600 
D8 0700 
D8 0800 
 
D8 1000 
D8 1015 
 
D8 2200 
D8 2300 
 
D9 1050 
D9 1100 
 
D9 1226 
D9 1300 
 
D10 0700 
D10 0800 
D10 0900 
D10 0939 
 
D10 1100 
D10 1200 
D10 1300 
 
D10 1500 
D10 1600 
 
D10 1800 
D10 1900 
 
D10 2100 
D10 2200 
D10 2300 
D11 0000 
 
D11 0300 
D11 0400 
D11 0500 
 
D11 0700 
D11 0800 
 
D11 1200 
D11 1300 
 
D11 1459 
D11 1500 
D11 1600 
 
D11 2300 
D12 0000 
D12 0100 
D12 0200 
D12 0300 
D12 0400 
D12 0500 
D12 0600 
 
D12 0800 
D12 0900 
 
D12 1100 
D12 1200 
D12 1300 
 
0 0 N/A 0 0 1 2 1 40   
 
In this patient, the algorithms would have dealt with missing parameters for mean arterial 
pressure, heart rate, noradrenaline and propofol. An interesting issue is identified with 
missing data for alfentanil. The actual rate prior to the missing data was 0.5 mg/h. Without 
access to the patient’s history, this probably represents a patient who no longer requires it. 
The infusion is started again at the very low rate of 0.5mg/h several hours later. It may be 
inappropriate to extrapolate under these circumstances. One solution would be an 
algorithm which detects a tapering dose to very low threshold and does not extrapolate on 
the assumption that this is a considered clinical decision. There were two episodes of two 
hours of missing FiO2 data. These were in the context of a high oxygen saturations and 
low FiO2 before and after which would have accrued no score in this case. Again it is 
  
97 
difficult to say if the patient who was near to discharge was not on any oxygen.  There is a 
single episode of missing oxygen saturation, again near the end of the patient’s stay. This 
is on day 12 between 0300 and 0400, the same time period as the second episode of 
missing FiO2. This raises the question of whether in the future (when rules which will have 
to be put in place to deal with more than one missing data point), if the score should be 
calculated if there are multiple extrapolated parameters. Finally, it is obvious from the 
table that there are multiple missing temperature time points. In only a single instance in 
the actual data was the temperature out with 36-38 
o
C (which scores zero points).  
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Table 4-6: Analysis of rules for handling missing values on patient 733 
 
PATIENT 733 (395 time points) 
Mean 
arterial 
Pressure 
Heart 
Rate 
Adren. Norad. Propofol Alfent. FIO2 SpO2 Temp. Temp. 
Cont. 
Temp 
Cont. 
D14 0650  
D14 0655 
D14 0630 
D14 0650 
D14 0655 
N/A nil D14 0650 
D14 0655 
D14 0630 
D14 0650 
D14 0655 
D1 0742 
D1 0800 
D3 1400 
D3 1500 
D1 0900 
D1 1000 
D1 1023 
 
D4 1000 
D4 1100 
 
D4 1254 
D4 1300 
 
D4 1500 
D4 1600 
 
D4 1800 
D4 1900 
D4 2000 
D4 2100 
D4 2200 
 
D5 0000 
D5 0100 
 
D5 0600 
D5 0700 
D5 0800 
D5 0844 
 
D5 1156 
D5 1200 
D5 1256 
D5 1300 
 
D5 2000 
D5 2100 
 
D5 2200 
D5 2300 
 
D6 1000 
D6 1003 
D6 1100 
 
D6 1300 
D6 1400 
 
D6 1600 
D6 1700 
 
D6 1900 
D6 2000 
D6 2000 
D6 2300 
 
D7 0100 
D7 0200 
 
D7 0400 
D7 0500 
 
D7 1109 
D7 1200 
 
D7 1600 
D7 1629 
D7 1700 
 
D7 1804 
D7 1900 
D 7 2000 
 
D7 2200 
D7 2300 
 
D8 0600 
D8 0700 
 
D8 2200 
D8 2300 
 
D9 0200 
D9 0300 
D9 0400 
 
D9 0600 
D9 0700 
D9 0800 
 
D9 2100 
D9 2200 
 
D11 0200 
D11 0300 
D11 0400 
D11 0500 
 
D11 1800 
D11 1900 
 
D11 2100 
D11 2200 
D12 0000 
D12 0100 
D12 0200 
 
D12 0400 
D12 0500 
 
D12 2100 
D12 2200 
D12 2300 
 
 
D13 0100 
D13 0200 
D13 0300 
D14 0400 
 
D13 0600 
D13 0700 
 
D14 0600 
D14 0630 
D14 0650 
D14 0655 
 
D14 1124 
D 141200 
 
D14 1400 
D14 1500 
D14 1600 
D14 1700 
 
D15 1000 
D15 1152 
D15 1200 
D15 1300 
 
D15 1900 
D15 2000 
 
D16 0800 
D16 0900 
 
D16 1200 
D16 1257 
1 1 N/A 0 1 1 1 1 41 
 
 
There is one episode of several missing data points for mean arterial pressure, heart rate, 
propofol and alfentanil. Interestingly they all occur when extra time points are recorded in 
between the routine hourly time points. Again this raises the question of what to do when 
there are multiple missing parameters potentially being extrapolated. The single episode of 
missing FiO2 data occurs just after the patient’s admission, again where there is an extra 
time point between two hourly time points. This raises the question of extrapolation with 
little information before to compare with. Again the dominant source of missing data is 
with temperature measurement. As with the previous example all of the temperature time 
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points within which the missing examples occur would score 0 points (with the exception 
of 2 instances). 
 
These analysis shows that apart from temperature (where almost all values fell in a range 
that would not alter the calculated score) there were very few examples of missing data 
with more than a single time point for all the other parameters. 
 
Nevertheless, to take this work forward these must be addressed. This analysis identifies 
some associations for more than one missing time point and identifies some further 
challenges for consideration of how to handle the data where there is more than one 
missing time point. 
 
Possible associations: 
- An event has occurred and the nurse at the bed space has recorded an additional time 
point with only a few parameters between the routine recorded hourly time points. 
A drug (e.g. noradrenaline, propofol) has been at a low level as the patient’s 
condition improves but then has to be started i.e. there is no “missing” data. 
- The patient has just been admitted and is very unstable and the focus of clinical care 
is on admitting and stabilising rather than recording data. 
- The patient is about to be discharged and some “missing” parameters have in fact 
been stopped. 
- Temperature appears to be a low priority parameter to record and is often omitted by 
nursing staff. 
 
Additional challenges: 
- What should occur where there is sparse data for a parameter before or after a period 
of missing data? 
- If at an hourly time point, how many extrapolated parameters is it reasonable to 
calculate the score with? 
- If there is a period of stability before and a period of instability after a series of 
missing values, how can you determine where the true value is likely to lie? 
 
It is likely that a series of hierarchical algorithms will have to be developed to account for 
these different situations. The first of these to be applied could be one which takes a mean 
of 3 time points before and after the missing values (and substitutes this value within the 
missing time points.)  If this is not possible then an algorithm should examine the value 
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immediately before and after the missing time points. Missing data closest to the “before 
value” should be substituted with that value and ditto for missing values closest to the 
“after value.” If there is an odd number then arbitrarily one extra missing value to align 
itself with the nearest “after value”. Alternatively (but much more complicated to achieve) 
the rest of the parameters could be analysed to ascertain in which direction they are 
changing to determine whether the values which are missing should more closely align 
with those before or after. Further, if a parameter has been slowly reducing, low level 
thresholds will have to be determined whereby the score is not extrapolated i.e. there is no 
“missing” data because the parameter in questions has been appropriately stopped. If the 
score is developed into a clinical tool, it would be important for the score calculated at a 
particular time point to be qualified by the number of extrapolated parameters. For 
example, a score of 18 with no extrapolated parameters might be displayed 18(0) and with 
3 extrapolated time points 18 (3) and so on.  
 
4.4. Results 
4.4.1 Application of the quantitative score to the unextrapolated data sets 
The quantitative score was applied to the three data sets (patients 708, 728 and 733). 
Initially this was to the data before the extrapolation rules were applied. An extract of 
patient 708 is shown in table 4-7. The complete data set for patient 708, with the scores for 
each time point, is recorded in Appendix I (the complete data sets for patients 728 and 733 
are not included due to their size). 
 
Table 4-7: Testing of the score on unextrapolated data (extract patient 708) 
 
Time Adrenaline Noradrenaline Fluids Propofol Alfentanil HR SpO2 FiO2 Urine Temp MAP Dialysis Score 
19/12/2006 
19:45:37      114.0 90.0      2 
19/12/2006 
20:00:00   500.0   111.0 92.0 100.0  37.7 62.0  11 
19/12/2006 
21:00:00   500.0   116.0 79.0 100.0   68.0  12 
19/12/2006 
22:00:00 1.0 2.0 500.0 60.0 1.5 99.0 69.0 100.0 80.0 38.1 62.0  19 
19/12/2006 
23:00:00 2.0 2.0 500.0 60.0 1.5 108.0 83.0 100.0 10.0  62.0  20 
20/12/2006 
00:00:00 2.8 4.0 250.0 60.0 1.5 110.0 100.0 100.0 15.0  59.0  19 
20/12/2006 
01:00:00 2.8 4.0 350.0 60.0 1.5 112.0 83.0 100.0 10.0 38.3 59.0  23 
20/12/2006 
02:00:00 2.8 4.0 100.0 60.0 1.5 109.0 83.0 100.0 25.0  63.0  18 
20/12/2006 
03:00:00 2.8 4.0 100.0 60.0 1.0 107.0 75.0 100.0 15.0 38.8 67.0  20 
20/12/2006 
04:00:00 2.8 4.0 100.0 60.0 1.0 112.0 76.0 100.0 0.0  80.0  15 
20/12/2006 
05:00:00 2.8 4.0 50.0 60.0 1.0 118.0 80.0 100.0  38.9 82.0  13 
20/12/2006 
06:00:00 2.8 4.0 100.0 60.0 1.0 121.0 82.0 100.0 35.0  83.0  13 
20/12/2006 
07:00:00 2.8 4.0 100.0 60.0 1.0 124.0 82.0 100.0 15.0 38.9 64.0  20 
20/12/2006 
08:00:00 2.8 4.0 50.0 60.0 1.0 126.0 85.0 100.0 10.0 39.8 66.0  20 
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At this point, on further analysis, there was a realisation that there was still an 
inconsistency in the way in which inspired oxygen concentration was being recorded. For 
example an inspired oxygen concentration of 0.8 was being recorded as 0.8, .8, 0.80, 8 
(assumed to be a transcription error) and 80% (not a fraction). It was decided to convert all 
forms of fractions to percentages. This is, of course, merely a change in nomenclature, 
does not affect the values awarded in the score, and is reflected (in bold) in table 4-8. 
 
Table 4-8: Extract from quantitative score showing changes in nomenclature for 
inspired oxygen concentration 
 
 
Oxygen Saturation (Sp02) 
(%) 
<75 75-89 90-94 95-100 - - - 
Unweighted 
Score 
Air 3 2 1 0 - - - 
Inspired 
Oxygen 
Fraction 
(FiO2) 
 
22-49 4 3 2 1 - - - 
50-79 5 4 3 2 - - - 
≥80 6 5 4 3 - - - 
PEEP / CPAP 
(cmH20) 
0-5 0 0 0 0 - - - 
6-8 4 3 2 1 - - - 
9-11 5 4 3 2 - - - 
≥12 6 5 4 3 - - - 
 
4.4.2 .Application of the score to extrapolated data sets   
The quantitative score, with extrapolation rules, was now applied to the data, with inspired 
oxygen concentration given consistently as a percentage. The quantitative score applied to 
extrapolated data set 708 is shown in Appendix II. 
 
4.4.3. Comparison of the application of the score to unextrapolated and  
extrapolated data 
To ascertain the effect of the extrapolation of data, the quantitative scores calculated pre- 
and post-implementation of the rules for handling missing data points, were compared. As 
patient 708’s data set only contains 40 data points, it is shown in its entirety in table 4-9.  
 
 
 
 
 
 
  
102 
 
Table 4-9: Calculated score from patient 708 pre- and post-extrapolation of data 
 
Differences are shown in bold. As this data set only contains 40 parameters it is shown in 
its entirety. 
 
Time Score pre extrapolation Score post extrapolation 
Day 1   
   
19/12/2006 19:45:37 2 2 
19/12/2006 20:00:00 11 11 
19/12/2006 21:00:00 12 12 
19/12/2006 22:00:00 19 19 
19/12/2006 23:00:00 20 20 
   
Day 2   
   
20/12/2006 00:00:00 19 19 
20/12/2006 01:00:00 23 23 
20/12/2006 02:00:00 18 19 
20/12/2006 03:00:00 20 20 
20/12/2006 04:00:00 15 16 
20/12/2006 05:00:00 13 16 
20/12/2006 06:00:00 13 14 
20/12/2006 07:00:00 20 20 
20/12/2006 08:00:00 20 20 
20/12/2006 09:00:00 17 20 
20/12/2006 10:00:00 20 20 
20/12/2006 11:00:00 16 19 
20/12/2006 12:00:00 18 18 
20/12/2006 13:00:00 20 20 
20/12/2006 13:37:00 9 20 
20/12/2006 14:00:00 18 21 
20/12/2006 15:00:00 19 20 
20/12/2006 16:00:00 20 20 
20/12/2006 17:00:00 17 21 
20/12/2006 18:00:00 18 18 
20/12/2006 19:00:00 16 17 
20/12/2006 20:00:00 4 17 
20/12/2006 21:00:00 20 20 
20/12/2006 22:00:00 19 19 
20/12/2006 23:00:00 17 20 
   
Day 3   
   
21/12/2006 00:00:00 21 21 
21/12/2006 01:00:00 20 20 
21/12/2006 02:00:00 19 22 
21/12/2006 03:00:00 19 22 
21/12/2006 04:00:00 20 23 
21/12/2006 05:00:00 23 24 
21/12/2006 06:00:00 18 25 
21/12/2006 07:00:00 23 25 
21/12/2006 08:00:00 22 25 
21/12/2006 09:00:00 11 14 
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As can be seen, extrapolation of the rules to handle missing single data points makes a 
difference to the score at several of the time points. These are perhaps better illustrated in 
graphical form. Figure 4-1 shows the results for patient 708 and figure 4-2 for patient 728 
(which has 278 time points).  The extrapolated scores have fewer peaks and troughs than 
the original scores, seen better in patient 708, as fewer time points are being displayed in a 
single graph. 
 
Figure 4-1: Quantitative score over time for patient 708 
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Figure 4-2: Quantitative score over time for patient 728 
Patient 728
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4.4.4. Hameodialysis events as represented by the score 
As the initial idea for a score of instability arose from an interest in cardiovascular 
instability during haemodialysis, the following analysis shows how the score changed 
during renal replacement therapy. Arrows in the graphs below show where haemodialysis 
occurred. Note that in patient 728 and 733 the first arrow is smaller than the others. This is 
because at Glasgow Royal Infirmary the first session of haemodialysis is characteristically 
2 hours in duration. 
 
The qualitative score over time is shown for the 3 patient’s data sets described earlier (708, 
728 and 733).  Figure 4-3 shows the complete Intensive Care stay for patient 708, figure   
4-4 approximately the first third of patient 728 and figure 4-5 the first fifth of patient 733.  
Patients 728 and 733 contain too many data points to compress into the one graph.  
 
Figure 4-3: Haemodialysis events as represented by the quantitative score of 
patient 708 
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Figure 4-4: Haemodialysis events as represented by the quantitative score on 
patient 728 
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Figure 4-5: Haemodialysis events as represented by the quantitative score on 
patient 733 
Patient 733 extrapolated score
0
2
4
6
8
10
12
14
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87
Time point
S
c
o
re
 
 
 
 
 
 
 
 
 
 
 
 
 
  
106 
4.5. Discussion 
For the first time there now exists a score which takes into account the level of 
physiological and pharmacological support which the patient is receiving. The score could 
now be applied to real patient data sets and give an indication of overall cardiovascular 
improvement or deterioration. It could theoretically be applied in real time at the patient’s 
bedside. 
 
Using anonymised data as per the agreement with the ethics committee resulted in certain 
limitations. There was no access to any clinical information for the patient’s whose data 
sets were being analysed. However, certain clinical events could be deduced e.g. blood 
pump speed recorded means that the patient was undergoing a period of renal replacement 
therapy. Being able to place lines of data in a clinical context would have been useful in 
certain situations. For example, in Chapter 6 a two stage discrimination experiment is 
described as part early work to validate the qualitative Intensive Care Unit - Patient 
Scoring System developed in Chapter 5.  In this, consultants were shown lines of data and 
asked whether they thought the patient was improving or deteriorating. It would have been 
useful (but not essential) to have been able to place this data within a clinical context. By 
definition there was reliance upon the CareVue administrators, who had other onerous 
commitments to download the data for us. Although they were extremely helpful in 
facilitating the studies, this could at times be a rate-limiting step.  
 
 
Work on the parameters recorded intermittently was not taken further at this stage because 
of the various problems identified in the last chapter e.g. the score changing because the 
parameter is or is not being recorded rather than the patient improving or deteriorating. 
These additional parameters could only be of potential interest if they are recorded at 
regular intervals throughout the patient stay. For example, in a highly unstable patient 
systemic vascular resistance (SVR) might be measured if they have cardiac output 
monitoring in place. In this case the score would be out of 51, not 48 (as a maximum of 3 
points are given for changes in SVR.  
 
Algorithms were applied to deal with a single missing value (with the exception of fluid 
inputs and urine output). In this chapter it was applied to 3 patient data sets at every time 
point accepting that on occasion the score would not be accurate because of more than one 
missing data point for a parameter. However, there was an assumption that nursing staff 
were unlikely to miss recording essential parameters for more than one time point in a row. 
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An analysis of the data sets shows that with the exception of temperature this assumption is 
correct.   
 
However, to take the quantitative score further, for it to be a potentially useful bed side 
tool, possible methods for dealing with multiple missing time points have been suggested. 
The alternative is for there to be no score recorded when there is missing data. Clearly this 
would be a major drawback were the score to be used as a clinical tool. 
 
The algorithms suggested could be tested by taking a data set and deliberately removing 
blocks of time points for different parameters. This could be done at different periods 
during the patient’s stay. The different types of algorithm could be applied and compared 
to the score calculated on the complete data to see which gives the most accurate reflection 
of the true score. This will form part of future work.  
 
The quantitative score does appear to have some merit. From the graphs above it shows 
improvements and deteriorations over time in the overall physiological state of the patient. 
However, to make the score more meaningful it would require further refinement to 
overcome its disadvantages. Although some of the ranges are based upon those in previous 
scores and common physiological facts, many are based on the experience of a single 
clinician. It could be refined by including a greater number of clinicians using some of the 
techniques described in chapter 3, e.g. a Delphi process or brain storming sessions to 
achieve a consensus about the parameters for inclusion and the ranges. As discussed, in the 
absence of a reference standard, the weighting of the score would be difficult. We could 
test it in a number of clinical scenarios to establish if the score attributed to various 
parameter ranges is credible to other experts. The relative weightings of parameters could 
then be altered to give the best fit. Therefore, although the score could have been 
improved, in the absence of a reference standard it would ultimately be justified by testing 
against expert opinion.   
 
Reflection on this problem led to the idea of examining it from a different angle. Rather 
than define ranges of parameters to give an arbitrary score between -3 and + 48 and then 
justify if clinically credible, an alternative approach was to capture and base the actual 
score on clinical expertise in the first place. This was the premise behind the Intensive Care 
Unit Patient Scoring System described in Chapter 5. It was hoped that it might better 
capture clinical interpretation of a situation than the quantitative score. For example, a 
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patient who is cardiovascularly stable in every respect except for requiring 100% would 
score moderately highly in the quantitative score, but in reality is clinically extremely ill. 
 
4.6. Conclusion 
Having overcome difficulties with missing or inconsistent data, the quantitative score of 
cardiovascular stability could be successfully applied to real patient data sets and quantify 
stability over time. Although this approach had merit it was judged that a more clinically 
credible, and alternative approach was to capture and base the actual score on clinical 
expertise in the first place. This was the premise of the Intensive Care Unit – Patient 
Scoring System described in Chapter 5. 
 
4.7. Acknowledgements 
I decided on the nomenclature and units used for recording the chosen parameters. The 
protocol for handling missing values was decided as a result of a clinical discussion 
between myself and Prof. Kinsella. The scoring system being tested was designed entirely 
by myself. 
 
The 3 data sets analysed were extracted from CareVue by the CareVue administrators. The 
data were pre-processed and my quantitative score was run against the cleaned data by our 
Computing Science Collaborators, to produce the graphical representations of quantitative 
score over time. 
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Chapter 5: Development of the Intensive Care Unit Patient Scoring System 
(ICU-PSS) 
 
Abstract 
5.1.1. Background 
The quantitative score developed could produce a measure of cardiovascular stability over 
time. However, it produced a number on a scale which was difficult to relate to clinically, 
and which relied upon one clinician’s experience. The aim was now to develop a 
qualitative 5 point scale underpinned by a sophisticated physiological rule base. 
 
5.1.2. Methods 
In the initial phase, two clinicians annotated real patient datasets and marked broad time 
periods on a 5 point scale of stability. In the next more detailed phase, one clinician 
annotated 10 data sets with 2761 predominantly hourly time points, and simultaneously 
described physiological rules to justify his annotations. These rules were used by a 
computer programme to annotate unseen datasets. The unseen datasets were also annotated 
by the clinician, and the computer prediction based on his rules, and his actual annotations, 
compared in a confusion matrix. Points of disagreement were analysed and the rule base 
refined.  
 
5.1.3. Results 
As a result of comparing his annotations with the computer prediction the clinician was 
able to produce a rule base which captured his clinical expertise. This process was repeated 
with two other senior Intensive Care Clinicians to produce a sophisticated set of 
physiological rules (The ICU-PSS), which underpinned the 5 point qualitative scale. 
 
5.1.4. Conclusions 
Through a process of gradual refinement, a complex series of physiological rules was 
developed which captured the clinical expertise of 3 senior Intensive Care Clinicians. This 
formed the Intensive Care Patient Scoring System (The ICU-PSS) 
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5.2. Introduction 
I had devised a quantitative scoring system for cardiovascular instability in Intensive Care 
Patients which took into account the level of support the patient required. However, it 
produced a number between -3 and +48 (for the parameters recorded at regular intervals). 
As with many clinical measurements, a numerical score has relatively little usefulness at 
the bedside. An obvious comparison could be made with visual analogue scores for pain, 
which are of less use than simple verbal rating scores. Rather than define ranges of 
parameters to give an arbitrary score between -3 and + 48 and then justify if clinically 
credible, an alternative approach was to capture and base the actual score on clinical 
expertise in the first place. It was felt that it would be more clinically relevant if the patient 
state could be summarised in a 5 level qualitative score. This chapter describes the design 
and refinement of such a 5 level qualitative score, with each level based on detailed and 
clinically reasoned quantitative rules. 
 
In 1946 De Groot described what is considered to be the first attempt to capture the 
performance of an expert 
114
. He was a skilled chess player and determined that the ability 
to play chess is “best captured in the task of selecting the next move for a given chess 
position taken from the middle of the game between two chess masters.” He postulated that 
if you give the same unfamiliar chess position to a number of different players of different 
skill levels then this should discriminate and capture innate expertise at playing the game. 
His group found that this expertise was not associated with looking ahead, rather with 
skilled pattern recognition that came from the storage in an expert’s memory of many 
different patterns built up over time.  In 1996 Ericsson and Lehmann postulated that 
experts have no innate ability in a domain, rather expertise arises from “extensive 
deliberate practice” 115. However, Camerer and Johnson argue that despite this, experts are 
susceptible to “systematic errors, biases, and limitations of performance” 116. This is 
described well in two related studies by Lewandowsky and Kirsner in 2000 
117
. In 
simulations 14 expert bush fire commanders with an average of 18.31 years of expertise 
were asked to predict the extent of a fire and the best method to bring it under control.  
Accuracy was high but large errors made when the two major predictors were in 
opposition. Secondly opposing predictions were made even when the conditions were kept 
the same. The authors postulated that experts may hold “separate, and sometimes even 
mutually exclusive, components of knowledge”. 
 
Ericsson argues in the acquisition of expertise that it is therefore better to observe an expert 
solving a task rather than ask them to describe what they are doing in the abstract
118
.This 
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was illustrated in part by earlier work by Jonson 
119
 who observed a medical professor’s 
explanation of his diagnostic process. When he accompanied the professor on his ward 
round he was struck by differences in his diagnostic technique in practice. When 
challenged the professor said “Oh, I know that, but you see I don’t know how I do 
diagnosis, and yet I need to teach things to students. I create what I think of as plausible 
means for doing tasks and hope students will be able to convert them into effective ones”. 
Therefore, to avoid inconsistency and bias, one of the fundamentals of knowledge 
acquisition to ask an expert to explain how they are solving a task in real time. 
 
In any study to capture expertise it is worth trying to dissect expertise into a number of 
components to better understand what it is you are trying to capture. The American 
psychologist Gary Klein divides expertise into knowledge “what you have to know” and 
skills “what you can do with that knowledge” 120 .The two are interrelated. As an expert 
gains knowledge in an area the skill which follows is the ability to spot anomalies. With 
experience causal frameworks are constructed in the mind as the expert rationalises why 
things happen in a particular manner. The ensuing skill is the ability to assess new 
situations. With greater knowledge and experience many thought processes and tasks 
become routine with and ability to make perceptual discriminations. This results in the 
ability to task prioritise, make rapid decisions and detect problems early.  
 
Knowledge elicitation (or cognitive task analysis in psychology) has no universally 
accepted classifications of methodology. Hoffman in 1995 proposed that they be divided 
into unstructured interviews, structured interviews, analysis of unfamiliar tasks and 
analysis of contrived tasks 
121
.
 
A more comprehensive suggested classification is provided 
by Klein in 2001 
120
. He suggests the following categories: Interview methods, observation 
methods and modelling methods. To deal with each in turn: 
 
Interview methods include structured, semi-structured and unstructured techniques. 
Concept maps are akin to a circuit diagram for an electrical appliance where the 
relationships between different ideas are explored. Critical decision analysis involves an 
expert recalling a specific incident. This is then analysed in an interview whose task is to 
elicit different strands of information from the expert 
122
. 
 
Observation methods include direct observation questioning. Process tracing allows the 
expert to verbalise what they are thinking, a so-called concurrent verbal protocol. In 
psychological terms the subject’s verbalisation reflects working memory and reflects the 
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cognitive processes associated with performing a task. These sessions are typically 
recorded so that transcripts can be made of the concurrent verbal protocols. They can be 
converted into “protorepresentations.” This means that some modelling is already 
completed at the pre-modelling stage. High and low fidelity simulation as well as 
expert/novice comparisons are self-explanatory. 
Modelling of the information gained during interviews or observational methods can be 
done in several ways. Sorting techniques are used to capture how experts order and 
compare concepts and can lead to knowledge about task prioritisation. Hierarchy-
generation utilises “laddering” to build taxonomies (a hierarchical classification of 
concepts) or other hierarchical structures e.g. decision networks. In Matrix-based 
techniques, grids are constructed where problems encountered are placed against possible 
solutions. This was the modelling technique used in the development of the Intensive Care 
Unit – Patient Scoring System described in this chapter).  
There is no correct way in which to undertake knowledge elicitation given that there are an 
infinite numbers of types of knowledge in existence. However, there are some guiding 
principles. Hoffman 
121
 argues that argues that a single technique should not be relied upon 
as it may potentially yield only partial information. Further knowledge, which is acquired 
early in the process, should “constrain subsequent knowledge elicitation.” Various authors, 
for example Brule and Blount in 1989 
123
 suggest possible stages in the knowledge 
elicitation process which are shown in the table 5-1. 
Table 5-1: Suggested stages for the knowledge acquisition process 
STAGE  METHOD  PURPOSES 
1 / 2 (identical 
stages) 
Unstructured Interviewing 
Observation of tasks familiar to the expert 
 
Researcher becomes familiar with the 
“domain” under investigation 
Generates a “first pass” knowledge base 
 
3/4 Structured interviews 
“Think aloud” problem solving (forming 
concurrent verbal protocols) 
Contrived tasks 
Provides some validity to stages 1/2 
Extends knowledge base 
Refines knowledge base 
Once these stages are complete the refined knowledge base can be modelled using the techniques described 
above, in the case of the ICU-PSS in confusion matrices. 
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5.3. Methods  
5.3.1. Development of broad classifications of instability 
The patient data sets on which the quantitative score was tested (708,723 and 728) were 
reviewed independently by two clinicians (myself and Prof. John Kinsella) for the entire 
patient stay. We each identified time periods during which the patient was deteriorating, 
stable, or improving, and gave reasons for our opinion, e.g. inotropes decreasing, inspired 
oxygen falling etc. This was done in the form of an interview with the computing 
scientists, which was recorded, and transcripts made. As this information was recorded by 
computing scientists either the medical terms used were explained, or lay language was 
used. 
 
In knowledge elicitation methodology, although there are no specific protocols, it is 
generally accepted that the first step in the process should be an interview (either 
unstructured or structured) between the expert and the researcher 
123
.These have several 
important functions. In knowledge elicitation parlance “bootstrapping” is the process 
whereby the researcher develops a “conceptual model of the domain.” 124 Neale goes on to 
suggest that this should be to the level of an apprentice. This is defined as “a student 
undergoing a programme of instruction beyond the introductory level” and someone who 
“assists someone at a higher level.” 121. This poses some challenges, particularly in this 
project. The researchers are computing scientists who although involved in a number of 
medically related studies previously have little medical knowledge, especially in Intensive 
Care. These interviews led to lengthy discussions between myself and the computing 
scientists explaining the relevant aspects of the “domain.” What was quickly appreciated 
was that completely routine terms and concepts to myself were completely alien to them. 
An example of a summary document I prepared and sent to them, as a reference of terms is 
included in the Appendix III of the thesis. 
 
Initial Interviews are important for the “experts” as they allow them to get used to 
interacting with the researcher and starting to examine the data. Further, structured 
interviews constrain the expert response and are more likely to result in systematic 
coverage of the domain 
125
. Specifically relating to this work, in these interviews myself 
and Prof. Kinsella examined data comprising the whole stay of three patients in Intensive 
Care. The aim was not to describe clinical situations (no clinical information was made 
available because of anonymisation), rather it was to describe whether the patient in our 
opinion from the physiological and pharmacological data in front of us was clinically 
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stable, improving or deteriorating. (Although no clinical history was available “blood 
pump speed” would indicate the patient undergoing a period of haemodialysis).  
The data reviewed was predominantly hourly but it was decided to comment on it in 
different blocks of time (usually 1 to 5 hour periods). The specific time periods were less 
important than the commentary given as to why the patient was very unstable, stable and 
so on. There were no prescribed time periods for analysis or comparison within the whole 
patient stay as the purpose of this exercise was to generate what is defined in knowledge 
language as a “first pass knowledge base.” 121. This knowledge base was a very basic 
description of 5 levels of stability of a patient from A (stable) to E (highly unstable). Note 
Prof. Kinsella and myself undertook the interviews at different times. There was no direct 
exploration of discordance or concordance at this stage. As an example the transcript with 
my opinions for patient 708 is shown in figure 5-1. All three complete transcripts are 
shown in Appendix IV. 
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Figure 5-1: Transcript of descriptions of stability for patient 708 
Time & Date Comments Condition of Patient 
19/12/06 19:45:37 – 19/12/06 
21:00:00 
Heart rate high, oxygen 
saturation low. Aggressive 
fluids are given in response to 
high heart rate. Test patient’s 
response to fluids. Despite 
being given the fluids, the blood 
pressure is low. Incubated at 
8pm. Very sick patient. Despite 
intubation, oxygen saturation 
only went up to 92. 
Very bad, getting worse 
19/12/06 22:00:00 Central line put in. Blood 
pressure not responding to 
Adrenaline and Noradrenaline. 
FiO2 and SpO2 are grim. Most 
likely septic as a lot of 
adrenaline and nor adrenaline 
given. 
Worse - Decreasing 
20/12/06 02:00:00 - 20/12/06 
04:00:00 
100% oxygen given but 
saturation decreasing. Increase 
in adrenaline and nor adrenaline 
but blood pressure still low. 
Worse - Decreasing 
20/12/06 05:00:00 - 20/12/06 
10:00:00 
Getting worse. Blood pressure 
not moving. Heart rate 
increasing. Urine output tailing 
off. Oxygen saturation dire. 
Worse - Decreasing 
20/12/06 13:00:00 - 20/12/06 
15:00:00 
High amounts of adrenaline and 
Noradrenaline. Blood pressure 
grim. No change, very unwell. 
Stable – No worse 
20/12/06 16:00:00 - 20/12/06 
17:00:00 
Oxygen worse. Noradrenaline 
increased. Not enough blood 
pressure for urine. 
Worse 
20/12/06 18:00:00 - 20/12/06 
20:00:00 
DIALYSIS 
Gets worse on dialysis. Blood 
pressure even lower. Oxygen 
saturation is slightly higher. 
Could be because fluid had built 
up in the lungs and has now 
been removed. 
On balance, stable 
Rest of session Gradual deterioration.  
Oxygen saturation and blood 
pressure continue to decrease. 
Becoming more and more 
septic. Patient in the end dies, 
probably from a cardiac 
arrest/deciding not to increase 
drugs further. 
Much worse 
 
The transcripts of these interviews were reviewed by myself for factual accuracy and 
corrected accordingly. Further misconceptions were discussed with the computing 
scientists. They then analysed the data and extracted the knowledge captured by 
identifying periods where we had said the patient was stable or unstable, improving or 
deteriorating and by grouping similar types of comments together generated a suggested 
scheme for descriptions of the 5 levels of stability. The classification is shown in table 5-2. 
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Table 5-2: Suggested classification of instability by the computing scientists based 
upon our annotations 
 
Level Clinical Summary 
1 (A) Patient’s CVS stabilized, with low or no 
AD/NADR, and reduced oxygen; Urine 
production often essentially normal. 
2 (B) Patient CVS stabilized, and probably needing 
less of AD / NADR, and reducing levels of 
sedatives & Oxygen. 
3 (C) Patient CVS system is effectively stabilised; 
probably on decreased dosage of AD / NADR 
 
4 (D) Patient’s CVS is beginning to stabilize but 
requires high doses of AD / NADR and / or fluid 
to retain stability. 
 
5 (E) Patient’s CVS is very unstable (which is usually 
true in early phases of resuscitation); low BP or 
rapidly changing AD / NADR, and large fluid 
inputs. 
6 Dead 
 
 
At this stage Prof. Kinsella and myself discussed this suggested classification and both 
agreed that it was a good reflection and ordering of our commentaries in the first set of 
interviews. However it was felt that at level C the wording “probably on decreased dosage 
of adrenaline / noradrenaline” should be changed to “probably on low dosage of 
adrenaline/noradrenaline” and to add in a comment about oxygen. It was also thought 
better to stress the relative levels of drug dosage than to have a commentary about rate of 
change. Therefore, discussion about concordance / discordance was at this stage and not at 
the interview stage. This broad classification was a useful anchor for future more detailed 
descriptions of instability classes. The revised classification is shown in table 5-3. 
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Table 5-3: Suggested classification of instability after review by Dr. Sim and  
Prof Kinsella 
Level Clinical Summary 
1 (A) Patient’s cardiovascular system stabilised, with 
low or no adrenaline / noradrenaline, and no or 
low levels of oxygen; urine production often 
essentially normal 
2  (B) Patient cardiovascular system stabilised, and 
probably needs low levels of adrenaline / 
noradrenaline, and low levels of sedatives and 
oxygen 
3 (C) Patient cardiovascular system is effectively 
stabilised; probably on low dosage of adrenaline 
/ noradrenaline and oxygen. 
4 (D) Patient’s CVS is beginning to stabilise but 
requires high doses of adrenaline / noradrenaline 
and / or fluid to retain stability. 
5 (E) Patient’s CVS is very unstable (which is usually 
true in early phases of resuscitation) with low BP 
and high HR or rapidly changing adrenaline / 
noradrenaline dosage, and requires substantial 
fluid inputs. 
6 Dead 
 
This classification was a capturing and refinement of what 2 clinicians thought the 5 broad 
stability levels represented.  
 
5.3.2 Using the broad classifications to assign levels of stability to datasets 
In knowledge elicitation methodology it is common practice to have more than one round 
of interviews between the researchers and expert (stage 1/2 in Brule and Blount’s 
suggested strategy for acquiring knowledge 
121
. On the basis of the first stage of interviews 
a 5 point scale giving a broad descriptions of patients in the different classes of stability 
had been derived from our comments (and then refined by myself and Prof. Kinsella). 
These second stage interviews took this process a step further and were a form of forward 
scenario simulation 
125
 whereby an expert is taken through a problem (in this case the data 
from patients in intensive care) and create some basic “if-then” rules. That is to say the 
entire patient stays from the 3 patients were reviewed by us both in the first set of 
interviews. For each day of the stay (in its entirety) an overall classification on the A to E 
scale was given and some reasons why a patient was placed in a particular category. The 
broad classifications from the first set of interviews were useful as a suggested structure 
(this is important as experts can be very inconsistent if asked to analyse a task completely 
in the abstract) 
118
. This served several purposes. Firstly there was opportunity to get used 
to looking at classifying data on an A to E scale and secondly I was able to start forming 
“rules” underpinning my classifications which would be required in the next very detailed 
experiment. This unstructured (at this stage) information became organised into my first 
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rule base that was used to detect inconsistencies in my subsequent more detailed 
annotations. Lastly the detailed transcripts were again reviewed by myself for factual 
inaccuracies and this was another opportunity to clarify more misconceptions held by the 
computing scientists i.e. the on going process of them becoming more familiar with the 
“domain.” 
 
The complete annotations for patients 708 and 728 with the explanations are given in the 
Appendix V. An extract is shown in figure 5-2. 
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Figure 5-2: Assigning stability levels and starting to formulate ranges for 
parameters to justify a stability level 
 
Patient 708 
Day Comments - Prof. 
Kinsella 
Level  Comments – Dr. Malcolm Sim Level  
Day 1 
19/12/06 
First thing, given patient 
fluid in a large volume and 
ADR & NORAD and it has 
taken several hours to get 
on top of the situation. Low 
BP, High HR and a lot of 
treatment used to get those 
values. MAP, adequate 
value is between 60 -100. 
HR >100 abnormal. 
Fluid > 1litre – high amount 
Fluid > 700ml – Starting to 
worry 
Supporting evidence, Urine 
and FiO2. Main points: 
 
1) Total fluids initially high 
E 100% oxygen but saturation only up 
to 90%. 
Heart Rate is very high 
 
E 
Day 2 
20/12/09 
Still unstable despite need 
for fluids decreasing. 
NORAD increases and 
ADR decreased. Still high 
HR & BP not impressive. 
IF BP in the 50s – losing 
the battle. Looking at trends 
in particular, the running 
average for MAP & HR. 
E Low oxygen saturation despite still at 
100% Oxygen. High Heart Rate and 
hypotensive despite both adrenaline 
and noradrenaline.  
 
1) Oxygen 
2) High HR despite ADR & 
NORAD 
3) Blood Pressure 
4) Urine Output 
 
Oxygen Saturation: 
 
96-94: Not bad 
Below 94: Bad 
90-84: Very Bad 
 
E 
Day 3 
21/12/09 
Remains unstable/dying. 
Increase in NORAD & 
ADR, BP decreasing and 
there is a fast HR. Average 
ADR & NORAD. Looking 
at trend of MAP. 
6 Patient stays bad 
 
1) Oxygen saturation bad and 
100% oxygen 
2) Blood Pressure & HR 
3) Urine 
 
Heart Rate 
 
HR > 140: Bad as heart doesn’t refill 
properly. 
E 
 
In the next stage of the experiment, the process of annotating data sets with an overall level 
of stability, and the formation of rules governing a level of stability assigned, was repeated 
on a much larger scale and in greater detail. This would lead to the formulation of a 
sophisticated rule base. In order to run this next experiment which was designed to show 
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and correct inconsistencies in my annotations of the stability of a patient I had to create a 
rule base which would be then be compared against these annotations. As above it has been 
shown that if you ask an “expert” to describe something they do subconsciously or 
intuitively in the abstract they are often significantly inconsistent 
118,119
. The same principle 
applies to this task. De novo ranges could have been created of relevant parameters that I 
perceived represented level A through to E. However knowledge elicitation methodology 
suggests it is better to first extract a basic knowledge base as you are more likely to tease 
out knowledge that is ingrained. Having done this in the first set of interviews I then 
started to formulate some basic “if - then” rules (e.g. “if oxygen saturation 84% then level 
E”) during the second set of interviews, having the framework of the 5 point classification 
to work form during the review of real patient data. These “if -then” rules were 
subsequently placed into the skeleton of the first rule base. This made the task of filling in 
the other ranges easier.”  
 
5.3.3. Detailed annotation of data sets and formulation of a rule base 
10 patient data sets were prepared for annotation and analysis. They contained all of the 
commonly collected physiological and drug data obtained from the Electronic Patient 
Record. There were up to 41 parameters, depending upon the infusions the patient was 
receiving, or if there was cardiac output monitoring attached. Examples of the main 
parameters are heart rate, mean arterial pressure, diastolic and systolic blood pressure, 
inspired oxygen concentration, oxygen saturation, central venous pressure, temperature, 
urine output, fluid administration and doses of adrenaline, noradrenaline, propofol, 
midazolam and alfentanil. Clearly, not all of these parameters would be present at every 
time point. The data were presented at predominantly hourly intervals throughout the 
patient stay, as this is the interval at which the nursing staff record and verify the 
information in the CareVue system. The details of the patients and the number of time 
points are shown in table 5-4. The total number of time points is 2761. Note that patient 
number 708 was used in the pilot. However, the annotation in the pilot was an overall 
stability level for a 24-hour period and not the much more detailed annotation at this stage 
of development.  
 
Table 5-4: Summary of the 10 annotated patient data sets 
Patient Code 696 705 707 708 720 728 733 738 751 782 
Number of time points 
(or instances) 
 
129 
 
576 
 
475 
 
40 
 
188 
 
281 
 
396 
 
110 
 
493 
 
73 
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I annotated the 10 data sets throughout the patients’ complete stay in Intensive Care, 2761 
points in total. Unlike the pilot annotations described above, I marked each recorded time 
point on a 5 point scale (A to E), using the descriptions in table 1 and my clinical 
experience as a starting point.  The complete annotations for patient 720 are recorded in the 
Appendix VI. The others are not included due to their length. An extract from patient 705 is 
shown below in table 5-5. 
 
As I annotated the data sets, I formulated a rule base for the key parameters regarding what 
should constitute their range e.g. an “A” mean arterial pressure or a “D” inspired oxygen 
saturation and so on. Figure 5-3 shows the first rule base I formulated capturing the clinical 
expertise underpinning my annotations. 
 
Table 5-5: Extract from my annotations of patient 705 
Time HR MAP CVP FiO2 SpO2 Norad. Adren. Prop. Alf. Hartmanns A-E Score 
            
Day 1                      
            
15/12/200
6 03:00            
15/12/200
6 03:06 129 73 0  100 0.4 2.4    D 
15/12/200
6 03:08 115 70   98      D 
15/12/200
6 03:15    0.5 100      D 
15/12/200
6 03:24        100 1  D 
15/12/200
6 04:00 120 80 24 0.6 98 0.9 1.6 100 1 125 D 
15/12/200
6 05:00 113 66  0.6 99 0.9 1.6 100 1 125 D 
15/12/200
6 06:00 114 66 27 0.55 94 1.3 1.6 80 0.5 125 C 
15/12/200
6 07:00 104 60  0.6 97 1.4 1 20  125 C 
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Figure 5-3:  First rule base underpinning my stability classifications 
 
Conditions to be met to score a 
particular level 
Ranges of parameters  
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 97-100% 
FiO2 is 0.21-0.4 
Heart Rate 60-80 
Mean Arterial Pressure is 65-85 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-96% 
FiO2 is 0.41-0.59 
Heart Rate 50-59 
Heart Rate 81-109 
Mean Arterial Pressure is 60-64 
Mean Arterial Pressure is 85-109 
Adrenaline 0.1-1.3 mg/h 
Noradrenaline 0.1-1.3 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 91-93% 
FiO2 is 0.6-0.69 
Heart Rate 45-49 
Heart Rate 110-120 
Mean Arterial Pressure is 55-59 
Mean Arterial Pressure is 110-119 
Adrenaline 1-1.4 mg/h 
Noradrenaline 1-1.4 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.84 
Heart Rate 121-140 
Heart Rate 40-44 
Mean Arterial Pressure is 50-54 
Mean Arterial Pressure is 120-129 
Adrenaline 1.5-1.9 mg/h 
Noradrenaline 1.5-1.9 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-88% 
FiO2 is 0.85-1.0 
Heart Rate 0-39 
Heart Rate 141-500 
Mean Arterial Pressure is 0-49 
Mean Arterial Pressure is 130-200 
Adrenaline 2.0-10 mg/h 
Noradrenaline 2.0-10 mg/h 
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5.3.4. Resolving inconsistencies between Dr Sim’s clinically based 
annotations and his rule base 
I needed to ascertain how consistent I was being in the use of the rule base I had 
formulated during the annotation of time points. Was my clinical opinion consistent with 
the rules I was formulating, characterising each level of the 5 point score?  If this were the 
case, the rule base incorporated into a computer programme which automatically scored 
the same data sets should agree with my scoring based on clinical experience.  
 
In order to test this hypothesis I made use of the INSIGHT system created by our 
computing science colleagues. This system allows clinicians to explore and remove 
inconsistencies in their classification of data
126
. In this particular case the rule base I had 
formulated (figure 5-3) was incorporated into INSIGHT, which then automatically 
assigned an A to E score for the 10 data sets. The difference between my clinical 
annotations and the automatic annotations based on my rule base was displayed in a series 
of confusion matrices, as illustrated in figure 5-4 
 
Figure 5-4:  An example of a confusion matrix 
 
 
 
A confusion matrix is a pictorial representation of, in this case, the A to E levels I assigned 
to the time points within a patient’s stay (observed) and the A to E levels the computer 
programme assigned to the same time points based on my rule base. A diagonal line from 
top left to bottom right represents a 100% agreement between my clinically based 
annotations and the computer’s annotations, adhering to the rules. The further away a 
matrix box is from this diagonal, the greater the difference between the clinical and 
computer scores. 
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In the following methodology, each box away from the diagonal was examined to ascertain 
the reasons for the disparities between the clinically based annotation and the computer 
prediction. This led to successive alterations in the rule base which captured clinical reality 
more accurately with each revision. 
 
5.3.5. Refinement of Dr. Sim’s rule base 
Refinement was achieved in two phases. My initial rule base was run against the 10 
patient, 2760 time point data set. The resulting confusion matrix is shown in figure 5-5.  
 
Figure 5-5: Confusion matrix of the initial rule base run against the 10 patient data 
set 
 
 
 
 
As can be seen the correlation between the initial rules and the data set is highest in the 
most severely unstable categories (92% agreement across the 10 data sets on observed E, 
expected E). It is worst for the most stable category (only 10% agreement in observed A, 
expected A across the 10 data sets). Many of the inconsistencies only differ by one 
category. For example expected C and observed C gives 40% agreement across the sets, 
but add in the observed C and expected D cell plus the observed C but expected B cell and 
this takes the agreement to 99%. 
 
Due to the large number of instances in some of the cells (831 in category A) the 
refinement was divided into two phases. In the first session I chose initially to concentrate 
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on patient 705 as this patient stay had the greatest number of time points (576) out of the 
10 contained within the data set. The initial rule base I articulated as I made the 
annotations (figure 3) was run against my clinical annotations of this patient’s data and 
presented as a confusion matrix in INSIGHT. As above if I was consistent with myself, 
then there should have been 100% agreement between my rule base and my clinical 
annotations. The confusion matrix for the initial rule set run against patient 705 is shown in 
figure 5-6. 
Figure 5-6: Confusion matrix of the initial rule base run against patient 705 (576 
data points) 
 
 
 
This process of refinement for each cell within the matrix was undertaken in the following 
order (given as observed / expected): A/E, B/E, C/E, B/D, D/B, A/C, A/B, B/A, D/E, D/C, 
B/C, D/C, B/D, C/B and C/D.  
 
With my computing science colleagues, I considered each cell in the confusion matrix for 
that patient in turn, where there was disagreement between what I had annotated 
(observed) and the result my rule base produced (expected). There were no instances where 
I had annotated level “E” and my rule base had annotated anything other than “E”. Within 
every other cell of the matrix there was disagreement. I looked at cells where there the 
disagreement was gross, i.e. I had observed A and the rule base had annotated an E. I 
examined each time point within the cell to try to understand the nature of the 
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disagreement. To make this task easier, I predominantly focused on 6 key parameters, 
namely heart rate, mean arterial pressure, oxygen saturation, inspired oxygen 
concentration, dose of adrenaline and noradrenaline.  
 
Figure 5-7 shows the transcript for the refinement of patient 705 in the exact order in 
which it occurred. This leads to the reasons for discordance and actions discussed after the 
transcript, and a refined rule base which is also shown after the transcript.  
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Figure 5-7: Transcript for the refinement of patient 705 
 
TRANSCRIPT OF SESSION 1, patient 705 
 
Annotation ‘A’ – Rules ‘E’ 
Row ID Parameter Action Comment/Rule Change 
457 HR Heart rate of 372 removed  
494 HR Heart rate of 7 removed  
544 HR Heart rate of 3 removed  
 
Annotation ‘B’ – Rules ‘E’ 
Row ID Parameter Action Comment/Rule Change 
577 SpO2 Changed annotation to E because saturation was low  
681 Heart Rate Heart Rate value of 16 removed  
 
Annotation ‘C’ – Rules ‘E’ 
Row ID Parameter Action Comment/Rule Change 
272 SpO2 Changed annotation to E as saturation had fallen and hence 
patient unstable 
 
 
Annotation ‘A’ – Rules ‘D’ 
Row ID Parameter Action Comment/Rule Change 
586 MAP Mean pressure too low for an ‘A’. Rules were changed for a 
category ‘D’ and agreed. Annotation changed to ‘D’. 
 
641 MAP Mean pressure too low for an ‘A’. Rules were changed for a 
category ‘D’ and agreed. Annotation changed to ‘D’. 
 
 
Annotation ‘B’ – Rules ‘D’ 
Row ID Parameter Action Comment/Rule Change 
172 FiO2 Annotated as a ‘B’ because FiO2 was getting better over 
time. Made the annotation a ‘C’ because the amount of 
Noradrenaline not as important. 
Examine relationship of Mean and 
Noradrenaline 
643 MAP Annotation changed to D because of the MAP. - 
 
Annotation ‘D’ – Rules ‘B’ 
Row ID Parameter Action Comment/Rule Change 
134 - Although there are some key parameters there, still missing 
data for some parameters. Annotation still most likely but 
changed to ‘Unclassified’ due to missing values. 
- 
135 - Limited data, probably gave ‘D’ based on averaging previous 
parameters. Annotation changed to unclassified. 
- 
252 - Would make the annotation a C as D was a bit harsh. - 
253 FiO2 Changed to C as FiO2 at 55% - 
254 FiO2 Changed to C as FiO2 at 55%  
256 FiO2 Changed to C as FiO2 at 55%  
259 FiO2 Changed to C as FiO2 at 55% May need to look at FiO2 
 
Also altered: 
Row ID Parameter Action Comment/Rule Change 
233  Annotation changed to E - 
234  Annotation changed to E - 
236 & 237  Annotation changed to E - 
242 – 249  Annotation changed to C - 
250 – 251  Annotation changed to unclassified - 
 
Annotation ‘A’ – Rules ‘C’ 
Row ID Parameter Action Comment/Rule Change 
322  Changed annotation to D - 
330 MAP Changed annotation to B because the Mean was low - 
359 MAP Changed annotation to B because the Mean was low - 
381 Heart Rate Annotation changed to C because Heart Rate was 114. - 
478 MAP Annotation changed to B because Mean was 58  
486 SpO2 Annotation changed to C because saturation was 93  
491 MAP Annotation changed to B because Mean was 57  
528 MAP Annotation changed to B because Mean was 57  
529 MAP Annotation changed to B because Mean was 57  
571 SpO2 Annotation changed to C because the saturation was 93  
323  Annotation changed to C  
324  Annotation changed to C  
325  Annotation changed to C  
326  Annotation changed to C  
587 MAP Annotation changed to B  
606 MAP Annotation changed to B  
613 MAP Annotation changed to B  
615 MAP Annotation changed to B  
640 MAP Annotation changed to B  
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Annotation ‘A’ – Rules ‘B’ 
Row ID Parameter Action Comment/Rule Change 
314 HR Annotation changed to B as heart rate was high  
316 HR Annotation changed to B as heart rate and mean high  
317 HR Annotation changed to B as heart rate was high  
318 HR Annotation changed to B as heart rate was high  
319 HR Annotation changed to B as heart rate was high  
320 HR Annotation changed to B as heart rate was high  
321 HR Annotation changed to B as heart rate was high  
327 HR Annotation changed to B as heart rate was high  
329 HR Annotation changed to B as heart rate was high  
331 HR Annotation changed to B as heart rate was high  
332 HR Annotation changed to B as heart rate was high  
   RULE CHANGE 
 
Rule ‘A’ , HR changed to (60-83) 
instead of (60-80) 
 
Rule ‘B’, HR changed to (84-109) 
333 HR Annotation changed to B as heart rate was high  
334 HR Annotation changed to B as heart rate was high  
335 HR Annotation changed to B as heart rate was high  
336 HR Annotation changed to B as heart rate was high  
337 HR Annotation changed to B as heart rate was high  
338 - 349 HR Annotation changed to B as heart rate was high  
350 HR Annotation changed to C because HR was 100 Might need a rule change for ‘C’, 
HR (110 – 100) 
351 HR Annotation changed to B as heart rate was high  
352 HR Small amount of values but still enough to change the 
annotation to B 
 
353  Annotation changed to B  
354  Annotation changed to B  
355 - 368 HR Annotation changed to B as heart rate was high  
363 HR & MAP Annotation changed to B because of both the HR and MAP  
369 HR & MAP Annotation changed to B because of both the HR and MAP  
370 - 377 HR Annotation changed to B because of the HR  
383 HR & MAP Annotation changed to B because of both the HR and MAP  
384 HR Annotation changed to B because of the heart rate  
453 HR & SpO2 Annotation changed to B because of the HR and an SpO2 of 
95 
 
454 HR & SpO2 Annotation changed to B because of the HR and the SpO2  
455 HR Annotation changed to B  
456 HR Annotation changed to B  
457  Annotation changed to B because of some of the other 
values. However some values missing and trending used. 
 
458 HR Annotation changed to B because of the heart rate  
459 - 469 HR Annotation changed to B because of the heart rate  
461 & 466 HR & MAP Annotation changed to B because of the heart rate and MAP  
469 HR, MAP and SpO2 Annotation changed to B because of the values for Heart 
Rate, MAP and SpO2 
 
470 HR Annotation changed to C because of the value for heart rate  
479 HR Annotation changed to B because of the value for heart rate  
480 SpO2 Annotation changed to B because the SpO2 was 96 Should the rule for ‘A’ be changed 
? SpO2 96 or above. 
482 – 484 SpO2 Annotation changed to B because of the value for SpO2  
485 HR & SpO2 Annotation changed to B because of the value for SpO2and 
the value for HR 
 
487 - 489 SpO2 Annotation changed to B because of the value for SpO2  
   RULE CHANGE 
 
‘B’ SpO2 changed to (94- 95) 
 
‘A’ SpO2 changed to (96 - 100) 
 
‘B’ HR changed to (84 - 99) 
 
‘C’ HR changed to (100 - 120) 
466 HR & MAP Annotation changed to B because of the value for HR and 
MAP 
 
490 FiO2 Annotation changed to B because of the value for FiO2  
492 FiO2 Annotation changed to B because of the value for FiO2  
493 FiO2 Annotation changed to B because of the value for FiO2  
494 – 507 FiO2 Annotation changed to B because of the value for FiO2  
508 SpO2 & FiO2 Annotation changed to B because of the values for SpO2 
and FiO2. 
 
509 - 523 FiO2 Annotation changed to B because of the value for FiO2  
524  SpO2  Annotation changed to B because of the values for SpO2.  
525 - 532 FiO2 Annotation changed to B because of the value for FiO2  
533 FiO2 & MAP Annotation changed to B because of the values for FiO2 and 
MAP 
 
534 - 537 FiO2 Annotation changed to B because of the value for FiO2  
538 FiO2 & HR Annotation changed to B because of the values for FiO2 and 
HR 
- 
539  FiO2 Annotation changed to B because of the value for FiO2 - 
540 - 543 FiO2 & HR Annotation changed to B because of the values for FiO2 and 
HR 
- 
544- 546 FiO2 Annotation changed to B because of the value for FiO2 - 
548 HR Annotation changed to B because of the value for Heart 
Rate 
- 
550 - 551 HR Annotation changed to B because of the value for Heart 
Rate 
- 
552 FiO2 Annotation changed to B because of the value for FiO2 - 
553 FiO2, HR, MAP, 
SpO2 
Annotation changed to B because of the values for FiO2, 
HR, MAP and SpO2 
- 
555 SpO2 Annotation changed to B because of the value for SpO2 - 
557   Should be A – Something wrong 
with the rules? 
564   Should be A 
598 SpO2 Annotation changed to B because of the value for SpO2 - 
600 SpO2 Annotation changed to B because of the value for SpO2 - 
617 HR Annotation changed to B because of the value for HR - 
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623 MAP Annotation changed to B because of the value for MAP - 
657 HR & MAP Annotation changed to B because of the values for Heart 
Rate and MAP. 
- 
706 FiO2 Annotation changed to B because of the value for FiO2 - 
   RULE CHANGE 
 
‘A’ , MAP changed to (60 - 84) 
 
‘B’ MAP changed to (57 - 59) 
 
‘C’ MAP changed to (55-58) 
636 MAP Annotation changed to B because of the value for MAP - 
 
Annotation ‘B’ – Rules ‘A’ 
Row ID Parameter Action Comment/Rule Change 
314 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
318 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
319 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
480 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
482 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
623 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
548 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
644 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
645 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
646 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
647 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
648 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
649 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
650 HR & SpO2 Annotation changed to A as HR and SpO2 had increased in 
rule changes 
- 
 
Annotation D – Rules E 
Row ID Parameter Action Comment/Rule Change 
284 - 303 FiO2 Misclassified as hadn’t noticed that the FiO2 was 1. 
Annotation changed to E 
 
207 FiO2 Misclassified as hadn’t noticed that the FiO2 was 1. 
Annotation changed to E 
 
   RULE CHANGE 
 
‘D’ Noradrenaline changed to (1.5 
– 2.4) 
 
‘E’ Noradrenaline changed to ( > 
2.4 ) 
 
‘D’ Adrenaline changed to (1.5 – 
2.4) 
 
‘E’ Adrenaline changed to ( > 2.4 
) 
283 HR Heart rate value removed as value was ‘8’.  
 
Annotation ’D’ – Rules ‘C’ 
Row ID Parameter Action Comment/Rule Change 
133  Annotation changed to unclassified as suggested that 
extrapolation was being used 
 
275  Annotation changed to C  
276  Annotation changed to C  
277  Annotation changed to C  
   RULE CHANGE 
 
‘C’ HR changed to (100 - 110) 
 
‘D’ HR changed to (111 - 140) 
281 – 283  Annotation changed to C  
302  Annotation changed to C. D was originally given as influenced 
by parameters further on in the dataset 
 
322  Annotation changed to C  
130  Annotation changed to E  
132  Annotation changed to unclassified  
 
Annotation ‘B’ – Rules ‘C’ 
Row ID Parameter Action Comment/Rule Change 
   RULE CHANGE 
 
‘B’ MAP changed to (55 - 59) 
 
‘C’ MAP changed to (52 - 54) 
 
‘D’ MAP changed to (50 – 51) 
 
 
 
Rule change created following errors: 
Annotation ‘D’ – Rules ‘C’ 
Row ID Parameter Action Comment/Rule Change 
641  Annotation changed to C  
643  Annotation changed to C  
586  Annotation changed to C  
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Annotation ‘B’ – Rules ‘D’ 
Row ID Parameter Action Comment/Rule Change 
472  Annotation changed to C  
 
Back to original list… 
Row ID Parameter Action Comment/Rule Change 
225  Annotation changed to unclassified because trending 
used as SpO2 low and FiO2 hasn’t changed 
 
310 SpO2 Annotation changed to C as didn’t notice the FiO2 value  
378 HR Annotation changed to C as the heart rate is in the 100s  
380 HR Annotation changed to C as the heart rate is in the 100s  
387 HR Annotation changed to C as the heart rate is in the 100s  
389 HR Annotation changed to C as the heart rate is in the 100s  
407 HR Annotation changed to C as the heart rate is in the 100s  
471 HR Annotation changed to C as the heart rate is in the 100s  
578 SpO2 & FiO2 Annotation changed to C as didn’t notice the SpO2 and 
the FiO2 
 
580 FiO2 Annotation changed to C as didn’t notice the FiO2  
612 FiO2 Annotation changed to C as didn’t notice the FiO2  
658 FiO2 Annotation changed to C as didn’t notice the FiO2  
 
Annotation None – Rules ‘B’ 
Row ID Parameter Action Comment/Rule Change 
1304  Left as unclassified  
 
Annotation ‘C’ – Rules ‘D’ 
Row ID Parameter Action Comment/Rule Change 
138  Annotation changed to ‘D’  
140  No action – left as a disagreement  
   RULE CHANGE 
 
‘B’, FiO2 changed to (0.41 – 0.54) 
 
‘C’, FiO2 changed to (0.55 – 0.69) 
156  Left to go back to  
157  Left to go back to  
164  Left to go back to  
 
 
Annotation ‘C’ – Rules ‘B’ 
Row ID Parameter Action Comment/Rule Change 
198 FiO2 Annotation changed to B because of the FiO2 value  
199 FiO2 Annotation changed to B because of the FiO2 value  
200 FiO2 Annotation changed to B because of the FiO2 value  
201 FiO2 Annotation changed to B because of the FiO2 value  
202 FiO2 Annotation changed to B because of the FiO2 value  
203 FiO2 Annotation changed to B because of the FiO2 value  
204 FiO2 Annotation changed to B because of the FiO2 value  
205 FiO2 Annotation changed to B because of the FiO2 value  
206 FiO2 Annotation changed to B because of the FiO2 value  
208 FiO2 Annotation changed to B because of the FiO2 value  
323 FiO2 Annotation changed to B as the oxygen was low  
324  Annotation changed to B  
 
 
Annotation ‘C’ – Rules ‘D’ 
Row ID Parameter Action Comment/Rule Change 
195  Annotation changed to D  
290  Annotation changed to D  
291  Annotation changed to D  
292  Annotation changed to D  
293  Annotation changed to D  
294  Annotation changed to D  
295  Annotation changed to D  
301  Annotation changed to D  
305  Annotation changed to D  
309  Annotation changed to D  
381 HR Annotation changed to D on the basis of the Heart Rate 
value 
 
472 HR Annotation changed to D on the basis of the Heart Rate 
value 
 
140 HR & Noradrenaline Annotation changed to D on the basis of the Heart Rate 
value and the Noradrenaline amount. 
 
   RULE CHANGE 
 
‘C’ Adrenaline changed to (1-1.7) 
 
‘C’ Noradrenaline changed to (1-1.7) 
 
‘D’ Adrenaline changed to  (1.8-2.4) 
 
‘D’ Noradrenaline changed to  (1.8-
2.4) 
164 HR Annotation changed to E as heart rate was very low May need to make change to HR 
rules as 42 is very low 
197  Annotation changed to D as FiO2 low  
   RULE CHANGE 
‘D’, HR changed to (43-45) 
 
‘C’, HR changed to (46-49) 
 
‘E’, HR changed to ( >43) 
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In the refinement of the confusion matrices the reasons for discordance were identified as: 
 
- Inadmissible readings: These are physiological impossibilities e.g. a heart rate of 372 or a 
heart rate of 3. The processing of the data is described later in this chapter. At this stage 
there were rules in place to deal with missing values for certain parameters but not extreme 
values. 
 
- Extrapolated data points (annotations changes to “unclassified”): In the rule base in the 
more stable categories the rules were “conjunctive”. That is to say all the parameters had to 
be present for the rule condition to be satisfied. For example for a time point to be in 
category “A” then all the parameters for oxygen saturation, inspired oxygen concentration, 
heart rate and mean arterial pressure had fall within prescribed ranges. It was decided that 
in some instances the expert had annotated a time point where there was missing 
information for some of the parameters that had not been dealt with by the extrapolation 
rules for the data. These time points were changed to “unclassified.” 
 
- Significant values overlooked: The “expert” annotating a time point agreed that he had 
overlooked a significant physiological abnormality during his scoring of the data. 
 
The INSIGHT tool was designed to demonstrate inconsistency between two perspectives 
on the same task i.e. a clinical annotation of a time point based on physiological data and a 
set of rules trying to articulate the clinical process. In the workings described later in the 
chapter there were few discrepancies between the far apart categories e.g. annotation B and 
rule set predicts E. However there was greater “inconsistency” in adjacent categories, in 
fact mainly between clinical annotation A but rule set predicts B. In my session with the 
computing scientists, if based on my clinical acumen I had consistently annotated e.g. level 
B but the rule set predicted C then a rule change was made to try and better capture clinical 
judgement. However when a rule change is made it then affects many of the other cells in 
the confusion matrix. Indeed it can increase agreement in the cell that is being refined at 
that moment, and either increase or decrease agreement in other cells. This leads to other 
possible discordance, namely: 
 
- Clinical annotations disagree consistently (often between adjacent cells). This led to a 
rule change. 
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- The expert did not feel a rule change was merited and annotation changed to be consistent 
with the rule set. This was often very subtle where the ranges are very narrow between 
categories for a parameter (particularly category A-B). In other words although the 
computer prediction was classifying an instance differently from my original annotation, 
on reflection the expert perceived it to still be clinically credible. 
 
- Where the expert was not prepared to change his annotation to “fit” the rules or where he 
did not feel a rule change was merited a small number of instances were labelled as 
“inconsistencies.” In other words the rule base as it stood (or changing the rule base) and 
the clinical annotations could not be reconciled.” 
 
The INSIGHT algorithms cannot calculate the proportions of discordance described above 
but this has been done manually for patient 705 and is shown in table 5-6. 
 
Table 5-6: Summary of types of discordance and actions taken for patient 705 
 
 
 
 
 
 
It is worth noting that it would have been possible to create a confusion matrix after each 
adjustment in the transcript for patient 705. This was not done in practice. The 
methodology was to examine instances when the observed and expected outcomes showed 
a discrepancy. The aim was to identify inadmissible readings, unclassified examples and 
situations where values were overlooked. Rule changes were only made where in hindsight 
the ranges appeared inappropriate. Such rule changes were infrequently made due to the 
significant risk of creating new inconsistencies. 
The confusion matrix after refinement of patient 705 is shown on figure 5-8. 
 
 
 
 
 
Number of instances in set  576 
Number of inadmissible values 5 
Number of annotations changed to “unclassified” 7 
Number on annotations that could not be 
reconciled i.e. “inconsistencies” 
7 
Number of annotations changed to another A-E 
level e.g. as significant piece of information 
overlooked 
46 
Number of annotations changed to be consistent 
with rules 
242 
Number of rule changes  10 
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Figure 5-8: Final confusion matrix after refinement of patient 705 
 
 
 
 
The refinement of patient 705 led to an interim rule base that would be run against the 
remaining 9 patient datasets. The initial rule base is shown in summarised form below in 
table 5- 7 followed in figure 5-9 by the interim rule base after refinement of patient 705. 
 
Table 5-7: Initial rule base prior to any refinement 
 
 SpO2 FiO2 HR MAP ADR. NORAD. 
A 97-100 0.21-0.4 60-80 65-85 0 0 
B 94-96 0.41-0.59 50 -59 
Or 
81-109 
60-64 
Or 
85-109 
0.1 -1.3 0.1 – 1.3 
C 91-93 0.6-0.69 45-49 
Or 
110-120 
55-59 
Or 
110-119 
1- 1.4 1 – 1.4 
D 89 - 91 0.7- 0.84 121-140 
Or 
40-44 
50-54 
Or 
120-129 
1.5- 1.9 1.5–1.9 
E 0-88 0.85 -1 141-500 0-49 
Or 
130-200 
2.0-10 2.0-10 
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Figure 5-9: Interim rule base following refinement of patient 705 (changes from 
original are shown in bold) 
 
Conditions to be met to score a 
particular level 
Ranges of parameters  
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 96-100% 
FiO2 is 0.21-0.4 
Heart Rate 60-83 
Mean Arterial Pressure is 60-84 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-95% 
FiO2 is 0.41-0.54 
Heart Rate 50-59 
Heart Rate 84-99  
Mean Arterial Pressure is 55-59  
Mean Arterial Pressure is 85-109  
Adrenaline 0.1-0.9 mg/h 
Noradrenaline 0.1-0.9 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 92-93% 
FiO2 is 0.55-0.69 
Heart Rate 46-49 
Heart Rate 100-110 
Mean Arterial Pressure is 52-54 
Mean Arterial Pressure is 110-119 
Adrenaline 1-1.7 mg/h 
Noradrenaline 1-1.7 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.84 
Heart Rate 110-140 
Heart Rate 43-45 
Mean Arterial Pressure is 50-51 
Mean Arterial Pressure is 120-129 
Adrenaline 1.8-2.4 mg/h 
Noradrenaline 1.8-2.4 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-88% 
FiO2 is 0.85-1.0 
Heart Rate 0-42 
Heart Rate 141-500 
Mean Arterial Pressure is 0-49 
Mean Arterial Pressure is 130-200 
Adrenaline 2.5-10 mg/h 
Noradrenaline 2.5-10 mg/h 
 
In the next stage of refinement the interim rule base was tested against the remaining 9 data 
sets. The resultant confusion matrix is shown in figure 5-10. 
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Figure 5-10: Confusion matrix produced when interim rule base is run against the 
9 remaining data sets 
 
 
 
 
 
In a similar process to the refinement of patient 705, the remaining 9 datasets were refined. 
At the start of this process the interim rule base after patient 705 was tested against the 
entire data set and gave a 58.3% agreement. Using the same methodology as before, the 
differences between my clinical annotations and the computer predictions using the refined 
rule base were resolved. Overall, 225 instances were viewed and there were 170 
unclassifiable time points. There were 6 further rule base changes, including the addition 
of several conjunctive rules i.e. x and y both have to occur at the same time. A summary of 
the types of refinement is shown in table 5-8. 
 
Table 5-8: Types of discordance and actions taken during the refinement of the 
remaining 9 patient data sets 
 
Number of instances in set 2185 
Number of inadmissible values 7 
Number of annotations changed to 
“unclassified” 
97 
Number on annotations that could not be 
reconciled i.e. “inconsistencies” 
16 
Number of annotations changed to be 
consistent with rules 
104 
Number of rule changes 6 
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Note that in the second phase the number of “unclassified” annotations was higher. One 
possible explanation is that this data set contained data from 9 patients and therefore 
contained 9 admissions time periods where data are often missing around this time of high 
activity to a degree that it could not be dealt with by the extrapolation rules in place.” 
The transcript from this session is not included here due to its considerable length (there 
were many more instances to analyse) but is included in the appendix of the thesis. The 
final confusion matrix after refinement of the remaining 9 patient data sets is shown in 
figure 5-11. 
 
Figure 5-11: Confusion matrix after refinement of the remaining 9 patient data sets 
 
 
 
5.3.6. Refinement of the rule base by a second clinician 
In the next stage of the process, a second clinician (Prof. Kinsella) annotated 3 data sets 
(708, 728 and 733). These contained 717 data points. The process of annotating the 10 data 
sets, previously done by myself, took many hours and was therefore unrealistic for other 
clinicians. Prof. Kinsella’s 3 sets contained a maximum of 36 parameters, of which he 
chose to view 18.  
 
My final rule base was tested against Prof. Kinsella’s annotations. Figure 5-12 shows the 
resulting confusion matrix. 
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Figure 5-12: Confusion matrix produced when the final rule base of Dr. Sim is run 
against the annotations of 3 data sets by Prof. Kinsella 
 
 
 
The agreement with my final rule base run against the 3 patients annotated by Prof. 
Kinsella was only 10.7% (40% for patient 708, 10.7% for patient 728 and 8.1% for patient 
733). In his analysis of the 3 patients, Prof Kinsella started with the most distant cells first, 
considering adjacent cells last. 14 annotations were changed to unclassified. 9 of these 
were due to missing data and 3 due to impossible extremes of physiology. Other 
refinements were similar to those described previously, namely a change of annotation 
because INSIGHT demonstrated that the expert had overlooked a significant value, or in 
adjacent cells either a rule change or a reclassification to fit the rues. The confusion matrix 
after refinement of the 3 patients is shown in figure 5-13. 
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Figure 5-13: Confusion matrix after the refinement of 3 patient data sets annotated 
by Prof. Kinsella 
 
 
 
 
This led to Prof. Kinsella’s final rule base which is shown in the results section.  
 
5.3.7. Refinement of the rule base by a third clinician 
In the next stage of the process, a third clinician (Dr. Hughes) annotated 3 data sets (708, 
728 and 733). Prof Kinsella’s final rule base was tested against Dr. Hughes’ annotations 
and the confusion matrix is shown in figure 5-14. 
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Figure 5-14: Confusion matrix produced when the final rule base of Prof. Kinsella 
is run against the annotations of 3 data sets by Dr. Hughes 
 
 
 
What is interesting about this confusion matrix is that the agreement is high between the 
confusion matrix of the first two clinicians and Dr. Hughes’ annotations at 90.6% (571/630 
instances). He annotated the same three patients as Prof. Kinsella (708, 728 and 733). Note 
that Prof. Kinsella annotated 717 time points and Dr. Hughes’ agreement includes 630 time 
points for the same 3 patients. Unfortunately during the refinement process there was a 
deletion of a block of annotations. INSIGHT has subsequently been altered to avoid this 
happening in the future. It was felt unreasonable to go back to the start of the session as 
bias could have been introduced by doing the same task twice.  
 
5 annotations were changed to “unclassified,” 7 annotations were changed due to 
overlooking significant values and 130 other changes were made, predominantly to 
adjacent categories. 5 rules changes were made, all to the ranges for mean arterial pressure. 
The confusion matrix after Dr. Hughes’ refinement is shown in Figure 5-15. 
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Figure 5-15: Confusion matrix after refinement of 3 patient data sets annotated by 
Dr. Hughes 
 
 
 
5.3.8. Final 3 clinician refinement of the rule base 
Finally, all 3 clinicians analysed the extent to which the rule base captured their expertise 
and discussed the boundaries of certain parameters. This was done over an afternoon by 
focussed round table discussion. All the parameters were reviewed and final boundaries for 
ranges discussed based on the rule set produced after the refinement by Dr. Hughes i.e. the 
3 clinician expertise. This led to the creation of the final rule base i.e. the Intensive Care 
Unit – Patient Scoring System. 
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5.4. Results 
5.4.1. Final rule base of Dr. M Sim 
Figure 5-16 shows my final rule base, produced after the annotation of 10 data sets. 
Changes from the earlier, intermediate refined rule base (after analysis of patient 705, 
figure 5-9) are shown in bold. 
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Figure 5-16: The final rule base of Dr. M. Sim 
Conditions to be met to score a 
particular level 
Ranges of parameters  
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 96-100% 
FiO2 is 0.21-0.4 
Heart Rate 60-83 
Mean Arterial Pressure is 60-84 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-95% 
FiO2 is 0.41-0.54 
Heart Rate 50-59 
Heart Rate 84-99  
Mean Arterial Pressure is 55-59  
Mean Arterial Pressure is 85-109  
Adrenaline 0.1-0.9 mg/h 
Noradrenaline 0.1-0.9 mg/h 
Dobutamine 0.1-10.5 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 92-93% 
FiO2 is 0.55-0.69 
Heart Rate 46-49 
Heart Rate 100-110 
Mean Arterial Pressure is 52-54 
Mean Arterial Pressure is 110-119 
Adrenaline 1-1.7 mg/h 
Noradrenaline 1-1.7 mg/h 
Dobutamine 10.6-25 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.83 
Heart Rate 111-140 
Heart Rate 43-45 
Mean Arterial Pressure is 49-51 
Mean Arterial Pressure is 120-129 
Adrenaline 1.8-2.4 mg/h 
Noradrenaline 1.8-2.4 mg/h 
Dobutamine 25.1-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Adrenaline 2.1-2.4 mg/h 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Dobutamine 33-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Adrenaline 2.1-2.4 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-88% 
FiO2 is 0.84-1.0 
Heart Rate 0-42 
Heart Rate 141-500  
Mean Arterial Pressure is 0-48  
Mean Arterial Pressure is 130-200  
Adrenaline 2.5-10 mg/h 
Noradrenaline 2.5-10 mg/h 
Dobutamine 42.1-200 mg/h 
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5.4.2. Final rule base of Prof. J. Kinsella (two clinician expertise) 
 
Figure 5-17 shows the final rule base of Prof. Kinsella, produced after the annotation of 3 
data sets. Changes from my final rule base (figure 5-16) are in bold. This rule base reflects 
the expertise of two clinicians. 
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Figure 5-17: Final rule base of Prof. J. Kinsella (two clinician expertise). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions to be met to score a particular 
level 
Ranges of parameters 
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 96-100% 
FiO2 is 0.21-0.4 
Heart Rate 60-83 
Mean Arterial Pressure is 60-84 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-95% 
FiO2 is 0.41-0.54 
Heart Rate 50-59 
Heart Rate 84-99  
Mean Arterial Pressure is 55-59  
Mean Arterial Pressure is 85-109  
Adrenaline 0.1-0.9 mg/h 
Noradrenaline 0.1-0.9 mg/h 
Dobutamine 0.1-10.5 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 92-93% 
FiO2 is 0.55-0.69 
Heart Rate 46-49 
Heart Rate 100-110 
Mean Arterial Pressure is 52-54 
Mean Arterial Pressure is 110-119 
Adrenaline 1-1.7 mg/h 
Noradrenaline 1-1.7 mg/h 
Dobutamine 10.6-25 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.93 
Heart Rate 111-140 
Heart Rate 43-45 
Mean Arterial Pressure is 49-51 
Mean Arterial Pressure is 120-129 
Adrenaline 1.8-2.4 mg/h 
Noradrenaline 1.8-2.4 mg/h 
Dobutamine 25.1-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Adrenaline 2.1-2.4 mg/h 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Dobutamine 33-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Adrenaline 2.1-2.4 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-88% 
FiO2 is 0.94-1.0 
Heart Rate 0-42 
Heart Rate 141-500  
Mean Arterial Pressure is 0-48  
Mean Arterial Pressure is 130-200  
Adrenaline 2.5-10 mg/h 
Noradrenaline 2.5-10 mg/h 
Dobutamine 42.1-200 mg/h 
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5.4.3. Final rule base of Dr. Hughes (three clinician expertise) 
Figure 5-18 shows the final rule base of Dr. Hughes, produced after the annotation of 3 
data sets. Changes from the final rule base of Prof Kinsella (capturing the expertise of two 
clinicians, figure 5-17) are shown in bold. This rule base benefits from the expertise of 
three clinicians. 
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Figure 5-18: The final rule base of Dr. M. Hughes (three clinician expertise) 
 
Conditions to be met to score a 
particular level 
Ranges of parameters  
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 96-100% 
FiO2 is 0.21-0.4 
Heart Rate 60-83 
Mean Arterial Pressure is 71-90 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-95% 
FiO2 is 0.41-0.54 
Heart Rate 50-59 
Heart Rate 84-99  
Mean Arterial Pressure is 66-70  
Mean Arterial Pressure is 91-99  
Adrenaline 0.1-0.9 mg/h 
Noradrenaline 0.1-0.9 mg/h 
Dobutamine 0.1-10.5 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 92-93% 
FiO2 is 0.55-0.69 
Heart Rate 46-49 
Heart Rate 100-110 
Mean Arterial Pressure is 60-65 
Mean Arterial Pressure is 100-109 
Adrenaline 1-1.7 mg/h 
Noradrenaline 1-1.7 mg/h 
Dobutamine 10.6-25 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.93 
Heart Rate 111-140 
Heart Rate 43-45 
Mean Arterial Pressure is 51-59 
Mean Arterial Pressure is 110-129 
Adrenaline 1.8-2.4 mg/h 
Noradrenaline 1.8-2.4 mg/h 
Dobutamine 25.1-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Adrenaline 2.1-2.4 mg/h 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Noradrenaline 2.1-2.4 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Dobutamine 33-42 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.75-0.79 
Adrenaline 2.1-2.4 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-88% 
FiO2 is 0.94-1.0 
Heart Rate 0-42 
Heart Rate 141-500  
Mean Arterial Pressure is 0-50 
Mean Arterial Pressure is 130-200  
Adrenaline 2.5-10 mg/h 
Noradrenaline 2.5-10 mg/h 
Dobutamine 42.1-200 mg/h 
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5.4.4. Final rule base of the Intensive Care Unit Patient Scoring System (ICU-
PSS) 
Figure 5-19 shows the final rule base of 3 three clinicians, produced after round table 
discussion. Changes from the final rule base of Dr. Hughes (capturing the expertise of 
three clinicians, figure 5-18) are shown in bold. This is the Intensive Care Unit Patient 
Scoring System (ICU-PSS). 
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Figure 5-19: Final rule base after the 3 clinician discussion, the ICU-PSS 
Conditions to be met to score a particular 
level 
Ranges of parameters  
If ALL of the parameters fall within the 
ranges described then time point is an A 
SpO2 is 96-100% 
FiO2 is 0.21-0.4 
Heart Rate 56-89 
Mean Arterial Pressure is 71-90 
If ANY of the parameters fall within the 
ranges described then time point is a B 
SpO2 is 94-95% 
FiO2 is 0.41-0.54 
Heart Rate 51-55 
Heart Rate 90-99  
Mean Arterial Pressure is 66-70  
Mean Arterial Pressure is 100-109  
Adrenaline 0.05-0.2 mg/h 
Noradrenaline 0.1-0.4 mg/h 
Dobutamine 0.1-20 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a C 
SpO2 is 92-93% 
FiO2 is 0.55-0.69 
Heart Rate 46-49 
Heart Rate 100-110 
Mean Arterial Pressure is 60-65 
Mean Arterial Pressure is 110-119 
Adrenaline 0.3-0.4 mg/h 
Noradrenaline 0.5-0.9 mg/h 
Dobutamine 21-40 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a D 
SpO2 is 89-91% 
FiO2 is 0.7-0.89 
Heart Rate 111-140 
Heart Rate 41-45 
Mean Arterial Pressure is 51-59 
Mean Arterial Pressure is 120-129 
Adrenaline 0.5-0.9 mg/h 
Noradrenaline 1-1.9 mg/h 
Dobutamine 41-60 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Adrenaline 0.5-0.9 mg/h 
Dobutamine 41-60 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Dobutamine 41-60 mg/h 
Noradrenaline 1-1.9 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
Adrenaline 0.5-0.9 mg/h 
Noradrenaline 1-1.9 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.7-0.89 
Dobutamine 41-60 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.7-0.89 
Noradrenaline 1-1.9 mg/h 
If ALL of the parameters fall within the 
ranges described then time point is a E 
FiO2 is 0.7-0.89 
Adrenaline 0.5-0.9 mg/h 
If ANY of the parameters fall within the 
ranges described then time point is a E 
SpO2 is 0-85% 
FiO2 is 0.9-1.0 
Heart Rate 0-40 
Heart Rate 141-300  
Mean Arterial Pressure is 0-50 
Mean Arterial Pressure is 130-200  
Adrenaline 1-10 mg/h 
Noradrenaline 2-10 mg/h 
Dobutamine 61-200 mg/h 
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5.5. Discussion 
The process of developing a new scoring system is challenging, not least because the aim 
was to devise a new score of instability in Intensive Care patients where no such 
previously validated score exists. (The difficulties of validating a new score under these 
circumstances are discussed in chapter 6). There are other methods by which we could 
have used to tackle this challenge. I will discuss the benefits and difficulties and potential 
weakness of the methodology used followed by the advantages and drawbacks of other 
strategies. 
 
In a new score capturing cardiovascular instability, there are no hard endpoints to use as a 
surrogate (or judge against a hypothetical construct). In the APACHE II score
21
 for 
example, it was a considerable task to undertake, but in this score used to predict mortality 
Knaus et al were able to improve upon the original APACHE score
22
. They did this by 
analysing databases containing thousands of patients and by multiple logistic regression 
were able to either weight differently or remove parameters in the acute physiology score 
which did not add to mortality prediction. It was not possible to employ this type of 
strategy in this research. 
 
The fundamental problem overcome in this work is that clinicians are inconsistent 
between what they say they do and what they actually do. To devise the new score we 
had to capture knowledge and express it in the form of physiological rules. There was a 
reluctance to ask clinicians to describe “rules” de novo (with no reference standard) as this 
is one of the key ways which experts (including in the field of medicine) can be completely 
inconsistent between what they say they do in the abstract and what they actually do in 
reality. This is the considerable advantage of the new computing based INSIGHT system 
which demonstrates to a clinician where his description in the abstract differs from his 
clinical judgment (although in this work was still in an artificial setting). 
 
A number of specific problems were encountered. The collaboration was with very 
experienced computer scientists. However, they had very little knowledge of Intensive 
Care. A lot of time was spent explaining basic physiology, critical care monitoring 
techniques, pathologies typically encountered and drugs used in the support of the 
critically ill (some documents prepared for them are included in the appendix for 
reference). Given the magnitude of the data used, this methodology would have been 
previously impossible to undertake manually This volume led to problems of standardising 
units, nonsense values entered and recorded in error by nursing staff and missing data. 
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Data was pre-processed to include algorithms to handle single missing data points. Future 
work will require the development of more sophisticated trending or INSIGHT itself to 
trend the score it is producing if enough similar parameters have not changed significantly. 
It will of course be easier to deal with missing data in the severely unstable categories 
where the rules are disjunctive. For example a patient’s oxygen saturation is 75% this 
automatically scores an “E” even if mean arterial pressure, heart rate and inspired oxygen 
concentration are missing.  
 
Hoffmann et al. 
121
 refer to the “bottleneck” of knowledge elicitation. They reckon that to 
transcribe 1 hour of an interview takes 24 hours subsequent work. This is particularly so 
when trying to describe the precise sequence of changes to annotations and reasons during 
the INSIGHT sessions (although it was possible to produce a detailed document for my 
two refinement sessions). To attempt to document every change made to an annotation in 
real time would make the sessions impracticable unless we had unlimited access to 
“expert” time. A possibility is that INSIGHT itself can be altered to allow the user to click 
a range of options as to why they are altering an annotation e.g. overlooked a significant 
value, missing data, changing his mind to be consistent with the rule set, making a new 
rule etc. 
 
There are some other potential weaknesses. Although the system does allow the user to see 
how they are being inconsistent between clinical rules to define instability in the abstract 
and there annotations based on clinical experience, if this were to be repeated in the future 
it would be useful to include a clinical outline of what was happening to the patients at the 
same time as the lines of data being scored. The context of this work was still somewhat 
artificial. 
 
The most contentious part of refinement was in general between adjacent categories, 
particularly “A” and “B.” The bands here are very tight e.g. the sigmoid shape of the 
oxyhaemoglobin dissociation curve makes it particularly so for oxygen saturation. In 
refinement the clinician either made a rule change or changed his mind to be consistent 
with the data or where the two could not be reconciled changed the annotation to 
“inconsistency.” Where a very small change in parameters can move the expert annotation 
up or down a category, it is difficult for the clinician to determine where the line should be 
drawn between a rule change to better model the data or an annotation change to be 
consistent with his abstract rule (when INSIGHT demonstrates inconsistency between what 
the abstract rules and clinical annotations.) However a subsequent analysis comparing 
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clinician 3’s final rule set (3 “experts”), the percentage agreement is higher between 
clinician 3’s final rule set run against clinician 2’s final data set than when run against 
clinician 1’s final data set. This would perhaps favour algorithm development. Further the 
initial agreement between clinician 1’s final rule set and clinician 2’s initial annotations 
was low (10.7%) but much higher between clinician 2’s final rule base (2 experts) and 
clinician 3’s initial annotations (90.6%). Although only in three clinicians these facts could 
suggest meaningful algorithm development. 
 
The table below is from a subsequent analysis which shows the agreement when each 
clinician’s final rule set is run against the final data set of the other clinicians. 
 
Table 5-9: Percentage agreement between final rule set of clinician 3 against the 
final data set of all individual clinicians 
 
Clinician 3’s final rule (3 
“experts”) set run against 
clinician 1’s final data set 
Clinician 3’s final rule set 
run against clinician 2’s 
final data set 
Clinician 3’s final rule set 
run against clinician 3’s 
final data set 
84.4% 88.8% 98.1% 
 
 
However, the counter argument is that clinician 1 introduces bias into clinician 2’s 
refinement who introduces bias into clinician 3’s refinement. This is because each clinician 
was starting with the rule base of the previous clinician (except for clinician 1). A potential 
way round this is for separate clinicians to make independent initial rule bases and use 
INSIGHT to show inconsistency and refine their rules.  
The independent rule bases could then be compared and areas of disagreement resolved. 
Another form of bias is the presence of the computing scientists sitting in the refinement 
sessions where the “expert” is perhaps more under pressure of time to make a decision 
about new rules or re-annotations. Since this work has been done the INSIGHT system is 
more “stable” and a detailed manual has been produced. The system can be installed on a 
PC and the user could now undertake an analysis independently from the computing 
scientists. 
There are several other methodologies potentially have used in the absence of a gold 
standard: 
 
- Panel of experts: A round table discussion could have been facilitated between 
“experts” in the field. We could have devised and refined instability rules this way. 
This method would have face and content validity but it would be more difficult to 
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test if it works or whether there is inconsistency between an abstract discussion and 
clinical reality.  
 
- Survey: A postal survey could have been sent out and asked a much larger number of 
clinicians to describe what they mean by instability in a 5 point scale with suggested 
ranges and collate the responses. A large enough sample would decrease the chance 
of inconsistency. 
 
- Delphi Process: Experts could answer detailed questionnaires on instability, giving 
suggested ranges, in two or more rounds. After each round, a clinical facilitator 
would provide an anonymous summary of the experts’ opinion and their reasons for 
their judgments. With each round it is possible that there would be closer consensus 
for what experts would class instability as over say a 5 point scale. The anonymity of 
this helps remove bias. 
 
- Clinical simulation: Experts could be shown mock scenarios of an accelerated patient 
stay in Intensive Care and asked to characterise why they are improving or 
deteriorating and try to characterise why. This would help eliminate the problem of 
describing instability in the abstract. 
 
All of the above methods could be used to produce a score of instability. None is perfect, 
as is the methodology used in this research. However, it did give the clinician feedback on 
what they might do in reality versus what they might to in the abstract which is a novel 
way of tackling the problem of designing a new score where there is no reference gold 
standard. 
 
In summary the process of repeated and gradual refinement led to a 5 point qualitative 
score which captured the clinical expertise of three senior Intensive Care clinicians. This 
score has the advantage that it can be calculated automatically and an infinite number of 
times during the patient stay. It provides an easy to understand 5 point scale summarising 
the overall clinical state of the patient.  
 
What now needed to be established was whether the score would be applicable to other 
units with a different case mix. Glasgow Royal Infirmary Intensive Care Unit has the 
general case mix found in most adult units, but is also a tertiary referral centre for complex 
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pancreatic surgery and burns. It was possible that the rule base developed at this centre 
might not be applicable to other units with a different case mix. It was also possible that 
this process would have to be repeated to capture the expertise of clinicians in other 
centres, to mould a rule base to their patient population.  
 
In the next chapter I shall describe the first stage in the validation of the score, and why I 
believe a problem of case mix does not actually apply. 
 
5.6. Conclusion 
Through a process refinement of physiological rules, a quantitative score of the stability of 
critically ill patients has been developed. The sophisticated physiological rule base 
underpinning the ranges, captures the expertise of 3 senior Intensive Care clinicians. 
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Chapter 6: First stage in the validation of the Intensive Care Unit - Patient 
scoring system 
  
6.1. Abstract 
6.1.1. Background 
The 5 point qualitative score developed, which encapsulated the expertise of three senior 
Intensive Care clinicians at one centre, had to be validated to ascertain if it was clinically 
credible. In the absence of a previously validated gold standard with which to make a 
comparison, a number of validation tests would have to be applied. The first of a series of 
tests (discriminant validity) is described in this chapter. 
 
6.1.2. Methods 
Two separate discrimination experiments, involving 10 Intensive Care Consultants from 
two hospitals not involved in the development of the score, were conducted. In the first 
experiment, they were shown random examples of two lines of hourly data, representing 
different combinations of two steps of either improvement or deterioration in the 
qualitative score. In the second experiment, the process was repeated using a series of 
random one-category changes in the qualitative score. In both experiments their clinical 
impressions of improvement or deterioration were compared with the score’s prediction. 
 
6.1.3. Results 
The 10 consultants, using their clinical acumen to score the examples, agreed with the 
scoring system’s prediction in 92.9% of cases where there was a two category change 
between the two lines of hourly data, and 90.9% in the one-category change examples. 
Both results were highly statistically significant. 
 
6.1.4. Conclusion 
The successful tests of discriminant validity are a useful foundation to full validation of the 
score. 
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6.2. Introduction 
In the previous chapter, I described the development of the Intensive Care Unit Patient 
Scoring System (ICU-PSS). The end product is a 5 level score which describes the overall 
physiological state of the patient, based on a sophisticated physiological rule base. It 
captures the clinical opinion and expertise of 3 clinicians in Intensive Care at a single 
centre. It was next necessary to validate the score. However, there was no previously 
validated gold standard with which to compare as this was a novel score. Therefore, in 
order to best validate this new score, more than one form of validation test would have to 
be applied. The different types of validation that could potentially be applied have been 
covered in the introductory chapter to the thesis. To recap, these are summarised in table  
6-1. 
 
Table 6-1: Summary of the different types of validity and their relevance to a novel 
scoring system 
 
Type of 
validity 
Pragmatic definition in 
relation to a novel 
instability score 
Can it be used 
to validate a 
new score of 
instability? 
Comments 
Face validity Score appears on the face of 
it to be a reasonable score of 
instability 
Yes Simple to do and useful. A 
weak form of validity as 
relies on expert opinion. They 
may all be incorrect.  
Content 
validity 
The score takes into account 
what most would regards 
are the key parameters of 
instability  
Yes Important to do but still relies 
upon professional consensual 
judgement. 
Criterion 
validity 
Score is correlated to a 
previously validated gold 
standard of instability 
No Cannot be done as there is no 
gold standard. 
Convergent 
validity 
When there is no change in 
level of instability in the 
score a clinician agrees 
Yes Useful in the absence of a 
gold standard. 
Discriminant 
validity 
When there is a change in 
the level of instability as 
judged by the score the 
clinician agrees 
Yes Useful in the absence of a 
gold standard. 
 
In this chapter two tests of discriminant validity are described, the first of a series of 
validation experiments which will be required for full validation of the score. I 
hypothesised that, if clinicians were shown clinical cases with different combinations of 
improvement or deterioration in the patient state as scored by the ICU-PSS, they should, 
using their clinical expertise, identify the same improvements or deteriorations in more 
than 50% of cases (random chance). I now describe the methodology looking, firstly, at 
improvements or deteriorations where there is a two category change in the score and, 
secondly, with a one category change in the score. 
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6.3. Methods 
6.3.1. Two step change experiment 
A dataset was prepared containing an amalgamation of several patients with 6827 time 
points in total, an extract of which is shown in table 6-2. 
 
Table 6-2: Extract from the 6827 time point dataset 
Case Time of Timepoint Adren. FiO2 HR Mean Norad. SpO2 Hypothesis 
1 18/09/2009 04:02   100 105  100 C-E 
2 18/09/2009 06:00  1 85 145  100 Missing Value 
3 18/09/2009 06:15       Missing Value 
4 18/09/2009 07:00  0.6 92 113  100 C-D 
5 18/09/2009 08:00  0.45 111 100  100 D-D 
6 18/09/2009 09:00  0.45 120 81  97 D-B 
7 18/09/2009 11:33  0.45     B-B 
8 18/09/2009 13:00  0.45 92 79  95 B-B 
9 18/09/2009 14:00  0.3 91 91  100 B-B 
 
In the hypothesis column there are two ICU-PSS assignments. The first letter represents 
the ICU-PSS at that time point, and the second represents the ICU-PSS score at the next 
hourly time point. Certain time points have not been scored due to missing data.  Although 
extrapolated data was used, the algorithms set up to do this only dealt with a single missing 
time point for a parameter. There will be missing data which the system (at present) cannot 
deal with.  The dataset was of a size such that there should be examples of all types of two 
step change in the qualitative score. 
 
Examples were extracted at random from the 6827 time point data set of all combinations 
of two step changes, namely A-C, B-D, C-E, C-A, D-B, E-C. A power calculation was 
undertaken to test if the prediction of positive change is better than 50 percent. This should 
show if clinicians are just guessing between the groups or if they can detect a real 
difference. For this, it was determined that a simple single proportion test with of a value 
greater than 50 percent was suitable. For an alpha of 0.05, a power of 0.9 and to detect a 
medium to small effect size (0.25 estimated) the sample size needed was to ask 5 
consultants, N=27.4, so say 30 in each group (large positive change, large negative 
change). Therefore with 10 consultants it was overpowered. This translated into 4 
examples of each type of two step change. Knowing that there was likely to be examples 
with missing data, more were selected than required i.e. 13 random examples of each type 
of two step change from the 6827 time point data set. The search however, only revealed 8 
examples of an A to C change from the entire data set. 
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The random examples from each category were ordered in a smaller spreadsheet. The full 
spreadsheet can be seen in Appendix VII. An extract is shown in table 3. The columns of 
interest are highlighted in bold. The first column is the type of change. Note that there are 
only 8 examples of a C-A change. The next column in bold is the INSIGHT case number. 
This is the number where the first line of data in the pair falls in the larger 6827 time point 
data set, which allowed reference back to this original data set. The ability to reference was 
required as the examples ordered in the smaller spreadsheet contained no physiological 
data. In the far right column it can be seen that there is a number, “not used” or “missing 
data”. Each example was manually checked in turn referring back to the original 6827 time 
point database until found 4 examples were found which contained the key core parameters 
(oxygen saturation, inspired oxygen concentration, heart rate, mean arterial pressure, 
noradrenaline and adrenaline). Within each category the filtering process was stopped 
when there were 4 examples with complete data and the other examples discarded. As 
above, the much smaller spread sheet showing 13 examples of each type of change (8 for 
A to C), where the process was stopped within a group of examples when 4 with complete 
data were identified, and examples not used because of incomplete data is shown in the 
appendix. Further there is a document showing every example rejected because of missing 
data.  
 
Therefore, in the extract from the smaller spreadsheet represented in table 6-3, out of the 8 
C-A examples 1 to 4 were marked and the rest marked “not used.” The first usable pair in 
the next category of change (D-B) started at 5 and so on. No randomisation was done of 
the usable examples, as they were already selected at random from the larger data base. 
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Table 6-3: Smaller spreadsheet containing from which examples of all types of 2 
step change were chosen 
 
Pair 
type 
First 
of 
group 
Last of 
group 
# of 
pairs 
Base-Line-in-
Spreadsheet 
Rand 
Num 
(Ordered) 
Spreadsheet 
row number 
INSIGHT 
Case 
Num Example 
CA 846 853 8 846 1 846 594 1 
CA    846 2 847 628 2 
CA    846 3 848 4049 3 
CA    846 4 849 4251 4 
CA    846 5 850 5040 Not used 
CA    846 6 851 6462 Not used 
CA    846 7 852 6507 Not used 
CA    846 8 853 6688 Not used 
         
DB 2043 2074 32 2043 17 2059 2976 5 
DB    2043 9 2051 867 6 
DB    2043 23 2065 3984 7 
DB    2043 10 2052 1380 Missing 
DB    2043 16 2058 2059 Missing 
DB    2043 30 2072 6257 8 
DB    2043 28 2070 5637 Not used 
DB    2043 18 2060 3464 Not used 
DB    2043 12 2054 1428 Missing 
 
There were now 6 types of category of change, with 4 examples in each with complete 
data. Each of the examples with two lines of physiological data was prepared into an 
individual table as one of 24 power point slides. An example of a power point slide is 
shown in figure 6-1 below. The 24 slides were randomised using an online random number 
generator 
127
.  
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Figure 6- 1: Example of a power point slide 
 
  
The 24 slides were shown to 5 consultants in ICU at the Western Infirmary Glasgow, and 5 
at Crosshouse Hospital Ayrshire. These hospitals were chosen as the consultants there 
were not involved in the design or testing of the ICU-PSS. One is a city centre ICU and 
one is a district general ICU. The consultants were instructed not to confer with each other, 
and were shown two slides, one with introductory comments (figure 6-2), and one with an 
example for practise (figure 6-3). They were then shown each slide in random order and 
asked to mark each pair of data as improved or deteriorated as shown on the scoring sheet. 
An extract is shown in figure 6-4. The entire slide show can be viewed in Appendix VIII 
and the scoring sheet in Appendix IX.  The consultants were given as much time as they 
needed for each example, and after they had completed the 24 examples they were marked 
using the scoring template (an extract of which is shown in figure 6-5. The whole sheet can 
be viewed in the Appendix X).   
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Figure 6-2: Introductory slide shown to the consultants 
 
 
Figure 6-3: Example of a case shown to the consultants 
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Figure 6-4: Extract of scoring system sheet given to the consultants 
 
ICU Patient Scoring System 
 
Please mark with an X in the appropriate box whether in your opinion the patient has improved or 
deteriorated 
 
 
 
Case Number Improved Deteriorated 
1   
2   
3   
4   
5   
6   
 
Figure 6-5: Extract of scoring system answer template used for marking 
 
Case Number Improved Deteriorated Actual Change 
1 X  E - C 
2 X  D - B 
3  X C - E 
4  X A - C 
5 X  E - C 
6 X  C - A 
7  X A - C 
8  X C - E 
 
The consultants’ results were then transcribed into an Excel spreadsheet for analysis.  
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6.3.2. One step change experiment 
There were many more examples of a one step change in the 6827 time point data set. The 
methodology was different for the selection. A smaller spreadsheet containing every 
different type of one step change was prepared. This comprised 1151 time points. These 
were as follows, given as category and ordered numbers within the new smaller database: 
A-B (2-60), B-A (61-120), B-C (121-252), C-B (253-391), C-D (392-594), D-C (595-812), 
D-E (813-980), E-D (981-1151). An extract of the 1151 time point dataset is shown in 
table 6-4. Note that there are 8 one step change category possibilities. Again 4 examples of 
each type of change was required. Using a random number generator 4 examples for each 
class was selected. The integrity of the data from the original 6827 time point data base 
was checked. If each of the 4 examples had all the same core parameters described then 
these examples were kept. If not the random generator picked another 4 examples and so 
on until 4 examples contained no missing data. The same process was used for the 
selection of pairs for each category. A detailed description of the number of times 4 
examples had to be picked at random for each class is shown in table 6-5. Once there were 
4 examples for each class they were randomised using a random number generator 
127
 to be 
shown the consultants. An example of the numbers generated is shown in figure 6-6.  
 
 
Table 6-4: Extract from the smaller data base showing all examples of a one step 
change 
 
 
Case 
Time of 
Timepoint Adren. FiO2 HR Mean SpO2 Hypothesis 
2 481 ########  0.4 76 82  AB 
3 535 ########  0.4 76 72  AB 
4 543 ########  0.4 84 89  AB 
5 587 ########  0.35 89 99  AB 
6 595 ########  0.28 88 88  AB 
7 601 ########  0.28 89 96  AB 
8 610 ########  0.28 77 92  AB 
9 629 ########  0.35 76 91  AB 
10 636 ########  0.24 68 90  AB 
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Figure 6-6: Data produced by the random number generator 
     True Random Number Service Random Integer Set Generator 
Here are your sets: 
  Set 1: 5, 12, 13, 53  
Timestamp: 2012-05-13 11:31:00 UTC             
© 1998-2012 Mads Haahr  
Valid XHTML 1.0 Transitional | Valid CSS 
                                                            Web Design by TSDA 
 
 
Table 6-5: Clusters of 4 numbers generated and the reasons for rejection 
 
Category Randomisation 
cycle 
Numbers 
generated 
Accepted / Rejected with 
reason 
AB 1 5, 12, 13, 53 Rejected - missing noradrenaline 
data in 13.  
 2 22, 36, 55, 57 Accepted 
BA 1 72, 80, 84, 102 Accepted 
BC 1 137, 148, 203, 227 Rejected - missing noradrenaline 
data in 148 
 2 158, 183, 191, 225 Rejected - missing mean arterial 
pressure data in 183 
 3 191, 200, 147, 241 Accepted 
CB 1 301, 312, 326, 338 Rejected - missing mean arterial 
pressure data in 312 
 2 276, 314, 324, 350 Accepted 
CD 1 449, 539, 544, 589 Rejected - missing FiO2 data in 
example 544 
 2 424, 458, 483, 564 Accepted 
DC 1 647, 648, 691, 800 Rejected - missing noradrenaline 
and mean arterial pressure data 
in 691 
 2 631, 636, 759, 797 Accepted 
DE 1 816, 820, 823, 920 Accepted 
ED 1 1086, 1096, 1097, 1098 Rejected - missing FiO2 and 
oxygen saturation data in  1096 
 2 1073, 1089, 1127, 1134 Rejected – adrenaline and 
noradrenaline data in 1127 
 3 991, 1053, 1102, 1104 Rejected - missing mean arterial 
pressure data in 1104 
 4 981, 994, 1028, 1074 Accepted 
 
 
With the pairs selected for each category, the physiological and drug data were extracted 
from the smaller data base, and 32 slides prepared for review by the consultants. The order 
of the slides was randomised by the online random number generator. The slides were then 
shown to the same consultants who took part in the two step change experiment. The 
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process of annotation was identical. The complete slide show is shown in Appendix XI, the 
answer sheet in Appendix XII and the answer template in the Appendix XIII. 
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6.4. Results 
6.4.1. Two step change experiment  
Table 6-6 shows the result for each consultant, i.e. a score out of 24 for the number of 
changes they identified in the same direction as the computer prediction. 
 
Table 6-6: Two step change experiment result 
Consultant 1 2 3 4 5 6 7 8 9 10 
Score 22 23 22 23 21 24 20 21 23 24 
 
In 223/240 instances or 92.9% of cases, the consultants identified the change in the same 
direction as the computer prediction. A mean square contingency coefficient (phi 
coefficient), which is a measure of the association of two binary variables, was applied to 
the results. This gives a number between -1 and +1, where +1 is 100% agreement. The 
coefficient for the two step experiment was 0.85, p=0.000 which is highly statistically 
significant.  
 
 
6.4.2. One step change experiment  
Table 6-7 shows the result for each consultant, i.e. a score out of 32 for the number of 
changes they identified in the same direction as the computer prediction. 
 
Table 6-7: Two step change experiment result 
Consultant 1 2 3 4 5 6 7 8 9 10 
Score 26 31 28 29 29 29 28 29 30 32 
 
In 291/320 instances or 90.9%, of cases the consultants identified the change in the same 
direction as the computer prediction. The phi coefficient is 0.82, p=0.000 which is highly 
statistically significant.  
 
6.4.3. Agreement for each type of category within the one and two step 
change experiments 
A subsequent analysis was undertaken to ascertain if certain category changes were more 
prone to agreement or disagreement in both the one and two step change experiments. 
Table 6-8 illustrates the agreement for each type of category in the one step experiment. In 
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the one step experiment there were 4 examples of each type of change shown to 10 
consultants giving a total of 40 instances of each type of change reviewed. 
 
Table 6-8: Agreement across the different one step category changes 
 
Type of 
change  
Number of instances where 
clinician disagreed with computer 
prediction (%) 
Number of instances where 
clinician agreed with computer 
prediction (%) 
A-B 4/40 (10) 36/40 (90) 
B-C 4/40 (10) 36/40 (90) 
C-D 0/40 (0) 40/40 (100) 
D-E 3/40 (7.5) 37/40 (92.5) 
E-D 5/40 (12.5) 35/40 (87.5) 
D-C 6/40 (15) 34/40 (85) 
C-B 4/40 (10) 36/40 (90) 
B-A 3/40 (7.5) 37/40 (92.5) 
 
 
Taking all the deteriorations and improvements together, 11/160 (6.9%) of deteriorations 
and 18/160 (11.2%) of improvements were not identified by the clinicians. In a small 
sample there is less agreement with the score when it is improving than deteriorating. 
Further the highest disagreement appears to be instances where the patient as judged by the 
score is highly unstable but improving (E-D and D-C). Otherwise there is a scattering of 
disagreement throughout the different classes. 
 
Table 6-9 shows a similar analysis is performed for the two step experiment. In the two 
step experiment there were 4 examples of each type of change shown to 10 consultants 
giving a total of 40 instances of each type of change reviewed. 
 
Table 6-9: Agreement across the different one step category changes 
 
Type of 
change 
Number of instances where clinician 
disagreed with computer prediction 
(%) 
Number of instances where clinician 
agreed with computer prediction (%) 
A-C 2/40 (5) 38/40 (95) 
B-D 6/40 (15) 34/40 (85) 
C-E 0/40 (0) 40/40 (100) 
E-C 6/40 (15) 34/40 (85) 
D-B 0/40 (0) 40/40 (100) 
C-A 3/40 (7.5) 37/40 (92.5) 
 
 
Again taking all the deteriorations and improvements together, 8/120 (6.7%) of 
deteriorations and 9/120 (7.5%) of improvements were not identified correctly. Again 
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within the limitations of this experiment clinicians identified slightly fewer improvements 
than deteriorations, the category with the highest frequency being E-C i.e. very unstable to 
moderately unstable. The percentage of the improvements missed is lower in the two step 
than one step experiment. 
 
Although overall there was a high level of agreement between the score’s classification of 
improvement or deterioration, there is a suggestion that the model does not fit so well with 
the clinicians in cases where there is improvement from the very unstable state. This could 
potentially be improved by a future experiment giving a clinician the context in which the 
instability is occurring. This could be done by showing lines of data before and after the 
two lines in question as well as supplying a medical summary of the patient’s condition.” 
 
6.5. Discussion 
This work represents the first stage of the validation process. As this work concerns the 
development of a new physiological scoring system of instability there is no gold standard 
available with which to compare it with i.e. so called criterion validity. Therefore 
validation has to be a mixture of other techniques and future work will focus on theses 
areas. 
 
Face validation: Does the test cover subjectively what it is supposed to be measuring? In 
order to test for face validity clinicians will be shown examples of changes within the score 
and no change within the score. They will be given a simultaneous clinical commentary 
about the patient’s state and asked whether they think “on the face of it” that changes 
within the score reflect what is happening clinically i.e. does it appear to capture clinical 
improvement or deterioration. 
 
Content Validity: Does the score represent all aspects of the instability it is trying to 
capture? The parameters which comprise the final ICU-PSS score will be shown to a group 
of experienced clinicians. They will be asked whether they feel that the parameters chosen 
to capture instability reflect what they themselves would have chosen if they had been 
designing a score. In a sense the score already has some indirect content validity given that 
when forming their rule base to score the data sets in its construction, two clinicians other 
than myself chose the same (although obvious) markers of instability i.e. heart rate, mean 
arterial pressure, inspired oxygen concentration, oxygen saturation and inotrope 
requirements.  
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Construct validity: Does the score measure what it proposes to identify and measure? As 
described construct validity comprises discriminant and convergent validity. A 
discriminant validation experiment was undertaken and successfully showed that when the 
score increases or decreases clinicians can (in the absence of clinical information) detect 
improvement or deterioration when the score changes by one or two steps. The 
disagreement is most marked when the score predicts an improvement from a very 
unstable state (E to D or E to C). As described some of the parameter bands are very 
narrow within these ranges and where the score may increase or decrease by a category 
with very little change in the parameters if they happen to sit very close to a boundary. The 
clinician may not detect or agree that there has been a change. This effect could possibly 
be reduced by the clinician having contemporaneous clinical information or data shown the 
patient’s physiological state before or after the period in question. To complement this 
discriminant validity experiment a convergent validity experiment would be useful i.e. 
when there is no change in the score the clinicians no not detect a difference. Clinicians 
will be shown random examples of no change i.e. A to A, B to B etc. and asked whether 
the patient has deteriorated, improved or their physiological state is unchanged. Clinical 
history and trending information will be important to again help overcome the situation 
where parameters in the period of interest in the data shown are very close to a boundary. 
 
The above are tests of validity. The score will also have to be shown to be reliable. If all 
the relevant data is present, collected properly from working equipment and processed 
appropriately by a computer algorithm then for given combinations of data there should be 
a consistent and reliable output. In terms of the clinicians a further experiment will be 
conducted to assess if they are consistent and reliable in their assessment. This could be 
done by showing a (large) series of lines of data, possibly with parameters around the 
middle of ranges. The clinician would then be asked to say whether the lines of data 
represented A (stable) through to (E) unstable. The same lines of data would be shown on 
more than one occasion to ascertain how reliable the clinician was with their own opinion 
and how reliably different clinicians when shown a line of data at a stability level mark it 
as such. 
 
This experiment was designed to test whether clinicians not involved with its development 
could detect a one step and two step improvement or deterioration within the score. The 
clinicians could only review the same data with which the score was calculated. This was 
successful with a high level of agreement. However, the study has a number of 
weaknesses. In practice clinicians do not make decisions based on isolated data, they 
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examine trends. Further they have access to the patient’s relevant medical history. In future 
experiments, if trends prior to and after the change of interest along with a clinical 
summary are included for the clinicians this could increase the agreement between the 
score’s prediction and clinical impression further.  
 
Part of the explanation for disagreement in the experiment undertaken may result from 
some of the bands for the parameters being narrow, particularly in the “A” and “D” ranges 
(stable). For example in the final rule base for the ICU-PSS an “A” oxygen saturation is 
95-100% and “B” oxygen saturation 93-94%. Similarly an “A” heart rate is 56-89 and a 
“B” heart rate 51-55. Imagine the situation where the clinician is shown a line of data 
where the heart rate is 54 and the saturation 94%. If the next line of data has a heart rate of 
56 and a saturation of 94% then the clinician may not record any change but the computer 
prediction had increased from a B to an A. Similarly for changes at the very unstable end 
of the score an “E” heart rate is 0-40, a “D” heart rate is 41-45 and a “D” oxygen saturation 
89-91%. Additional clinical and trending information may therefore help to reduce 
disagreement between the score and clinical impression where the lines of data fall very 
close to parameter boundaries. 
 
In validity terms this was a type of construct validity (which comprises convergent and 
discriminant validity). However in this initial phase we only tested if where there was 
discriminant validity i.e. did the clinicians detect that two lines of physiological data are 
different. Convergent validity was not tested i.e. if the clinicians are shown two lines of 
physiological data which are judged in scoring terms to be the same that they identify them 
as such. This will be part of future work. This could be done by showing the clinicians a 
number of examples within the score an A to A, B to B etc. and asking them if the patient 
has improved, stayed the same or deteriorated. Given that the parameter bands discussed 
earlier are narrow in certain parts of the score this would be better done by giving a clinical 
history and trending information to decrease the chance of disagreement when a parameter 
lies close to the boundary between two categories. 
 
In these experiments of discriminant validity the examples of lines of data were screened 
prior to being used in the slide shows. This was to be certain that they contained the 
minimum number of parameters required by the ICU-PSS to reliably calculate a score 
between time points. These were oxygen saturation, inspired oxygen concentration, heart 
rate, mean arterial pressure, noradrenaline and adrenaline requirements. If any of these 
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were missing between the two lines of data then the example was rejected as the score 
could give an incorrect prediction due to lack of data rather than an actual change. In a 
similar manner the examples were screened for nonsense values e.g. an oxygen saturation 
in single figures. Three examples are shown below in figure 6-7. 
 
Figure 6-7: Examples of rejected pairs of lines of data 
Insight Case Number 1255 
 
FiO2 HR MAP Noradrenaline SpO2 
0.4 123 66 0.8 4 
0.4 108 65 0.7 97 
 
The prediction is E-C, but apparent improvement is due to a typo in the entry for SpO2 rather than the patient being in 
stability level E to start with.  
 
Insight Case Number 2059 
 
 
 
 
 
Prediction is D-B, but apparent improvement is due to missing Heart rate, mean arterial pressure and oxygen saturation.  
 
Insight Case Number 1428 
 
FiO2 HR MAP Norad SpO2 
0.5 99 79 1.8 98 
0.5 99 79  98 
 
Prediction is D-B, but apparent improvement is due to missing noradrenaline. 
 
The complete record of every case which was rejected in the selection process and the 
reasons is recorded in the Appendix XIV of the thesis. Despite algorithms developed to 
handle missing values the rules only allow for a single missing value in a sequence and so 
there will still be instances which the algorithms could not have dealt with. 
 
To recap the algorithms developed to extrapolate and deal with missing single time points 
to enable the testing of the quantitative score were also applied to the datasets that were 
scored in the design of the qualitative score. To summarise, it was agreed that if there was 
a single missing value within in a sequence for a particular parameter then the previously 
recorded value would be used. This applied to heart rate, mean arterial pressure, oxygen 
saturation, inspired oxygen concentration, temperature and inotrope doses. For urine output 
if the preceding value was less than 100mls and there was a single missing time point then 
the previous value was used. If more than one missing time point is was assumed that 
nursing staff were recording a cumulative total and an average taken. Fluids were not 
extrapolated. Consistency was also applied to drug doses i.e. drugs of a particular 
FiO2 HR MAP Norad SpO2 
0.45 121 61  98 
0.5     
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concentration running at a particular rate were all converted to mg/h dose of the drug. 
Inspired oxygen concentration was recorded in an inconsistent manner (as a fraction or 
percentage). It was agreed that all fractions would be converted to a percentage prior to 
analysis. This is summarised in the table 6-10. 
 
Table 6-10: Summary of handling of a single missing data point 
Parameter Action for a Single Missing Value 
Adrenaline Use previously recorded value 
Noradrenaline Use previously recorded value 
Propofol Use previously recorded value 
Alfentanil Use previously recorded value 
Heart Rate Use previously recorded value 
SpO2 Use previously recorded value 
FiO2 Use previously recorded value 
Urine If previous value less than 100 replace missing 
value with previous value. 
 
Otherwise look forward in the data to the next 
value, take the average of it over the missing 
values and then replace missing values with that 
average. 
Temperature Use previously recorded value 
MAP Use previously recorded value 
Fluids Do nothing 
 
With future work the algorithms will be made more sophisticated by having increased 
trending. Currently the nurses at the bed space enter the data manually into CareVue. If 
there is missing data at a particular time it may be possible to extrapolate from data which 
is auto charted by the System but not verified by nursing staff. 
 
As can be seen there are considerable challenges in the validation of a new score of 
instability particularly in the absence of a previously validated gold standard. Several other 
different validation methods will have to be used in a series of further experiments to 
achieve this aim. 
 
6.6. Conclusion 
The Intensive Care Unit Patient Scoring System has undergone the first stage of validation 
and shown to be clinically credible by 10 Intensive Care consultants not involved in the 
score’s development. This was due to a high level of agreement between a series of 
improvements and deteriorations in levels of the score and their clinical acumen during 
two discrimination validation experiments. 
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Chapter 7: Applications of the Intensive Care Unit Patient Scoring System 
Identifying and predicting myocardial damage in the critically ill patient 
using physiological scoring 
 
7.1. Abstract 
7.1.1. Background  
The validated quantitative score was now applied to clinical problems. Myocardial damage 
is common in Intensive Care patients and is associated with a poor outcome. I 
hypothesised that through analysis of physiological disturbance alone, it should be possible 
to detect when myocardial damage is occurring in the absence of cardiac biomarkers. 
Further, it should then be possible to predict when myocardial damage is occurring. 
 
7.1.2. Methods 
Two clinicians reviewed physiological data sets from Intensive Care patients. They 
initially identified periods of physiological disturbance they believed could be associated 
with myocardial damage occurring. On subsequent more detailed analysis, they 
characterised this physiological disturbance in a rule base using a combination of ranges of 
parameters from the ICU-PSS occurring for a set duration. This rule base was then used to 
scan further physiological data sets. The association between the rule base “firing” within 
72 hours (natural decay of troponin) before or after a positive troponin, in a sequence of 
troponin rises, was established. In a second experiment to predict where myocardial 
damage is occurring, the rule base was applied to data sets, to ascertain if it “fired” in the 
72 hours prior to the first troponin rise in a sequence of high troponins. 
 
7.1.3. Results 
In the detection of myocardial damage, the rule set correctly fired in 25/33 (75.8%), 95% 
CI: 57.7% to 88.9% cases of high troponin sequences (true positive) and did not fire in 
8/33 (24.2%) cases of high troponin sequences (false negative). The rule set did not fire in 
4/20 (20%), 95% CI: 5.9% to 43.7% of sequences of negative troponins (true negative) and 
did fire in 16/20 (80%) of sequences of negative troponins (false negative). Positive 
predictive value of the test 61% (95% CI: 44.5% to 75.8%). Negative predictive value of 
the test 33.3% (95% CI: 10.1% to 65%). 
 
In the prediction of myocardial damage an extended rule set fired in 14/16 (87.5%), 95% 
CI: 61.6% to 98.1% cases before the first troponin in a sequence of positive troponins (true 
positive), and did not fire in 2/16 (12.5%) cases before the first troponin in a sequence of a 
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positive troponins (false negative). The extended rule set did not fire in 8/14 cases (57.1%), 
95% CI: 28.9% to 82.2% before the first troponin in a sequence of negative troponins (true 
negative), and did fire in 6/14 (42.9%) of cases before the first troponin in a sequence of 
negative troponins. Positive predictive value of the test 70% (95% CI: 45.7% to 88%).  
Negative predictive value of the test 80% (95% CI: 44.4% to 96.9%). 
 
7.1.4. Conclusion 
This preliminary work leads to a hypothesis that it may possible to detect and predict 
myocardial damage using physiological scoring alone 
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7.2. Introduction 
With the Intensive Care Unit Patient Scoring System developed and validated, I next 
wanted to use the score to examine certain unanswered critical care questions. Firstly, was 
it possible to detect myocardial damage occurring in ICU patients from physiological 
disturbance alone, rather than rely on cardiac biomarkers such as troponin (described in 
this chapter). Secondly, was it then possible to predict the occurrence of myocardial 
damage. 
 
As described in the introduction, myocardial damage is an independent risk factor for both 
short and long term mortality in critically ill patients
80
. Systematic screening demonstrates 
that myocardial damage is common in the critically ill
82
. Despite a significant influence on 
outcome, I have not been able to identify any published studies on the optimum 
management for mortality reduction in critically ill patients, once myocardial damage has 
taken place. It would therefore be useful to identify impending damage. 
 
Two recent consensus conferences have led to a new classification of myocardial 
infarction
75, 76
 based on pathophysiology. Type I myocardial damage results from the 
rupture of an atherosclerotic plaque, with subsequent ischaemia and necrosis of myocardial 
cells in the territory of a coronary artery.  This is a rare occurrence in the ICU population
79
. 
I postulated that it is more often a myocardial oxygen supply and demand mismatch, Type 
II damage in this classification, which is the cause of myocardial injury in the critically ill. 
A large proportion of critically ill patients have markedly deranged physiology. They may 
simultaneously have extremes of heart rate and blood pressure, either high or low, 
occurring in different combinations, coupled with hypoxia or poor tissue oxygen 
utilisation. This can result in global myocardial ischaemia due to a supply and demand 
mismatch rather than ischaemia due to a disruption in coronary artery flow 
128
. 
 
 
I postulated that if the majority of myocardial damage occurring in the critically ill is due 
to a supply and demand imbalance, then physiological derangement occurring before and 
around the time of myocardial damage should be able to be characterised and detected by 
means of a physiologically based rule system such as the ICU-PSS. It should then be 
possible to apply the rule base to predict when myocardial damage is going to occur. In 
other words, could the rule set detect where myocardial damage was occurring 
(association) within a sequence of positive troponins and secondly could the rule set 
predict the occurrence of the first troponin rise in a sequence of positive troponins 
(causation). Due to the 72 hour decay of troponin within the blood, discrete sequences of 
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raised troponins (or negative troponins) were used for analysis (more detail is provided in 
the methods section). Specifically taking each hypothesis in turn: 
 
Detection (Association) of physiological disturbance with myocardial damage 
If the hypothesis is true that most troponin rises are caused by type two damage 
(myocardial oxygen supply and demand imbalance) then the physiological disturbance 
leading to this imbalance may be detected by rules capturing this disturbance. The rules 
would examine the time period 72 hours before a troponin rise (within a sequence) since 
with the natural decay of troponin it is still detectable 72 hours after an initial rise (possibly 
actually a little longer at very low levels). The rules capturing physiological disturbance 
would also examine the period after a troponin rise to capture the possibility of a 
significant cardiac event itself causing cardiovascular instability. For example this might 
include a patient who has developed cardiogenic shock and is hypotensive and hypoxic, or 
a patient who has damaged their conducting system and has a brady/tachy arrhythmia. This 
is a less likely scenario but it was felt important to capture it in the proposed model. 
 
Prediction (Causation) of myocardial damage with physiological disturbance 
In order to test a second hypothesis that it is possible to predict where myocardial damage 
is occurring based on physiological derangement, only the 72 hours before the first 
troponin rise within a sequence would be examined. Again, 72 hours would be chosen as 
the time period due to the natural decay of troponin within the blood. 
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7.3. Methods  
7.3.1. Detection of myocardial damage 
Data sets were collected from 51 critically ill patients with dialysis dependent renal failure 
who had routine serial troponin values recorded in the Intensive Care Unit at Glasgow 
Royal Infirmary. This was a far greater number of data sets than used previously. The data 
were initially stored in the CareVue system, anonymised, and extracted by the database 
managers as Excel spreadsheets, before being processed using ACHE (Architecture for 
Clinical Hypothesis Examination) described previously 
88
. Handling the quantity of data 
used in this study manually would have been an extremely difficult task and error-prone. 
 
In this study, the ACHE pre-processing tool was used to produce formatted Excel 
spreadsheets, with data comprising routinely collected physiological parameters and 
interventions. These were inspired oxygen concentration, oxygen saturation, heart rate, 
heart rate delta (the change in heart rate between two sequential hours), mean arterial 
pressure, mean arterial pressure delta, urine output, central venous pressure, doses of 
inotropes, vasoconstrictors, fluid administered and troponin values.  
 
Given an increasing body of literature on the significance of a raised troponin in the 
critically ill, and to facilitate this and other studies, troponin-I measurement is performed 
three times per week in this ICU as well as when clinically indicated. Troponin I levels 
were considered to be negative if they were less than 0.05 micromoles/litre. Below this 
level there is high level of laboratory error associated with the assay.  They were 
considered raised (positive) if greater than or equal to 0.05 micromoles/litre.  
 
The data were presented for interpretation using the INSIGHT data display and 
manipulation system previously developed by the group 
126
. Figure 7-1 shows an example 
of the data displayed in the INSIGHT system. All of the data sets can be viewed in the 
appendix. 
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Figure 7-1: Layout of data as presented in the INSIGHT system 
Case Adren Dobut. FiO2 HR HR 
Delta 
% 
Mean Mean 
Delta % 
Norad SpO2 SpO2 
Delta 
% 
Troponin Urine Hypothesis 
1438   0.60 123.00 -8.89 61.00 -16.44  93.00 -2.11  80.00 no_event 
1439   0.60 123.00 0.00 64.00 4.92  96.00 3.23  110.00 no_event 
1440   0.60 129.00 4.88 78.00 21.88  92.00 -4.17  150.00 no_event 
1441   0.65 130.00 0.78 59.00 -24.36  93.00 1.09  50.00 event 
1442   0.65 127.00 -2.31 58.00 -1.69  96.00 3.23  65.00 event 
1443   0.65 125.00 -1.57 54.00 -6.90  98.00 2.08  90.00 event  
1444   0.65 125.00 0.00 57.00 5.56  97.00 -1.02  110.00 event 
1445   0.00 126.00 0.80 58.00 1.75  97.00 0.00  80.00 event 
1446   0.65 132.00 1.76 61.00 5.17  97.00 0.00  160.00 no_event 
1447   0.65 140.00 6.06 67.00 9.84  97.00 0.00  110.00 no_event 
1448   0.65 143.00 2.14 65.00 -2.99  92.00 -5.15  160.00 event 
1449   0.90 147.00 2.80 62.00 -4.62  97.00 5.43  75.00 event 
1450   0.90 143.00 -2.72 67.00 8.06  97.00 0.00  75.00 event 
1451   0.80 141.00 -1.40 84.00 25.37  96.00 -1.03  150.00 event 
1452   0.90 143.00 1.42 67.00 -20.24  97.00 1.04   event 
1453   0.75 142.00 -0.70 74.00 10.45  95.00 -2.06  80.00 event 
1454   0.65 141.00 -0.70 78.00 5.41  96.00 1.05  80.00 event 
1455   0.50 138.00 -2.13 62.00 -20.51  98.00 2.08  105.00 no_event 
1456   0.50 131.00 -5.07 63.00 1.61  100.0
0 
2.04  125.00 no_event 
1457   0.40 132.00 0.76 74.00 17.46  100.0
0 
0.00  130.00 no_event 
1458   0.40 133.00 0.76 74.00 0.00  93.00 -7.00  75.00 no_event 
1459            70.00 no_event 
1460   0.45 121.00  63.00   96.00    no_event 
1461   0.40 122.00 0.83 66.00 4.76  97.00 1.04  90.00 no_event 
1462   0.40 120.00 -1.64 69.00 4.55  99.00 2.06  125.00 no_event 
1463   0.40 119.00 -0.83 64.00 -7.25  98.00 -1.01  120.00 no_event 
1464   0.40 120.00 0.84 67.00 4.69  100.0
0 
2.04  115.00 no_event 
1465   0.40 118.00 -1.67 66.00 -1.49  100.0
0 
0.00  100.00 no_event 
1466   0.40 123.00 4.24 70.00 6.06  96.00 -4.00  130.00 no_event 
1467   0.40 119.00 -3.25 58.00 -17.14  97.00 1.04  90.00 event 
1468   0.40 118.00 -0.84 65.00 12.07  98.00 1.03  75.00 no_event 
1469   0.40 121.00 2.54 71.00 9.23  99.00 1.02  110.00 no_event 
1470   0.40 112.00 -7.44 64.00 -9.86  99.00 0.00  110.00 no_event 
1471   0.40 111.00 -0.89 62.00 -3.13  99.00 0.00  80.00 no_event 
1472   0.40 111.00 0.00 61.00 -1.61  99.00 0.00  130.00 no_event 
1473   0.40 121.00 9.01 74.00 21.31  98.00 -1.01 0.14 70.00 no_event 
1474   0.40 117.00 -3.31 69.00 -6.76  98.00 0.00  80.00 no_event 
1475   0.40 116.00 -0.85 71.00 2.90  96.00 -2.04  120.00 no_event 
1476   0.40 123.00 6.03 71.00 0.00  96.00 0.00  65.00 no_event 
1477             no_event 
1478   0.40 126.00  77.00   97.00   105.00 no_event 
1479             no_event 
1480   0.40 119.00  64.00   97.00   65.00 no_event 
1481   0.40 125.00 5.04 87.00 35.94  97.00 0.00  100.00 no_event 
1482   0.40 118.00 -5.60 66.00 -24.14  97.00 2.06  40.00 no_event 
1483   0.40 118.00 0.00 66.00 0.00  97.00 -2.02   no_event 
 
In a preliminary review using INSIGHT, 6 randomly selected patient data sets, consisting 
of the entire sequence of predominantly hourly physiological and intervention data for the 
patient’s ICU stays, were analysed by Prof. J. Kinsella and myself. We independently 
analysed 3664 hours of data in total, having confirmed that all relevant parameters which 
we both would need to undertake the assessment were being displayed. We independently 
identified time periods of physiological derangement which we considered to be consistent 
with potential myocardial damage. We summarised these time periods of physiological 
derangement in broad terms as follows: 
 
- Low values of oxygen saturation, extreme values of heart rate and mean arterial 
pressure. 
- Additionally, high inspired oxygen concentration or large doses of inotropes.  
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In the initial review, only positive troponins (range 0.05 to 49.99 micromoles/litre) were 
displayed. Troponins which were measure but negative were not displayed in the initial 
review of the data. Figure 7-2 describes the initial review of the data. 
 
Figure 7-2: Summary of the initial review of the data 
 
 
In the second phase of the experiment, the 51 data sets were divided randomly into two 
smaller sets, one comprising 17 (a training data set) and the other 34 (a testing set), using 
the one third / two thirds split which is commonly used in statistical and computational 
model building 
129
. 
 
All the data from the training data set were reviewed by the two clinicians (6827 hours of 
data in total). This now included positive and negative troponins. On this occasion we were 
specific about ranges of derangement for each physiological parameter, by using ranges 
from the ICU-PSS. Specifically, we considered any value for oxygen saturation, mean 
arterial pressure or heart rate falling within the most extreme category (E) sufficient to be 
consistent with potentially causing myocardial damage. In addition, the situation where 2 
of these values fell within the next category (D) was also considered to be significant. This 
degree of derangement, e.g. a low mean arterial pressure with hypoxia and tachycardia, 
would be typical of conditions which could lead to a myocardial oxygen supply and 
6 patient data sets displayed to two clinicians. 3664 hours 
of data reviewed 
Periods of derangement consistent with myocardial 
damage occurring identified 
Physiological derangement consistent with causing myocardial damage 
described in broad terms e.g. extreme tachycardia, low oxygen saturation  
Data pre-processed using ACHE and displayed in 
INSIGHT  
51 datasets collected 
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demand imbalance characteristic of type II myocardial damage. Level “D” and “E” rules 
are shown in figure 3 below. 
 
Figure 7-3: Level “D” and “E” rules from the Intensive Care Unit Patient Scoring 
System 
 
Oxygen Saturation 86 - 91% 
Inspired Oxygen Concentration 0.70 - 0.89 
Heart Rate 41 - 45 or 111 - 140 beats per minute 
Mean Arterial Pressure 51 - 59 or 120 -129 mmHg 
 
Having characterised the degree of derangement consistent with precipitating myocardial 
damage, we now considered the effect of duration of the physiological disturbance. Data 
from the17 patient training set were again reviewed independently by the 2 clinicians. Prof. 
Kinsella considered 4 hourly time points out of 6, and myself 3 out of 5 with the described 
derangements could be sufficient to cause myocardial damage. After discussion it was 
agreed to accept 3 out of 5 time points (Figure 7-4). 
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Figure 7-4: Summary of the second phase of the experiment 
 
In the subsequent analysis, unless all the conditions specified in a rule were met, the rule 
set did not “fire.” More detail of this, and the computing aspects of the various processes 
described above, can be found in a recent publication by our group
130
. 
When applying this rule set, the typical profile of troponin concentrations (rises and 
decays) in the blood were considered (Figure 7-5). 
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Figure 7-5: Typical rise and fall of troponin within the blood after myocardial 
damage (from Sleeman Moss, Sim, Kinsella: Predicting Adverse Events 130) 
 
 
 
 
 
 
 
A = Initial rise of troponin, B= plateau phase, C= decay of troponin in blood 
 
Troponins are sampled 3 times per week at Glasgow Royal Infirmary (Monday, 
Wednesday and Friday) as part of routine care and when clinically indicated. Although the 
standard rise and decay model of troponin within the blood was used in the hypothesis, 
given the constraints of the frequency with which the test is undertaken there was the 
possibility that there would only be one, more likely two and if fortunate three troponins 
around a single damage causing event. Further by chance there was the possibility of 
having two very similar troponins if we happened to sample at the start of the rise (A in the 
figure 5 above) and at the end of the decay (C in figure 5 above). Some examples from the 
actual data are shown below. The pattern of recorded troponins in patient 2660 (figure 7-6) 
and patient 2203 (figure 7-7) approximate to the rise and decay of troponin in the idealised 
graph above. In patient 2260 more samples have been taken by chance in the rise phase 
and in patient 2203 in the decay phase. More frequent troponin sampling may result in 
closer similarities to the shape of the idealised graph. 
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Figure 7-6: A real patient example of a troponin rise and decay with predominant 
sampling in the rise phase 
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Figure 7-7: A real patient example of a troponin rise and decay with predominant 
sampling in the decay phase 
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Patient 1807 (figure 7-8) illustrates a potential problem in the model. In this case there has 
been a very large rise in troponin. Although the initial fall is quick there are still very low 
levels of troponin detected for a large number of time points afterwards. This could be due 
to the delayed clearance of troponin in patients with acute renal failure. Again, greater 
sampling could help distinguish between delayed excretion and a new ischaemic event i.e. 
if the time points were separated by a troponin which has been measured and undetected. 
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Figure 7-8: A real patient example showing a prolonged decay phase 
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7.3.1.1. Definition of sequences of troponin 
As it can take up to 72 hours for the troponin from an initial rise to decay from the blood, 
in the subsequent analysis of the rule base it was applied not to individual positive or 
negative troponins but to sequences of positive or sequences of negative troponins as a 
whole within the data set. A sequence of positive troponins represents an initial rise greater 
or equal to 0.05 micromoles/litre, followed by subsequent decay of troponin.  A sequence 
of negative troponins is where there have been regular troponin assays performed over a 
given time period, but no rise detected. These definitions are represented pictorially in 
figure 7-9.  
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Figure 7-9: Positive and Negative sequences of troponin (from Moss, Sleeman, Sim, 
Kinsella: Using Cardiovascular Derangements to Predict Raised Troponin Levels 
131
) 
 
 
The next stage was to determine if at least one of the positive troponins in a sequence of 
positive troponin levels was either preceded or followed (within 72 hours) by a firing of a 
rule. The reciprocal hypothesis was also tested, i.e. none of the negative troponins within a 
sequence causes the firing of a rule. On this basis the following terms were defined: 
 
A true positive is a sequence of positive troponin values, at least one of which is preceded 
or followed within 72 hours by the conditions specified in the rule base. 
 
A true negative is a sequence of negative troponin values, none of which is preceded or 
followed within 72 hours by the conditions specified in rule base. 
A false positive is a sequence of negative troponin values, at least one of which is preceded 
or followed within 72 hours by the conditions specified in the rule base. 
 
A false negative is a sequence of positive troponin values, none of which is preceded or 
followed within 72 hours by the conditions specified in the rule base. 
 
The patients in this study had dialysis dependent renal failure, which is well known to 
affect the troponin decay curve in the blood. However, as per our definition of a true 
positive, in this study we are describing a new positive troponin within a sequence of 
positive troponins occurring after a recorded negative troponin. That is to say a true 
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positive for the purposes of study represents a new myocardial event, rather than reflecting 
delayed clearance of troponin as a result of renal failure.  
 
7.3.2. Methods - Prediction (causation) of myocardial damage due to 
physiological disturbance 
In order to test the system for the prediction of myocardial damage, the testing data set was 
examined again using the extended rule base. As above, the testing set contained 33 
sequences of high troponins and 22 sequences of negative troponins. Due to inconsistency 
of recorded data immediately after the patient was admitted, (a period when nursing and 
medical staff can be very busy and not all data are necessarily recorded), the first 12 time 
points (approximately the first 12 hours after admission) were removed from the analysis. 
This decreased the number of sequences to 27 high and 19 low.  
 
For the purposes of the analysis: 
A true positive is a firing of the extended rule base in the 72 hours prior the first raised 
troponin in a sequence of high troponins. 
A false positive is a firing of the extended rule base in the 72 hours prior the first negative 
troponin in a sequence of negative troponins. 
A true negative is where there is no firing of the extended rule base in the 72 hours prior 
the first negative troponin in a sequence of negative troponins. 
A false negative is where there is no firing of the extended rule base in the 72 hours prior 
to the first raised troponin in a sequence of high troponins. 
 
The first raised troponin in a sequence of high troponins would be represented by time 
point 5 and the first negative troponin in a sequence of negative troponins by time point 1 
in figure 7-9 above. 
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7.4. Results  
7.4.1. Detection (association of physiological disturbance) and Myocardial 
Damage 
The 17 patient training data set contained 6827 time points of patient data, including 68 
troponin recordings. Fourteen sequences of positive troponin values and 14 sequences of 
negative troponins (from regular testing) were identified in total. Two of the sequences of 
positive troponins were not included in the analysis as they occurred within the first six 
hours after admission to Intensive Care (and the physiological derangement leading to this 
may have occurred prior to ICU admission).  
 
7.4.1.1. Analysis of where the troponin rises occurred in the training and 
testing data sets 
The following analysis shown in figure 10 demonstrates where troponin rises occurred 
within the data sets. It is perhaps easier to see visually where the rises and falls (as akin to 
the idealised figure shown earlier) are happening in this manner. The very large number of 
time points makes this difficult in graphical form. The first column shows basic 
information about length of stay of each patient. The second column shows where the 
troponins were measure during the patient stay and whether they were positive or negative 
recorded as 0). The figure in brackets beside the actual time is the time point within the 
patient stay where a troponin rise or negative troponin is occurring. This is included to 
make it easier to see where the first troponin in a sequence has occurred. This is because in 
some of the analysis if the first troponin rise was within 72 hours, that sequence was 
disregarded as it is possible any cardiovascular instability causing it may have happened 
before the patient was admitted to Intensive Care. 
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Figure 7-10. Occurrence of troponin rises within the training and testing data sets 
The 17 patient “training” data set 
Demographics  Actual time into admission (time point) Troponin Rises 
Patient 1667 
Admit Day 1, 01.18 
Discharge Day 5, 15.00 
120 time points recorded 
Day 3, 05.40(56) 
Day 4, 06.05(84) 
Day 5, 0600 (110) 
0.3 
0.1 
0.05 
Patient 1713 
Admit Day 1, 1500 
Discharge Day 16, 1700 
257 time points 
Day 2, 05.30  (17) 
Day 6, 06.00  (119) 
Day 8, 06.00  (169) 
Day 10, 06.00  (219) 
0.07 
0.04 
0.23 
0.07 
Patient 1883A 
Admit Day 1, 07.00 
Discharge Day 34, 15.00 
916 time points 
 
Day 3, 06.00  (79) 
Day 6, 05.30  (133) 
Day 7, 13.00  (169) 
Day 9, 06.00  (217) 
Day 11, 06.00 (277) 
Day 12, 06.00 (301) 
Day 13, 06.00 (328) 
Day 16, 06.00 (406) 
Day 18, 06.00  (460) 
Day 20, 06.00 (511) 
Day 21, 06.00 (537) 
Day 21, 08.35 (540) 
Day 23, 06.00 (590) 
Day 25, 06.00 (640) 
Day 27, 06.00 (695) 
Day 30, 06.00 (775) 
Day 32, 06.04 (826) 
Day 34, 06.00 (878) 
0.24  
0.35  
0.11  
0.15  
0.08  
0 
0  
0  
0  
0.04  
0.06  
0.06  
0.07  
0  
0  
0  
0  
0  
Patient 1906 
Admit Day 1, 13.00 
Discharge Day 74, 09.27 
1792 time points 
 
Day 4, 05.58(67) 
Day 6, 06.00 (124) 
Day 9, 07.15 (203) 
Day 11, 06.00 (256) 
Day 13, 06.00 (307) 
Day 16, 06.00 (386) 
Day 18, 06.04 (437) 
Day 19, 04.00 (464) 
Day 20, 06.00  (497) 
Day 23, 06.00  (575) 
Day 25, 06.00(626) 
Day 27, 06.00 (677) 
Day 30, 08.00 (759) 
Day 32, 06.00 (809) 
Day 34, 06.00(859) 
Day 37, 06.00 (936) 
Day 39, 06.00 (986) 
Day 41, 06.00(1045) 
Day 50, 06.00 (1119) 
Day 54, 06.00  (1221) 
Day 57, 04.00(1307) 
Day 59, 04.00 (1363) 
Day 60, 05.36 (1421) 
Day 63, 06.00 (1498) 
Day 65, 06.00  (1548) 
Day 67, 05.30  (1597) 
Day 70, 06.00 (1675) 
Day 74, 06.00  (1772) 
1.54  
2.71  
0.84  
0.35  
0.17  
0.09  
0.08  
0  
0  
0 
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0.09  
0  
0  
0 
0 
0  
Patient 1933 
Admit Day 1, 18.00 
Discharge Day 8, 19.00 
184 time points 
Day 1, 22.00  (7) 
Day 2, 06.00  (16) 
Day 4, 06.00  (67) 
Day 6, 06.00  (118) 
Day 7, 06.00  (145) 
0.16  
0.23  
0.26  
0.13  
0.12 
Patient 1948 
Admit Day 1, 07.00 
Discharge 2, 03.00 
12 time points 
Day 1, 17.00  (1) 1.1 
Patient 1969 
Admit Day 1, 20.00 
Discharge Day 9, 18.00 
202 time points 
Day 2, 05.30  (12) 
Day 3, 06.00  (39) 
Day 5, 06.00  (89) 
Day 8, 06.00  (164) 
0 
0 
0 
0 
Patient 2121 
Admit Day 1, 13.00 
Discharge Day 3, 01.00 
39 time points 
 
 
Day 1, 14.38  (3) 
Day 2, 06.00  (19) 
 
0 
0 
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Patient 2138A 
Admit Day 1, 00.00 
Discharge Day 27, 13.35 
692 time points 
 
Day 1, 06.00  (8) 
Day 3, 05.37  (60) 
Day 5, 09.00  (110) 
Day 7, 06.00  (162) 
Day 10, 06.00  (244) 
Day 14, 06.00  (352) 
Day 16, 15.00  (415) 
Day 17, 06.21  (433) 
Day 19, 06.00  (490) 
Day 21, 06.00  (546) 
Day 24,06.00  (622) 
0.3  
0.18 
0.14  
0.15  
0.05  
0  
0 
0  
0  
0  
0  
Patient 2174 
Admit Day 1, 12.00 
Discharge Day 10, 14.00 
232 time points 
Day 1, 12.40 (2) 
Day 3, 06.00  (46) 
Day 8, 06.00  (173) 
Day 10, 06.00 (223)  
0 
0 
0 
0 
Patient 2188 
Admit Day 1, 05.00 
Discharge Day 2, 08.00 
33 time points 
Day 1, 05.45  (2) 2.26 
Patient 2189 
Admit Day 1, 18.00 
Discharge day 10, 08.00 
233 time points 
Day 2, 06.20  (16) 
Day 4, 06.00  (67) 
Day 4, 19.00  (81) 
Day 6, 06.00  (118) 
Day 9, 06.00  (191) 
0.04  
0.33  
0.18  
0.11 
0.07  
 
Patient 2284A 
Admit Day 1, 17.00 
Discharge Day 14, 11.40 
339 time points 
Day 10, 06.00  (15) 
Day 4, 05.30  (89) 
Day 6, 06.00 (145) 
Day 6, 08.30  (148) 
Day 6, 19.00  (163) 
Day 8, 05.58  (205) 
Day 9, 02.30  (253) 
Day 10, 06.00  (282) 
Day 11, 06.00  (333)  
0.04  
0  
0  
0  
0  
0.14  
0.14  
0.22  
2.57  
Patient 2303A 
Day 1, 18.55 
Discharge 27, 18.00 
686 time points 
 
Day 1, 19.00  (2) 
Day 4, 06.00  (67) 
Day 5, 06.00  (93) 
Day 6, 06.00  (120) 
Day 10, 06.00  (224) 
Day  11, 06.00  (249) 
Day 12, 06.00  (275) 
Day 13, 06.00  (304) 
Day 14, 05.30  (332) 
Day 15, 06.00  (363) 
Day 18, 06.00  (440) 
Day 20, 06.00  (490) 
Day 22, 06.00  (540) 
Day 25, 06.58  (623) 
Day 27, 06.05  (674)  
0.66  
50  
20.8  
14  
3  
2.71  
1.66  
2.12  
1.52  
0.83  
0.61  
0.48  
0.26  
0.09  
0.06  
Patient 2342A 
Admit Day 1, 21.00 
Discharge Day 11, 14.00 
237 time points 
 
Day 2 06.00  (7) 
Day 2 19.00 (21) 
Day 3 04.54  (31) 
Day 6 05.30  (114) 
Day 8 06.00  (164) 
Day 10 05.00  (213)  
0 
0 
0.04 
0 
0 
0 
Patient 2585 
Admit Day 1, 18.00  
Discharge Day 3, 20.00 
58 time points 
Day 3, 06.006 (43) 3.18 
Patient 2644 
Admit Day 1, 04.02  
Discharge day 31, 14.00 
794 time points 
 
Day 1, 06.15  (3) 
Day 4, 06.00  (79) 
Day 6, 06.00  (129) 
Day 8, 06.00  (180) 
Day 11, 06.00  (270) 
Day 13, 06.00  (321) 
Day 14, 06.00  (350) 
Day 15, 06.00  (375) 
Day 18, 06.00  (451) 
Day 20, 04.00  (499) 
Day 22, 05.30  (551) 
Day 25, 06.00  (626) 
Day 27, 06.00  (676) 
Day 29, 06.00  (727)  
0 
0 
0  
0.14 
0.07  
0.31  
0.1 
0.04  
0  
0  
0  
0  
0  
0.07  
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The 34 patient “testing set” 
  
Demographics Actual time into admission (time point) Troponin Rises 
Patient 1536 
Admit Day 1, 12.00 
Discharge 66, 12.00 
1684 time points 
 
Day 2, 06.00  (20) 
Day 3, 06.34  (47) 
Day 5, 05.57  (98) 
Day 7, 06.00  (151) 
Day 11, 06.00  (264) 
Day  12, 06.00  (289) 
Day  17, 05.00  (415) 
Day 19,  06.00  (467) 
Day 21,  06.00  (521) 
Day 24,  06.00  (596) 
Day  28,  06.00  (697) 
Day 31, 06.00  (774) 
Day 33, 06.00  (825) 
Day 35, 06.00  (877) 
Day 38, 06.00  (953) 
Day 42, 06.00  (1058) 
Day 45, 06.00  (1138) 
Day 47, 06.00  (1189) 
Day 48, 06.00  (1214) 
Day 49, 06.00  (1241) 
Day 51, 06.00  (1291) 
Day 54, 06.00  (1373) 
Day 56, 06.00  (1423) 
Day 66, 05.00  (1677)  
0.34  
0.22  
0.04  
0  
0  
0  
0 
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0  
0 
Patient 1697 
Admit Day 1, 08.00 
Discharge Day 3, 11.59 
59 time points 
Day 1, 09.00 (2) 
 
0 
Patient 1748 
Admit Day 1, 17.00 
Discharge Day 20, 22.00 
503 time points 
 
Day 3, 06.00 (39) 
Day 3, 11.40  (46) 
Day  5, 06.00  (91) 
Day 10, 06.00  (224) 
Day  12, 06.00  (279) 
Day 15, 06.00  (358) 
Day 17, 05.44  (409) 
Day 19, 06.00  (461)  
0.06  
0.06 
0.04  
0  
0  
0  
0  
0  
Patient 1757 
Admit Day 1, 10.40 
Discharge Day 2, 13.00 
30 time points 
Day 1, 10.40  (1) 
Day 2, 06.00  (22) 
 
0 
0 
 
Patient 1774 
Admit Day 1, 04.00 
Discharge Day 26, 22.28 
672 time points 
 
Day 3, 06.00 (55) 
Day  5, 06.00  (105) 
Day  7, 06.00 (155) 
Day  14, 06.00 (335) 
Day  15, 05.50  (360) 
Day  16, 06.00  (389) 
Day  17, 05.37  (414) 
Day  19, 06.00  (465) 
Day  24, 05.30 (603) 
Day  26, 05.00 (653)  
0.16 
1.19  
9.4  
1.66 
2.4  
4.01  
2.38 
1.86  
0.95  
0.51  
Patient 1822 
Admit Day 1, 04.00 
Discharge Day 37, 17.10 
990 time points 
 
Day 3, 05.00  (57) 
Day 4, 06.00  (92) 
Day  5, 06.00  (120) 
Day  8, 06.00  (204) 
Day  10, 06.00  (262) 
Day 12, 06.00  (315) 
Day 15, 06.00  (398) 
Day  20, 06.00  (532) 
Day  22, 06.00  (585) 
Day  24, 06.00  (636) 
Day  26, 06.00  (687) 
Day  26, 08.20  (690) 
Day 29, 06.00  (763)  
0.06  
0  
0.09  
0  
0  
0  
0.05  
0  
0  
0.05  
0  
0  
0  
Patient 1965 
Admit Day 1, 13.00 
Discharge Day 4, 20.00 
87 time points 
Day 2, 06.00  (20)  
Day 4,  06.00  (73)  
 
0.18 
0.95 
Patient 2017 
Admit Day 1, 19.00 
Discharge Day 10, 14.00 
261 time points 
 
 
 
 
 
Day 1, 19.45  (3) 
Day 4, 06.00  (88) 
Day 6, 06.00  (139) 
Day 7, 06.00  (191) 
Day 8 14.30  (232)  
0.12  
14.5  
5.49  
4.26  
2.61  
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Patient 2030 
Admit Day 1, 15.00 
Discharge Day 21, 10.16 
528 time points 
Day 2, 06.00  (17) 
Day 7, 06.00  (142) 
Day 11, 06.00  (244) 
Day 14, 06.00  (327) 
Day 16, 06.00  (376) 
Day 18, 06.00  (427) 
Day 21, 05.10  (503)  
0.51  
0.07  
0  
0  
0  
0  
0 
Patient 2158 
Admit Day 1, 23.25 
Discharge Day 9, 10.00 
208 time points 
 
Day 2 24/4/9 06.00  (9) 
Day 5 27/4/9 05.40 (97) 
Day 6 28/4/9 05.28  (129) 
Day 7 29/4/9 04.49  (156) 
Day 8 30/4/9 06.49  (185) 
Day 9 1/5/9 06.00  (204)  
0  
0  
0  
0  
0  
0  
 
 
 
Patient 2265  
Admit Day 1, 14.00 
Discharge Day 45, 22.00 
1134 time points 
 
Day 4, 06.00  (72) 
Day 5, 06.00  (97) 
Day 5, 20.08  (113) 
Day 6, 06.00  (124) 
Day 7, 06.00  (150) 
Day 12, 06.00  (277) 
Day 13, 06.00  (302) 
Day 14, 06.00  (328) 
Day 15, 06.00  (356) 
Day 17, 06.00  (407) 
Day 19, 06.00  (457) 
Day 24, 05.00  (585) 
Day 26, 06.00  (636) 
Day 27, 06.00  (661) 
Day 31, 04.56  (761) 
Day 33, 06.00  (818) 
Day 35, 06.00  (869) 
Day 38, 07.00  (947) 
Day 39, 06.00  (971) 
Day 40, 06.00  (990) 
Day 42, 06.00  (1040) 
Day 45, 06.00  (1121)  
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Patient 2313 
Admit Day 1, 15.00 
Discharge Day 30, 00.20 
801 time points 
 
Day 2, 06.00  (17) 
Day 4,  06.00  (67) 
Day  9, 05.29  (207) 
Day 11, 06.00  (259) 
Day 13, 06.00  (310) 
Day 16, 06.00  (391) 
Day 18, 06.00  (446) 
Day 20, 06.00  (499) 
Day 23, 09.57  (582) 
Day 24, 06.00  (603) 
Day 25, 06.00  (631) 
Day 27, 06.00  (690) 
Day 30, 06.00  (773)  
0  
0  
0  
0  
0  
0  
0  
0  
0.07  
0  
0  
0  
0.09  
Patient 2328 
Admit Day 1, 04.00 
Discharge Day 10, 08.00 
247 time points 
 
Day 1, 07.48  (5) 
Day 1, 14.00  (13) 
Day 2, 07.00  (31) 
Day 3, 06.00  (55) 
Day 5, 06.00  (110) 
Day 6, 10.55  (140) 
Day 7, 05.08  (161) 
Day 10, 05.25  (244)  
0.61  
1.23  
4.37  
2.31  
1.77  
1.48  
1.24  
0.66  
Patient 2457 
Admit Day 1, 23.00 
Discharge Day 17, 16.00 
332 time points 
 
Day 3, 04.13  (60) 
Day 5, 06.16  (114) 
Day 7, 06.00  (164) 
Day 10, 06.00  (244) 
Day 12, 06.00  (297)  
0.39  
0.16  
0.08  
0  
0  
Patient 2607 
Admit Day 1, 22.00 
Discharge Day 9, 00.00 
104 time points 
Day 2, 01.00  (4) 
Day 4, 06.00  (60) 
 
0  
2.91  
 
Patient 2660 
Admit Day 1, 17.00 
Discharge day 11, 12.00 
253 time points 
 
Day 2, 06.00  (16) 
Day 2, 16.30  (28) 
Day 3, 06.00  (42) 
Day 4, 06.00  (69) 
Day 7, 06.00  (145) 
Day 9, 06.00  (196) 
Day 11, 06.00  (246)  
0  
0.07  
0.11  
0.23  
0  
0  
0  
Patient 2698 
Admit Day 1, 13.00 
Discharge Day 3,  12.00 
52 time points 
Day 1, 21.50  (11) 
Day 3, 05.00  (44) 
 
0.08  
0.31 
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Patient 1684 
Admit Day 1, 23.00 
Discharge Day 3, 14.00 
44 time points 
Day 2, 00,15  (3) 
Day 2,  06.00 (9) 
Day 4,  06.00  (35) 
 
0.48  
1.85 
4.26  
 
 
 
 
Patient 1689 
Admit Day 1, 23.00 
Discharge Day 3, 09.00 
37 time points 
Day 3, 06.00  (34) 
 
0.2  
 
 
 
Patient 1720 
Admit Day 1, 16.56 
Discharge Day 19, 19.00 
463 time points 
Day 3, 09.00  (44) 
Day 4, 03.39  (64) 
Day 6, 06.00  (118) 
Day 16, 05.30  (375) 
Day 18,  06.00  (425)  
2.35  
1.25  
0.57  
0.05  
0.05  
Patient 1721 
Admit Day 1, 02.00 
Discharge Day 3, 20.00 
73 time points 
Day 2, 21.51  (48) 
Day 3,  06.18  (58) 
 
0 
0 
 
Patient 1726 
Admit Day 1, 14.00 
Discharge 1 Day 2, 16.00 
34 time points 
Day 2, 07.06  (24) 
 
0.07 
 
Patient 1727 
Admit Day 1, 13.00 
Discharge Day 11, 04.00 
243 time points 
Day 2,  06.00  (22) 
 
1.73 
 
Patient 1750 
Admit Day 1, 07.00 
Discharge Day 5,  21.17 
151 time points 
Day 2, 06.00  (30) 
Day 4, 06.00  (101) 
 
0  
0.08  
 
Patient 1807 
Admit Day 1, 04.00 
Discharge Day 30, 15.00 
760 time points 
Day 1, 04.56  (2) 
Day 2, 07.11  (32) 
Day 3, 11.10  (64) 
Day 4, 06.00  (83) 
Day 9, 05.30  (210) 
Day 13, 06.00  (311) 
Day 14, 05.42  (336) 
Day 18, 06.00  (439) 
Day 20, 06.00  (489) 
Day 23, 06.00  (573) 
Day 27, 06.00  (674) 
Day 30, 06.00  (749)  
3.24 
6.38  
13.6 
6.88  
0.44  
0.19  
0.19  
0.13  
0.11  
0.09  
0.09  
0.06  
Patient 1818 
Admit Day 1, 17.00 
Discharge Day 5, 18.00 
109 time points 
Day 2, 17.14  (31) 
Day 3, 05.00  (43) 
Day 5, 06.00  (96) 
 
0.44  
0.27  
0.07  
 
Patient 1951  
Admit Day 1 18.00 
Discharge Day 21 20.00 
220 time points 
Day 14, 16.03  (45) 
Day 15, 06.00  (59) 
Day 17,  06.00  (107) 
Day 20, 06.00  (180)  
0.06  
0.12  
1.78  
0.45  
Patient 2039 
Admit Day 1, 21.00 
Discharge Day 18, 06.00 
434 time points 
 
Day 1, 22.00  (3) 
Day 2, 06.00  (11) 
Day 3, 06.00  (36) 
Day 4, 10.30  (68) 
Day 5, 09.42  (92) 
Day 6, 06.00  (113) 
Day 7, 07.27  (140) 
Day 10, 06.00  (214) 
Day 13, 06.00  (303) 
Day 15, 06.00  (359) 
Day 17, 06.00  (409)  
0.87  
2.23  
1.46  
0.62  
0.36  
0.41  
0.24  
0.08  
0.18  
0.06  
0  
Patient 2231 
Admit Day 1, 14.00 
Discharge Day 11, 18.00 
258 time points 
 
 
 
 
 
 
 
 
 
 
 
 
Day 1, 14.00  (1) 
Day 4, 06.00  (69) 
Day 6, 06.00  (119) 
Day 8, 06.00  (169) 
Day 11, 06.00  (244)  
0 
0 
0 
0 
0 
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Patient 2273 
Admit Day 1, 14.00 
Discharge Day 18, 14.47 
440 time points 
 
 
Day 1, 18.35 (7) 
Day  1,  20.20  (11) 
Day  2, 05.14  (25) 
Day  3, 06.00  (55) 
Day  3, 14.45  (66) 
Day  5, 06.00  (108) 
Day  8, 05.30  (183) 
Day  10, 00.00  (228) 
Day  10, 06.00  (234) 
Day  10, 10.00  (238) 
Day  12, 05.00  (283) 
Day  15, 06.00  (359)  
0.12  
0.16  
0.2  
0.14  
0.13  
0.08  
0.14  
0.09  
0.1  
1  
0.04  
0  
Patient 2506 
Admit Day 1, 11.00 
Discharge Day 7, 19.00 
181 time points 
Day 2, 06.00  (31) 
Day 5, 06.00  (110) 
 
2.59  
0.48  
 
Patient 2524 
Admit Day 1,  06.00 
Discharge Day 7, 14.00 
168 time points 
Day 2, 06.00  (27) 
Day 5, 05.08  (107) 
Day 7, 06.00  (159) 
 
0.85  
0.32  
0.15  
 
Patient 2547 
Admit Day 1,  06.00 
Discharge Day 4, 18.00 
102 time points 
Day 2, 09.15  (38) 
Day 4, 06.19  (88) 
 
2  
1.65  
 
Patient 2554 
Admit Day 1, 15.00 
Discharge Day 5,  11.30 
113 time points 
Day 2, 06.00  (17) 
Day 5, 06.00  (108) 
 
0.07  
0.05  
 
 
The rule base was initially run against the 17 patient training data set to see if there was an 
association between it firing and the presence of actual myocardial damage as evidenced 
by raised troponins. The results are shown in table 7-1. 
 
Table 7-1: Results when the rule base is run on the 17 patient data training set 
 Sequences of High 
Troponins 
Sequences of Negative 
Troponins 
Rule set “fires”  8 out of 12 (66.7%) 
i.e. True Positive 
10 out of 14 (71.4%) 
i.e. False Positive 
Rule set does not “fire” 4 out of 12 (33.3%) 
i.e. False Negative 
4 out of 14 (28.6%) 
i.e. True Negative 
 
 
After this initial analysis, and in an attempt to increase the true positive rate, a further rule 
base was produced to include derangements from category C on the ICU-PSS, thus making 
the original rule base more extensive. This extended rule base was run again on the 17 
patient data set and the results shown in table 7-2. 
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Table 7-2: Results when the extended rule base is run against the 17 patient 
training data set 
 
 Sequences of High 
Troponins 
Sequences of Negative 
Troponins 
Rule set “fires”  12 out of 12 (100%) 
i.e. True Positive 
13 out of 14 (92.9%) 
i.e. False Positive 
Rule set does not “fire” 0 out of 12 (0%) 
i.e. False Negative 
1 out of 14 (7.1%) 
i.e. True Negative 
 
The more extended rule base was then run against data sets from the remaining 34 patients 
(the testing data set described above). These 34 patient dataset contained 11,776 time 
points of patient data, including 198 troponin readings. From these data sets 33 sequences 
of positive troponin values and 22 sequences of negative troponin values were identified 
(see figure 10 above for the precise details of where these sequences occurred). Two out of 
the 22 sequences of negative troponins were removed as they occurred within the first 6 
hours after admission. The results are shown in table 7-3 and the different rule bases are 
summarised in figure 7-11. 
 
Table 7-3: Results when the more sophisticated rule base is run against the 34 
patient testing set 
 
 Sequences of High 
Troponins 
Sequences of Negative 
Troponins 
Rule set “fires”  25 out of 33 (75.8%) 
i.e. True Positive 
16 out of 20 (80%) 
i.e. False Positive 
Rule set does not “fire” 8 out of 33 (24.2%) 
i.e. False Negative 
4 out of 20 (20%) 
i.e. True Negative 
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Figure 7-11: Sequence of testing and final modification to the rule base 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rule base extended by including derangements from level C in the ICU-PSS 
Rule base run against the 17 patient training data set (see table 1) 
Extended rule base run against the 17 patient training data set (see table 2) 
Extended rule base run against 34 patient testing data set (see table 3) 
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7.4.2. Results - Prediction of myocardial damage 
Table 7-4 shows the analysis of 72 hours prior to the first raised troponin in the 27 
sequences of high troponins, and first negative troponin in the 19 sequences of negative 
troponins.  
 
Table 7-4: Applying the extended rule base to the 72 hours prior to the 27 
sequences of high and 19 sequences of negative troponins 
 
 Sequences of High 
Troponins 
Sequences of Negative 
Troponins 
Extended rule base fires 
before  the first 
troponin of the troponin 
sequence 
14 out of 27 (51.9%) 
i.e. True Positive 
6 out of 19 (31.6%) 
i.e. False Positive 
Extended rule base does 
not fire before  the first 
troponin of the troponin 
sequence 
13 out of 27 (48.1%) 
i.e. False Negative 
13 out of 19 (68.4%) 
i.e. True Negative 
 
 
The first observation is that the false negative rate is high at 48.1%. That is to say, there is 
no firing of the extended rule base in the 72 hours prior to the first raised troponin in a 
sequence of high troponins. A further analysis showed that in 11 out of the 13 cases, the 
first troponin rise in a sequence of raised troponins occurred early in the patient’s stay in 
ICU. Specifically, the mean time point for the first high troponin in the 13 sequences 
identified as true positives was 208, yet only the 33
rd
 time point for the first raised troponin 
in sequences identified as false negatives.  It is therefore possible that the physiological 
derangement leading to the myocardial damage was occurring prior to the patient’s 
admission to ICU. It is also worth noting that in an analysis of the 13 sequences 
comprising the true negatives there were 5 instances where the first negative troponin in 
the sequence occurred within 72 hours of the patient’s admission into ICU. Therefore there 
could have been a firing of the rule base before the patient’s admission, which could mean 
that some of the true negatives are actually false positives. The results are presented again 
in table 7-5, with a reduced number of sequences reflecting those taken out of the analysis 
due to being early in the patient’s admission to ICU. That is to say, the cardiovascular 
derangement could have happened before the patient’s admission (if we take 72 hours as 
the time for decay of troponin). 
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Table 7-5: Results with sequences of troponin (high and negative) occurring early 
in the patient’s admission to ICU removed 
 
 Sequences of High 
Troponins 
Sequences of Negative 
Troponins 
Extended rule base fires 
before  the first 
troponin of the troponin 
sequence 
14 out of 16 (87.5%) 
i.e. True Positive 
6 out of 14 (42.9%) 
i.e. False Positive 
Extended rule base does 
not fire before  the first 
troponin of the troponin 
sequence 
2 out of 16 (12.5%) 
i.e. False Negative 
8 out of 14 (57.1%) 
i.e. True Negative 
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7.5 Discussion.  
This preliminary work leads to a hypothesis that it may possible to detect myocardial 
damage using physiological scoring alone based on commonly recorded ICU physiological 
parameters and drug infusion data, rather than traditional biomarkers. Further in a similar 
manner it may be possible to predict where myocardial damage is going to occur based on 
physiological disturbance alone. 
 
However, in the evaluation of a new test, e.g. occurrence or non occurrence of an event 
with a binary predictor e.g. presence or absence (alternatively above or below a cut off 
point) it is common to summarise the data in a two by two contingency table 
132 
as shown 
in table 7-6. 
 
Table 7-6: A two by two contingency table 
 
 Outcome/Event present Outcome/Event absent 
Predictor / test positive A (True positive) B (False positive) 
Predictor / test  
Negative 
C (False negative) D (True negative) 
 
From this table a number of statistical descriptions can be defined (this shall be described 
in relation to this work in the context of prediction of troponin positive events). 
 
A true positive (A) is where the rule set fires before the first positive troponin within a 
sequence of positive troponins. 
A false positive (B) is where the rule set fires before the first negative troponin within a 
sequence of negative troponins. 
A false negative(C) is where the rule set does not fire before the first positive troponin 
within a sequence of positive troponins. 
A true negative (D) is where the rule set does not fire before the first negative troponin 
within a sequence of negative troponins. 
 
From these basic definitions the sensitivity and specificity of the rules set to predict 
myocardial damage can be defined: 
 
Sensitivity is the ability of the rule set to correctly fire before the first positive troponin 
within a sequence of positive troponins i.e. A/(A+C) in the above table. For example if the 
rule set were to have a 70% sensitivity then it would fire in 70% of instances before the 
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first positive troponin in a sequence of positive troponins but not fire in 30% of cases 
before the first positive troponin within a sequence of positive troponins. 
 
Specificity is the ability of the rule set not to fire before the first negative troponin within a 
sequence of negative troponins i.e. D/(D +B). For example if the rule set had an 80% 
specificity it would not fire in 80% of instances before the first negative troponin within a 
sequence of negative troponins but would fire in 20% of cases before the first negative 
troponin within a sequence of negative troponins. 
 
For this “test” although the ideal would be a high sensitivity and high specificity, in 
practice a high sensitivity is more important (initially) than a high specificity. This is 
because the practical implications of a false positive in a future system would be non-
invasive bedside tests e.g. 12 lead ECG or an ECHO. What is perhaps more relevant to a 
clinician is the positive predictive and negative predictive value of a test. 
 
Positive predictive value is where the rule set fires, what is the likelihood of this being 
before the first troponin in a sequence of positive troponins i.e. A / (A+B). 
 
Negative predictive value is where the rule set does not fire, what is the likelihood of this 
being before the first negative troponin in a sequence of negative troponins i.e. D/ (C+D). 
 
In this subsequent analysis the confidence intervals are now given along with the positive 
and negative predictive value of the rule base. (Two types of confidence intervals can be 
constructed around proportions (asymptotic and exact). Asymptotic assumes a normal 
approximation of the sampling distribution. When the sample size is small this normal 
assumption cannot be made and exact e.g. 95% confidence intervals are more appropriate.) 
Confidence intervals were calculated using Medcalc
133
. 
 
Tables 7-7 and 7-8 show the results when the rule base and extended rule base (to include 
derangements from level C in the scoring system) are run against the training data set (17 
patients). This was to test if a positive troponin within a sequence was preceded or 
followed by a firing of these rule bases i.e. association of myocardial damagae with 
physiological disturbance. Given that the numbers in the 2x2 table are small and the 
confidence intervals large, nothing meaningful can be drawn from the data. The most 
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relevant set of results are in Table 7-9 as this shows the data when the extended rule set is 
run against the 34 patient testing data set.  
 
7.5.1 Myocardial detection (association) 
Table 7-7: Results when the rule base is run on the 17 patient training data set 
 
 Sequence of High 
Troponins 
Sequence of Negative 
Troponins 
Rule set “fires” 8/12 (66.7%) 
 
i.e. True Positive 
10/14 (71.4%) 
 
i.e. False Positive 
Rule set does not “fire” 4/12 (33.3%) 
 
i.e. False Negative 
4/14 (28.6%) 
 
i.e. False Negative 
Sensitivity 66.7% 95% CI: 35% to 89.9% 
Specificity 28.6% 95% CI: 8.6% to 58.1% 
Positive predictive value 44.4% 95% CI: 21.6% to 69.2% 
Negative predictive value 50% 95% CI: 16% to 84% 
 
 
Table 7-8: Results when the extended rule base is run against the 17 patient 
training data set 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sequence of High 
Troponins 
Sequence of Negative 
Troponins 
Rule set “fires” 12/12 (100%) 
 
i.e. True Positive 
13/14 (92.9%) 
 
i.e. False Positive 
Rule set does not “fire” 0/12 (0%) 
 
i.e. False Negative 
1/14 (7.1%) 
 
i.e. False Negative 
Sensitivity 100% 95% CI: 73.4% to 100% 
Specificity 7.1% 95% CI: 1.19% to 33.9% 
Positive predictive value 48% 95% CI: 27.8% to 68.7% 
Negative predictive value 100% 95% CI: 16.6% to 100% 
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Table 7-9: Results when the more sophisticated rule base is run against the 34 
patient testing set 
  
 Sequence of High 
Troponins 
Sequence of Negative 
Troponins 
Rule set “fires” 25/33 (75.8%) 
 
i.e. True Positive 
16/20 (80%) 
 
i.e. False Positive 
Rule set does not “fire” 8/33 (24.2%) 
 
i.e. False Negative 
4/20 (20%) 
 
i.e. False Negative 
Sensitivity 75.8% 95% CI: 57.7% to 88.9% 
Specificity 20% 95% CI: 5.9% to 43.7% 
Positive predictive value 61% 95% CI: 44.5% to 75.8% 
Negative predictive value 33.3% 95% CI: 10.1% to 65% 
 
There is a suggestion from the data that the sensitivity of the rule set is moderately high at 
75.7% but in the context of moderately wide confidence intervals. The specificity and 
negative predictive value of the rule set is low. The confidence intervals of the positive 
predictive value are so wide that no weight can be put on the figure of 61%. 
 
A similar analysis is shown now for the rule base and myocardial prediction. 
Table 7-10 shows the results to ascertain if the extended rule set fires (or not) in the 72 
hours before a rise in the first troponin within a sequence of troponins (or the first negative 
troponin within a sequence of negative troponins). Again the confidence intervals are wide 
so nothing meaningful can be drawn from the results.  
 
Table 7-11 shows the results when troponins (negative and positive) occurring early within 
the patient stay are removed (as any cardiovascular disturbance causing them will not 
necessarily be detected by the rule set). This had the effect of reducing the number of 
sequences of high troponins to 16 and negative troponins to 14. 
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7.5.2 Myocardial prediction (causation) 
 
Table 7-10: Applying the extended rule base to the 72 hours prior to the 27 
sequences of high and 19 sequences of negative troponins 
 
 
 Sequence of High 
Troponins 
Sequence of Negative 
Troponins 
Rule set “fires” 14/27 (51.8%) 
 
i.e. True Positive 
6/19 (31.6%) 
 
i.e. False Positive 
Rule set does not “fire” 13/27 (48.1%) 
 
i.e. False Negative 
13/19 (68.4%) 
 
i.e. False Negative 
Sensitivity 51.8% 95% CI: 32% to 71.3% 
Specificity 68.4% 95% CI: 43.5% to 87.4% 
Positive predictive value 70% 95% CI: 45.7% to 88% 
Negative predictive value 50% 95% CI: 29.9% to 70.1% 
 
 
Table 7-11: Results with sequences of troponins (high and negative) occurring 
early in the patient’s admission to ICU removed 
 
 
 
 
 
 
 
 
 
 
 
As might be expected from the small numbers the confidence intervals are sufficiently 
wide so that no meaningful conclusions can be drawn. There is a perhaps however a signal 
towards sensitivity (87.5% with confidence intervals 61.6% to 98.1%). 
  
The rule base from the ICU-PSS underpinning the work, is distilled from the collective 
experience of three senior intensive care clinicians, and validated by 10 ICU consultants 
from two other hospitals. Electronic patient records in intensive care are a relatively new 
phenomenon. Analysing data on this scale would have been impossible using traditional 
paper records. For this exploratory study, over three thousand hours of data were 
examined. This required the use of various sophisticated computing tools, because manual 
manipulation of these data was impracticable. For that reason, the storage, processing and 
 Sequence of High 
Troponins 
Sequence of Negative 
Troponins 
Rule set “fires” 14/16 (87.5%) 
 
i.e. True Positive 
6/14 (42.9%) 
 
i.e. False Positive 
Rule set does not “fire” 2/16 (12.5%) 
 
i.e. False Negative 
8/14 (57.1%) 
 
i.e. False Negative 
Sensitivity 87.5% 95% CI: 61.6% to 98.1% 
Specificity 57.1% 95% CI: 28.9% to 82.2% 
Positive predictive value 70% 95% CI: 45.7% to 88% 
Negative predictive value 80% 95% CI: 44.4% to 96.9% 
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manipulation of data in this way to examine a clinical problem has not previously been 
undertaken. Other groups have tried to detect myocardial damage automatically with ECG 
analysis using neural networks with some success
134
. Our system has the advantage of 
using physiological disturbance alone, and of potentially being able to detect impending 
damage before ECG abnormalities occur. 
 
For myocardial association (detection) the false negative rate (i.e. the final rule set does not 
fire in certain cases when myocardial damage has subsequently occurred.) is moderately 
high. There are a number of possibilities. In this study I have used hourly data points, as 
currently physiological values have to be entered manually into the electronic patient 
record, then verified by the nurse at the bed space. Human nature being what it is, if there 
have been fluctuations in the parameter around the time of recording, there is a danger that 
the less extreme variation will be recorded. Also, there is a risk of missing some brief but 
significant physiological disturbance. It possible, but unlikely, that a patient could have 50 
minutes of profound hypotension occurring between two hourly time points. This extreme 
disturbance would not be “seen” by the system. Increasing the frequency of observations, 
increasing the number of clinicians, and using more patient data sets will allow further 
refinement of the model in order to reduce the false negative rate.  
 
An alternative explanation for the false negatives is that, in a subset of ICU patients with 
sepsis, the supply / demand imbalance characteristic of type II damage may be only part of 
the reason for myocardial injury. There is evidence, using coronary sinus thermodilution 
catheters, that coronary artery blood flow is not significantly different between septic and 
non septic ICU patients when their heart rate is less than 100 beats per minute, and may be 
greater in the septic group when the heart rate exceeds 100 beats per minute. 
Microvascular thrombi formation in the absence of overt physiological disturbance may 
play a role
135. 
All of these factors may be exacerbated by the myocardial depressant 
cytokines (interleukins-2, 4, 6, 8, 10 and tumour necrosis factor alpha) characteristic of 
severe sepsis
136. 
If such microvascular thrombi leading to myocardial damage occur in the 
absence of physiological disturbance, the system will not detect these events. 
 
There is a high false positive rate. Not all physiological derangement which causes the rule 
base to trigger will result in myocardial damage in every individual. It may be that these 
are patients with no underlying flow limiting coronary artery disease who are able to cope 
with more extreme physiological stressors. Ultimately, however, a high false positive rate 
is less concerning, as the rule base firing will be a prompt to simple and non-invasive 
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investigation. The frequency of false positives may fall with further experience and 
refinement of the system.   
 
In terms of myocardial prediction, the patient in Intensive Care is often sedated, and may 
not display typical symptoms of myocardial ischaemia. The current literature does not 
suggest any effective treatments for type II myocardial damage once it has occurred in the 
intensive care population
137
. Moreover, it is now well documented that the occurrence of 
myocardial damage does considerably increase predicted mortality and the length of ICU 
stay 
138,139
. 
 
The results from the prediction study are encouraging. However the false positive rate only 
increases from 51.9% to 87.5% once the sequences of troponin (high and negative) 
occurring early in the patient’s admission to ICU are removed. However it is my aim that 
any future system utilising the rule base could be used in areas other than ICU. For 
example, there is no reason why a future system could not be used in a high dependency 
area or acute medical receiving ward, and perhaps start to pick up the characteristic 
physiological disturbances leading to type II myocardial damage. 
 
This study had several weaknesses that could be addressed in future work. Although 52 
patient data sets were used, the number of positive and negative sequences was small (27 
sequences of positive and 19 sequences of negative troponins). In statistical terms this 
makes it more likely that the confidence intervals will be wider. Further, more than one 
sequence could have come from the same patient and it is possible that it is the same 
continued myocardial supply/demand imbalance occurring at different times causing  
ongoing damage rather than discrete events. With routine 3 times per week troponin 
sampling it is possible that a troponin that was only very mildly elevated had decayed and 
was undetected when sampled even though the rule set had correctly “fired.” Nursing staff 
at Glasgow Royal either record manually or verify physiological data automatically 
downloaded into CareVue at hourly time points. It is possible that there could be profound 
periods of physiological disturbance occurring between the points that the nursing staff 
record that the rule set does not “see.” The combination of rules chosen and their duration 
is only one of a large number of other combinations and variations. It may be that other 
combinations with different durations model better. 
 
The work was also undertaken retrospectively. Future work would be done prospectively 
using a much larger cohort of patients. Greater numbers would have the advantage of lack 
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of reliance on more than one event within the same patient. Greater troponin sampling 
frequency would identify more clearly if the rise and decay of troponin in Intensive Care 
patients is as per the ideal figure seen in textbooks. Renal impairment is common and the 
decay phase in particular may be prolonged. Further, increased sampling would decrease 
the chance of missing a small troponin rise that has already decayed by the time it is 
sampled under the current regime. The rule set could run on auto charted data from 
CareVue and be calculated automatically many times an hour. This would decrease the 
chance of profound physiological disturbance being missed between two hourly time 
points currently recorded. It would be interesting to model different combinations of rules 
and of different duration to ascertain if they give a better fit. Finally it would be useful to 
measure the new generation of highly sensitive troponins in addition to the current 
troponin test to see if the rules are detecting or predicting a troponin rise, but it is not being 
seen due to the sensitivity of the troponin test itself. 
 
7.5.3. Future work 
My future aim is to develop a bedside system which, using data from routine monitoring 
attached to the patient, will detect characteristic patterns of physiological derangement 
which lead to myocardial damage. Having demonstrated that it is possible to detect 
myocardial damage using physiological disturbance alone, I will work to refine this 
theoretical model, and incorporate it into a real time bedside system which alerts the health 
care professional to impending myocardial damage. This will initially prompt simple 
bedside tests, e.g. a 12 lead ECG, bedside echocardiography or a troponin measurement. 
 
This could, at first with high fidelity simulation and then with further study, lead to 
interventions at an earlier stage, e.g. increase in FiO2, fluid boluses, beta blockade and so 
on. The type of intervention would depend on the type of derangement and would be 
occurring before damage has occurred. The system could also be used in different clinical 
environments, e.g. high dependency or other areas with a suitable level of monitoring.  
 
It is now clear that a raised troponin is an independent risk factor for poorer ICU, hospital 
and long term outcome. It is also clear that, once it has occurred, there is little evidence on 
how to treat a patient or indeed how to reduce the mortality risk. Therefore a system which 
can predict impending damage and trigger further intervention may be clinically useful. 
Indeed the detection and timeliness of intervention in these areas may ultimately affect 
outcome.  
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7.6. Conclusion 
These preliminary studies lead to the hypothesis that it may be possible to detect 
myocardial damage and predict its occurrence, based on physiological disturbance alone. 
This will require further study based on analysis of prospectively collected and much 
larger data sets 
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damage. In the second, more detailed phase, I analysed a further 6827 predominantly 
hourly time points of data, and in discussion with Prof Kinsella we agreed what rules 
occurring in what duration, from the ICU-PSS, would constitute the rule set which would 
be used to detect and predict myocardial damage. I agreed with the computing scientists 
what characterised a sequence of troponins based on the natural decay in blood. The rule 
set was applied on my behalf to the data sets by the computing scientists.  
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Chapter 8: Patient Outcomes: Associations between mean ICU-PSS score, 
troponin rise during admission and outcome 
  
8.1. Abstract 
8.1.1. Introduction 
The APACHE II score combines physiological derangement with diagnostic information to 
reach an APACHE II predicted mortality. I hypothesised that there is a correlation between 
the patient’s overall cardiovascular state (as measured by the ICU-PSS) and patient 
outcome. Further, as myocardial damage in the critically ill is caused by an imbalance 
between myocardial oxygen supply and demand,  
there should also be a correlation between the size of a troponin rise (representing a greater 
and more sustained physiological derangement) and outcome. 
 
8.1.2. Methods 
In a first study, a data base was created from ward watcher of 54 patients. APACHE II 
score, predicted mortality, whether medical or surgical diagnosis, and outcome were 
recorded. Physiological data from this cohort was extracted from CareVue. The hourly 
ICU-PSS score was converted to a numeric scale (A=1 to E=5) and a mean score of the 
ICU-PSS was calculated for periods during the stay. In a second study, data from 100 
consecutive ICU admissions from July to October 2009 was extracted from the Ward 
Watcher System and the CareVue. These included APACHE II score, APACHE II 
predicted mortality, size of first troponin rise, day of first troponin rise, highest troponin 
rise, date of highest troponin rise, and patient outcome (alive / dead). The troponins were 
grouped into 4 ranges (<0.04, 0.04-0.19, 0.20-1.99, ≥2.0) and mean APACHE II score, 
mean APACHE II predicted mortality, and ICU mortality calculated. 
 
8.1.3. Results 
In the first study, 26/54 patients had a medical and 28/54 a surgical diagnosis. 17/26 
medical and 8/28 surgical patients died. Mean values for survivors and non survivors in the 
different groups at different time periods were calculated. In this preliminary work the 
computer programme used to calculate these values could not, at this stage, apply 
appropriate statistical tests.  
For all patients: 29 alive, 25 dead. Mean score Day 1, 3.79 (alive)/4.28(dead). Mean Score 
day 1-2, 3.79 (alive)/4.29 (dead). Mean score total stay, 3.12 (alive)/4.23 dead. 
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For patients with a medical diagnosis: 9 alive, 17 dead. Mean score Day 1, 3.39 
(alive)/4.32(dead). Mean Score day 1-2, 3.44 (alive)/4.29 (dead). Mean score total stay, 
2.76 (alive)/4.28 dead. 
For patients with a surgical diagnosis: 20 alive, 8 dead. Mean score Day 1, 3.98 
(alive)/4.18(dead). Mean Score day 1-2, 3.95 (alive)/4.30 (dead). Mean score total stay, 
3.29 (alive)/4.13 dead. 
 
In the second study, 23/100 patients were excluded from analysis (no troponin data or 
excluded from APACHE II scoring). The mean APACHE II predicted mortality, and actual 
ICU mortality for the different troponin ranges were respectively <0.04 (24%, 13.3%, 
n=30), 0.04-0.19 (42%, 13.3%, n=15), 0.2-1.99 (38.5%, 22.7%, n=22) and ≥2.0 (50.7%, 
40%, n=10). 
 
8.1.4. Conclusion 
This preliminary work leads to the hypothesis that there is a correlation between patient’s 
mean cardiovascular scores (as captured by the ICU-PSS) and, in certain groups, outcome. 
There is an association between level of troponin rise and Intensive Care Mortality. 
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8.2. Introduction 
A patient’s APACHE II score as calculated in the first 24 hours is combined with an 
APACHE II diagnosis to give an APACHE II predicted mortality. This is the gold standard 
prediction of patient outcome currently in use in Scotland. The higher the APACHE II 
score, the higher the predicted mortality. Unit predicted mortality can be calculated and 
compared with actual mortality to give a standardised mortality ratio (SMR)
 11
 
I postulated therefore that there is a correlation between the patient’s overall cardiovascular 
state (as measured by the ICU-PSS) and patient outcome. Similarly as most troponin rises 
in Intensive Care are caused by a myocardial supply / demand imbalance, I postulated that 
there should also be a correlation between the size of a troponin rise (representing a greater 
and more sustained physiological derangement) and outcome. 
 
8.3. Methods 
8.3.1. Possible correlation between mean ICU-PSS score and outcome 
I prepared a data set from 54 anonymised patients admitted to Glasgow Royal Infirmary 
Intensive Care Unit. The data collected included their APACHE II Score, APACHE II 
predicted mortality, reason for admission to the unit (APACHE III definition), 
corresponding APACHE II diagnosis and their outcome (dead or alive). These data were 
extracted from the Ward Watcher System. The full data set can be seen in Appendix XV. 
An extract is shown in table 8-1. 
 
Table 8-1: An extract from the 54 patient data set 
 
Patient-ID Start/Fin Outcome APACHE II 
Predicted 
Mortality Med Diag. 
1536 13 Alive 29 77.2 Medical 
1667 1697 Dead 33 84.5 Medical 
1689 1861 Alive 22 58.9 Medical 
1695 18614 Dead 31 75.4 Medical 
1697 1898 Alive 24 35.5 Medical 
1711 18654 Dead 20 35.5 Medical 
1720 2214 Alive 28 63.7 Surgical 
1721 2677 Alive 18 44.4 Surgical 
1726 2750 Alive 17 26.2 Surgical 
1727 2784 Dead 29 69.6 Medical 
1742 18666 Alive 16 23.3 Surgical 
1748 3027 Alive 23 62.3 Surgical 
1750 3530 Dead 18 29.1 Medical 
1757 3681 Alive 22 14 Medical 
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Physiological data from the Electronic Patient Record of each of these patients was then 
analysed. The predominantly hourly time point ICU-PSS score (A-E) was converted to a 
numerical score with A=1 point, B=2 points and so on. The mean score of these time 
points during various parts of the patient stay was then calculated. These were a mean 
score for the first day in ICU, day 1-2 and the total stay. These conversions and 
calculations would be extremely difficult manually and were done automatically by a 
computer workbench, the “I-predictor” created by our computing science colleagues. This 
programme also allowed examination of correlations between ICU-PSS scores and the 
demographic data base I had created 
140
.  
 
The patients were separated into those with either a medical or surgical diagnosis and as to 
whether their outcome was survival or death. Mean scores were then calculated for these 
groups as a whole for day 1, day 1-2 and total stay in Intensive Care.   
 
8.3.2. Possible correlation between size of troponin rise and outcome 
I audited 100 consecutive ICU admissions from July to October 2009. Data were extracted 
from the Ward Watcher System and the Electronic Patient Record. This work was made 
possible, as from 2009, troponins have been recorded regularly as part of routine clinical 
care, as well as when there is a specific clinical indication. The parameters were, date of 
admission to ICU, date of discharge from ICU, length of stay (days), age, sex, APACHE II 
score, APACHE II predicted mortality, size of first troponin rise, day of first troponin rise, 
highest troponin rise, date of highest troponin rise, and patient outcome (alive / dead). The 
full data set can be viewed in Appendix XVI. An extract is shown in table 8-2 below. 
 
 
Table 8-2: Extract from data set for analysis between troponin rises and outcome 
 
 Date of 
admission 
Date of 
discharge 
Length 
of stay 
(days) Age M/F Apache II 
Predicted 
mortality 
1st 
Troponin 
Day of 
1st 
troponin  
rise 
Highest  
troponin  
Day of 
highest 
troponin 
rise 
Alive 
(1)/ 
Dead 
(0) 
12/10/2009 15/10/2009 2.9 70 F 28 59.4 5.01 1 6.54 2 0 
10/10/2009 14/10/2009 4 58 F Readmission Readmission 3.21 1 3.21 1 1 
09/10/2009 14/10/2009 4.5 76 M Readmission Readmission 0.13 1 0.13 1 1 
08/10/2009 09/10/2009 0.9 33 M 11 6.3 <0.04  Y <0.04  Y 1 
08/10/2009 12/10/2009 3.6 35 F 19 27 0.27 2 0.27 2 1 
08/10/2009 14/10/2009 6.1 43 F 33 75.6 <0.04 Y <0.04  Y 0 
06/10/2009 08/10/2009 1.5 77 F 16 23.3 23.8 1 23.8 1 1 
 
 
In the table a troponin value of <0.04 indicates a troponin sampled on routine clinical 
testing but in which there is no rise. In such circumstances a “Y” in the day of first 
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troponin, and day highest troponin rise columns, merely indicates that a troponin was 
recorded and is negative i.e. there is no day of first rise.  
 
Of the 100 patients on whom data were collected, 13 were excluded as there was no 
APACHE II data (readmissions, length of stay < 8 hours, age < 16 years or burns). A 
further 10 patients were excluded as there was no troponin data available. The mean length 
of stay in this group was 0.6 days and they were not admitted long enough to have a 
sample collected for routine testing. 77 patients were analysed in total. This is represented 
in figure 8-1.  
 
Figure 8-1: Flow chart summarising the 23 patients excluded from the analysis 
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8.4. Results 
8.4.1. Correlation between mean ICU-PSS and outcome 
54 patients were analysed. 28/54 patients had a surgical and 26/54 had a medical diagnosis. 
Table 8-3 shows the raw data, with mean scores for medical, surgical and all patients in 
both outcome alive and outcome dead categories. 
 
Table 8-3: Overall outcome per diagnostic category 
 
 
 
 
 
 
 
8.4.2. Correlation between troponin rise and outcome 
A positive troponin I was greater than 0.04 micrograms / litre. For the purposes of the 
analysis I arbitrarily assigned those patients who had no troponin elevation or those who 
had a troponin rise into 4 categories. These were a troponin of less than 0.04 micrograms / 
litre (no rise), 0.04-0.19 micrograms / litre (low), 0.2-1.99 micrograms / litre (medium) and 
greater or equal to 2.00 micrograms / litre (high).Table 8-4 shows the results of assigning 
the 77 patients included in the analysis to these categories. 
 
Table 8-4: Analysis of the 77 patients by troponin range 
 
 Troponin 
<0.04 
Troponin 
0.04-0.19 
Troponin 
0.20-1.99 
Troponin 
≥2.0 
Number of patients 30 15 22 10 
Mean APACHE II 16 20.9 22 24.8 
Mean APACHE II 
predicted hospital 
mortality (%) 
24 42 38.5 50.7 
Actual ICU mortality (%) 13.3 13.3 22.7 40 
 
The range of troponin rises was 0.04-23.8 micrograms/litre. The low troponin group had an 
ICU mortality of 13.3%, the medium group 22.7% and the high group 40%. The 3 
categories of troponin positive patients were more ill than the troponin negative patients, 
having both higher APACHE II score and predicted mortalities. From these results, there is 
a correlation between an increasing troponin rise and ICU mortality. 
 
 
Time Period All patients Medical diagnosis Surgical diagnosis 
 Alive Dead Alive Dead Alive Dead 
Number of patients 29 25 9 17 20 8 
Day 1  
Mean ICU-PSS score 
3.79 4.28 3.39 4.32 3.98 4.18 
Day 1-2  
Mean ICU-PSS score 
3.79 4.29 3.44 4.29 3.95 4.30 
Total stay in ICU 
Mean ICU-PSS score 
3.12 4.23 2.76 4.28 3.29 4.13 
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8.5. Discussion 
8.5.1. ICU-PSS and patient outcome 
In this experiment the predominantly hourly time points of the patient’s stay was scored 
using the ICU-PSS on the A-E scale. This was converted to a numerical value, A=1, B=2 
etc. This approach has simplicity but has a number of drawbacks. A non-linear categorical 
scale is being converted into a numerical score from which a mean is calculated. The data 
was subject to the extrapolation and nonsense values algorithms described earlier in the 
thesis but these have their limitations. Clearly if a “mean” is being calculated the A to E 
score has to be accurate before conversion to a numerical value. Two other checks before 
using this programme have to be undertaken. The users have to be satisfied themselves that 
the data is satisfactory by manually checking for significant missing values. Secondly the 
programme can itself flag to the user where there is missing data.  
 
Unfortunately at the stage of development of the system, it was only able to convert the 
categorical scale into a numerical value and calculate a mean. It was not able to calculate 
standard deviations or interquartile ranges. This will clearly be important for future 
development. The table below shows the raw data, with mean scores for medical, surgical 
and all patients in both outcome alive and outcome dead categories. 
 
As can be seen there is a suggestion that the mean scores are worse in the non-survivors 
than survivors. However, no appropriate statistical tests have been applied. This system 
does not take into account the different lengths of stay of the various patients. Future work 
could focus on this problem in a different manner by examining the different proportions 
of the patient’s stay spent in different categories of the score. This would avoid the 
difficulties above of converting ordinal to numerical data. 
 
Therefore, in this preliminary work there may be a correlation between mean 
cardiovascular scores (as captured by the ICU-PSS) and, in certain groups their outcome. 
Further work with appropriate statistical tests will be required to confirm or refute this 
hypothesis. This would be of interest as the ICU-PSS is a purely physiologically based 
score and is diagnosis independent. Compare this to the APACHE system. This requires 
diagnostic criteria to be combined with an APACHE score to obtain a predicted mortality, 
and therefore has its own inherent problems. There can be inconsistency and inaccuracy in 
applying diagnostic criteria, as the Ward Watcher data are often entered by inexperienced 
junior staff.  There can also be inaccuracy and inconsistency in entering the physiological 
data.  It a study by Goldhill et al 
141
, checking points assigned for 8 physiological 
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variables, applying strict APACHE II criteria 20.6%, of these points were higher and 6.7% 
of the points lower than originally entered into the study ICU’s data base. This had the 
effect of raising that ICU’s predicted mortality from 24.8 to 27.8%. Further, in the 
APACHE II score, the difficulty in determining inspired oxygen concentration in 
spontaneously breathing patients has an impact on the acute physiology score component 
142
. 
 
There would be several advantages of the ICU-PSS in the future as a predictor of mortality. 
There are none of the inconsistencies in data entry or ambiguity in the components of the 
score, it is diagnosis independent, it could be calculated automatically and can be 
calculated at various points throughout the patient stay (potentially giving a more accurate 
prediction of outcome with time).  
 
8.5.2. Troponin rise in ICU and outcome 
The results demonstrate an increasing ICU mortality as the ranges of troponin also 
increase. Previous studies have examined this phenomenon and found similar trends, but 
some of these were in purely medical ICUs 
80
. These results confirm that the trend in 
mortality holds true in a mixed Scottish ICU with a higher than average APACHE II score.  
 
The recent universal definition of myocardial infarction has helped clarify thinking on this 
issue 
76
. Critically ill patients have disordered cardiovascular function characterised by 
different combinations of hypo- or  hypertension, tachy- or bradycardia and a high 
incidence of coexisting cardiovascular disease. A rise in cardiovascular biomarkers is taken 
to indicate myocardial damage, but the elevated levels found in multiple organ failure, 
sepsis and burns do not necessarily indicate the development of a myocardial infarction, 
due to lack of ECG changes or a specific wall motion abnormality on echocardiography.  
 
Although I found no change in ICU mortality in patients in the range 0.04-0.19 
micrograms / litre versus patients with no troponin rise, a recent much larger study of 663 
patients by Reynolds 
76
 showed a trend towards lower odds of hospital survival in patients 
with minor elevation in the range 0.05-0.12 micrograms / litre (again using Troponin-I). 
The study was undertaken in a mixed medical and surgical unit where patients have 
troponin sampled daily. Interestingly 52% of their patients had a troponin rise there whilst 
in Intensive Care, which is similar to the rate I found in the ICU of Glasgow Royal 
Infirmary. Further, in a recent study conducted in the Beth Israel Deaconess Medical 
Centre, Velasquez et al
 
examined a cohort of 3250 patients who had one or more troponins 
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measured during their admission 
139
.1219 of those had at least one positive result. They 
demonstrated an increase in all cause mortality at 1000 days in patients with minor 
troponin rises (0.01 to 0.1ng/ml in their assay). 
 
In future work, I will extend the data base and focus on minor troponin elevation ranges 
only to ascertain if the effect demonstrated in other studies holds true for a mixed Scottish 
ICU population. Small troponin rises are likely to be overlooked by most clinicians as 
there is no evidence how to treat them in the absence of overt coronary artery disease or on 
the mechanism of their effect on mortality.  
 
8.6. Conclusions 
This preliminary work leads to the hypothesis that there is a correlation between patient’s 
mean cardiovascular scores (as captured by the ICU-PSS) and, in certain groups outcome. 
This will have to be investigated further using appropriate statistical tests applied to larger 
datasets. There is an association between level of troponin rise and Intensive Care 
Mortality. 
 
8.7. Acknowledgements 
I prepared the data base for the ICU-PSS outcome study and the troponin outcome study. I 
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study to ascertain the relationship between mean ICU-PSS and outcome in different groups 
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Chapter 9: Final Discussion and future direction 
The initial aim of this thesis was to ascertain if haemodialysis in Intensive Care patients is 
a haemodynamically unstable therapy. From an initial and simple experiment, it became 
clear that a more sophisticated scoring system would have to be designed to answer this 
question. This resulted in the development of a novel quantitative score for cardiovascular 
instability. Although this approach was shown to have some merit, it became apparent that, 
to overcome the deficiencies of this score and of other currently available scores in 
Intensive Care, a different strategy was required. This led to the development and first 
stages of development of a novel quantitative score underpinned by a sophisticated 
physiological rule base, to summarise the overall state of a patient. This was a major part 
of the work of this thesis.  
 
The qualitative score has the advantage over the quantitative score that it captures the 
expertise of several clinicians. It was shown to be clinically credible in a series of studies 
with clinicians from different hospitals not involved in the development of the score. This 
score comes closer to an ideal score. It is calculated from routinely collected data and takes 
into account the amount of physiological and pharmacological support a patient is 
receiving (treatment effect). It could theoretically be calculated an infinite number of 
times, be automated, and displayed in real time. Early work suggests that it may 
discriminate outcomes in a diagnosis independent fashion. This could be of importance, as 
currently available scores such as APACHE II exclude certain diagnostic groups, e.g. 
burns. Further, it can be calculated from time zero and patients are not excluded from using 
the ICU-PSS because they have been admitted for less than 8 hours. Future work with the 
score will look to establishing if combining the score with, e.g., the APACHE II diagnostic 
codes will improve prediction of patient outcomes. The score’s positive predictive power 
may also increase over time after admission, with repeated calculation. 
 
Using physiological data on the scale in this body of work presented enormous challenges 
which for all practical purposes would have been impossible with traditional paper based 
records. Our collaborators were computing science colleagues who had very little 
knowledge of critical care and its terminology. A lot of very basic terms which are obvious 
to practising clinicians were alien to them and a lot of time was spent educating them in the 
“domain.” For any final bedside score the issue of missing data or consistently missing 
parameters will have to be dealt with. Rules were introduced so that parameters were 
converted and presented in a consistent manner. Rules were also introduced to deal with 
single missing values in data sets and to exclude “nonsense” values. This will have to be 
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taken further in the future. It would also be useful to have an increased sampling 
frequency. The limit in this research was the hourly frequency of recordings currently 
undertaken by nursing staff. In the future it may be possible to make use of the auto chart 
function of CareVue. This will be particularly important in the prediction of type II 
myocardial damage.  
 
Quantitative score - The weakness of this score is that the parameters and weightings were 
derived by a single researcher. Using this work as a starting point the score will be refined 
by conducting a brainstorming session with a group of clinicians. During this session they 
will be asked to define regularly recorded parameters and appropriate ranges. These will 
then be incorporated into a new set of rules and tested on real patient data sets to determine 
if they show trends in improvements and deteriorations. The major difficulty in developing 
the scores has been a lack of a standard reference with which to compare. In the absence of 
this the new score could be tested in a series of clinical scenarios with a separate group of 
clinicians not involved in its development. This would assess whether the score is 
clinically credible to them. At this stage any final refinements to the weightings of 
parameters could be made. 
Qualitative score - It would be useful to expand the number of clinicians scoring data sets 
and undergoing sessions with INSIGHT to expose inconsistencies. Since the initial work 
was done with the INSIGHT system, a comprehensive user manual has been written and it 
can now be used by the individual themselves independently from the computing 
scientists. This will help to remove any bias. It would be interesting to use other 
methodologies to define the rules in an A to E score. This could include facilitating a round 
table discussion of “experts” in the field. This method would have better face and content 
validity but would be more difficult to test there is inconsistency between an abstract 
discussion and clinical reality. A Delphi exercise could also be done but this may require 
several rounds to refine rules. The anonymity of responses would help reduce bias as the 
responder would not be directly influenced by a peer. Experts could also be shown mock 
scenarios of an accelerated patient stay in Intensive Care and asked to summarise why they 
are improving or deteriorating and describe why. This would help eliminate the problem of 
describing instability in the abstract. 
Validation of the qualitative score – Only a series of discrimination experiments as the first 
stage of full validation have been undertaken thus far. To recap a suggested scheme for 
completing this process:  For face validation clinicians will be shown examples of changes 
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within the score and no change within the score. They will be given a simultaneous clinical 
commentary about the patient’s state and asked whether they think “on the face of it” that 
changes within the score reflect what is happening clinically i.e. does it appear to capture 
clinical improvement or deterioration. For content validation parameters which comprise 
the final ICU-PSS score will be shown to a group of experienced clinicians. They will be 
asked whether they feel that the parameters chosen to capture instability reflect what they 
themselves would have chosen if they had been designing a score. In a sense the score 
already has some indirect content validity given that when forming their rule base to score 
the data sets in its construction, two clinicians other than myself chose the same (although 
obvious) markers of instability i.e. heart rate, mean arterial pressure, inspired oxygen 
concentration, oxygen saturation and inotrope requirements.  
As above discriminant validity experiments have already been undertaken. These 
successfully showed that when the score increases or decreases clinicians can (in the 
absence of clinical information) detect improvement or deterioration when the score 
changes by one or two steps. To complement this discriminant validity experiment a 
convergent validity experiment would be useful i.e. when there is no change in the score 
the clinicians no not detect a difference. Clinicians will be shown random examples of no 
change i.e. A to A, B to B etc. and asked whether the patient has deteriorated, improved or 
their physiological state is unchanged. Clinical history and trending information will be 
important to again help overcome the situation where parameters in the period of interest in 
the data shown are very close to a boundary. The score will also have to be shown to be 
reliable. If all the relevant data is present, collected properly from working equipment and 
processed appropriately by a computer algorithm then for given combinations of data there 
should be a consistent and reliable output. In terms of the clinicians a further experiment 
will be conducted to assess if they are consistent and reliable in their assessment. This 
could be done by showing a (large) series of lines of data, possibly with parameters around 
the middle of ranges. The clinician would then be asked to say whether the lines of data 
represented A (stable) through to (E) unstable. The same lines of data would be shown on 
more than one occasion to ascertain how reliable the clinician was with their own opinion 
and how reliably different clinicians when shown a line of data at a stability level mark it 
as such. 
Myocardial association and prediction - Due to the large confidence intervals around both 
the positive predictive and negative predictive value of the rule base, this initial work was 
hypothesis generating. To overcome the weaknesses within the original studies which 
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might have led to this, future work would be done prospectively using a much larger cohort 
of patients. This would avoid reliance on detecting more than one event within the same 
patient. Greater troponin sampling frequency would identify more clearly if the rise and 
decay of troponin in Intensive Care patients is as per the ideal figure seen in textbooks and 
would decrease the chance of missing a small troponin rise that has already decayed by the 
time it is sampled under the current regime. The rule bases would be tested in a non-renal 
failure population to avoid the confounding factor of prolonged troponin delay. The rule 
set could run on auto charted data from CareVue and be calculated automatically many 
times an hour which would decrease the chance of profound physiological disturbance 
being missed between two hourly time points currently recorded. It would be interesting to 
model different combinations of rules and of different durations to ascertain if they give a 
better fit. It would also be useful to measure the new generation of highly sensitive 
troponins in addition to the current troponin test to see if the rules are detecting or 
predicting a troponin rise, but it is not being seen due to the sensitivity of the troponin test 
itself. This would initially require an analysis of the typical profile for rise and fall of 
highly sensitive troponins within the blood after a myocardial event. 
Outcomes - This will be approached in a different manner. Rather than mean Intensive 
Care Unit - Patient Scoring System score over time, I will examine the percentage time in a 
24 hour period spent at a particular level in the score and its association with outcome. 
The future - I plan to develop a bedside monitor using the score in real time to give an 
overall summary of the physiological state of the patient. Initially, I will test a prototype in 
a high fidelity simulation to ascertain if clinical behaviour is altered with and without the 
assistance of the monitor. I hope that it can be introduced into clinical practice as an aid to 
less experienced staff who may not recognise deterioration in apparently “normal” 
physiological parameters, while the amount of support the patient requires is silently 
increasing. 
 
In summary, in this thesis I have described the development and first stages in the 
validation of a novel scoring system for patients in Intensive Care which goes some way to 
addressing the problems of currently available scores. This could lead to a commercially 
available bedside monitor capable of increasing patient safety and of improving clinical 
outcomes. 
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Appendices 
 
Appendix I 
Patient 708 - Testing of the quantitative score on unextrapolated data 
 
Time Adrenaline Noradrenaline Fluids Propofol Alfentanil HR SpO2 FiO2 Urine Temp MAP Dialysis Score 
Day 1              
19/12/2006 
19:45:37      114.0 90.0      2 
19/12/2006 
20:00:00   500.0   111.0 92.0 100.0  37.7 62.0  11 
19/12/2006 
21:00:00   500.0   116.0 79.0 100.0   68.0  12 
19/12/2006 
22:00:00 1.0 2.0 500.0 60.0 1.5 99.0 69.0 100.0 80.0 38.1 62.0  19 
19/12/2006 
23:00:00 2.0 2.0 500.0 60.0 1.5 108.0 83.0 100.0 10.0  62.0  20 
Day 2              
20/12/2006 
00:00:00 2.8 4.0 250.0 60.0 1.5 110.0 100.0 100.0 15.0  59.0  19 
20/12/2006 
01:00:00 2.8 4.0 350.0 60.0 1.5 112.0 83.0 100.0 10.0 38.3 59.0  23 
20/12/2006 
02:00:00 2.8 4.0 100.0 60.0 1.5 109.0 83.0 100.0 25.0  63.0  18 
20/12/2006 
03:00:00 2.8 4.0 100.0 60.0 1.0 107.0 75.0 100.0 15.0 38.8 67.0  20 
20/12/2006 
04:00:00 2.8 4.0 100.0 60.0 1.0 112.0 76.0 100.0 0.0  80.0  15 
20/12/2006 
05:00:00 2.8 4.0 50.0 60.0 1.0 118.0 80.0 100.0  38.9 82.0  13 
20/12/2006 
06:00:00 2.8 4.0 100.0 60.0 1.0 121.0 82.0 100.0 35.0  83.0  13 
20/12/2006 
07:00:00 2.8 4.0 100.0 60.0 1.0 124.0 82.0 100.0 15.0 38.9 64.0  20 
20/12/2006 
08:00:00 2.8 4.0 50.0 60.0 1.0 126.0 85.0 100.0 10.0 39.8 66.0  20 
20/12/2006 
09:00:00 2.8 4.0 50.0 60.0 1.0 127.0 86.0 100.0   69.0  17 
20/12/2006 
10:00:00 2.8 4.0 50.0 60.0 1.0 123.0 85.0 100.0 10.0 39.2 63.0  20 
20/12/2006 
11:00:00 2.8 4.0 50.0 60.0 1.0 118.0 91.0 100.0   58.0  16 
20/12/2006 
12:00:00 2.2 4.0 50.0 60.0 1.0 116.0 95.0 100.0 5.0 38.7 59.0  18 
20/12/2006 
13:00:00 2.2 4.0 50.0 60.0 1.0 117.0 81.0 100.0 0.0  58.0  20 
20/12/2006 
13:37:00      117.0 81.0 100.0   58.0  9 
20/12/2006 
14:00:00 2.2 4.5  60.0 1.0 115.0 82.0 100.0  38.6 58.0  18 
20/12/2006 
15:00:00 2.2 5.0  60.0 1.0 114.0 89.0 100.0 5.0  54.0  19 
20/12/2006 
16:00:00 2.2 5.0  60.0 1.0 113.0 91.0 100.0 0.0 38.9 57.0  20 
20/12/2006 
17:00:00 2.2 5.0  60.0 1.0 112.0 77.0 100.0   63.0  17 
20/12/2006 
18:00:00 2.2 5.0  60.0 1.0 112.0 90.0 100.0 30.0 38.8 53.0 Dialysis 18 
20/12/2006 
19:00:00 2.2 5.0  60.0 1.0 111.0 91.0 100.0   53.0 Dialysis 16 
20/12/2006 
20:00:00 2.2 5.0  60.0 1.0  92.0 100.0    Dialysis 4 
20/12/2006 
21:00:00 2.2 5.0  60.0 1.0 111.0 93.0 100.0 0.0 38.5 52.0  20 
20/12/2006 
22:00:00 2.2 5.0  60.0 1.0 112.0 91.0 100.0 0.0  51.0  19 
20/12/2006 
23:00:00 2.2 5.0  60.0 1.0 112.0 87.0 100.0   50.0  17 
Day 3              
21/12/2006 
00:00:00 2.2 5.0  60.0 1.0 113.0 88.0 100.0 0.0 38.5 53.0  21 
21/12/2006 
01:00:00 2.2 5.0  60.0 1.0 113.0 88.0 100.0 0.0  51.0  20 
21/12/2006 
02:00:00 2.2 5.0  60.0 1.0 113.0 91.0 100.0   47.0  19 
21/12/2006 
03:00:00 2.2 5.0  60.0 1.0 114.0 93.0 100.0   48.0  19 
21/12/2006 
04:00:00 2.2 5.0  60.0 1.0 113.0 93.0 100.0  39.4 46.0  20 
21/12/2006 
05:00:00 2.2 5.0  60.0 1.0 114.0 89.0 100.0 0.0  45.0  23 
21/12/2006 
06:00:00 2.2     114.0 88.0 100.0  40.3 46.0  18 
21/12/2006 
07:00:00 2.2 5.0  60.0 1.0 113.0 89.0 100.0 0.0  47.0  23 
21/12/2006 
08:00:00 2.2 5.0  60.0 1.0 112.0 89.0 100.0  40.8 47.0  22 
21/12/2006 
09:00:00      113.0 89.0 100.0   47.0  11 
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Appendix II 
Patient 708 - Quantitative score applied to final extrapolated data 
 
Time Adrenaline Noradrenaline Fluids Propofol Alfentanil HR SpO2 FiO2 Urine Temp MAP Dialysis Score 
Day 1                           
19/12/2006 
19:45:37      114.0 90.0      2 
19/12/2006 
20:00:00   500.0   111.0 92.0 100.0  37.7 62.0  11 
19/12/2006 
21:00:00   500.0   116.0 79.0 100.0  37.7 68.0  12 
19/12/2006 
22:00:00 1.0 2.0 500.0 60.0 1.5 99.0 69.0 100.0 80.0 38.1 62.0  19 
19/12/2006 
23:00:00 2.0 2.0 500.0 60.0 1.5 108.0 83.0 100.0 10.0  62.0  20 
Day 2                           
20/12/2006 
00:00:00 2.8 4.0 250.0 60.0 1.5 110.0 100.0 100.0 15.0  59.0  19 
20/12/2006 
01:00:00 2.8 4.0 350.0 60.0 1.5 112.0 83.0 100.0 10.0 38.3 59.0  23 
20/12/2006 
02:00:00 2.8 4.0 100.0 60.0 1.5 109.0 83.0 100.0 25.0 38.3 63.0  19 
20/12/2006 
03:00:00 2.8 4.0 100.0 60.0 1.0 107.0 75.0 100.0 15.0 38.8 67.0  20 
20/12/2006 
04:00:00 2.8 4.0 100.0 60.0 1.0 112.0 76.0 100.0 0.0 38.8 80.0  16 
20/12/2006 
05:00:00 2.8 4.0 50.0 60.0 1.0 118.0 80.0 100.0 0.0 38.9 82.0  16 
20/12/2006 
06:00:00 2.8 4.0 100.0 60.0 1.0 121.0 82.0 100.0 35.0 38.9 83.0  14 
20/12/2006 
07:00:00 2.8 4.0 100.0 60.0 1.0 124.0 82.0 100.0 15.0 38.9 64.0  20 
20/12/2006 
08:00:00 2.8 4.0 50.0 60.0 1.0 126.0 85.0 100.0 10.0 39.8 66.0  20 
20/12/2006 
09:00:00 2.8 4.0 50.0 60.0 1.0 127.0 86.0 100.0 10.0 39.8 69.0  20 
20/12/2006 
10:00:00 2.8 4.0 50.0 60.0 1.0 123.0 85.0 100.0 10.0 39.2 63.0  20 
20/12/2006 
11:00:00 2.8 4.0 50.0 60.0 1.0 118.0 91.0 100.0 10.0 39.2 58.0  19 
20/12/2006 
12:00:00 2.2 4.0 50.0 60.0 1.0 116.0 95.0 100.0 5.0 38.7 59.0  18 
20/12/2006 
13:00:00 2.2 4.0 50.0 60.0 1.0 117.0 81.0 100.0 0.0  58.0  20 
20/12/2006 
13:37:00 2.2 4.0  60.0 1.0 117.0 81.0 100.0 0.0  58.0  20 
20/12/2006 
14:00:00 2.2 4.5  60.0 1.0 115.0 82.0 100.0 0.0 38.6 58.0  21 
20/12/2006 
15:00:00 2.2 5.0  60.0 1.0 114.0 89.0 100.0 5.0 38.6 54.0  20 
20/12/2006 
16:00:00 2.2 5.0  60.0 1.0 113.0 91.0 100.0 0.0 38.9 57.0  20 
20/12/2006 
17:00:00 2.2 5.0  60.0 1.0 112.0 77.0 100.0 0.0 38.9 63.0  21 
20/12/2006 
18:00:00 2.2 5.0  60.0 1.0 112.0 90.0 100.0 30.0 38.8 53.0 Dialysis 18 
20/12/2006 
19:00:00 2.2 5.0  60.0 1.0 111.0 91.0 100.0 30.0  53.0 Dialysis 17 
20/12/2006 
20:00:00 2.2 5.0  60.0 1.0 111.0 92.0 100.0 30.0  53.0 Dialysis 17 
20/12/2006 
21:00:00 2.2 5.0  60.0 1.0 111.0 93.0 100.0 0.0 38.5 52.0  20 
20/12/2006 
22:00:00 2.2 5.0  60.0 1.0 112.0 91.0 100.0 0.0  51.0  19 
20/12/2006 
23:00:00 2.2 5.0  60.0 1.0 112.0 87.0 100.0 0.0  50.0  20 
Day 3                           
21/12/2006 
00:00:00 2.2 5.0  60.0 1.0 113.0 88.0 100.0 0.0 38.5 53.0  21 
21/12/2006 
01:00:00 2.2 5.0  60.0 1.0 113.0 88.0 100.0 0.0  51.0  20 
21/12/2006 
02:00:00 2.2 5.0  60.0 1.0 113.0 91.0 100.0 0.0  47.0  22 
21/12/2006 
03:00:00 2.2 5.0  60.0 1.0 114.0 93.0 100.0 0.0  48.0  22 
21/12/2006 
04:00:00 2.2 5.0  60.0 1.0 113.0 93.0 100.0 0.0 39.4 46.0  23 
21/12/2006 
05:00:00 2.2 5.0  60.0 1.0 114.0 89.0 100.0 0.0 39.4 45.0  24 
21/12/2006 
06:00:00 2.2 5.0  60.0 1.0 114.0 88.0 100.0 0.0 40.3 46.0  25 
21/12/2006 
07:00:00 2.2 5.0  60.0 1.0 113.0 89.0 100.0 0.0 40.3 47.0  25 
21/12/2006 
08:00:00 2.2 5.0  60.0 1.0 112.0 89.0 100.0 0.0 40.8 47.0  25 
21/12/2006 
09:00:00      113.0 89.0 100.0 0.0  47.0  14 
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Appendix III 
Document for computing scientists explaining the quantitative score 
 
Explanation of Scoring System 
 
Heart Rate (HR) 
Needs no explanation. A very fast of slow rate can impair the filling of the heart and may represent an 
abnormal heart rhythm. 
 
Mean Arterial Blood Pressure (MAP) 
This is probably more relevant in the Intensive Care setting than systolic and diastolic blood pressure. For 
your interest it is derived from the equation: 
 
Mean Arterial Pressure = Diastolic Pressure + 0.333 (Systolic Pressure – Diastolic Pressure) 
 
Too low a pressure and you do not perfuse vital organs e.g. kidneys, too high a pressure and you increase 
your chance of heart attack, stroke etc. 
 
Central Venous Pressure (CVP) 
This gives an indication of filling of the right side of the heart i.e. blood coming back to the heart from the 
body. Usually measured via a line inserted into the internal jugular or subclavian veins. If when a patient’s 
blood pressure is low you give them a fluid bolus and their CVP remains unchanged then this is an indication 
that they can cope with more fluid before commencing a drug to increase the blood pressure (inotropes). If 
the CVP increases dramatically then this is an indication that they are well filled with fluid. 
 
Cardiac Output (CO) 
This is the product of your heart rate and stroke volume (the amount of blood ejected from your heart with 
each contraction). If you have a heart attack and a failing heart is struggling to eject blood then your cardiac 
output will be low. 
 
Cardiac Index (CI) 
A way of comparing people of different body sizes. Derived by taking cardiac output and dividing by body 
surface area (for an average 70kg man this is 1.7m
2
 ). 
 
Stroke Volume 
The amount of blood ejected from the heart with each contraction. Within certain limits, the more blood 
returning to the heart the greater the stroke volume (Frank-Starling relationship). 
 
Stroke Volume Variance 
Reflects the variation in stroke volume caused by changes in intrathorcic pressure when e.g. a patient is being 
ventilated. The greater the variance the more likely it is that the patient still requires extra fluid. 
 
Systemic Vascular Resistance (SVR) 
In simplistic terms the resistance against which the heart must contract to eject blood into the body. If a 
patient is septic they are often vary vasodilated and may have a low SVR. To raise their blood pressure 
appropriate therapy would comprise fluid and a drug which “tightens up” their circulation e.g. noradrenaline 
(see later).  
 
Systemic Vascular Resistance Index (SVRI) 
As for cardiac index this corrects SVR for body surface area. 
 
Oxygen Delivery (D02) 
This is the amount of oxygen delivered to the peripheral tissues and is obtained by multiplying the arterial 
oxygen content of blood (20mls/100mls blood) and the cardiac output (5 litres) giving a figure of 
1000mls/min. 
 
Oxygen Saturation (Sp02) 
Oxygen is transported in the blood by being bound to haemoglobin (as well as a small dissolved fraction). 
The oxygen saturation is the %haemoglobin saturation with oxygen. If you draw a graph of haemoglobin 
saturation (%) against oxygen tension (kPa) (which drives the oxygen to bind with the haemoglobin) then 
you get a sigmoid shaped graph. This explains why a saturation of 75% although not a low number is 
actually very serious. The saturation is measured by a finger or ear probe, which uses infrared light. 
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Temperature 
Self-explanatory except to say that extremes of high and low are bad for many body systems e.g. at high 
temperatures various enzymatic processes start to become disturbed. 
 
Urine Output 
Self-explanatory. Roughly speaking you need to perfuse your kidneys with a mean pressure of 60mmHg to 
produce urine. This may be more in a patient with high blood pressure. 
 
Propofol 1% 
A phenolic derivative used by injection to induce general anaesthesia. It may be used in lower concentration 
to sedate patients in Intensive Care. It causes a dose-dependent reduction in vascular tone that reduces 
systemic vascular resistance (SVR), central venous pressure (CVP) and cardiac output (CO). Heart rate 
remains relatively unchanged. 
 
Alfentanil 
A synthetic opiate. Used in higher doses during general anaesthesia but in lower doses to sedate patients in 
Intensive Care. May cause vasodilation (hence lower SVR), slowing of the heart rate and low blood pressure 
(hypotension). 
 
Adrenaline 
A naturally occurring catecholamine. It is a positive inotrope (a drug which increases the force of contraction 
of the heart) and hence raises blood pressure. At higher doses it also increases systemic vascular resistance 
(SVR). It is used in Intensive Care to raise blood pressure in patients with low cardiac output when they are 
adequately filled with fluid. 
 
Noradrenaline 
Another catecholamine. Like adrenaline it is a positive inotrope. However its main effect is to “tighten up” 
the peripheral circulation and is thus used to raise blood pressure in patients where it is low because of a low 
systemic vascular resistance e.g. in sepsis. In practice patients often require a mixture of adrenaline and 
noradrenaline for blood pressure support. 
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Appendix IV 
Complete transcript of discussion with the computer scientists which lead to 
classification of broad levels of stability 
 
Patient 733  
 
Overall: Medium Worst 
 
General Description: 
 
Patient is unstable until around the morning of the 13
th
 when patient starts to stabilise. Apart from the odd 
‘blip’ patient is on a general upwards trend. 
 
Detailed Description: 
 
Time & Date Comments Condition of Patient 
8/01/07 10:00:00 Probably intubated, hence 
Propofol which affects the 
blood pressure. Blood pressure 
low so gave some fluids 
Getting Worse 
8/01/07 11:00:00 FiO2 probably turned down to 
check oxygen saturation 
 
8/01/07 13:00:00 - 18:00:00 Slightly worse as blood 
pressure not increased whilst 
on a higher amount of 
Noradrenaline. 
Worse 
8/01/07 19:00:00 - 9/01/07 
00:00:00 
Worse than when patient first 
admitted. Heart rate is higher 
and oxygen level is very bad 
Worse 
9/1/07 02:00:00 – 9/01/07 
06:00:00 
Slightly better oxygen 
saturation and blood pressure 
better  
Slight improvement 
09/01/07 07:00:00 - 09/01/07 
14:00:00 
Much worse. Very bad at 
13:30. Oxygen very bad, 
Noradrenaline has increased 
whilst blood pressure has 
decreased 
Much worse 
09/01/07 16:01:00 - 09/01/07 
19:00:00 
DIALYSIS  
Not much better. Dialysis may 
have been predicted because 
urine output and blood 
pressure not good  
Worse 
09/01/07 20:00:00 - 10/01/07 
00:00:00 
Not much change after 
dialysis. Urine low, it appears 
kidneys have taken a hit. 
Possibly Septic 
No change 
10/01/07 11:00:00 - 10/01/07 
11:00:00 
DIALYSIS 
Little better on dialysis. 
Noradrenaline down, oxygen 
down, but Noradrenaline 
increased. Blood Pressure okay 
but on increased Noradrenaline 
Wobble at 11:09:00 – prob 
down to cardiovascular 
problems 
No change 
10/01/07 17:00:00 Bit better after dialysis No change/ Slight 
improvement 
11/01/07 02:00:00 - 11/01/07 
05:00:00 
Better Improvement 
11/01/07 06:00:00 - 11/01/07 
10:00:00 
DIALYSIS 
Slight increase in oxygen. 
No change 
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Blood Pressure down a little 
Noradrenaline increased 
11/01/07 11:00:00 - 11/01/07 
13:00:00 
Blood pressure increased after 
dialysis. Much better now as 
Noradrenaline has gone 
Improvement 
11/01/07 14:00:00 - 11/01/07 
17:00:00 
Stable Stable/ No change 
11/01/07 18:00:00 - 11/01/07 
23:00:00 
Wobble. Blood pressure down, 
FiO2 up. 
Worse again. Perhaps down to 
secretions in the lung. 
Worse 
Morning of 12/01/07 Much better Big improvement 
12/01/07 18:00:00 DIALYSIS 
Blood pressure okay but 
Propofol has been increased. 
Bit more unstable on dialysis. 
Oxygen increased, in response 
to major wobble on dialysis. 
Towards end of session starts 
to adapt to dialysis. 
Worse on dialysis 
13/01/07 02:00:00 - 13/01/07 
10:00:00 
Blood pressure low despite less 
Propofol. Not quite as good but 
less oxygen has been given. 
Slight improvement 
13/01/07 10:00:00 – 14/01/07 
04:00:00 
Better again, stable. Oxygen 
probably not going to get any 
lower than 35%. 
Improvement/Stable 
14/01/07 05:00:00 - 14/01/07 
13:00:00 
Good. Making urine again. 
Best patient has been. 
Improvement 
14/01/07 14:00:00 - 14/01/07 
13:00:00 
DIALYSIS 
Oxygen has been increased on 
dialysis. Alfentanil and 
Propofol lower on dialysis. 
Patient little bit worse on 
dialysis. 
Worse 
15/01/07 00:00:00 - 15/01/07 
05:00:00 
Propofol up a little, Blood 
pressure down a little 
No change 
15/01/07 06:00:00 - 15/01/07 
15:00:00 
DIALYSIS 
Initially fine on dialysis. Slight 
wobble at start as FiO2 
increased back up. Recovered 
from wobble much quicker. 
No change 
15/01/07 16:00:00 – 16/01/07 
06:00:00 
No change. Everything okay. 
Controlled, stable. 
No change 
16/01/07 & 17/01/07 Oxygen fine, HR decreasing. 
Slowly things are getting 
better. Coping well with 
dialysis 
Improvement 
18/01/07 Fine, HR fine No change 
19/01/07 & 20/01/07 Blood pressure not changing 
much on dialysis 
No change 
21/01/07 & 22/01/07 Stability, low oxygen and heart 
rate fine. 
Improvement 
23/01/07 FiO2 of 28 often when taking 
the tube out of the patient. 
Starting to make urine. 
Improvement 
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Patient 708 
 
Overall: Worst 
 
General Description: 
 
Patient enters ICU almost as sick as a patient can be. They then deteriorate throughout the session resulting in 
what is suspected as the patient dying. 
 
Time & Date Comments Condition of Patient 
19/12/06 19:45:37 – 19/12/06 
21:00:00 
Heart rate high, oxygen 
saturation low. Aggressive 
fluids are given in response to 
high heart rate. Test patient’s 
response to fluids. Despite 
being given the fluids, the 
blood pressure is low. 
Intubated at 8pm. Very sick 
patient. Despite incubation, 
oxygen saturation only went up 
to 92. 
Very bad, getting worse 
19/12/06 22:00:00 Central line put in. Blood 
pressure not responding to 
Adrenaline and Noradrenaline. 
FiO2 and SpO2 are grim. Most 
likely septic as a lot of 
adrenaline and nor adrenaline 
given. 
Worse - Decreasing 
20/12/06 02:00:00 - 20/12/06 
04:00:00 
100% oxygen given but 
saturation decreasing. Increase 
in adrenaline and nor 
adrenaline but blood pressure 
still low. 
Worse - Decreasing 
20/12/06 05:00:00 - 20/12/06 
10:00:00 
Getting worse. Blood pressure 
not moving. Heart rate 
increasing. Urine output tailing 
off. Oxygen saturation dire. 
Worse - Decreasing 
20/12/06 13:00:00 - 20/12/06 
15:00:00 
High amounts of adrenaline 
and Noradrenaline. Blood 
pressure grim. No change, very 
unwell. 
Stable – No worse 
20/12/06 16:00:00 - 20/12/06 
17:00:00 
Oxygen worse. Noradrenaline 
increased. Not enough blood 
pressure for urine. 
Worse 
20/12/06 18:00:00 - 20/12/06 
20:00:00 
DIALYSIS 
Get worse on dialysis. Blood 
pressure even lower. Oxygen 
saturation is slightly higher. 
Could be because fluid had 
built up in the lungs and has 
now been removed. 
On balance, stable 
Rest of session Gradual deterioration.  
Oxygen saturation and blood 
pressure continue to decrease. 
Becoming more and more 
septic. Patient in the end dies, 
probably from a cardiac 
arrest/deciding not to increase 
drugs further. 
Much worse 
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Patient 728 
 
Overall: Least Worst 
 
General Description: 
 
Initially get worse upon admittance to ICU and then stabilise morning of the 9/01/07 
 
Time & Date Comments Condition of Patient 
05/01/07 17:00:00 - 05/01/07 
18:00:00 
Must be worried about blood 
pressure as a lot of fluid has 
been given to the patient. Quite 
bad situation. 
Bad 
05/01/07 18:00:00 Intubated. Blood pressure poor 
considering lots of fluid has 
been given. 
 
05/01/07 19:00:00 - 05/01/07 
21:00:00 
Blood pressure still low but 
given Noradrenaline. Heart rate 
is high. Overall deterioration. 
Worse - Decreasing 
05/01/07 22:00:00 - 05/01/07 
23:00:00 
No better. Oxygen saturation 
unchanged but FiO2 has 
decreased. Noradrenaline has 
been increased to maintain 
blood pressure. 
No change 
06/01/07 00:00:00 - 06/01/07 
06:00:00 
Blood pressure bit better and 
urine a bit better, heart rate is 
okay. Sedation has been 
lowered. Fluid down. 
Bit more stable 
06/01/07 15:00:00 - 06/01/07 
18:00:00 
Blood pressure worse. Heart 
rate okay. Sedation the same. 
Stable 
06/01/07 20:00:00 - 06/01/07 
21:00:00 
DIALYSIS 
Blood pressure copes well on 
dialysis. Oxygen saturation 
okay. Heart rate unchanged. 
Sedation cut back. 
Stable 
06/01/07 22:00:00 - 07/01/07 
06:00:00 
Blood pressure doesn’t really 
alter. Noradrenaline turned 
down. 
Stable 
07/01/07 07:00:00 - 07/01/07 
12:00:00 
Oxygen much the same and 
saturation lower. Blood 
pressure quite low and 
Noradrenaline has been 
reduced. Overall improvement.  
Slight improvement 
07/01/07 13:00:00 - 07/01/07 
18:00:00 
DIALYSIS 
Blood pressure not altered and 
coped well on dialysis. At 
times slightly worse 
Slightly worse 
07/01/07 19:00:00 – 08/01/07 
09:00:00 
Wobble after dialysis  
Noradrenaline back on to 
maintain blood pressure. 
Deterioration. 
Slightly worse 
08/01/07 10:00:00 - 16/01/07 
16:00:00 
DIALYSIS 
Blood pressure lower. Still on 
Noradrenaline. Slight blood 
pressure hit. 
Slightly worse 
08/01/07 17:00:00 - 08/01/07 
20:00:00 
Blood pressure unaltered. 
Oxygen lower. 
Stable 
Improvement 
08/01/07 21:00:00 - 09/01/07 
08:00:00 
Bit of improvement. Oxygen 
decreased. 
Improvement 
09/01/07 09:00:00 - 09/01/07 
14:00:00 
DIALYSIS 
Blood pressure fine. 
Oxygen the same. Propofol 
Stable 
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decreased. Coped well on 
dialysis. 
Afternoon of 09/01/07 and 
Morning of 10/01/07  
Noradrenaline stopped and 
blood pressure okay. Slight 
improvement. 
Improvement 
10/01/07 12:00:00 - 10/01/07 
16:00:00 
DIALYSIS 
Blood pressure doesn’t change 
much. 
Stable 
Evening of 10/01/07 and 
morning of 11/01/07 
Very stable. 
Producing reasonable volumes 
of urine. 
Improvement 
11/01/07 12:00:00  - 11/01/07 
20:00:00 
DIALYSIS 
Slight drop in blood pressure 
Slightly worse 
12/01/07 Fine low oxygen. Blood 
pressure fine. Heart Rate fine. 
Improvement 
12/01/07 16:00:00 DIALYSIS 
Slight drop of blood pressure 
Slightly worse 
Rest of session Happier situation. Temperature 
coming down. Heart rate 
getting slower.  
Lot better. 
 
Improvement 
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Appendix V 
Assigning stability levels and starting to formulate ranges for parameters 
 
Patient 708 
 
Day Comments – John Level 
Given - 
John 
Comments - Malcolm Level 
Given - 
Malcolm 
Day 1 
19/12/06 
First thing, given patient 
fluid in a large volume 
and ADR & NORAD 
and it has taken several 
hours to get on top of the 
situation. Low BP, High 
HR and a lot of 
treatment used to get 
those values. MAP, 
adequate value is 
between 60 -100. HR 
>100 abnormal. 
Fluid > 1litre – high 
amount 
Fluid > 700ml – Starting 
to worry 
Supporting evidence, 
Urine and FiO2. Main 
points: 
 
1) Total fluids initially 
high 
E 100% oxygen but saturation only 
up to 90%. 
Heart Rate is very high 
 
E 
Day 2 
20/12/09 
Still unstable despite 
need for fluids 
decreasing. NORAD 
increases and ADR 
decreased. Still high HR 
& BP not impressive. IF 
BP in the 50s – losing 
the battle. Looking at 
trends in particular, the 
running average for 
MAP & HR. 
E Low oxygen saturation despite 
still at 100% Oxygen. High Heart 
Rate and hypotensive despite both 
adrenaline and noradrenaline.  
 
5) Oxygen 
6) High HR despite ADR & 
NORAD 
7) Blood Pressure 
8) Urine Output 
 
Oxygen Saturation: 
 
96-94: Not bad 
Below 94: Bad 
90-84: Very Bad 
 
E 
Day 3 
21/12/09 
Remains unstable/dying. 
Increase in NORAD & 
ADR, BP decreasing and 
there is a fast HR. 
Average ADR & 
NORAD. Looking at 
trend of MAP. 
6 Patient stays bad 
 
4) Oxygen saturation bad 
and 100% oxygen 
5) Blood Pressure & HR 
6) Urine 
 
Heart Rate 
 
HR > 140: Bad as heart doesn’t 
refill properly. 
E 
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Patient 728 
 
Day Comments - John Level 
Given - 
John 
Comments - Malcolm Level 
Given - 
Malcolm 
Day 1 
05/01/07 
Getting fluid, starting 
NORAD, HR quite high 
(looks at peak). MAP 
quite low despite large 
amount of FLUID and 
NORAD 
E 100% oxygen required. 
Despite a lot of fluid and a lot of 
norad. , blood pressure is low.  
1) Oxygen 
2) Blood Pressure low 
despite NORAD & 
FLUID 
3) HR 
4) Urine 
E 
Day 2 
06/01/07 
Beginning to stabilise. 
NORAD dose stable. BP 
miles better (in normal 
range). HR good. 
Looking at a balance of 
fluids, drugs and BP. 
D 100% oxygen down to 75% and 
saturation okay. Blood Pressure 
bit better and requiring less fluid. 
 
1) Oxygen and Saturation 
2) Blood Pressure 
3) Fluid 
 
MAP  
 
Look at a particular value 
60 for normal people 
70/80 normal for ICU 
D 
Day 3 
07/01/07 
Stable, off NORAD – 
good. Little dip in BP 
but still in okay range. 
HR okay. Balance of 
decreasing vasopressor. 
D -> C Oxygen down to 65% and 
saturation maintained. Blood 
pressure okay and heart rate okay. 
NORAD coming down. Urine 
variable 
 
1) Oxygen and Saturation 
2) NORAD 
3) Urine 
C 
Day 4 
08/01/07 
Not getting much fluid, 
low level of NORAD, 
cardiovascular stable, 
MAP and HR in range. 
C  
1) Oxygen and Saturation 
2) Blood Pressure, HR & 
NORAD 
3) Urine 
 
 
B 
Day 5 
09/01/07 
Better – Oxygen not 
high, BP fine, NORAD 
disappears. Healthy BP 
– no change on dialysis. 
B Down to 50% oxygen and 
saturation still okay. Blood 
pressure good on smaller amount 
of inotrope. Heart rate coming 
down and urine still not quite 
right. 
 
1) Oxygen and Saturation 
2) HR 
3) Urine 
B 
Day 6 
10/01/07 
Better – urine vol not 
happened as in kidney 
failure. All ranges 
normal. No 
ADR/NORAD, lower 
oxygen. Handled 
dialysis well. Fluid 
doesn’t appear. 
B 40% oxygen – as low as it gets. 
Good saturation. Blood pressure 
good, no inotrope used.  Urine 
being made. 
 
1) Oxygen and Saturation 
2) Blood Pressure & 
inotrope 
3) Urine 
 
A 
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Day 7 
11/01/07 
Really stable. BP fine, 
HR fine. Handled 
dialysis no problems. 
A Still 40% oxygen and good 
saturation, MAP good and no 
inotrope given, urine being made. 
 
1) Oxygen and Saturation 
2) MAP & inotrope 
3) HR 
4) Urine 
A 
Day 8 
12/01/07 
Same as Day 7 A Same as Day 7 A 
Day 9 
13/01/07 
Same as Day 7 A Same as Day 7 A 
Day 10 
14/01/07 
Receiving a sedative just 
to keep him in bed. 
A Same as Day 7 A 
Day 11 
15/01/07 
Same as Day 7 A Same as Day 7 A 
Day 12 
16/01/07 
80 an hour fluid – 
normal drip, probably 
pulled the tube out. 
Suddenly started 
producing urine. 
Wouldn’t give that a 
score. 
A Same as Day 7 A 
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Appendix VI 
Annotations of patient 720 by Dr. M. Sim 
 
Time HR MAP CVP FiO2 SpO2 
Urine 
(mls/h) 
Prop. 
(mg/h) 
Hart. 
(mls/h) 
Gelo. 
Alfent. 
(mg/h) 
Dialysis 
Adren. 
(mg/h) 
Sodium 
Chloride 
(mls/h)  
Norad 
(mg/h) 
Score 
A-E 
                
Day 1                             
 
                
29/12/2006 17:00 102 78 7 1 96 60 100 0 
      
E 
29/12/2006 17:10 107 71 
  
100 
         
E 
29/12/2006 18:00 104 74 7 1 95 30 100 125 500 
     
E 
29/12/2006 19:00 106 70 9 0.8 99 5 100 125 500 
     
D 
29/12/2006 20:00 108 69 9 0.7 98 0 100 125 
      
D 
29/12/2006 21:00 109 64 11 0.7 98 0 100 125 
      
D 
29/12/2006 22:00 109 64 12 0.6 99 240 20 125 
      
D 
29/12/2006 23:00 105 66 9 0.6 94 30 0 125 
 
0.5 
    
D 
                
Day 2                             
 
                
30/12/2006 00:00 106 72 10 0.6 93 
  
125 
 
0.5 
    
D 
30/12/2006 01:00 112 83 11 0.6 91 110 
 
125 
 
0.5 
    
D 
30/12/2006 02:00 110 71 11 0.6 91 
  
125 
 
0.5 
    
D 
30/12/2006 03:00 109 69 13 0.6 92 100 
 
125 
 
0.5 
    
D 
30/12/2006 04:00 105 59 7 0.7 93 50 
 
125 250 0.5 
    
D 
30/12/2006 05:00 106 56 8 0.7 91 50 
 
125 250 0.5 
    
D 
30/12/2006 06:00 109 55 8 0.7 93 40 
 
125 
 
0.5 
    
D 
30/12/2006 07:00 103 54 12 0.7 67 35 
 
125 
 
0.5 
    
D 
30/12/2006 08:00 110 64 13 0.7 97 45 
 
125 500 0.5 
    
D 
30/12/2006 09:00 106 66 20 0.7 99 30 
 
125 
 
0.5 
    
D 
30/12/2006 10:00 103 65 23 0.7 100 45 
 
125 
 
0.5 
    
D 
30/12/2006 11:00 103 56 14 0.7 100 25 
 
125 500 0.5 
    
D 
30/12/2006 12:00 100 56 13 1 99 
  
125 500 0.5 
    
E 
30/12/2006 12:35 
 
56 14 0.7 
          
E 
30/12/2006 13:00 99 54 12 1 99 30 
 
125 
 
0.5 Dialysis 
   
E 
30/12/2006 14:00 110 72 9 0.95 96 25 
 
125 500 0.5 Dialysis 0.6 
  
E 
30/12/2006 15:00 127 75 4 0.95 98 30 
 
125 
 
0.5 
 
0.6 
  
E 
30/12/2006 16:00 128 85 
 
0.9 99 15 
 
125 
 
0.5 
 
1 
  
E 
30/12/2006 17:00 120 99 10 0.9 95 20 
 
125 
 
0.5 
 
1 
  
E 
30/12/2006 18:00 117 86 8 0.9 94 20 
 
125 
 
0.5 
 
1 
  
E 
30/12/2006 19:00 110 77 7 0.9 98 15 
 
60 
 
1 
    
E 
30/12/2006 20:00 112 69 12 0.9 96 20 
   
1 
 
1 60 
 
E 
30/12/2006 21:00 111 69 15 0.9 92 15 
  
500 1 
 
1 
  
E 
30/12/2006 22:00 108 59 42 0.9 91 15 
   
1 
 
1 60 
 
E 
30/12/2006 23:00 115 78 16 1 91 15 
   
1 
 
1 60 0.4 E 
                
Day 3                             
 
                
31/12/2006 00:00 115 66 13 1 95 10 
   
1 
 
0.8 60 0.6 E 
31/12/2006 01:00 113 63 14 1 95 0 
   
1 
 
0.8 60 0.6 E 
31/12/2006 02:00 111 65 13 1 94 5 
   
1 
 
0.8 60 0.8 E 
31/12/2006 03:00 111 67 19 1 96 20 
   
1 
 
0.6 60 0.9 E 
31/12/2006 04:00 113 60 19 1 91 0 
   
1 
 
0.2 60 1.1 E 
31/12/2006 04:41 
             
1.4 E 
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31/12/2006 05:00 115 69 18 1 92 5 
  
500 1 
 
0.2 60 1.4 E 
31/12/2006 05:18 
             
1.3 E 
31/12/2006 05:40 
         
1 
   
1.1 E 
31/12/2006 06:00 114 76 24 1 98 0 
   
1 
  
60 1.1 E 
31/12/2006 07:00 119 71 27 1 100 5 
   
1 
  
60 1 E 
31/12/2006 08:00 111 63 26 1 100 40 
   
1 
  
60 1 E 
31/12/2006 09:00 109 64 14 1 95 10 
   
1 
  
60 1 E 
31/12/2006 10:00 108 76 21 1 97 10 
   
1 Dialysis 
 
60 1 E 
31/12/2006 10:25 108 76 21 1 97 
         
E 
31/12/2006 11:00 111 66 17 
  
0 
    
Dialysis 
  
1 E 
31/12/2006 12:00 119 73 
 
1 94 5 
  
250 
 
Dialysis 0.2 
 
1.6 E 
31/12/2006 13:00 115 71 17 1 95 
   
250 1 Dialysis 0 
 
1.6 E 
31/12/2006 14:00 110 76 13 1 95 5 
   
1 Dialysis 
  
1.6 E 
31/12/2006 14:25 
   
1 94 
         
E 
31/12/2006 15:00 154 67 15 1 96 10 
   
1 Dialysis 
  
1.4 E 
31/12/2006 16:00 139 70 
 
1 95 10 
   
1 Dialysis 
  
1.4 E 
31/12/2006 17:00 78 82 18 1 95 0 
   
0.5 
   
1.4 E 
31/12/2006 18:00 77 89 
 
1 95 0 
   
0.5 
   
1.4 E 
31/12/2006 19:00 80 82 18 1 95 10 
   
0.5 
   
0.8 E 
31/12/2006 20:00 84 81 16 1 96 10 
   
1 
   
0.8 E 
31/12/2006 21:00 85 81 
 
1 95 10 
   
1 
   
0.8 E 
31/12/2006 22:00 90 72 12 1 95 10 
   
1 
   
0.8 E 
31/12/2006 23:00 86 71 12 1 98 10 
   
1 
   
0.8 E 
                
Day 4                             
 
                
01/01/2007 00:00 89 74 11 1 97 5 
   
1 
   
0.8 E 
01/01/2007 01:00 89 76 
 
1 97 5 
   
1 
   
0.8 E 
01/01/2007 02:00 90 69 
 
1 96 5 
   
1 
   
0.8 E 
01/01/2007 03:00 95 68 12 1 98 5 
   
1 
   
0.8 E 
01/01/2007 04:00 95 71 14 1 97 0 
   
1 
   
0.8 E 
01/01/2007 05:00 97 70 11 1 98 5 
   
1 
   
0.8 E 
01/01/2007 06:00 96 65 11 1 99 0 
   
1 
   
0.8 E 
01/01/2007 07:00 92 82 21 1 96 0 
   
1 
   
0.8 E 
01/01/2007 08:00 94 87 22 1 97 25 
   
1 
   
0.8 E 
01/01/2007 09:00 94 71 18 1 97 0 
       
0.8 E 
01/01/2007 09:27 94 71 18 1 97 
         
E 
01/01/2007 10:00 94 83 16 1 99 0 
    
Dialysis 
  
0.8 E 
01/01/2007 11:00 83 75 16 1 97 25 
    
Dialysis 
  
0.8 E 
01/01/2007 12:00 84 78 16 1 96 5 
    
Dialysis 
  
0.8 E 
01/01/2007 13:00 77 77 11 0.95 93 10 
    
Dialysis 
  
0.8 E 
01/01/2007 14:00 79 82 6 0.9 96 0 
    
Dialysis 
  
0.8 D 
01/01/2007 15:00 72 89 9 0.85 95 0 
    
Dialysis 
  
0.8 D 
01/01/2007 16:00 75 83 5 0.8 96 0 
    
Dialysis 
  
0.7 D 
01/01/2007 17:00 80 91 6 0.75 94 
        
0.7 D 
01/01/2007 18:00 85 91 7 0.75 93 
        
0.4 D 
01/01/2007 19:00 85 86 12 0.8 93 15 
       
0.3 C 
01/01/2007 20:00 84 85 12 0.8 94 0 
       
0.3 C 
01/01/2007 21:00 86 84 12 0.8 95 0 
       
0.3 C 
01/01/2007 22:00 87 78 12 0.8 94 20 
       
0.3 C 
01/01/2007 23:00 88 66 11 0.8 93 0 
       
0.3 D 
                
Day 5                             
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02/01/2007 00:00 90 63 10 0.8 94 0 
       
0.3 D 
02/01/2007 01:00 92 64 10 0.85 96 0 
       
0.3 D 
02/01/2007 02:00 95 72 11 0.85 97 5 
       
0.3 D 
02/01/2007 03:00 97 71 12 0.85 97 0 
       
0.3 D 
02/01/2007 04:00 91 73 12 0.85 97 0 
       
0.3 D 
02/01/2007 05:00 94 73 12 0.85 98 0 
       
0.3 D 
02/01/2007 06:00 91 75 11 0.85 98 0 
       
0.3 D 
02/01/2007 07:00 91 80 15 0.85 98 20 
       
0.3 D 
02/01/2007 08:00 91 73 14 0.85 99 0 
       
0.1 D 
02/01/2007 09:00 90 76 15 0.85 99 
        
0.1 D 
02/01/2007 09:58 90 76 15 0.85 99 
         
D 
02/01/2007 10:00 91 71 14 0.7 95 
     
Dialysis 
  
0.1 C 
02/01/2007 11:00 90 67 14 0.7 96 25 
    
Dialysis 
   
C 
02/01/2007 12:00 91 68 12 0.7 100 0 
    
Dialysis 
   
C 
02/01/2007 13:00 88 74 17 0.6 100 15 
    
Dialysis 
   
B 
02/01/2007 14:00 90 74 16 0.5 100 0 
    
Dialysis 
   
B 
02/01/2007 15:00 88 72 17 0.45 98 0 
    
Dialysis 
   
B 
02/01/2007 16:00 87 72 16 0.55 100 15 
    
Dialysis 
   
B 
02/01/2007 17:00 86 80 16 0.55 97 0 
        
B 
02/01/2007 18:00 83 76 16 0.55 96 0 
        
C 
02/01/2007 19:00 94 64 16 0.65 96 5 
        
C 
02/01/2007 20:00 90 69 14 0.65 96 0 
        
C 
02/01/2007 21:00 91 64 15 0.7 98 0 
        
C 
02/01/2007 22:00 94 67 19 0.7 97 0 
        
C 
02/01/2007 23:00 94 61 16 0.7 97 10 
        
C 
               
C 
Day 6                             C 
               
C 
03/01/2007 00:00 98 60 16 0.7 100 0 
        
C 
03/01/2007 01:00 103 60 17 0.7 100 0 
        
C 
03/01/2007 02:00 109 65 17 0.7 100 0 
  
250 
     
C 
03/01/2007 03:00 106 65 15 0.7 97 20 
        
C 
03/01/2007 04:00 106 70 18 0.7 98 0 
        
C 
03/01/2007 05:00 107 73 16 0.7 98 
         
C 
03/01/2007 06:00 108 75 20 0.7 99 
         
C 
03/01/2007 07:00 105 70 16 0.7 100 
         
C 
03/01/2007 08:00 103 71 16 0.7 100 20 
        
C 
03/01/2007 09:00 106 69 14 0.7 100 10 
        
C 
03/01/2007 10:00 100 66 15 0.65 98 5 
        
C 
03/01/2007 10:03 100 66 15 0.65 98 
         
C 
03/01/2007 11:00 99 62 16 0.7 95 0 
        
C 
03/01/2007 12:00 101 60 14 0.75 95 5 
    
Dialysis 
   
D 
03/01/2007 13:00 101 63 12 0.75 96 
     
Dialysis 
   
D 
03/01/2007 14:00 103 64 15 0.75 96 7 
    
Dialysis 
   
D 
03/01/2007 15:00 102 59 11 0.75 97 0 
    
Dialysis 
   
D 
03/01/2007 16:00 101 61 10 0.75 98 5 
    
Dialysis 
   
D 
03/01/2007 17:00 102 59 15 0.75 100 5 
    
Dialysis 
   
D 
03/01/2007 18:00 100 55 10 0.75 100 0 
        
D 
03/01/2007 19:00 104 54 10 0.75 100 0 
        
D 
03/01/2007 20:00 102 49 11 0.8 92 0 
        
D 
03/01/2007 21:00 108 69 12 0.8 97 0 
  
500 
     
D 
03/01/2007 21:20 
   
0.8 93 
         
D 
03/01/2007 22:00 105 70 27 0.8 95 
         
D 
03/01/2007 23:00 107 78 19 0.8 98 20 
        
D 
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Day 7                             
 
                
04/01/2007 00:00 104 69 33 0.8 98 0 
        
D 
04/01/2007 01:00 106 69 18 0.8 98 0 
        
D 
04/01/2007 02:00 103 62 
 
0.8 97 5 
        
D 
04/01/2007 03:00 106 68 17 0.8 98 0 
        
D 
04/01/2007 04:00 106 67 19 0.8 97 0 
        
D 
04/01/2007 05:00 112 63 17 0.85 95 0 
        
E 
04/01/2007 06:00 103 59 21 0.85 98 0 
    
Dialysis 
   
E 
04/01/2007 07:00 108 57 19 0.85 100 20 
    
Dialysis 
   
E 
04/01/2007 08:00 110 59 19 0.85 100 0 
    
Dialysis 
   
E 
04/01/2007 09:00 108 56 18 0.85 100 0 
    
Dialysis 
   
E 
04/01/2007 10:00 111 54 20 0.85 100 0 
    
Dialysis 
   
E 
04/01/2007 11:00 113 54 23 0.85 100 0 
    
Dialysis 
   
E 
04/01/2007 12:00 110 52 19 0.8 100 0 
        
E 
04/01/2007 12:08 113 54 23 0.85 100 
         
E 
04/01/2007 13:00 111 67 18 0.85 100 0 
        
E 
04/01/2007 14:00 109 57 19 0.85 96 0 
        
E 
04/01/2007 15:00 111 59 20 0.85 95 0 
        
E 
04/01/2007 18:00 115 61 15 0.95 98 0 
        
E 
04/01/2007 19:00 115 59 14 0.95 99 0 
        
E 
04/01/2007 20:00 116 58 15 0.95 99 15 
        
E 
04/01/2007 21:00 114 58 15 0.95 100 0 
        
E 
04/01/2007 22:00 114 52 14 0.95 100 0 
        
E 
04/01/2007 23:00 109 53 20 0.95 100 0 
        
E 
                
Day 8                             
 
                
05/01/2007 00:00 112 61 20 0.95 100 0 
        
E 
05/01/2007 01:00 108 57 17 0.95 100 10 
        
E 
05/01/2007 02:00 107 51 16 0.95 98 0 
  
250 
     
E 
05/01/2007 03:00 104 53 22 0.95 96 
        
0.8 E 
05/01/2007 04:00 109 62 19 0.95 96 0 
       
0.4 E 
05/01/2007 05:00 113 59 19 0.95 97 0 
       
0.6 E 
05/01/2007 06:00 117 64 17 1 97 0 
       
0.6 E 
05/01/2007 07:00 116 65 17 1 97 0 
       
0.7 E 
05/01/2007 08:00 115 59 17 1 96 0 
       
0.7 E 
05/01/2007 09:00 120 63 16 1 95 0 
       
0.7 E 
05/01/2007 10:00 116 58 13 1 93 0 
       
0.7 E 
05/01/2007 11:00 117 55 18 1 97 0 
    
Dialysis 
  
1.2 E 
05/01/2007 12:00 123 81 18 1 98 15 
    
Dialysis 
  
0.8 E 
05/01/2007 12:12 117 55 18 1 97 
         
E 
05/01/2007 13:00 117 65 17 0.95 95 0 
    
Dialysis 
  
1 E 
05/01/2007 14:00 116 68 17 0.95 98 0 
    
Dialysis 
  
1 E 
05/01/2007 15:00 115 66 17 0.9 96 15 
    
Dialysis 
  
1.1 E 
05/01/2007 16:00 116 67 17 0.9 96 
     
Dialysis 
  
1.1 E 
05/01/2007 17:00 113 65 17 0.9 97 0 
    
Dialysis 
  
1.1 E 
05/01/2007 18:00 117 62 18 0.95 97 
        
1.1 E 
05/01/2007 19:00 116 60 17 0.95 96 
        
1.1 E 
05/01/2007 20:00 117 64 18 0.95 96 0 
       
1.1 E 
05/01/2007 21:00 118 61 
 
0.95 96 20 
       
1.3 E 
05/01/2007 22:00 119 53 0 0.95 94 0 
       
2 E 
05/01/2007 23:00 122 62 
 
0.95 95 0 
       
2 E 
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Day 9                             
 
                
06/01/2007 00:00 124 75 -2 0.95 93 0 
       
2 E 
06/01/2007 01:00 116 
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Appendix VII 
Database for selection of pairs for two step change experiment 
Pair 
type 
First 
of 
group 
Last of 
group 
# of 
pairs 
Base-Line-
in-
Spreadsheet 
Rand 
Num 
(Ordered) 
Spreadsheet 
row 
number 
INSIGHT 
Case 
Num 
Batch Status Example 
CA 846 853 8 846 1 846 594 1  1 
CA    846 2 847 628 1  2 
CA    846 3 848 4049 1  3 
CA    846 4 849 4251 1  4 
CA    846 5 850 5040 1  5 
CA    846 6 851 6462 1  6 
CA    846 7 852 6507 1  7 
CA    846 8 853 6688 1  Not used 
           
DB 2043 2074 32 2043 17 2059 2976 1  8 
DB    2043 9 2051 867 1  9 
DB    2043 23 2065 3984 1  10 
DB    2043 10 2052 1380 1  Missing 
DB    2043 16 2058 2059 1  Missing 
DB    2043 30 2072 6257 1  11 
DB    2043 28 2070 5637 1  12 
DB    2043 18 2060 3464 1  13 
DB    2043 12 2054 1428 1  Missing 
DB    2043 20 2062 3898 1  Missing 
DB    2043 13 2055 1476 1  Missing 
DB    2043 22 2064 3966 1  Missing 
DB    2043 3 2045 582 1  14 
           
EC 5081 5095 15 5081 12 5092 5871 1  15 
EC    5081 14 5094 5891 1  Missing 
EC    5081 10 5090 5494 1  Missing 
EC    5081 2 5082 1255 1  Missing 
EC    5081 3 5083 2088 1  Missing 
EC    5081 13 5093 5874 1  16 
EC    5081 4 5084 2403 1  Missing 
EC    5081 1 5081 742 1  17 
EC    5081 7 5087 4992 1  Missing 
EC    5081 15 5095 6216 1  18 
EC    5081 5 5085 2417 1  Missing 
EC    5081 6 5086 4906 1  19 
EC    5081 11 5091 5720 1  Missing 
           
AC 171 183 13 171 1 171 589 1  Missing but 
could 
extrapolate) 
AC    171 2 172 593 1  ok 
AC    171 3 173 638 1  ok 
AC    171 4 174 3478 1  ok 
AC    171 5 175 4050 1  ok 
AC    171 6 176 4232 1  ok 
AC    171 7 177 4271 1  ok 
AC    171 8 178 4276 1  ok 
AC    171 9 179 5039 1  ok 
AC    171 10 180 5064 1  ok 
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AC    171 11 181 5083 1  ok 
AC    171 12 182 5091 1  ok 
AC    171 13 183 6526 1  ok 
           
BD 805 839 35 805 29 833 5634 1  ok 
BD    805 22 826 3967 1  Missing 
BD    805 17 821 3318 1  Missing 
BD    805 18 822 3341 1  Missing 
BD    805 6 810 630 1  ok 
BD    805 11 815 1421 1  Missing 
BD    805 1 805 11 1  ok 
BD    805 2 806 445 1  ok 
BD    805 30 834 5636 1  Missing 
BD    805 28 832 5632 1  ok 
BD    805 10 814 876 1  ok 
BD    805 23 827 4042 1  ok 
BD    805 14 818 1854 1  Missing 
           
CE 2014 2035 22 2014 3 2016 619 1  ok 
CE    2014 13 2026 4977 1  Missing 
CE    2014 6 2019 3081 1  Missing 
CE    2014 10 2023 4905 1  ok 
CE    2014 22 2035 6776 1  Missing 
CE    2014 8 2021 4880 1  ok 
CE    2014 18 2031 5745 1  Missing 
CE    2014 11 2024 4956 1  ok 
CE    2014 1 2014 1 1  Missing 
CE    2014 21 2034 6309 1  Missing 
CE    2014 9 2022 4885 1  Missing 
CE    2014 17 2030 5721 1  Missing 
CE    2014 15 2028 5224 1  Missing 
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Appendix VIII 
Slide show for ICU-PSS 2 step change experiment 
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Appendix IX 
Scoring sheet for ICU-PSS 2 step experiment 
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Appendix X 
Answer template for ICU-PSS 2 step experiment 
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Appndix XI 
Slide show for ICU-PSS 1 step change experiment 
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Appendix XII 
Scoring sheet for ICU-PSS 1 step experiment 
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Appendix XIII 
Answer template for ICU-PSS 1 step experiment 
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Appendix XIV 
Reasons for rejection of pairs of data used in the 2 step changes experiment 
(with both Insight Case Numbers) 
 
High Level Summary 
 
Most of the rejected pairs are because apparent improvement or deterioration was caused 
by missing parameter(s) rather than actual improvement or deterioration. 
 
I also for the purposes of this experiment required a minimum “core” set of parameters. 
These were FiO2, heart rate, MAP and SpO2. After the 1 stage change experiment is 
complete we can examine the clinician’s ability to discriminate using less than this core 
set. 
 
There were also two examples in the selected pairs in the B-D two step change which in 
fact from the spread sheet were D-D, so I ignored these. 
 
For ease I have made a table of each rejected pair rather than you having to scroll through 
the larger data set each time.  
 
Insight Case Number 1380-1381  
 
FiO2 HR MAP Norad SpO2 
 134 61 1.2 95 
0.5    95 
 
Prediction is D-B, but apparent improvement is due to missing HR, MAP, and 
Noradrenaline/ 
 
Insight Case Number 2059-2060 
 
FiO2 HR MAP Norad SpO2 
0.45 121 61  98 
0.5     
 
Prediction is D-B, but apparent improvement is due to missing HR, MAP and SpO2/ 
 
Insight Case Number 1428-1429 
 
FiO2 HR MAP Norad SpO2 
0.5 99 79 1.8 98 
0.5 99 79  98 
 
Prediction is D-B, but apparent improvement is due to missing noradrenaline. 
 
Insight Case Number 3898-3899 
 
FiO2 HR MAP Norad SpO2 
0.5 77 81 1.2 98 
0.5 77 81  98 
 
Prediction is D-B, but apparent improvement is due to missing noradrenaline. 
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Insight Case Number 1476-1477 
 
FiO2 HR MAP Norad SpO2 
0.5 95 68 1.8 100 
0.5 95 68  100 
 
Prediction is D-B, but apparent improvement is due to missing noradrenaline. 
 
Insight Case Number 3966-3967 
 
FiO2 HR MAP Norad SpO2 
0.8 93 66 0.2 92 
 90    
 
Prediction is D-B, but apparent improvement is due to missing FiO2, MAP, noradrenaline 
and SpO2. 
 
Insight Case Number 5891-5892 
 
Adrenaline  FiO2 HR MAP  SpO2 
1.4  0.4 109 63  99 
  0.4 109 63  99 
 
Prediction is E-C, but apparent improvement is due to missing Adrenaline 
 
Insight Case Number 5494-5495 
 
FiO2 HR MAP Noradrenaline SpO2 
0.7 109 70 1.8 98 
 105 65  97 
 
Prediction is E-C, but apparent improvement is due to missing FiO2 and Noradrenaline 
 
Insight Case Number 1255-1256 
 
FiO2 HR MAP Noradrenaline SpO2 
0.4 123 66 0.8 4 
0.4 108 65 0.7 97 
 
Prediction is E-C, but apparent improvement is due to a typo in the entry for SpO2 
 
Insight Case Number 2088-2089 
 
FiO2 HR MAP Noradrenaline SpO2 
1 104 87  100 
 104 87  100 
 
Prediction is E-C, but apparent improvement is due to missing FiO2 
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Insight Case Number 2403-2404 
 
FiO2 HR MAP Noradrenaline SpO2 
0.45 156 61  98 
0.45   0.8 98 
 
Prediction is E-C, but apparent improvement is due to missing heart rate and MAP 
 
Insight Case Number 4992-4993 
 
FiO2 HR MAP Noradrenaline SpO2 
 95 130  100 
 88 118  97 
 
 
Prediction is E-C, which is probably correct but for the purposes of the experiment I 
wanted to be consistent and required a minimum data set of FiO2, HR, MAP and SpO2. 
After completion of the one step change experiment then we can focus on two and one step 
changes with fewer core parameters. 
 
Insight Case Number 2417-2418 
 
FiO2 HR MAP Noradrenaline SpO2 
0.45 145 78 0.8 95 
   0.9  
 
Prediction is E-C, but apparent improvement is due to missing FiO2, HR, MAP and SpO2. 
 
Insight Case Number 5720-5721 
 
FiO2 HR MAP Noradrenaline SpO2 
0.65 109 69 2.8 94 
0.65 109 69  94 
 
Prediction is E-C, but apparent improvement is due to missing noradrenaline. 
 
Insight Case Number 589-590 
 
FiO2 HR MAP Noradrenaline SpO2 
0.35 87 98  98 
 107 86  99 
 
Prediction is A-C, but apparent FiO2 was missing and I wanted a minimum core data set 
(in this case it could have been extrapolated as it was 0.35 for several hours before and 
after). 
 
Insight Case Number 3967-3968 
 
FiO2 HR MAP Noradrenaline SpO2 
 90    
0.8 95 72 0.2 95 
 
Prediction is B-D, but apparent deterioration is due to missing FiO2, MAP, noradrenaline 
and SpO2. 
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Insight Case Number 3318-3319 
 
FiO2 HR MAP Noradrenaline SpO2 
0.35 126   97 
0.35 127   100 
 
Prediction is D-D, for some reason this appeared in the selected pairs document as a B-D 
so I moved on to the next one. 
 
Insight Case Number 3341-3342 
 
FiO2 HR MAP Noradrenaline SpO2 
0.3 131   100 
0.3 134   100 
 
Prediction is D-D, for some reason this appeared in the selected pairs document as a B-D 
so I moved on to the next one. 
 
Insight Case Number 1421-1422 
 
FiO2 HR MAP Noradrenaline SpO2 
0.4 90 74  97 
0.4 98 82 1.8 97 
 
Prediction is B-D, but apparent deterioration is due to missing noradrenaline. 
 
Insight Case Number 5636-5637 
 
FiO2 HR MAP Noradrenaline SpO2 
0.35 99 71  99 
0.35 113 88 0.3 99 
 
Prediction is B-D, but apparent deterioration is due to missing noradrenaline, but could 
have probably been extrapolated as was 0.3 for several hours before. 
 
Insight Case Number 1854-1855 
 
FiO2 HR MAP Noradrenaline SpO2 
0.4   0.1 99 
0.4 122 69 0.4 98 
 
Prediction is B-D, but apparent deterioration is due to missing heart rate and MAP. 
 
Insight Case Number 4977-4978 
 
FiO2 HR MAP Noradrenaline SpO2 
 101 118  100 
 103 144  100 
 
 
Prediction is C-E which is probably correct but the lack of FiO2 meant there was not the 
core data set. 
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Insight Case Number 3081-3082 
 
FiO2 HR MAP Noradrenaline SpO2 
0.3 108   97 
0.3 103 50 0.2 98 
 
Prediction is C-E, but apparent deterioration is due to lack of MAP and noradrenaline. 
 
Insight Case Number 6776-6777 
 
Adrenaline  FiO2 HR MAP  SpO2 
0.4  0.1 95 88  97 
  0.9 102 75  98 
 
Prediction is C-E, but apparent deterioration is due to lack of adrenaline. It had only been 
started one hour before this so would be difficult to extrapolate. 
 
Insight Case Number 5745-5746 
 
FiO2 HR MAP Noradrenaline SpO2 
0.55 101    
1 98 73 1.7 97 
 
Prediction is C-E, but apparent deterioration is due to lack of MAP, noradrenaline and 
SpO2. 
 
Insight Case Number 1-2 
 
FiO2 HR MAP Noradrenaline SpO2 
 100 105  100 
1 85 145  100 
 
Prediction is C-E, but apparent deterioration is due to lack of FiO2. 
Insight Case Number 6309-6310 
 
FiO2 HR MAP Noradrenaline SpO2 
0.55 84 71  100 
 170    
 
Prediction is C-E, although real due to increase in heart rate there are missing core 
parameters of FiO2, MAP and SpO2. 
 
Insight Case Number 4885-4886 
 
FiO2 HR MAP Noradrenaline SpO2 
0.3 101   100 
0.3 118 142  100 
 
Prediction is C-E, although real due to increase in heart and high MAP there are missing 
core parameters i.e. MAP 
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Insight Case Number 5721-5722 
 
FiO2 HR MAP Noradrenaline SpO2 
0.65 109 69  94 
0.65 110 69 2.8 97 
 
Prediction is C-E, but apparent deterioration is due to lack of noradrenaline which had 
been quite fluctuant before this so would have been hard to extrapolate. 
 
Insight Case Number 5224-5225 
 
FiO2 HR MAP Noradrenaline SpO2 
0.5 105   94 
0.5 103 0  95 
 
Prediction is C-E, but there is no MAP so missing core parameters. 
 
MS 20/5/12 
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Appendix XV 
Data base created to examine ICU-PSS and outcome 
 
Table for outcomes 
Patient-ID Start/Fin Outcome APACHE II 
Predicted 
Mortality Med Diag. 
1536 13 Alive 29 77.2 Medical 
1667 1697 Dead 33 84.5 Medical 
1689 1861 Alive 22 58.9 Medical 
1695 18614 Dead 31 75.4 Medical 
1697 1898 Alive 24 35.5 Medical 
1711 18654 Dead 20 35.5 Medical 
1720 2214 Alive 28 63.7 Surgical 
1721 2677 Alive 18 44.4 Surgical 
1726 2750 Alive 17 26.2 Surgical 
1727 2784 Dead 29 69.6 Medical 
1742 18666 Alive 16 23.3 Surgical 
1748 3027 Alive 23 62.3 Surgical 
1750 3530 Dead 18 29.1 Medical 
1757 3681 Alive 22 14 Medical 
1774 3711 Dead 22 42.4 Medical 
1781 18719 Alive 17 26.2 Surgical 
1807 4383 Alive 32 78 Surgical 
1818 5142 Alive 19 48 Surgical 
1822 5251 Dead 22 42.4 Medical 
1933 8950 Alive 20 21.3 Surgical 
1948 9134 Dead 17 36.2 Medical 
1951 9146 Dead 22 58.9 Surgical 
1965 9366 Dead 21 41.6 Surgical 
1969 9453 Alive 30 49.3 Medical 
1970 19258 Alive 14 18.6 Surgical 
2017 9655 Alive 23 58.5 Surgical 
2030 9916 Alive 38 92.6 Surgical 
2039 10444 Dead 33 84.7 Medical 
2119 19278 Dead 21 55.3 Surgical 
2121 10878 Dead 23 58.5 Surgical 
2138 10917 Alive 25 47.1 Surgical 
2158 11609 Dead 20 47.6 Medical 
2174 11817 Dead 9 9.9 Medical 
2188 12049 Dead 45 97.2 Medical 
2189 12082 Dead 31 68.1 Medical 
2220 19615 Alive 12 14.6 Surgical 
2231 12315 Alive 29 79.9 Surgical 
2265 12573 Dead 35 79.3 Surgical 
2273 13707 Alive 34 66.6 Medical 
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2284 14147 Dead 18 19.7 Surgical 
2303 14486 Alive 32 82.5 Medical 
2313 15172 Dead 11 8.1 Surgical 
2327 20729 Dead 41 93 Surgical 
2328 15973 Dead 43 86.7 Medical 
2342 16220 Alive 30 72.6 Surgical 
2457 16457 Alive 25 70 Surgical 
2506 16789 Alive 36 55.8 Medical 
2524 16970 Alive 28 72.7 Medical 
2527 17138 Alive 24 65.7 Surgical 
2585 17353 Dead 34 82.6 Medical 
2607 17411 Dead 21 38.9 Medical 
2644 17515 Alive 32 56.6 Surgical 
2660 18309 Alive 25 53.1 Surgical 
2698 18562 Dead 33 85.8 Medical 
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Appendix XVI 
Data base created to examine troponin level and outcome 
 
Date 
Admit Date Out L.O.S. Age M/F Apache II Pred. Mort. 
1st 
Troponin 
Day 1st 
troponin 
Highest 
Troponin  
Day 
Highest 
Troponin 
Alive 
(1)/ 
Dead 
(0) 
10/10/2009 19/11/2009 40.6 72 M Readmission Readmission 0.33 2 6.47 24 0 
09/10/2009 14/10/2009 4.5 76 M Readmission Readmission 0.13 1 0.13 1 1 
08/10/2009 09/10/2009 0.9 33 M 11 6.3 <0.04  Y <0.04  Y 1 
08/10/2009 12/10/2009 3.6 35 F 19 27 0.27 2 0.27 2 1 
08/10/2009 14/10/2009 6.1 43 F 33 75.6 <0.04 Y <0.04  Y 0 
06/10/2009 08/10/2009 1.5 77 F 16 23.3 23.8 1 23.8 1 1 
06/10/2009 07/10/2009 1.1 35 M 7 7.6 0.16 2 0.16 2 1 
05/10/2009 06/10/2009 0.9 64 F 16 23.5 <0.04  Y <0.04  Y 1 
04/10/2009 08/10/2009 4 57 F 16 1.1 <0.04  Y <0.04  Y 1 
03/10/2008 02/11/2009 30 59 M 19 12.2 0..04 1 0.1 2 1 
03/10/2009 04/10/2009 1.1 41 M 27 75.9 0.36 2 0.36 2 0 
02/10/2009 09/10/2009 6.6 58 F 17 19.7 1.57 2 1.57 2 1 
02/10/2009 08/10/2009 5.7 72 M 11 17.4 0.25 4 0.25 4 1 
02/10/2009 04/10/2009 2 59 M 33 85.8 0.08 1 0.31 3 0 
02/10/2009 02/10/2009 0.5 36 F 7 0.3 <0.04  Y <0.04  Y 1 
29/09/2009 09/10/2009 9.6 33 F Readmission Readmission <0.04  Y <0.04  Y 1 
29/09/2009 01/10/2009 2.4 40 M 4 2.9 <0.04  Y <0.04  Y 1 
28/09/2009 29/09/2009 1.2 27 M 23 63.7 0.07 1 0.07 1 1 
27/09/2009 29/09/2009 1.8 75 M 17 25.9 <0.04 Y <0.04  Y 1 
25/09/2009 25/09/2009 0.2 25 F <8 hours < 8 hours N N N N 1 
24/09/2009 26/09/2009 1.9 82 M 16 23.5 0.08 2 0.08 2 1 
24/09/2009 25/09/2009 1.2 47 M 27 75.9 N N N N 0 
22/09/2009 02/10/2009 9.8 73 M 25 53.1 0.07 2 0.23 4 1 
22/09/2009 26/09/2009 3.9 69 M 20 35.5 0.88 2 0.88 2 1 
26/09/2009 27/09/2009 0.7 59 M 7 4.7 N N N N 1 
21/09/2009 22/09/2009 1.5 72 M 15 28.2 0.7 1 4.48 1 1 
20/09/2009 22/09/2009 1.9 16 M 23 45.7 N N N N 1 
20/09/2009 22/09/2009 1.9 22 M 20 1.9 1.28 1 1.28 1 1 
20/09/2009 21/09/2009 0.9 60 F 18 1.4 <0.04 Y <0.04 Y 1 
19/09/2009 23/09/2009 3.9 33 F 11 12.9 <0.04 Y <0.04 Y 1 
19/09/2009 19/09/2009 0.6 84 F 25 35.9 N N N N 0 
14/09/2009 16/09/2009 1.7 71 M 23 46 0.16 3 0.16 3 1 
14/09/2009 02/10/2009 18.6 76 M 20 35.5 0.47 5 0.47 5 1 
13/09/2009 15/09/2009 1.7 39 F 23 45.7 1.03 1 1.03 1 1 
13/09/2009 13/09/2009 0.2 44 M < 8 hours < 8 hours N N N N 0 
11/09/2009 14/09/2009 2.9 53 M 23 41.1 0.29 4 0.29 4 1 
10/09/2009 18/09/2009 8.2 75 F 25 68.9 0.07 2 0.08 3 1 
09/09/2009 10/09/2009 1.2 78 M 39 92.9 0.43 1 0.43 1 1 
08/09/2009 10/09/2009 1.9 50 F 17 16.1 <0.04 Y <0.04 Y 1 
07/09/2009 10/09/2009 3 63 M 13 14 <0.04 Y <0.04 Y 1 
07/09/2009 08/09/2009 1.6 75 F 36 83.2 6.3 1 6.8 1 0 
06/09/2009 06/09/2009 0.1 24 M <8 hours < 8 hours N N N N 1 
06/09/2009 06/09/2009 0.3 79 M 16 23.4 0.31 1 0.31 1 1 
06/09/2009 07/09/2009 1.1 26 M 11 23.4 <0.04 Y <0.04 Y 1 
04/09/2009 09/09/2009 4 63 M 21 38.9 2.91 4 2.91 4 0 
04/09/2009 05/09/2009 0.6 35 M 10 5.6 N N N N 1 
04/09/2009 09/09/2009 5.1 60 M 21 35.6 2 4 2 4 1 
03/09/2009 04/09/2009 1.4 61 F 19 32.2 <0.04 Y <0.04 Y 1 
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03/09/2009 06/09/2009 3.8 78 F 24 52.5 0.27 1 0.27 1 0 
03/09/2009 04/09/2009 1.8 65 F 23 41.3 0.04 2 0.04 2 1 
02/09/2009 03/09/2009 0.4 70 F 37 86.7 N N N N 0 
01/09/2009 01/09/2009 0.4 47 F 34 82.6 N N N N 0 
31/08/2009 01/09/2009 0.7 47 F 19 1.6 <0.04 Y <0.04 Y 1 
31/08/2009 07/09/2009 7 50 F Readmission Readmission <0.04 Y <0.04 Y 1 
30/08/2009 03/09/2009 4.4 55 F 25 68.9 <0.04 Y <0.04 Y 1 
29/08/2009 31/08/2009 2.1 51 M 34 82.6 3.18 3 3.18 3 0 
27/08/2009 29/08/2009 2.3 48 F 17 21.7 0.48 2 0.48 2 1 
25/08/2009 27/08/2009 2.3 78 M 24 49.3 0.05 1 0.12 2 0 
24/08/2009 16/09/2009 22.7 49 M Burn Burn 0.1 15 0.1 15 1 
24/08/2009 28/08/2009 4 67 F 15 34 <0.04 Y <0.04 Y 1 
24/08/2009 28/08/2009 4 50 F Burn Burn <0.04 Y <0.04 Y 1 
23/08/2009 26/08/2009 3 75 M 15 34 <0.04 Y <0.04 Y 1 
23/08/2009 04/09/2009 12.2 76 M 21 14 0.19 1 1.54 2 1 
22/08/2009 24/08/2009 1.5 42 M 17 34.5 2.13 2 2.13 2 1 
22/08/2009 28/08/2009 5.7 16 F 9 3.6 <0.04 Y <0.04 Y 1 
22/08/2009 23/08/2009 1.2 15 M 15 years old 15 years old N N N N 1 
21/08/2009 22/08/2009 0.7 67 F 14 9.4 0.19 2 0.19 2 1 
21/08/2009 30/08/2009 8.7 44 M 15 30.4 <0.04 Y <0.04 Y 1 
21/08/2009 21/08/2009 0.2 50 M <8 hours <8 hours N N N N 0 
21/08/2009 22/08/2009 1.4 51 F 10 19.9 <0.04 Y <0.04 Y 1 
20/08/2009 24/08/2009 3.8 59 M Readmission Readmission 0.07 2 0.07 2 1 
19/08/2009 21/08/2009 1.7 63 M 13 13.4 <0.04 Y <0.04 Y 1 
19/08/2009 25/08/2009 5.9 70 F 17 37 <0.04 Y <0.04 Y 0 
18/08/2009 21/08/2009 3.2 40 M 24 65.7 2 2 2 2 1 
18/08/2009 19/08/2009 1 52 M 27 60.1 N N N N 0 
16/08/2009 20/08/2009 4.2 48 F Burn Burn <0.04 Y <0.04 Y 0 
14/08/2009 15/08/2009 0.5 36 M 19 16.4 0.8 2 0.8 2 1 
14/08/2009 14/08/2009 0.7 23 M 9 3.6 0.61 1 0.61 1 1 
13/08/2009 06/09/2009 23.9 31 F 26 64.9 0.06 1 0.06 1 1 
13/08/2009 23/08/2009 9.7 68 F 27 46 0.16 2 0.16 2 1 
13/08/2009 17/08/2009 3.9 33 M 12 9.3 <0.04 Y <0.04 Y 1 
13/08/2009 19/08/2009 6.2 59 M 28 72.7 0.07 2 0.07 2 1 
10/08/2009 22/08/2009 12.6 54 F 16 23.2 <0.04 Y <0.04 Y 0 
09/08/2009 12/08/2009 2.4 72 F 26 66.2 0.07 1 0.11 2 0 
08/08/2009 11/08/2009 2.8 29 M 21 2.2 0.74 3 0.74 3 1 
08/08/2009 08/08/2009 0.5 61 M 12 8.7 0.13 1 0.22 1 1 
07/08/2009 08/08/2009 0.4 40 F 3 2.4 N N N N 1 
06/08/2009 15/08/2009 8.6 40 M 21 51.2 <0.04 Y <0.04 Y 1 
06/08/2009 12/08/2009 6.3 52 F 36 55.8 2.59 2 2.59 2 1 
05/08/2009 06/08/2009 0.6 58 F 20 38.1 N N N N 1 
05/08/2009 10/08/2009 5.3 39 M 35 89 <0.04 Y <0.04 Y 1 
03/08/2009 08/08/2009 5.7 75 M 34 86.3 0.25 2 0.63 3 0 
02/08/2009 06/08/2009 3.5 36 M 13 24.6 0.07 2 0.07 2 1 
02/08/2009 05/08/2009 2.6 37 M 19 28.7 0.11 2 0.11 2 1 
31/07/2009 01/08/2009 0.8 63 M 9 9.9 <0.04 Y <0.04 Y 1 
31/07/2009 06/08/2009 5.5 57 M 15 21 <0.04 Y <0.04 Y 1 
31/07/2009 01/08/2009 1 79 F 33 87.7 1.32 2 1.32 2 0 
30/07/2009 02/08/2009 2.9 64 F 19 17.7 0.16 2 0.16 2 1 
30/07/2009 20/08/2009 21.2 71 F 20 35.5 <0.04 Y <0.04 Y 0 
30/07/2009 31/07/2009 1.4 68 M 21 2.2 <0.04 Y <0.04 Y 1 
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